# Stoffers_2012_Psychological therapies for people with borderline personality disorder._1

Cochrane
Library

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality
disorder (Review)

Stoffers-Winterling JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K

Stoffers-Winterling JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. 
Psychological therapies for people with borderline personality disorder. 
Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD005652. 
DOI: 10.1002/14651858.CD005652.pub2.

www.cochranelibrary.com

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 1: BPD total severity.......
Analysis 1.2. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 2: Inappropriate anger.....
Analysis 1.3. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 3: Affective instability......
Analysis  1.4.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  4:  chronic  feelings  of
emptiness..............................................................................................................................................................................................
Analysis 1.5. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 5: Impulsivity..................
Analysis 1.6. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 6: Suicidality...................
Analysis 1.7. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 7: Suicidality...................
Analysis 1.8. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 8: Parasuicidality............
Analysis 1.9. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 9: Parasuicidality............
Analysis  1.10.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  10:  Interpersonal
problems................................................................................................................................................................................................
Analysis  1.11.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  11:  Avoidance  of
abandonment........................................................................................................................................................................................
Analysis  1.12.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  12:  Identity
disturbance............................................................................................................................................................................................
Analysis  1.13.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  13:  Dissociation/
psychoticism..........................................................................................................................................................................................
Analysis 1.14. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 14: Depression..............
Analysis 1.15. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 15: Anxiety....................
Analysis  1.16.  Comparison  1:  Comprehensive  psychotherapies:  active  vs.  control  conditions,  Outcome  16:  General
psychopathology...................................................................................................................................................................................
Analysis 1.17. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 17: Mental health status/
functioning.............................................................................................................................................................................................
Analysis 1.18. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 18: Leaving the study
early........................................................................................................................................................................................................
Analysis 1.19. Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 19: Leaving the study
early: sensitivity analysis (non-rural areas only)................................................................................................................................
Analysis 2.1. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 1:
BPD total severity..................................................................................................................................................................................
Analysis 2.2. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 2:
Inappropriate anger..............................................................................................................................................................................
Analysis 2.3. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 3:
Affective instability................................................................................................................................................................................
Analysis 2.4. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 4:
Chronic feelings of emptiness..............................................................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
3
25
26
26
30
31
32
34
53
58
59
60
61
74
134
140
141
141
142

142
142
143
143
144
145

146

146

146

147
148
149

150

151

153

157

157

158

158

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.5. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 5:
Impulsivity.............................................................................................................................................................................................
Analysis 2.6. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 6:
Impulsivity.............................................................................................................................................................................................
Analysis 2.7. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 7:
Suicidality..............................................................................................................................................................................................
Analysis 2.8. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 8:
Parasuicidality.......................................................................................................................................................................................
Analysis 2.9. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 9:
Parasuicidality.......................................................................................................................................................................................
Analysis 2.10. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 10:
Interpersonal problems........................................................................................................................................................................
Analysis 2.11. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 11:
Dissociation/psychoticism....................................................................................................................................................................
Analysis 2.12. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 12:
Depression.............................................................................................................................................................................................
Analysis 2.13. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 13:
Anxiety...................................................................................................................................................................................................
Analysis 2.14. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 14:
General psychopathology.....................................................................................................................................................................
Analysis 2.15. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 15:
Mental health status/functioning.........................................................................................................................................................
Analysis 2.16. Comparison 2: Non-comprehensive psychotherapeutic interventions: active vs. control conditions, Outcome 16:
Leaving the study early........................................................................................................................................................................
Analysis 3.1. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 1: BPD total severity.........
Analysis 3.2. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 2: Inappropriate anger......
Analysis 3.3. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 3: Impulsivity....................
Analysis 3.4. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 4: Suicidality.....................
Analysis 3.5. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 5: Parasuicidality..............
Analysis 3.6. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 6: Psychoticism................
Analysis 3.7. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 7: Depression...................
Analysis 3.8. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 8: Anxiety..........................
Analysis  3.9.  Comparison  3:  Comprehensive  psychotherapies:  active  vs.  active  conditions,  Outcome  9:  General
psychopathology...................................................................................................................................................................................
Analysis 3.10. Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 10: Mental health status/
functioning.............................................................................................................................................................................................
Analysis  3.11.  Comparison  3:  Comprehensive  psychotherapies:  active  vs.  active  conditions,  Outcome  11:  Leaving  the  study
early........................................................................................................................................................................................................
Analysis 4.1. Comparison 4: Non-comprehensive psychotherapeutic interventions: active vs. active conditions, Outcome 1: BPD
total severity..........................................................................................................................................................................................
Analysis  4.2.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  2:
Affective instability................................................................................................................................................................................
Analysis  4.3.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  3:
Suicidality..............................................................................................................................................................................................
Analysis  4.4.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  4:
Parasuicidality.......................................................................................................................................................................................
Analysis  4.5.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  5:
Interpersonal problems........................................................................................................................................................................
Analysis  4.6.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  6:
Identity disturbance..............................................................................................................................................................................
Analysis  4.7.  Comparison  4:  Non-comprehensive  psychotherapeutic  interventions:  active  vs.  active  conditions,  Outcome  7:
Leaving the study early........................................................................................................................................................................
Analysis 5.1. Comparison 5: Funnel plot, Outcome 1: Parasuicidality...............................................................................................
Analysis 5.2. Comparison 5: Funnel plot, Outcome 2: By sample size - parasuicidality...................................................................
ADDITIONAL TABLES....................................................................................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

159

160

160

160

161

161

162

162

163

163

164

167
167
167
168
168
168
169
169
170

170

170

172

172

173

173

173

173

174

175
177
178

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

APPENDICES.................................................................................................................................................................................................
FEEDBACK.....................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
NOTES...........................................................................................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

191
196
199
199
200
200
200
200
200
200

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality disorder

Jutta M Stoffers-Winterling1, Birgit A Völlm2, Gerta Rücker3, Antje Timmer4, Nick Huband5, Klaus Lieb6a

1Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany. 2Department of Forensic Psychiatry,
Center for Neurology, University Rostock, Rostock, Germany. 3Institute of Medical Biometry and Statistics, Faculty of Medicine and
Medical Center – University of Freiburg, Freiburg, Germany. 4Department of Health Services Research, Carl von Ossietzky University of
Oldenburg, Oldenburg, Germany. 5Division of Psychiatry & Applied Psychology, University of Nottingham Innovation Park, Nottingham,
UK. 6Leibniz Institute for Resilience Research (LIR), Mainz, Germany

aShared last authorship

Contact: Klaus Lieb, klaus.lieb@unimedizin-mainz.de, klaus.lieb@ukmainz.de.

Editorial group: Cochrane Developmental, Psychosocial and Learning Problems Group.
Publication status and date: Stable (no update expected for reasons given in 'What's new'), published in Issue 9, 2020.

Citation: Stoffers-Winterling JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline
personality disorder. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD005652. DOI: 10.1002/14651858.CD005652.pub2.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Psychotherapy is regarded as the first-line treatment for people with borderline personality disorder. In recent years, several disorder-
specific interventions have been developed. This is an update of a review published in the Cochrane Database of Systematic Reviews (CDSR)
in 2006 and it was superseded by a new review (with the same title) in the CDSR in 2020.

Objectives

To assess the effects of psychological interventions for borderline personality disorder (BPD).

Search methods

We searched the following databases: CENTRAL 2010(3), MEDLINE (1950 to October 2010), EMBASE (1980 to 2010, week 39), ASSIA (1987 to
November 2010), BIOSIS (1985 to October 2010), CINAHL (1982 to October 2010), Dissertation Abstracts International (31 January 2011),
National Criminal Justice Reference Service Abstracts (15 October 2010), PsycINFO (1872 to October Week 1 2010), Science Citation Index
(1970 to 10 October 2010), Social Science Citation Index (1970 to 10 October 2010), Sociological Abstracts (1963 to October 2010), ZETOC (15
October 2010) and the metaRegister of Controlled Trials (15 October 2010). In addition, we searched Dissertation Abstracts International
in January 2011 and ICTRP in August 2011.

Selection criteria

Randomised studies with samples of patients with BPD comparing a specific psychotherapeutic intervention against a control intervention
without any specific mode of action or against a comparative specific psychotherapeutic intervention. Outcomes included overall BPD
severity, BPD symptoms (DSM-IV criteria), psychopathology associated with but not specific to BPD, attrition and adverse effects.

Data collection and analysis

Two review authors independently selected studies, assessed the risk of bias in the studies and extracted data.

Main results

Twenty-eight  studies  involving  a  total  of  1804  participants  with  BPD  were  included.  Interventions  were  classified  as  comprehensive
psychotherapies if they included individual psychotherapy as a substantial part of the treatment programme, or as non-comprehensive
if they did not.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Among comprehensive psychotherapies, dialectical behaviour therapy (DBT), mentalisation-based treatment in a partial hospitalisation
setting  (MBT-PH),  outpatient  MBT  (MBT-out),  transference-focused  therapy  (TFP),  cognitive  behavioural  therapy  (CBT),  dynamic
deconstructive psychotherapy (DDP), interpersonal psychotherapy (IPT) and interpersonal therapy for BPD (IPT-BPD) were tested against
a control condition. Direct comparisons of comprehensive psychotherapies included DBT versus client-centered therapy (CCT); schema-
focused therapy (SFT) versus TFP; SFT versus SFT plus telephone availability of therapist in case of crisis (SFT+TA); cognitive therapy (CT)
versus CCT, and CT versus IPT.

Non-comprehensive  psychotherapeutic  interventions  comprised  DBT-group  skills  training  only  (DBT-ST),  emotion  regulation  group
therapy  (ERG),  schema-focused  group  therapy  (SFT-G),  systems  training  for  emotional  predictability  and  problem  solving  for
borderline personality disorder (STEPPS), STEPPS plus individual therapy (STEPPS+IT), manual-assisted cognitive treatment (MACT) and
psychoeducation (PE). The only direct comparison of an non-comprehensive psychotherapeutic intervention against another was MACT
versus MACT plus therapeutic assessment (MACT+). Inpatient treatment was examined in one study where DBT for PTSD (DBT-PTSD) was
compared with a waiting list control. No trials were identified for cognitive analytical therapy (CAT).

Data were sparse for individual interventions, and allowed for meta-analytic pooling only for DBT compared with treatment as usual (TAU)
for four outcomes. There were moderate to large statistically significant effects indicating a beneficial effect of DBT over TAU for anger (n
= 46, two RCTs; standardised mean difference (SMD) -0.83, 95% confidence interval (CI) -1.43 to -0.22; I2 = 0%), parasuicidality (n = 110,
three RCTs; SMD -0.54, 95% CI -0.92 to -0.16; I2 = 0%) and mental health (n = 74, two RCTs; SMD 0.65, 95% CI 0.07 to 1.24 I2 = 30%). There
was no indication of statistical superiority of DBT over TAU in terms of keeping participants in treatment (n = 252, five RCTs; risk ratio 1.25,
95% CI 0.54 to 2.92).

All remaining findings were based on single study estimates of effect. Statistically significant between-group differences for comparisons of
psychotherapies against controls were observed for BPD core pathology and associated psychopathology for the following interventions:
DBT, DBT-PTSD, MBT-PH, MBT-out, TFP and IPT-BPD. IPT was only indicated as being effective in the treatment of associated depression.
No statistically significant effects were found for CBT and DDP interventions on either outcome, with the effect sizes moderate for DDP and
small for CBT. For comparisons between different comprehensive psychotherapies, statistically significant superiority was demonstrated
for DBT over CCT (core and associated pathology) and SFT over TFP (BPD severity and treatment retention). There were also encouraging
results for each of the non-comprehensive psychotherapeutic interventions investigated in terms of both core and associated pathology.

No data were available for adverse effects of any psychotherapy.

Authors' conclusions

There  are  indications  of  beneficial  effects  for  both  comprehensive  psychotherapies  as  well  as  non-comprehensive  psychotherapeutic
interventions for BPD core pathology and associated general psychopathology. DBT has been studied most intensely, followed by MBT,
TFP, SFT and STEPPS. However, none of the treatments has a very robust evidence base, and there are some concerns regarding the quality
of individual studies. Overall, the findings support a substantial role for psychotherapy in the treatment of people with BPD but clearly
indicate a need for replicatory studies.

P L A I N   L A N G U A G E   S U M M A R Y

Psychological therapies for borderline personality disorder

People  with  borderline  personality  disorder  often  have  difficulties  controlling  their  emotions  and  impulses,  and  find  it  hard  to  keep
relationships. They can experience feelings of emptiness, suffer quick changes in mood and they may harm themselves. Problems coping
with abandonment and a rapidly changing view of other people can form part of their difficulties. All of these things make it hard for them
to engage with any treatment they may be offered. Those who are able to engage often find it hard to stick with the treatment and leave
before the end. Certain types of psychological treatment ('talking therapies') have been developed in recent years to help people with
this disorder. This review summarises what is currently known about the effects of these treatments. It updates a review published in the
Cochrane Database of Systematic Reviews (CDSR) in 2006 and it was superseded by a new review (with the same title) in the CDSR in 2020.

We  found  28  studies  that  had  involved  a  total  of  1804  people  with  borderline  personality  disorder.  These  studies  examined  various
psychological treatments. Some of these are called 'comprehensive' treatments because the person talks one-to-one with a professional
for at least part of the time. Other treatments are called 'non-comprehensive' because they do not involve this one-to-one work.

A number of studies have been carried out on one particular type of comprehensive treatment, called Dialectical Behaviour Therapy. For
this treatment, there were sufficient studies for us to pool the results and draw conclusions. The results indicate Dialectical Behaviour
Therapy is helpful for people with borderline personality disorder. Effects included a decrease in inappropriate anger, a reduction in self-
harm and an improvement in general functioning.

There were generally too few studies to allow firm conclusions to be drawn about the value of all the other kinds of psychotherapeutic
interventions  evaluated.  However,  single  studies  show  encouraging  findings  for  each  treatment  that  was  investigated,  both
'comprehensive' and 'non-comprehensive' types. More research is needed.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

3

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Dialectical Behaviour Therapy (DBT) versus treatment as usual (TAU) for people with borderline personality disorder

DBT vs. TAU for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: DBT
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Control

DBT

BPD total severity -
DBT vs. TAU
mean number of BPD
criteria met
Follow-up: 6 months

The mean BPD total sever-
ity score - DBT vs. TAU in
the control groups was
4.2 criteria

The mean BPD total severity score
- DBT vs. TAU in the intervention
groups was
0.29 standard deviations lower
(1.17 lower to 0.59 higher)

Inappropriate anger -
DBT vs. TAU
STAXI2 anger out, STAXI
anger trait
Follow-up: 6-12 months

The mean inappropri-
ate anger score - DBT vs.
TAU ranged across control
groups from
17.9 to 40.08 points

The mean inappropriate anger score
- DBT vs. TAU in the intervention
groups was
0.83 standard deviations lower
(1.43 to 0.22 lower)

Impulsivity - DBT vs.
TAU
BPDSI-IV3
Follow-up: 12 months

The mean impulsivity
score - DBT vs. TAU in the
control groups was
1.06 points

The mean impulsivity score - DBT vs.
TAU in the intervention groups was
0.17 standard deviations lower
(0.74 lower to 0.39 higher)

Suicidality - DBT vs.
TAU
BSS4
Follow-up: 6 months

The mean suicidality score
- DBT vs. TAU in the con-
trol groups was
41.5 points

The mean suicidality score - DBT vs.
TAU in the intervention groups was
1.26 standard deviations lower
(2.24 to 0.29 lower)

Parasuicidality - DBT
vs. TAU
acts of self-mutilation
Follow-up: 6-12 months

The mean parasuicidality
score - DBT vs. TAU ranged
across control groups
from
1.0 to 41.6 points

The mean parasuicidality score - DBT
vs. TAU in the intervention groups
was
0.54 standard deviations lower
(0.92 to 0.16 lower)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

20
(1 study)

⊕⊕⊝⊝
low 1

SMD -0.29 (-1.17
to 0.59)

46
(2 studies)

⊕⊕⊝⊝
low 1

SMD -0.83 (-1.43
to -0.22)

48
(1 study)

20
(1 study)

⊕⊕⊝⊝
low 1

⊕⊕⊝⊝
low 1

SMD -0.17 (-0.74
to 0.39)

SMD -1.26 (-2.24
to -0.29)

110
(3 studies)

⊕⊕⊕⊝
moderate 5

SMD -0.54 (-0.92
to -0.16)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
parasuicidality - DBT
vs. TAU

acts of self-mutilation

Follow-up: 6 months

Interpersonal prob-
lems - DBT vs. TAU
WHOQOL-Bref6-social
relationships multiplied
by (-1)
Follow-up: 12 months

Dissociation/psychoti-
cism - DBT vs. TAU
DES7
Follow-up: 6 months

677 per 1000

751 per 1000

(528 to 1000)

RR 1.11

51

(0.78 to 1.57)

(1 study)

⊕⊕⊝⊝
low 1

The mean interpersonal
problems score - DBT vs.
TAU in the control groups
was
49.73 points

The mean interpersonal problems
score - DBT vs. TAU in the interven-
tion groups was
0.04 standard deviations higher
(0.54 lower to 0.61 higher)

The mean dissocia-
tion/psychoticism score -
DBT vs. TAU in the control
groups was
30.6 points

The mean dissociation/psychoticism
score - DBT vs. TAU in the interven-
tion groups was
0.9 standard deviations lower
(1.83 lower to 0.03 higher)

48
(1 study)

⊕⊕⊝⊝
low 1

SMD -0.04 (-0.61
to 0.54)

20
(1 study)

⊕⊕⊝⊝
low 1

SMD -0.9 (-1.83
to 0.03)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Total sample size less than 100
2Spielberger Anger Expression Scale
3Borderline Personality Disorder Severity Index
4Beck Scale for Suicidal Ideation
5Total sample size less than 400
6World Health Organization quality of life assessment
7Dissociative Experiences Scale

Summary of findings 2.   Dialectical Behaviour Therapy (DBT) versus general management (GM) according to APA guidelines for people with
borderline personality disorder

DBT vs. general management according to APA guidelines for people with borderline personality disorders

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

5

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: DBT
Comparison: general management (GM)

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

GM

DBT

BPD total severity
ZAN-BPD1 total
Follow-up: mean 12
months

The mean BPD total sever-
ity score in the control
groups was
8.16 points

The mean BPD total severity score in
the intervention groups was
0.04 standard deviations lower
(0.33 lower to 0.25 higher)

Inappropriate anger -
DBT vs. GM
STAXI3-anger out
Follow-up: mean 12
months

Parasuicidality - DBT
vs. GM
mean no. of suici-
dal and self-injurious
episodes
Follow-up: mean 12
months

The mean inappropriate
anger score - DBT vs. GM
in the control groups was
5.11 points

The mean inappropriate anger score -
DBT vs. GM in the intervention groups
was
0.03 standard deviations lower
(0.32 lower to 0.26 higher)

The mean parasuicidality
score - DBT vs. GM in the
control groups was
12.87 points

The mean parasuicidality score - DBT
vs. GM in the intervention groups was
0.23 standard deviations lower
(0.52 lower to 0.06 higher)

Interpersonal prob-
lems - DBT vs. GM
IIP-C4 total
Follow-up: mean 12
months

The mean interpersonal
problems score - DBT vs.
GM in the control groups
was
101.58 points

The mean interpersonal problems
score - DBT vs. GM in the intervention
groups was
0.03 standard deviations lower
(0.32 lower to 0.26 higher)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

180
(1 study)

⊕⊕⊕⊝
moderate 2

180
(1 study)

⊕⊕⊕⊝
moderate 2

180
(1 study)

⊕⊕⊕⊝
moderate 2

180
(1 study)

⊕⊕⊕⊝
moderate 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

Very low quality: We are very uncertain about the estimate.

1Zanarini rating scale for borderline personality disorder
2Total sample size less than 400
3Spielberger Anger Expression Scale
4Inventory of interpersonal problems-Circumplex Scales

Summary of findings 3.   Dialectical Behaviour Therapy (DBT) versus community treatment by experts (CTBE) for people with borderline personality
disorder

DBT compared to community treatment by experts (CTBE) for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: DBT
Comparison: CTBE

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Community treatment by ex-
perts

DBT

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Suicidality
SBQ1
Follow-up:
mean 12
months

The mean suicidality score in
the control groups was
32.8 points

The mean suicidality score in the inter-
vention groups was
0.12 standard deviations lower
(0.54 lower to 0.30 higher)

89
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Suicidal Behaviours Questionnaire
2Total sample size less than 100

6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

7

Summary of findings 4.   Dialectical Behaviour Therapy for BPD with post-traumatic stress disorder (DBT-PTSD) versus waiting list (WL) for people
with borderline personality disorder

DBT-PTSD compared to waiting list (WL) for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: inpatient
Intervention: DBT-PTSD
Comparison: WL

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Waiting list

DBT-PTSD

The mean BPD total severity
score in the control groups
was
2.26 points

The mean BPD total severity score in the
intervention groups was
0.74 standard deviations lower
(1.47 to 0.01 lower)

The mean dissociation score
in the control groups was
19.99 points

The mean dissociation score in the inter-
vention groups was
0.34 standard deviations lower
(1.06 lower to 0.38 higher)

BPD total sever-
ity
BSL1
Follow-up: mean
3 months

Dissociation
DES3
Follow-up: mean
3 months

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

31
(1 study)

⊕⊕⊝⊝
low 2

30
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline Symptom List
2Total sample size less than 100
2Dissociative Experiences Scale

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

Summary of findings 5.   Mentalisation-Based Treatment-partial hospitalisation (MBT-PH) versus treatment as usual (TAU) for people with borderline
personality disorder

MBT-PH compared to TAU for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: partial hospitalisation
Intervention: MBT-PH
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

MBT-PH

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Suicidality
no. of participants with suicide at-
tempt (last 6 months)
Follow-up: mean 18 months

Parasuicidality
no. of participants with self-mutilating
behaviour (last 6 months)
Follow-up: mean 18 months

Interpersonal problems
IIP2
Follow-up: mean 18 months

632 per 1000

51 per 1000
(6 to 366)

RR 0.08 
(0.01 to 0.58)

38
(1 study)

842 per 1000

371 per 1000
(202 to 682)

RR 0.44 
(0.24 to 0.81)

38
(1 study)

The mean inter-
personal problems
score in the control
groups was
2.6 points

The mean interpersonal prob-
lems score in the intervention
groups was
2.22 standard deviations
lower
(3.04 to 1.39 lower)

38
(1 study)

⊕⊕⊝⊝
low 1

⊕⊕⊝⊝
low 1

⊕⊕⊝⊝
low 1

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Total sample size less than 100

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

9

2Inventory of interpersonal problems

Summary of findings 6.   Mentalisation-Based Treatment-outpatient (MBT-out) versus treatment as usual (TAU) for people with borderline
personality disorder

MBT-out compared to TAU for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: MBT-out
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

MBT-out

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Suicidality
no. of participants with life-threatening
suicide attempts (last 6 months)
Follow-up: mean 18 months

Parasuicidality
no. of participants with self-harm inci-
dents (last 6 months)
Follow-up: mean 18 months

Interpersonal problems
IIP2
Follow-up: mean 18 months

254 per 1000

28 per 1000
(8 to 117)

RR 0.11 
(0.03 to 0.46)

134
(1 study)

⊕⊕⊕⊝
moderate 1

429 per 1000

240 per 1000
(146 to 394)

RR 0.56 
(0.34 to 0.92)

134
(1 study)

⊕⊕⊕⊝
moderate 1

The mean inter-
personal problems
score in the control
groups was
1.65 points

The mean interpersonal
problems score in the inter-
vention groups was
0.95 standard deviations
lower
(1.30 to 0.59 lower)

134
(1 study)

⊕⊕⊕⊝
moderate 1

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
0

1Total sample size less than 400
2Inventory of interpersonal problems

Summary of findings 7.   Transference-Focused Psychotherapy (TFP) versus community treatment by experts (CTBE) for people with borderline
personality disorder

TFP compared to CTBE for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: TFP
Comparison: CTBE

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

CTBE

TFP

The mean BPD to-
tal severity score in
the control groups
was
5.63 criteria

The mean BPD total severi-
ty score in the intervention
groups was
0.55 standard deviations
lower
(0.95 to 0.16 lower)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

104
(1 study)

⊕⊕⊕⊝
moderate 1

212 per 1000

135 per 1000
(57 to 319)

RR 0.64 
(0.27 to 1.51)

104
(1 study)

⊕⊕⊕⊝
moderate 1

673 per 1000

734 per 1000
(565 to 942)

RR 1.09 
(0.84 to 1.40)

104
(1 study)

⊕⊕⊕⊝
moderate 1

BPD total severity
mean number of BPD criteria met. Scale
from: 0 to 9.
Follow-up: mean 12 months

Suicidality
no. of participants with suicidal act (last
12 months)
Follow-up: mean 12 months

Parasuicidality
no. of participants with self-harming be-
haviour (last 12 months)
Follow-up: mean 12 months

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
1

Very low quality: We are very uncertain about the estimate.

1Total sample size less than 400

Summary of findings 8.   Cognitive-Behavioural Therapy (CBT) versus treatment as usual (TAU) for borderline personality disorder

CBT compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: CBT
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

CBT

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Suicidality - CBT vs. TAU
no. of participants with suicidal act (last
12 months)
Follow-up: mean 12 months

Parasuicidality - CBT vs. TAU
no. of participants with self-harming be-
haviour (last 12 months)
Follow-up: mean 12 months

Interpersonal problems score
IIP-SC2
Follow-up: mean 12 months

438 per 1000

342 per 1000
(206 to 556)

RR 0.78 
(0.47 to 1.27)

101
(1 study)

⊕⊕⊕⊝
moderate 1

574 per 1000

672 per 1000
(494 to 918)

RR 1.17 
(0.86 to 1.6)

99
(1 study)

⊕⊕⊕⊝
moderate 1

The mean inter-
personal problems
score in the control
groups was
55 points

The mean Interpersonal
problems score in the inter-
vention groups was
0.23 standard deviations
higher
(0.16 lower to 0.63 higher)

99
(1 study)

⊕⊕⊕⊝
moderate 1

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Total sample size less than 400
2 Inventory of Interpersonal Problems-short form

Summary of findings 9.   Dynamic-Deconstructive Psychotherapy (DDP) versus treatment as ususal (TAU) for people with borderline personality
disorder

DDP compared to TAU for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: DDP
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

DDP

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

BPD total severity
BEST1
Follow-up: mean 12
months

The mean BPD total
severity score in the
control groups was
38.4 points

The mean BPD total severity score in the
intervention groups was
0.44 standard deviations lower
(1.16 lower to 0.29 higher)

30
(1 study)

600 per 1000

534 per 1000
(282 to 1000)

RR 0.89 
(0.47 to 1.67)

30
(1 study)

Parasuicidality
no. of participants
with parasuicide (last 3
months)
Follow-up: mean 12
months

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

Dissociation
DES3
Follow-up: mean 12
months

The mean dissociation
score in the control
groups was
22.3 points

The mean dissociation score in the inter-
vention groups was
0.25 standard deviations higher
(0.47 lower to 0.97 higher)

30
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline evaluation of severity over time
2Total sample less than 100
3Dissociative Experiences Scale

Summary of findings 10.   Interpersonal Psychotherapy (IPT) versus clinical management (CM) for people with borderline personality disorder

IPT compared to CM for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: IPT
Comparison: CM

Outcomes

Illustrative comparative risks* (95%
CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evi-
dence
(GRADE)

Comments

Assumed risk

Corresponding risk

CM

IPT

No primary outcomes available
Follow-up: mean 6 months

39
(1 study)

⊕⊕⊝⊝
low

No primary out-
comes available

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Summary of findings 11.   Interpersonal Psychotherapy adapted for BPD (IPT-BPD) versus clinical management (CM) for people with borderline
personality disorder

IPT-BPD compared to CM for people with borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: IPT-BPD
Comparison: CM

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

CM

IPT-BPD

BPD total severity
BPDSI-IV1-total score
Follow-up: mean 8
months

The mean BPD total
severity score in the con-
trol groups was
33.46 points

The mean BPD total severity score in
the intervention groups was
0.03 standard deviations lower
(0.62 lower to 0.56 higher)

Anger
BPDSI-IV1-anger
Follow-up: mean 8
months

The mean anger score in
the control groups was
5.25 points

The mean anger score in the interven-
tion groups was
0.01 standard deviations higher
(0.58 lower to 0.60 higher)

Affective instability
BPDSI-IV1-affective in-
stability
Follow-up: mean 8
months

Chronic feelings of
emptiness
BPDSI-IV1-emptiness
Follow-up: mean 8
months

Impulsivity
BPDSI-IV1-impulsivity
Follow-up: mean 8
months

The mean affective in-
stability score in the
control groups was
6.63 points

The mean affective instability score in
the intervention groups was
0.92 standard deviations lower
(1.54 to 0.30 lower)

The mean chronic feel-
ings of emptiness score
in the control groups
was
7.12 points

The mean chronic feelings of empti-
ness score in the intervention groups
was
0.09 standard deviations higher
(0.50 lower to 0.68 higher)

The mean impulsivity in
the control groups was
6.26 points

The mean impulsivity in the interven-
tion groups was
0.91 standard deviations lower
(1.53 to 0.28 lower)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

44
(1 study)

44
(1 study)

44
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

44
(1 study)

⊕⊕⊝⊝
low 2

44
(1 study)

⊕⊕⊝⊝
low 2

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
5

Parasuicidality
BPDSI-IV1-parasuicidal
behaviour
Follow-up: mean 8
months

Interpersonal prob-
lems
BPDSI-IV1-interpersonal
relationships
Follow-up: mean 8
months

The mean parasuicidal-
ity score in the control
groups was
1.99 points

The mean parasuicidality score in the
intervention groups was
0.02 standard deviations higher
(0.58 lower to 0.61 higher)

The mean interperson-
al problems score in the
control groups was
6.97 points

The mean interpersonal problems
score in the intervention groups was
0.82 standard deviations lower
(1.44 to 0.20 lower)

44
(1 study)

⊕⊕⊝⊝
low 2

44
(1 study)

⊕⊕⊝⊝
low 2

Avoidance of abandon-
ment

BPDSI-IV1-abandonment

The mean avoidance of
abandonment score in
the control group was

6.1 points

The mean avoidance of abandonment
score in the intervention groups was

44
(1 study)

⊕⊕⊝⊝
low 2

0.01 standard deviations higher

(-0.58 lower to 0.60 higher)

The mean identity disturbance score in
the intervention group was

44
(1 study)

⊕⊕⊝⊝
low 2

0.03 standard deviations lower

(-0.62 lower to 0.56 higher)

The mean identity dis-
turbance score in the
control group was

2.49 points

The mean dissocia-
tion/paranoid ideation
score in the control
group was

4.09 points

The mean dissociation/paranoid
ideation score in the intervention
group was

0.10 standard deviations higher

(-0.49 lower to 0.70 higher)

44
(1 study)

⊕⊕⊝⊝
low 2

Follow-up: mean 8
months

Identity disturbance

BPDSI-IV1-identity dis-
turbance

Follow-up: mean 8
months

Dissociation/paranoid
ideation

BPDSI-IV1-paranoid
ideation

Follow-up: mean 8
months

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Very low quality: We are very uncertain about the estimate.

1Borderline personality disorder severity index
2Total sample size less than 100

Summary of findings 12.   Dialectical Behaviour Therapy-skills training only (DBT-ST)versus standard group (SG) for borderline personality disorder

DBT skills training only compared to standard group for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: DBT skills training only
Comparison: standard group

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Standard group

DBT skills training only

The mean BPD total sever-
ity score in the control
groups was
4.44 points

The mean BPD total severity score in
the intervention groups was
1.01 standard deviations lower
(1.55 to 0.47 lower)

The mean anger score in
the control groups was
3.88 points

The mean anger score in the interven-
tion groups was
0.84 standard deviations lower
(1.37 to 0.30 lower)

The mean affective insta-
bility score in the control
groups was
4.66 points

The mean affective instability score in
the intervention groups was
1.07 standard deviations lower
(1.61 to 0.52 lower)

The mean chronic feelings
of emptiness score in the
control groups was
5.00 points

The mean chronic feelings of empti-
ness score in the intervention groups
was
0.43 standard deviations lower
(0.95 lower to 0.09 higher)

BPD total severity
CGI-BPD1-global
Follow-up: mean 3
months

Anger
CGI-BPD1-anger
Follow-up: mean 3
months

Affective instability
CGI-BPD1-affective in-
stability
Follow-up: mean 3
months

Chronic feelings of
emptiness
CGI-BPD1-emptiness
Follow-up: mean 3
months

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

59
(1 study)

59
(1 study)

59
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

59
(1 study)

⊕⊕⊝⊝
low 2

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

Impulsivity
CGI-BPD1-impulsivity
Follow-up: mean 3
months

The mean impulsivi-
ty score in the control
groups was
4.11 points

The mean impulsivity score in the in-
tervention groups was
0.61 standard deviations lower
(1.14 to 0.09 lower)

Suicidality
CGI-BPD1-suicidality
Follow-up: mean 3
months

Interpersonal prob-
lems
CGI-BPD1-unstable re-
lationships
Follow-up: mean 3
months

Dissociation/psy-
choticism
BPRS3
Follow-up: mean 3
months

The mean suicidality score
in the control groups was
2.55 points

The mean suicidality score in the inter-
vention groups was
0.10 standard deviations lower
(0.61 lower to 0.41 higher)

The mean interpersonal
problems score in the con-
trol groups was
4.44 points

The mean interpersonal problems
score in the intervention groups was
0.29 standard deviations lower
(0.80 lower to 0.23 higher)

The mean dissocia-
tion/psychoticism score in
the control groups was
11.89 points

The mean dissociation/psychoticism
score in the intervention groups was
-0.66 standard deviations lower
(-1.18 to -0.13 lower)

59
(1 study)

59
(1 study)

59
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

59
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Clinical global impression scale for borderline personality disorder patients
2Total sample size less than 400
3Brief psychiatric rating scale

Summary of findings 13.   Emotion regulation group training (ERG) versus treatment as usual (TAU) for borderline personality disorder

ERG compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient

1
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

Intervention: ERG
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

ERG

BPD total severity
BEST1
Follow-up: mean 4.5
months

The mean BPD total sever-
ity score in the control
groups was
34.7 points

The mean BPD total severity score in
the intervention groups was
1.02 standard deviations lower
(1.92 to 0.11 lower)

Affective instability
DERS3-emotional dys-
regulation
Follow-up: mean 4.5
months

Impulsivity
DERS3-impulse
dyscontrol
Follow-up: mean 4.5
months

Parasuicidality
DERS3-self-harm fre-
quency (transformed)
Follow-up: mean 4.5
months

The mean affective insta-
bility score in the control
groups was
115.8 points

The mean affective instability score in
the intervention groups was
1.65 standard deviations lower
(2.65 to 0.65 lower)

The mean impulsivi-
ty score in the control
groups was
17.1 points

The mean impulsivity score in the in-
tervention groups was
1.30 standard deviations lower
(2.24 to 0.36 lower)

The mean parasuicidal-
ity score in the control
groups was
4.48 points

The mean parasuicidality score in the
intervention groups was
0.98 standard deviations lower
(1.88 to 0.09 lower)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

22
(1 study)

22
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

22
(1 study)

⊕⊕⊝⊝
low 2

22
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline Evaluation of Severity over Time
2Total sample size less than 100

1
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
3Difficulties in Emotion Regulation Scale

Summary of findings 14.   Schema-Focused Therapy-Group (SFT-G) versus treatment as usual (TAU) for borderline personality disorder

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

1
9

SFT-G compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: SFT-G
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

SFT-G

BPD total severity
BSI1
Follow-up: mean 8
months

The mean BPD total sever-
ity score in the control
groups was
32.75 points

The mean BPD total severity score in
the intervention groups was
1.66 standard deviations lower
(2.54 to 0.78 lower)

Affective instability
DIB-R3-affect
Follow-up: mean 8
months

The mean affective insta-
bility score in the control
groups was
9.83 points

The mean affective instability score in
the intervention groups was
1.41 standard deviations lower
(2.26 to 0.57 lower)

Impulsivity
DIB-R3-impulses
Follow-up: mean 8
months

The mean impulsivi-
ty score in the control
groups was
5.58 points

The mean impulsivity score in the in-
tervention groups was
1.92 standard deviations lower
(2.85 to 1.00 lower)

The mean interpersonal
problems score in the con-
trol groups was
12 points

The mean interpersonal problems
score in the intervention groups was
1.94 standard deviations lower
(2.87 to 1.02 lower)

interpersonal prob-
lems
DIB-R3-interpersonal
Follow-up: mean 8
months

Dissociation/psy-
choticism
DIB-R3-cognition
Follow-up: mean 8
months

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

28
(1 study)

28
(1 study)

28
(1 study)

28
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

The mean dissocia-
tion/psychoticism score in
the control groups was
4.25 points

The mean dissociation/psychoticism
score in the intervention groups was
1.37 standard deviations lower
(2.21 to 0.53 lower)

28
(1 study)

⊕⊕⊝⊝
low 2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline Syndrome Index
2Total sample size less than 100
3Diagnostic Interview for BPD-Revised

Summary of findings 15.   Systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS) versus
treatment as usual (TAU) for borderline personality disorder

STEPPS compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: STEPPS
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

STEPPS

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

BPD total severity
BEST1
Follow-up: mean 5
months

Affective instability
ZAN-BPD3-affective
subscale
Follow-up: mean 5
months

The mean BPD total sever-
ity score in the control
groups was
34.1 points

The mean BPD total severity score in
the intervention groups was
0.17 standard deviations lower
(0.52 lower to 0.19 higher)

The mean affective insta-
bility score in the control
groups was
4.9 points

The mean affective instability score in
the intervention groups was
0.32 standard deviations lower
(0.67 lower to 0.04 higher)

124
(1 study)

⊕⊕⊕⊝
moderate 2

124
(1 study)

⊕⊕⊕⊝
moderate 2

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

2
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

2
1

Impulsivity
BIS4
Follow-up: mean 5
months

Interpersonal prob-
lems
ZAN-BPD3-disturbed
relations
Follow-up: mean 5
months

Dissociation/psy-
choticism
ZAN-BPD3-cognitive
subscale
Follow-up: mean 5
months

The mean impulsivi-
ty score in the control
groups was
76.8 points

The mean impulsivity score in the in-
tervention groups was
0.29 standard deviations lower
(0.64 lower to 0.07 higher)

The mean interpersonal
problems score in the con-
trol groups was
3.2 points

The mean interpersonal problems
score in the intervention groups was
0.42 standard deviations lower
(0.78 to 0.06 lower)

124
(1 study)

⊕⊕⊕⊝
moderate 2

124
(1 study)

⊕⊕⊕⊝
moderate 2

The mean dissocia-
tion/psychoticism score in
the control groups was
3.00 points

The mean dissociation/psychoticism
score in the intervention groups was
0.42 standard deviations lower
(0.78 lower to 0.06 higher)

124
(1 study)

⊕⊕⊕⊝
moderate 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline Evaluation of Severity over Time
2Total sample size less than 200
3Zanarini rating scale for borderline personality disorder
4Barrett Impulsiveness Scale

Summary of findings 16.   Systems training for emotional predictability and problem solving for borderline personality disorder + individual therapy
(STEPPS+IT) versus treatment as usual (TAU) for borderline personality disorder

STEPPS+IT compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: STEPPS+IT

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

STEPPS+IT

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

BPD total severity
BPD-401
Follow-up: mean 4.5 months

The mean BPD total
severity score in the
control groups was
95.1 points

The mean BPDtotal severity
score in the intervention groups
was
0.55 standard deviations low-
er
(1.11 lower to 0.00 higher)

52
(1 study)

⊕⊕⊝⊝
low 2

Impulsivity
no. of participants scoring above
BPDSI-IV3 impulsivity cut-off score
Follow-up: mean 4.5 months

Parasuicidality
no. of participants scoring above
BPDSI-IV3 parasuicide cut-off score
Follow-up: mean 4.5 months

733 per 1000

682 per 1000
(484 to 946)

RR 0.93 
(0.66 to 1.29)

58
(1 study)

433 per 1000

572 per 1000
(338 to 962)

RR 1.32 
(0.78 to 2.22)

58
(1 study)

Interpersonal problems
WHOQOL-BREF4-social relation-
ships (mean scores multiplied by
-1)
Follow-up: mean 4.5 months

The mean interper-
sonal problems score
in the control groups
was
-12.00 points

The mean interpersonal prob-
lems score in the intervention
groups was
0.27 standard deviations low-
er
(0.81 lower to 0.27 higher)

53
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Borderline Personality Disorder Checklist-40
2Total sample size less than 100

2
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

3Borderline Personality Disorder Severity Index
4World Health Organization Quality of Life Assessment-Bref

Summary of findings 17.   Manual-assisted cognitive treatment (MACT) versus treatment as usual (TAU) for borderline personality disorder

MACT compared to TAU for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: MACT
Comparison: TAU

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

MACT

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Suicidality
SBQ1
Follow-up: mean 1.5
months

Parasuicidality
PHI3-deliberate self-
harm frequency
Follow-up: mean 1.5
months

The mean suicidality score
in the control groups was
17.67 points

The mean suicidality score in the inter-
vention groups was
0.86 standard deviations lower
(1.63 to 0.07 lower)

The mean parasuicidal-
ity score in the control
groups was
3.63 points

The mean parasuicidality score in the in-
tervention groups was
0.88 standard deviations lower
(1.67 to 0.10 lower)

28
(1 study)

28
(1 study)

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Suicidal Behaviours Questionnaire
2Total sample size less than 100
3Parasuicide History Interview

2
3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Summary of findings 18.   Psychoeducation (PE) versus waiting list (WL) for borderline personality disorder

Psychoeducation compared to waiting list for borderline personality disorder

Patient or population: patients with borderline personality disorder
Settings: outpatient
Intervention: psychoeducation
Comparison: waiting list

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Waiting list

Psychoeducation

The mean impulsivi-
ty score in the control
groups was
0.05 points

The mean impulsivity score in the in-
tervention groups was
0.47 standard deviations lower
(1.04 lower to 0.10 higher)

The mean interperson-
al problems score in the
control groups was
-0.05 points

The mean interpersonal problems
score in the intervention groups was
0.75 standard deviations lower
(1.33 to 0.16 lower)

Impulsivity
ZAN-BPD1-impulsivi-
ty baseline to endpoint
change
Follow-up: mean 3
months

Interpersonal problems
ZAN-BPD1-stormy rela-
tionships baseline to end-
point change
Follow-up: mean 3
months

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

50
(1 study)

⊕⊕⊝⊝
low 2

50
(1 study)

⊕⊕⊝⊝
low 2

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Zanarini Rating scale for Borderline Personality Disorder
2Total sample size less than 100

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

2
4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

According  to  current  diagnostic  criteria,  borderline  personality
is  characterised  by  a  pervasive  pattern  of
disorder  (BPD) 
instability  in  affect  regulation,  impulse  control,  interpersonal
relationships and self-image. Clinical hallmarks include emotional
dysregulation,  impulsive  aggression,  repeated  self-injury  and
chronic  suicidal  tendencies  (Lieb  2004).  Whereas  some  authors
have suggested that BPD is a variant of affective disorders (Akiskal
2004),  others  claim  only  partially  overlapping  aetiologies  (Paris
2007).  Despite  its  controversial  nature,  borderline  personality
disorder is the focus of great interest. Its importance stems from the
huge suffering of the persons concerned, the functional impairment
(Skodol  2002)  caused  and  from  the  significant  impact  it  has  on
mental health services (Zanarini 2004Zanarini 2004a).

The  Diagnostic  and  Statistical  Manual  of  Mental  Disorders  (DSM-
IV-TR)  (APA  2000a)  definition  of  BPD  comprises  nine  criteria
that  cover  the  above  features;  for  a  definite  diagnosis  five  of
these  must  be  met,  and  a  probable  diagnosis  requires  four.  The
competing International Classification of Diseases in its 10th edition
(ICD-10) refers to the condition 'Emotionally Unstable Personality
Disorder'  (F60.3),  of  which  there  is  an  impulsive  type  (F60.30)
and a borderline type (F60.31) (WHO 2003). The latter essentially
overlaps with the DSM-IV definition of BPD. A significant problem
with  this  type  of  definition  is  that  it  is  possible  for  two  people
to  satisfy  the  criteria  and  yet  have  very  different  personalities.
This heterogeneity is a major problem in assessing the impact of
an intervention. Additional to the specific BPD criteria, DSM-IV-TR
and ICD-10 provide general diagnostic criteria for any personality
disorder that must also be met.

The  prevalence  of  BPD  is  estimated  at  about  1.5%  in  the
general  population  (Torgersen  2005),  but  higher  (up  to  20%)
among  psychiatric  inpatients  and  prison  populations,  and  it  is
predominantly  diagnosed  in  women  (75%;  APA  2000APA  2000a).
There  are  particular  problems  with  its  diagnosis  in  adolescents
and young adults where existential dilemmas may mistakenly be
classified  as  BPD  (DSM-IV).  BPD  commonly  co-occurs  with  mood
disorders, substance misuse, eating disorders and post-traumatic
stress disorder (PTSD), and is also associated with other personality
disorders  (McGlashan  2000).  Recent  findings  also  suggest  a  close
association between BPD and adult attention-deficit/hyperactivity
disorder (ADHD). Prevalence estimates of comorbid adult ADHD in
people with BPD range from 16% (Philipsen 2008) up to 38% (Ferrer
2010), and genetic analyses underline a genetic correlation of traits
of  both  disorders  (Distel  2011).  Suicidal  behaviour  is  reported  to
occur in up to 84% of patients with BPD (Soloff 2002), with comorbid
mood  disorders  or  substance  use  being  the  most  relevant  risk
factors for completion (Black 2004).

Although  the  short-  to  medium-term  outcome  of  BPD  is  poor,
similar  to  that  of  schizophrenia,  there  is  some  evidence  that  the
long-term follow-up course is more favourable with remission rates
of about 88% within 10 years (Zanarini 2007). However, remission
here only means that diagnostic criteria are not fulfilled and not the
absence of any symptoms. Indeed, whereas acute symptoms, such
as  self-mutilation,  help-seeking  suicide  threats  or  attempts  and
impulsivity decrease with time in most cases, affective symptoms
reflecting  areas  of  chronic  dysphoria,  such  as  chronic  feelings
of  emptiness,  intense  anger  or  profound  abandonment,  largely

Cochrane Database of Systematic Reviews

remain  (Zanarini  2007).  The  majority  of  people  with  BPD  thus
continue to experience significant levels of symptoms. Risk factors
for  a  poorer  long-term  outcome  are  a  comorbid  substance  use
disorder; PTSD; an anxious cluster disorder (Zanarini 2005, Zanarini
2007);  family  history  of  psychiatric  disorder  (especially  mood
disorder  and  substance  use  disorder),  and  demographic  factors,
such as older age, longer treatment history, pathological childhood
experiences, temperament problems and poor adult psychosocial
functioning (Zanarini 2007). It is estimated that about 60% to 70%
of  patients  with  BPD  make  suicide  attempts,  although  the  rate
of  completed  suicides  is  far  less.  Zanarini  and  colleagues  found
suicide rates of 4% during a 10-year follow-up (Zanarini 2007).

Description of the intervention

Psychotherapeutic interventions for BPD encompass a broad range
of  treatments.  As  for  any  other  mental  disorder,  established
psychotherapies  from  the  major  psychotherapeutic  schools  are
used, such as psychodynamic psychotherapy, cognitive behaviour
therapy  (CBT)  or  client-centered  therapy.  In  addition,  several
specific  psychotherapeutic  approaches  have  been  developed  in
the  last  decades  to  meet  the  challenges  of  BPD  treatment.
These  disorder-specific  approaches  are  based  on  principles  of
the  established  psychotherapeutic  schools,  but  they  are  usually
precisely  structured  and  manualised.  Strategies  are  provided  for
addressing interpersonal difficulties, which are a core problem for
people with BPD and lead to difficulties in forming a therapeutic
alliance.  Most  BPD-specific  psychotherapies  include  treatment
contracts,  actively  take  measures  to  minimise  premature  non-
completion of treatment and provide a crisis intervention protocol
(De Groot 2008).

Among  the  psychological  interventions  used  with  people  with
BPD,  the  most  commonly  used  are  transference-focused  therapy
(TFP),  dialectical  behaviour  therapy  (DBT),  mentalisation-based
treatment (MBT), schema-focused therapy (SFT) and the systems
training 
for  emotional  predictability  and  problem  solving
(STEPPS).  Most  of  these  treatments  are  designed  as  outpatient
psychotherapies  of  six  to  12  months  duration  with  one  or  two
weekly  individual  sessions.  Some  also  include  additional  group
therapy sessions.

In  this  review,  we  categorise  therapies  involving  substantial  one-
to-one work as 'comprehensive' and those without this element as
'non-comprehensive'.

How the intervention might work

According to the treatment guidelines of the American Psychiatric
Association (APA), "clinical experience suggests that most patients
with  borderline  personality  disorder  will  need  some  form  of
extended psychotherapy in order to resolve interpersonal problems
and attain and maintain lasting improvements in their personality
and overall functioning" (APA 2001, p.18), whereas drug treatment
is accredited an adjunctive role.

Psychotherapeutic  treatments  are  based  on  their  specific
assumptions about the aetiology and maintenance of the disorder.
Broadly  speaking,  psychoanalytic  therapies  aim  to  help  their
patients  understand  and  reflect  on  their  inner  mental  processes
and  make  links  between  their  past  and  current  difficulties.
Treatments based on CBT place emphasis on self-directed learning
processes;  patients  are  encouraged  to  identify  their  core  beliefs,

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

evaluate  and  modify  their  behaviour  accordingly  and  gain  new
experiences.

As mentioned previously, numerous disorder-specific approaches
have  been  derived  from  the  major  psychotherapeutic  schools.
Some  of  the  most  prominent  are  dialectical  behavioural
therapy,  mentalisation-based  therapy,  schema-focused  therapy
and transference-focused psychotherapy.

Dialectical behavioural therapy (DBT) (Linehan 1993) is a complex
psychological  intervention  that  was  developed  using  some  of
the  principles  of  CBT  in  combination  with  mindfulness-based
and  systemic  strategies.  It  aims  to  change  behaviour  and  the
ability to contain difficult feelings by focusing on improving skills,
stress tolerance, emotion regulation, interpersonal behaviour and
mindfulness.

Mentalisation-based  therapy  (MBT)  (Bateman  2004)  is  a  complex
psychoanalytically-based psychological intervention that aims to
increase  the  reflective  or  mentalising  capacity  of  the  individual,
helping the person to understand and recognise the feelings they
evoke in others and the feelings they experience themselves.

Schema-focused  therapy  (SFT)  (Young  2003)  draws  from  both
behavioural  and  psychoanalytic  theories  and  helps  people  with
BPD to identify their self-defeating core themes arising from unmet
emotional  needs  in  childhood  and  presenting  as  maladaptive
coping  styles  in  adulthood.  The  goal  of  SFT  is  to  aid  patients  in
getting their needs met.

Transference-focused psychotherapy (TFP) (Clarkin 1999) strives to
achieve integrated representations of self and others, modification
of primitive defence operations and resolution of identity diffusion
by analysis of the transference within the therapeutic relationship.
Primitive  object  relations  (for  example,  split,  polarised)  may
be  transformed  to  advanced  ones  (for  example,  differentiated,
integrated).

In summary, psychotherapeutic approaches claim slightly different
mechanisms  of  action,  according  to  their  underlying  specific
aetiology  models.  A  common  element  is  that  they  aim  to
ameliorate  BPD  pathology  by  use  of  verbal  communication.
Psychoanalytically-based  therapies  usually  emphasise  and  use
the  therapeutic  relationship  as  a  model  for  other  relationships,
whereas  cognitive  behaviour  therapy-based  therapies  primarily
aim  at  acquiring  new  learning  experiences  and  general  self-
management skills.

Why it is important to do this review

In  addition  to  the  suffering  experienced  by  people  with  BPD  and
their relatives, considerable direct costs arise from the significant

Cochrane Database of Systematic Reviews

demands they make on health professionals. In medical settings,
people  with  BPD  often  present  after  having  self-harmed  or  in
suicidal crisis and are treated in emergency settings. In many cases,
repeated psychiatric hospitalisations occur. Additionally, according
to a US study more than 80% of patients with BPD are in individual
psychotherapy for at least half of a six-year period (Zanarini 2004),
though  treatment  settings  and  provisions  for  patients  with  BPD
vary across different countries. However, it remains unclear which
treatments  are  helpful.  This  review  aims  to  provide  a  systematic
summary of the evidence from randomised controlled trials to help
people  with  BPD  and  their  health  care  workers  make  informed
decisions about their treatment.

This is an update of a Cochrane review previously published in 2006
(Binks  2006).  At  that  time,  the  authors  concluded  that  "some  of
the  problems  frequently  encountered  by  people  with  borderline
personality  disorder  may  be  amenable  to  talking/behavioural
treatments but all therapies remain experimental and the studies
are too few and small to inspire full confidence in their results." A
number of new studies on this topic has become available in the
meantime, so that an update of the evidence seems timely.

O B J E C T I V E S

To  evaluate  the  effects  of  psychological  interventions  for  people
with borderline personality disorder (BPD).

M E T H O D S

Criteria for considering studies for this review

Types of studies

studies 

involving  parallel-arm 

Randomised 
comparisons
examining  psychotherapeutic  interventions  for  people  with  BPD
were included. Data from randomised cross-over studies up to the
point of first cross-over were eligible for inclusion (first phase only).
We  excluded  data  from  subsequent  phases  of  cross-over  trials
because of the characteristically unstable course of BPD. In studies
where  participants  served  as  their  own  controls  (within-subject
comparisons), we used first period data only (Elbourne 2002). For
further details, see Unit of analysis issues.

Types of participants

Adults (aged 18 years or over) with a diagnosis of BPD according
to  DSM  criteria  (see  table  below),  however  diagnosed.  Since  the
introduction of the diagnosis in 1980, the operational criteria have
only changed marginally. Studies in which at least 70% participants
had a formal diagnosis of BPD were included.

DSM-III ( APA 1980 )

DSM-IV-TR ( APA 2000 )

301.83 Borderline Personality Disorder

301.83 Borderline Personality Disorder

Diagnostic criterion A (5 of the following are required)

Diagnostic criterion A: A pervasive pattern of instability of inter-
personal relationships, self-image, and affects, and marked im-
pulsivity beginning by early adulthood and present in a variety
of contexts, as indicated by five (or more) of the following:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(6) intolerance of being alone, e.g., frantic efforts to avoid being
alone, depressed when alone

(1) frantic efforts to avoid real or imagined abandonment - note:
do not include suicidal or self-mutilating behavior covered in cri-
terion 5

(2) a pattern of unstable and intense interpersonal relation-
ships, e.g., marked shifts of attitude, idealization, devaluation,
manipulation (consistently using others for one's own ends)

(2) a pattern of unstable and intense interpersonal relationships
characterized by alternating between extremes of idealization and
devaluation

(4) identity disturbance manifested by uncertainty about sever-
al issues relating to identity, such as self-image, gender identi-
ty, long-term goals or career choice, friendship patters, values,
and loyalties, e.g., 'Who am I', 'I feel like I am my sister when I
am good'

(3) identity disturbance: markedly and persistently unstable self-
image or sense of self 

(1) impulsivity or unpredictability in at least two areas that are
potentially self-damaging, e.g., spending, sex, substance use,
shoplifting, overeating, physically self-damaging acts

(4) impulsivity in at least two areas that are potentially self-dam-
aging (e.g., spending, sex, substance abuse, reckless driving, binge
eating) - note: do not include suicidal or self-mutilating behavior
covered in criterion 5

(7) physically self-damaging acts, e.g., suicidal gestures, self-
mutilation, recurrent accidents or physical fights

(5) recurrent suicidal behavior, gestures, or threats, or self-muti-
lating behavior 

(5) affective instability: marked shifts from normal mood to de-
pression, irritability, or anxiety, usually lasting a few hours and
only rarely more than a few days, with a return to normal mood

(6) affective instability due to a marked reactivity of mood (e.g., in-
tense episodic dysphoria, instability, or anxiety usually lasting a
few hours and only rarely more than a few days)

(8) chronic feelings of emptiness or boredom

(7) chronic feelings of emptiness

(3) inappropriate, intense anger or lack of control of anger, e.g.,
frequent displays of temper, constant anger

(8) inappropriate, intense anger or difficulty controlling anger
(e.g., frequent displays of temper, constant anger, recurrent physi-
cal fights)

(9) transient, stress-related paranoid ideation or severe dissociate
symptoms

Diagnostic criterion B: If under 18, does not meet the criteria
for Identity Disorder

Types of interventions

Experimental interventions

according to classes of interventions, and defined these classes as
follows:

Experimental  interventions  comprised  any  well-defined,  theory-
driven  psychotherapeutic  treatment.  According  to  the  index  of
Medical Subject Headings (MeSH), the thesaurus of the US National
Library  of  Medicine's  controlled  vocabulary,  psychotherapy  was
defined as "treatment of mental illness or emotional disturbances
primarily  by  verbal  or  nonverbal  communication"  (NLM  2009).
We  considered  all  types  of  psychotherapy,  regardless  of
theoretical orientation or treatment setting, including, for example,
psychodynamic  therapy,  CBT,  systemic  therapy  or  eclectic
therapies designed for BPD treatment. We also included any kind
of  treatment  setting,  that  is,  inpatient,  outpatient  or  partially
hospitalised. Trials on relaxation techniques and patient education
programs were also eligible.

After all relevant trials had been identified and the variety of types
of  interventions  became  clear,  we  decided  to  arrange  the  results

comprehensive 

a) 
individual
psychotherapies: 
psychotherapy  as  substantial  part  of  the  intervention;  additional
group  therapy  may  or  may  not  be  included;  duration  of  at  least
three months;

includes 

b) non-comprehensive psychotherapeutic interventions: does not
include  individual  psychotherapy  as  a  substantial  part  of  the
intervention.

If the same interventions were tested in different settings (that is,
outpatient, inpatient, partially hospitalised), we did not pool them
together but treated them as different kinds of interventions.

Comparator interventions

Eligible comparator interventions were grouped as follows:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

• unspecific control interventions; includes clinical management
(CM), standard care (SC), treatment as usual (TAU) or waiting list
(WL) (these are conditions without any specific mode of action);
• comparative  specific  psychotherapeutic  interventions;  well-

defined and theory-driven (head-to-head comparison).

Concomitant  drug  treatment  was  allowed  if  applied  to  both
treatment conditions.

Types of outcome measures

Outcomes  were  either  self-rated  or  interviewer-assessed.  Only
adequately validated measures were included. Studies were only
included  if  they  provided  data  that  could  be  used  for  effect  size
calculation for at least one of the primary or secondary outcomes
defined below.

If a study provided more than one measure for the same construct
(for  example,  depression),  the  measure  most  often  used  in  the
whole pool of included studies was used for effect size calculation
in  order  to  minimise  heterogeneity  of  outcomes  in  form  and
content. If a study reported the data of two assessment instruments
that  were  equally  frequently  used,  two  review  authors  (JS,  BV)
discussed the issue and chose the one that they judged was most
adequate for assessment of patients with BPD. Self-rated measures
were  preferred.  We  combined  self-  and  observer-rated  measures
in  the  same  analysis  if  no  self-reported  measure  was  available
and  it  seemed  appropriate  to  do  so  in  terms  of  content  validity.
The  possibility  of  heterogeneity  was  examined  by  considering  I2
values  and  a  visual  inspection  of  forest  plots  (see  Assessment  of
heterogeneity).

Primary outcomes

The following outcomes were defined as primary outcomes.

• Overall BPD severity
• Severity of single BPD criteria according to DSM, subsumed into

the following symptom clusters:
◦ affective dysregulative cluster symptoms

▪ anger
▪ affective instability
▪ chronic feelings of emptiness

◦ impulsive cluster symptoms

▪ impulsivity
▪ suicidality:  severity  of  intent  of  killing  oneself.  Includes
continuous  measures  of  intent  severity  or  numbers  of
suicidal acts and dichotomous measures of proportions of
participants with suicidal acts.

▪ parasuicidality:  tendency  or  severity  of  intent  of  doing
self-inflicted  harm.  Includes  continuous  measures  of
severity  and  dichotomous  measures  of  proportion  of
participants with parasuicidal episodes.

◦ interpersonal cluster symptoms

▪ interpersonal problems general
▪ avoidance of abandonment

◦ cognitive cluster symptoms
▪ identity disturbance
▪ dissociation/stress-related paranoid ideation

Cochrane Database of Systematic Reviews

Secondary outcomes

• Depression
• Anxiety
• General  psychopathology:  composite  measures  of  current

general psychpathology)

• Mental  health  status/functioning:  measures  of  general
psychosocial  functioning  on  a  hypothetical  continuum  of
mental health to mental illness or full function to disability.

• Leaving the study early
• Adverse effects

Search methods for identification of studies

Electronic searches

We searched the following databases.

• Cochrane Central Register of Controlled Trials (CENTRAL), 2010,

Issue 3, part of The Cochrane Library

• MEDLINE, 1950 to current, searched 15 October 2010
• EMBASE, 1980 to 2010, Week 39, searched 15 October 2010
• ASSIA, 1987 to current, searched 17 November 2010
• BIOSIS, 1985 to current, searched 12 October 2010
• CINAHL, 1982 to current, searched 8 October 2010
• Dissertation Abstracts International, searched 31 January 2011
• ICTRP, searched August 2011
• metaRegister of Controlled Trials, searched 15 October 2010
• National Criminal Justice Reference Service Abstracts, searched

15 October 2010

• PsycINFO, 1872 to October Week 1 2010
• Science Citation Index, 1970 to 10 October 2010
• Social Science Citation Index, 1970 to 10 October 2010
• Sociological  Abstracts,  1963  to  current,  searched  11  October

2010

• Zetoc (conference search), searched 15 October 2010

We  included  search  terms  for  all  types  of  personality  disorder  in
the search strategy as this is one of a series of personality disorder
reviews.  Search  terms  and  syntax  were  modified  as  necessary
for  each  database  (Appendix  1).  There  were  no  restrictions  on
language, date or document format.

Searching other resources

Relevant journals such as the Journal of Personality Disorders, the
American Journal of Psychiatry, Archives of General Psychiatry, the
British Journal of Psychiatry and the Journal of Clinical Psychiatry
were  surveyed  on  a  regular  basis.  Additionally,  we  contacted
the  lead  authors  of  published  RCTs  via  e-mail  and  kept  track  of
any  developments  presented  at  relevant  international  meetings
including  the  conferences  of  the  International  Society  for  the
Study  of  Personality  Disorders  (ISSPD;  ISSPD  2007;  ISSPD  2009;
ISSPD  2011)  and  the  1st  International  Congress  of  the  European
Society for the Study of Personality Disorders (ESSPD 2010). We also
searched  trial  registers  in  order  to  identify  any  ongoing  research
(see  Appendix  2).  Cross-references  from  relevant  literature  were
also traced.

'Summary  of  findings'  tables  are  provided  for  the  primary
outcomes.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Data collection and analysis

Selection of studies

Database and clinical trial register searches yielded 38,701 records,
which were imported into ProCite reference management software.
After  electronic  and  manual  deduplication,  there  were  28,535
records. We used the global search in ProCite to identify obviously
irrelevant records (for example, about "borderline hypertension" or
"borderline fractures"). The remaining 2458 records were divided

up  amongst  various  review  authors  (NH,  MF,  NS,  MP)  to  assess
study eligibility using titles and abstracts. All were double-checked
by  a  second  review  author  (JD).  After  exclusion  of  1955  records,
the remaining 503 references were made available in full text and
assessed  by  two  review  authors  independently  (JD,  JS).  At  this
stage, multiple reports of the same study were linked together. If
the two review authors disagreed, a third person (BV) adjudicated
upon inclusion or exclusion. At the end of this process, 91 records
for 28 RCTs were included in quantitative synthesis (see Figure 1)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

Data extraction and management

Data were independently extracted by two review authors (JS, BV)
using  standardised  data  extraction  forms  and  double-entry  into
the  Review  Manager  software.  Any  discrepancies  were  resolved
through  discussion  or,  if  required,  by  an  adjudicator  (KL).  We
contacted study authors where publications reported incomplete
data or where relevant subsample data were lacking.

Assessment of risk of bias in included studies

Risk of bias was assessed using The Cochrane Collaboration's tool
for  assessing  risk  of  bias  (Higgins  2011).  Assessments  included
ratings  of  the  likelihood  for  selection  bias  (random  sequence
generation,  concealment  of  allocation),  detection  bias  (blinding
of  outcome  assessors),  reporting  bias  (selective  reporting),
performance  bias  (treatment  adherence),  bias  due  to  allegiance
effects and attention bias.

Selection bias and reporting bias were assessed using the criteria
for  judging  respective  risks  of  bias  as  delineated  in  the  Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).

Though  the  importance  of  blinding  and  the  possibility  of  bias
due  to  lack  of  blinding  are  beyond  question,  it  is  still  unclear
how  this  issue  should  best  be  dealt  with  in  research  practice
(Boutron 2008). We did not judge the likelihood of detection bias
due  to  inadequate  blinding  of  patients  and  personnel,  since  in
psychotherapy  outcome  research  it  is  quite  impossible  to  blind
therapists and patients, and both also need to be informed about
theoretical  frameworks  of  the  therapy  provided  to  gain  an  in-
depth understanding of the conditions and postulated mechanisms
of  change.  However,  if  interviewer-rated  measures  were  used,
we  assessed  the  likelihood  of  detection  bias  due  to  inadequate
blinding of outcome assessors.

In addition, we assessed the likelihood of performance bias due to
inadequate treatment adherence. The risk of bias was judged low
if any means had been undertaken to assure adequate treatment
adherence, for example, by regular supervision or use of adherence
ratings of videotaped or audiotaped therapy sessions.

Psychotherapy trials are especially prone to bias due to "allegiance
bias".  That  means,  that  "despite  care  in  design,  the  therapeutic
allegiance  of  the  experimenter  might  in  some  way  influence
the  results"  (Luborsky  1975,  p.  1003).  However,  the  existence  of
the allegiance bias hypothesis, that advantageous findings result
from the investigators' allegiances rather than from their inherent
superiority, has yet to be proved (Leykin 2009).

Last,  the  likelihood  of  bias  due  to  different  amounts  of  attention
given to the treatment groups was rated (attention bias). Findings
of  beneficial  effects  by  one  treatment  may  primarily  result  from
simply being paid attention to or being provided with any kind of
intervention  rather  than  from  a  specific  mechanism  of  action.  If
there was a substantial difference of attention, this was regarded as
possibly introducing bias, irrespective of other treatment options
the participants may have used from other providers.

The  'Risk  of  bias'  tool  was  applied  by  two  review  authors
independently (JS, BV), and discrepancies were discussed in order
to  arrive  at  a  consensus.  A  third  person  (KL)  could  have  been
called upon, but that was not necessary. All 'Risk of bias' domains
mentioned  above  were  included  in  a  graph  (see  Figure  2)  and
summary (Figure 3). Trials were included irrespective of risk of bias,
but possible impacts on effect estimates are discussed (see Quality
of the evidence).

Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of outcome assessment (detection bias): All outcomes
Selective reporting (reporting bias)
Treatment adherence?
Allegiance effect improbable?
Attention bias: equal amounts of attention to all groups (obligatory treatment components)?

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study

?
)
s
t
n
e
n
o
p
m
o
c

t
n
e
m
t
a
e
r
t

y
r
o
t
a
g
i
l
b
o
(

s
p
u
o
r
g

l
l
a

o
t

n
o
i
t
n
e
t
t
a

f
o

s
t
n
u
o
m
a

l
a
u
q
e

:
s
a
i
b
n
o
i
t
n
e
t
t

A

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b
n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o
f
o
g
n
i
d
n
i
l

B

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(

n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s
m
o
d
n
a
R

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

)
s
a
i
b
g
n
i
t
r
o
p
e
r
(

g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

?
e
l
b
a
b
o
r
p
m

i

t
c
e
f
f
e

e
c
n
a
i
g
e
l
l

A

?
e
c
n
e
r
e
h
d
a

t
n
e
m
t
a
e
r
T

Bateman 1999
Bateman 2009
Bellino 2006
Bellino 2007
Bellino 2010
Blum 2008
Bos 2010
Carter 2010
Cottraux 2009
Davidson 2006
Doering 2010
Farrell 2009
Giesen-Bloo 2006
Gratz 2006
Gregory 2008
Koons 2001

+ + + ? + -
-
+ + + + + - +
- + -
+ + + ?
+ + + ? + + +
- + -
+ ? + ?
-
+ + -
? + -
+ + -
? + + -
+ + + ? ? + -
+ + + + + + +
-
+ + + + + -
+ + + + + ? +
-
+ ?
+ + + ? + + +
-
+ ? + ? ?
+ + + + + - +
? ? + ? + + +

? + -

-

-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Gregory 2008
Koons 2001
Linehan 1991
Linehan 1994
Linehan 2006
McMain 2009
Morey 2010
Nadort 2009
Soler 2009
Steil 2010
Turner 2000
Van den Bosch 2005
Weinberg 2006
Zanarini 2008

? ? + ? + + +
+ ? + ? + -
-
-
+ ? + ? + -
+ + + ? + - +
-
+ + + + + ?
? ? ? ? + + +
? + ? + ? + +
+ ? + ? ? + +
+ + + + + -
-
? ? + ? + + -
-
+ ? + ? + ?
? ? + + - + -
-
? ? ? ? ?

-

Measures of treatment effect

Continuous data

Standardised mean differences (SMDs) were calculated on the basis
of  post-treatment  group  results.  If  the  direction  of  a  scale  was
opposite  to  most  of  the  other  scales,  the  corresponding  mean
values were multiplied by -1. Following (Cohen 1988), SMD scores
around 0.20 were regarded small, scores of 0.50 as moderate and
scores of 0.80 or more as large.

In single studies, for example Giesen-Bloo 2006, effect sizes could
not be calculated for some outcomes since data were not reported
in a format usable for SMD calculation.

Dichotomous data

intention-to-treat 

Regarding  dichotomous  outcomes,  the  risk  ratio  (RR)  was
(ITT)  basis.  We  made
computed  on  an 
the  conservative  assumption  that  all  participants  who  were  lost
to  post-treatment  assessment  had  an  unfavourable  outcome,  for
example,  they  had  left  because  the  treatment  had  not  been
acceptable  for  them.  All  calculations  were  done  using  the  latest
release of the Review Manager software (RevMan 2011).

Unit of analysis issues

Repeated observations

have  sought  direct  estimates  of  the  effect  (for  example,  an  odds
ratio  with  its  confidence  interval)  from  an  analysis  that  properly
accounted  for  the  cluster  design.  Alternatively,  we  would  have
extracted or calculated effect estimates and their standard errors
as  for  a  parallel  group  trial  and  adjusted  the  standard  errors  to
account for the clustering (Donner 1980). This would have required
information  on  an  intra-class  correlation  coefficient  (ICC),  which
describes  the  relative  variability  in  outcome  within  and  between
clusters (Donner 1980). We would have extracted this information
from the articles if available; otherwise, we would have contacted
the  authors  or  used  external  estimates  obtained  from  similar
studies.  We  would  have  searched  for  closest  matching  scenarios
(with  regard  to  both  outcome  measures  and  types  of  clusters)
from existing databases of ICCs (Ukoumunne 1999) and if we had
been unable to identify any, we would have performed sensitivity
analyses  using  a  high  ICC  of  0.1,  a  moderate  ICC  of  0.01  and  a
small  ICC  of  0.001.  We  recognise  that  these  values  are  relatively
arbitrary but would have preferred to use them to adjust the effect
estimates and their standard errors due to the implausibility that
the  ICC  is  actually  zero.  Subsequently,  we  would  have  combined
the estimates and their corrected standard errors from the cluster-
randomised trials with those from parallel designs using the generic
inverse variance method in Review Manager 5 (RevMan 2011).

None  of  the  included  studies  applied  a  cluster-randomisation
procedure.

Study estimates were calculated on basis of post-treatment group
results. Interim observations were not used.

Multi-arm trials

Cross-over trials

Elbourne 2002

Though  cross-over  studies  were  eligible,  no  such  study  was
available for inclusion. See Appendix 3 for information about future
updates of this review.

Cluster-randomised trials

We  intended  to  follow  the  guidance  on  statistical  methods  for
cluster-randomised trials described in the Cochrane Handbook for
Systematic  Reviews  of  Interventions  (Higgins  2011a).  We  would

We would have included all eligible outcome measures for all trial
arms  in  this  review.  If  there  had  been  more  than  two  arms  of  a
trial  meeting  the  inclusion  criteria,  each  referring  to  a  different
treatment, we would have included them as different comparisons
(Higgins 2011a). If two or more arms referred to the same type of
treatment, we would have combined these groups to create a single
pair-wise comparison (Higgins 2011b).

There were no multi-arm trials.

Dealing with missing data

In cases of incomplete reporting of outcomes stated as having been
assessed, we contacted the study authors.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Effect  sizes  were  preferably  calculated  on  the  basis  of  ITT  data.
If  only  available  case  analysis  (ACA)  data  were  reported,  we
calculated effect sizes on this basis. In case of dichotomous data
that  were  not  presented  on  the  basis  of  ITT  data,  the  number  of
participants lost in each group were added to the participants with
unfavourable results, acting on the assumption that most patients
with BPD do not get lost at random.

For  continuous  outcomes  we  used  per  protocol  analysis  as
available  from  the  reports  (that  is,  results  are  based  on  the
number  of  patients  at  follow-up).  If  data  were  not  reported  in
an immediately usable way but required processing before being
analysed, a statistician (GR) was consulted. This was the case for the
study of Blum 2008 where standard deviations of mean values had
to be calculated from standard errors.

such  as  depression,  addictive  behaviour  or  post-traumatic
stress  disorder,  having  undergone  psychotherapy  previously)  or
treatment  characteristics  (duration  less  or  more  than  one  year)
could not be performed due to lack of studies.

There were only single studies available per comparison except for
DBT versus TAU (Analysis 1.2; Analysis 1.8; Analysis 1.17; Analysis
1.18).  The  DBT  versus  TAU  studies  studies  did  not  vary  clinically
with regard to predefined subgroup criteria, so we did not perform
subgroup analyses.

Statistical heterogeneity in terms of an I2score exceeding 75% was
only found for one analysis (Analysis 1.18). We discussed reasons
(Effects of interventions, 1.1.9) and undertook a post-hoc sensitivity
analysis (Analysis 1.19).

Assessment of heterogeneity

Sensitivity analysis

We assessed studies for clinical homogeneity with respect to type of
therapy, therapy setting and control group. For any studies judged
as  clinically  homogeneous  and  adequate  for  pooling,  statistical
heterogeneity  was  investigated  by  both  visual  inspection  of  the
graphs  and  the  I2  statistics  (Higgins  2003).  An  I2  score  of  >  75%
was regarded as representing considerable heterogeneity (Higgins
2011c).

We  intended  to  carry  out  meta-analyses  even  if  there  was
substantial  concern  about  heterogeneity,  but  to  interpret  the
results with caution, discuss possible reasons and investigate them
by conducting subgroup analyses.

Assessment of reporting biases

We  planned  to  use  funnel  plots  for  comparisons  with  sufficient
primary  studies.  No  single  comparison  included  sufficient  effect
estimates to allow for drawing of a conclusive funnel plot.

However,  we  drew  a 
for  the  one  outcome
funnel  plot 
(parasuicidality)  for  which  data  were  available  from  18  out  of
the  22  included  controlled  comparisons.  Some  studies  reported
continuous  and  some  dichotomous  measures,  but  the  majority
used  continuous  measures;  we  therefore  decided  to  re-express
dichotomous outcomes as SMDs using the approach of Chinn 2000.

Data synthesis

If  several  effect  estimates  were  available,  these  were  pooled  and
their 95% confidence interval (CI) calculated. The random-effects
model  was  used,  as  some  degree  of  clinical  heterogeneity  was
present in most cases.

Separate  comparisons  were  performed  by  type  of  intervention,
that  is,  all  approaches  were  analysed  separately  (for  example,
DBT  versus  control,  MBT  versus  control),  as  were  comparisons
of  the  same  type  of  psychotherapy  to  different  kinds  of  controls
(for  example,  DBT  versus  treatment  as  usual;  DBT  versus  general
management). In addition, separate comparisons were done if the
same psychotherapy was delivered in different treatment settings
(that  is,  MBT-partially  hospitalised  setting  versus  control,  MBT-
outpatient versus control).

Subgroup analysis and investigation of heterogeneity

to  participant
Pre-planned 
characteristics (sex, presence of distinct psychiatric comorbidities

subgroup  analyses  according 

Sensitivity analyses for the primary outcomes were planned to be
performed as follows.

• Trials  requiring  participants  to  have  a  certain  psychiatric

comorbidity in addition to BPD were to be excluded.
• Only ITT-data based outcomes were to be included.

Given  the  small  numbers  of  effect  estimates  per  comparison
and  outcome,  we  did  not  conduct  sensitivity  analyses,  as  this
would  only  have  led  to  omitting  results.  Instead,  we  strived  to
make  trial  characteristics  as  well  as  all  potential  shortcomings
of  methodological  quality  explicit  (compare  Characteristics  of
included studies tables and Risk of bias in included studies section
of  the  Description  of  studies  section)  and  to  critically  discuss  all
findings.

R E S U L T S

Description of studies

Results of the search

All  electronic  databases  and  search  periods  are  listed  in  the
Methods  section  (see  Electronic  searches)  and  in  Appendix  1
and  Appendix  2.  There  were  no  language,  date  or  document
format 
is  part  of  a  series  of
review 
reviews  on  interventions  for  personality  disorders  and  so  a
very  comprehensive  search  strategy  was  used  covering  all
psychotherapeutic  and/or  pharmacological  treatment  of  any
personality disorder.

restrictions.  This 

The searches generated 38,701 records altogether, of which 10,166
were identified as duplicates. After screening of titles and abstracts,
503  citations  merited  closer  inspection.  Assessment  of  full  texts
lead  to  the  exclusion  of  362  records:  164  were  not  trials;  143  did
not have psychotherapy as the intervention; 30 were not RCTs, and
25  were  excluded  on  the  grounds  of  sample  characteristics.  This
left 141 records. 32 of those records related to 28 different ongoing
studies  (see  Ongoing  studies).  Eighteen  records  related  to  eight
different RCTs that either had not assessed any of the pre-defined
outcomes of interest of this review or did not provide usable data
were excluded. This left 91 eligible papers altogether (see Included
studies),  that  is,  primary  or  secondary  publications  of  primary
studies, conference proceedings and trial register entries, covering
28 different RCTs that were included in quantitative syntheses (see
Figure 1).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Included studies

For essential characteristics of the 28 included studies, please see
Characteristics  of  included  studies.  The  studies  were  published
between  1991  and  2010:  three  during  the  1990s,  another  three
between 2000 and 2005 and a much larger number (22) between
2006 and 2010.

Design

All  primary  studies  were  randomised,  parallel-arm  trials.  Most
studies (n = 19) were conducted at a single site. The remaining nine
had several participating study centres, that is, n = 2 ( Koons 2001;
Bateman  2009;  Cottraux  2009;  McMain  2009;  Bos  2010;  Doering
2010),  n  =  3  (Davidson  2006),  n  =  4  (Giesen-Bloo  2006)  or  n  =  8
(Nadort 2009) study sites.

Sample sizes

The sample sizes ranged from n = 16 to n = 180. Altogether, n = 1804
participants were included (mean = 64.4, SD = 42.7). Six trials had
sample sizes of more than 100 participants (Davidson 2006; Linehan
2006; Blum 2008; Bateman 2009; McMain 2009; Doering 2010).

Setting

All  but  two  trials  were  conducted  in  an  outpatient  setting.  In
contrast,  participants  of  the  Bateman  1999  study  were  partially
hospitalised if allocated to the experimental group, but remained
outpatients  if  allocated  to  the  control  group.  The  study  of  Steil
2010  tested  DBT-PTSD,  an  adaption  of  DBT  for  the  treatment  of
patients with BPD with comorbid posttraumatic stress disorder. It
includes  several  stages  from  a  diagnostic  outpatient  phase  to  an
inpatient  stay  and  an  additional  outpatient  booster  session  after
the  end  of  inpatient  treatment.  However,  the  main  interventions
were conducted in an inpatient setting.

Participants

Sex

Twelve studies consisted of female participants only (Linehan 1991;
Linehan 1994; Koons 2001; Van den Bosch 2005; Gratz 2006; Linehan
2006;  Weinberg  2006;  Zanarini  2008;  Farrell  2009;  Carter  2010;
Doering  2010;  Steil  2010).  All  remaining  studies  were  mixed  but
predominantly female. More than 75% of participants were female
in  Turner  2000;  Davidson  2006;  Giesen-Bloo  2006;  Bellino  2007;
Blum  2008;  Gregory  2008;  Bateman  2009;  Cottraux  2009;  McMain
2009;  Nadort  2009;Soler  2009;  Bos  2010;  Morey  2010.  Only  three
studies  had  less  than  75%  female  participants  (Bateman  1999:
57.9%; Bellino 2006: 60.0%; Bellino 2010: 67.3%).

Diagnostic criteria and means of assessment

Participants  were  diagnosed  as  having  BPD  according  to  DSM-III
(Linehan  1991),  DSM-III-R  (Koons  2001;  Linehan  1994;  Bateman
1999;  Turner  2000;  Farrell  2009)  or  DSM-IV  (Van  den  Bosch  2005;
Bellino 2006; Davidson 2006; Giesen-Bloo 2006; Gratz 2006; Linehan
2006;  Weinberg  2006;  Bellino  2007;  Blum  2008;  Gregory  2008;
Zanarini 2008; Bateman 2009; Cottraux 2009; McMain 2009; Nadort
2009;Soler 2009; Bellino 2010; Bos 2010; Carter 2010; Doering 2010;
Morey 2010; Steil 2010).

The presence of BPD was confirmed by some standardised means
of assessment in all studies. The most frequently used assessment
instrument  was  the  Structured  Clinical  Interview  for  DSM-III-R
(Spitzer  1985)  or  DSM-IV  (First  1997)  personality  disorders  (SCID-

Cochrane Database of Systematic Reviews

II).  It  was  used  by  Linehan  1994;  Bateman  1999;  Koons  2001;
Van  den  Bosch  2005;  Bellino  2006;  Davidson  2006;  Giesen-Bloo
2006;  Linehan  2006;  Weinberg  2006;  Bellino  2007;  Gregory  2008;
Bateman  2009;  Nadort  2009;  Soler  2009;  Bellino  2010;  Bos  2010;
Doering  2010.  Other  DSM-oriented  means  of  assessment  were
the  Structured  Interview  for  DSM-IV  Personality  (SIDP-IV;  Pfohl
1997),  which  was  used  by  Blum  2008,  and  the  International
Personality Disorder Examination (IPDE; Loranger 1995), which was
used  by  Carter  2010,  Steil  2010  and  McMain  2009.  Carter  2010
specifically  used  the  IPDE-self  rating  screening  questionnaire  the
preliminary findings of which were confirmed in clinical interviews
by  a  psychiatrist.  Turner  2000  used  a  preceding  version  of  IPDE,
the  Personality  Disorders  Examination  (PDE;  Loranger  1988).  The
Diagnostic  Interview  for  DSM-IV  Personality  Disorders  (DIPD-IV;
Zanarini 1987) was used in the studies of Gratz 2006; Zanarini 2008
and Morey 2010). Another frequently used standardised interview
was the DIB (Gunderson 1981) or DIB-R (Zanarini 1989), which was
originally developed to categorically assess BPD not as defined by
DSM but as conceptualised by J.G. Gunderson and his group before
publication of DSM-III. It is indicative of a diagnosis of BPD but can
not be relied upon to make a DSM diagnosis due to its somewhat
different conceptualisation (Rush 2005). It was used additionally to
another DSM-oriented interview by Linehan 1994; Bateman 1999;
Turner 2000; Weinberg 2006; Zanarini 2008; Soler 2009. It was used
as only standardised means of diagnostic assessment by Cottraux
2009  and  Linehan  1991,  but  the  DSM  diagnosis  was  additionally
confirmed by clinical interviews. Farrell 2009 also used DIB-R but
also the Borderline Syndrome Index (BSI; Conte 1980).

Exclusion criteria

People with evidence of mental impairment, organic brain disorder,
insufficient  commend  of  the  language  spoken,  severe  disabling
organic  conditions,  dementia  or  neurologic  diseases,  place  of
residence  too  far  from  the  study  centre  or  being  in  coercive
treatment were not eligible for most studies. Comorbid personality
disorders  were  no  reason  for  exclusion  from  most  trials,  but
Koons 2001; Giesen-Bloo 2006; Cottraux 2009; Carter 2010; Doering
2010;  and  Nadort  2009  excluded  those  with  antisocial  features
or  full  antisocial  personality  disorder  and  Bellino  2010  did  not
include  people  with  any  comorbid  personality  disorder.  Of  the
axis-I disorders, schizophrenia, schizoaffective and other psychotic
disorders  were  reasons  for  exclusion  from  all  studies  except  Bos
2010.  Bipolar  disorder,  mostly  not  further  specified,  was  also
a  very  common  reason  for  exclusion,  except  for  the  studies  of
Blum  2008;  Gregory  2008;  Cottraux  2009;  Farrell  2009;  McMain
2009;  Bos  2010;  Morey  2010.  Gratz  2006;  Zanarini  2008;  Bateman
2009;  McMain  2009  specified  that  only  people  with  bipolar  I
disorder  were  excluded.  Other  common  reasons  for  exclusion
were  substance-related  disorders.  People  with  current  substance
abuse  were  not  eligible  for  the  studies  of  Bateman  1999;  Bellino
2006;  Bellino  2007;  Bellino  2010;  Morey  2010.  Dependence  was  a
reason  for  exclusion  from  the  trials  of  Bateman  2009  (opiates);
Linehan  1991;  Linehan  1994;  Koons  2001;  Davidson  2006;  Gratz
2006; Weinberg 2006; Zanarini 2008; Cottraux 2009; McMain 2009;
Soler  2009;  Doering  2010  (any  substance).  People  with  acute
substance dependence were excluded from the studies of Giesen-
Bloo 2006 and Nadort 2009 if clinical detoxification was required
but  could  enter  the  trial  afterwards.  In  contrast,  all  participants
of  Gregory  2008  had  a  current  diagnosis  of  alcohol  abuse  or
dependence.  Both  Giesen-Bloo  2006  and  Nadort  2009  excluded
possible  participants  with  a  dissociative  identity  disorder  and
those with attention-deficit/hyperactivity disorder. Soler 2009 was

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

the  only  study  explicitly  excluding  people  with  a  current  major
depressive  episode.  Severity-related  reasons  for  exclusion  were
rare. For the Soler 2009 study, people with a CGI-S score of ≧ 4, that
is, moderately ill or worse, were not eligible. Acute danger to self
and/or others as reason for ineligibility was explicitly specified only
by Gratz 2006; Weinberg 2006; Bos 2010.

Severity of illness/level of functioning

There was no standard way of reporting or describing the overall
severity of illness or the level of functioning of study participants.

The Global Assessment of Functioning Scale (GAF; APA 1987) was
used  by  five  trials.  On  a  scale  from  one  (persistent  danger  of
severely  hurting  self  or  others  )  to  100  (superior  functioning),
participants of Bateman 2009 and Farrell 2009 scored between 41
and  50  and  thus  had  "serious  symptoms  (for  example,  suicidal
ideation,  severe  obsessional  rituals,  frequent  shoplifting)  OR  any
serious impairment in social, occupational, or school functioning
(for  example,  no  friends,  unable  to  keep  a  job)".  Participants  of
Zanarini  2008;  McMain  2009;  Doering  2010  scored  between  51
and 60 and therefore had "moderate symptoms (for example, flat
affect  and  circumstantial  speech,  occasional  panic  attacks)  OR
moderate  difficulty  in  social,  occupational,  or  school  functioning
(for example, few friends, conflicts with peers or co-workers)".

Another  trial  used  the  Global  Assessment  Scale  (GAS;  Endicott
1976),  the  scale  that  the  GAF  originally  was  derived  from.  It  also
uses  a  1  to  100  continuum,  with  1  indicating  the  lowest  level  of
functioning in a hypothetical continuum of mental illness to health.
Participants of Linehan 1994 scored between 31 and 40 on average
at  baseline,  which  indicates  "major  impairment  in  several  areas,
such  as  work,  family  relations,  judgment,  thinking  or  mood  OR
some  impairment  in  reality  testing  or  communication  OR  single
serious suicide attempt".

Another  widely  used  measure  was  the  Clinical  Global  Impression
Scale (CGI, Guy 1976). Scores on its Severity of Illness Subscale (CGI-
S) range from 1 = "not ill at all" to 7 = "among the most extremely
ill".  In  primary  studies  included  here,  the  average  CGI-S  baseline
scores  described  samples  as  "mildly  to  moderately  ill"  (Bellino
2007), "moderately to markedly ill" (Bellino 2006) or "markedly to
severely ill" (Blum 2008; Cottraux 2009; Bellino 2010).

An adaptation of CGI for BPD (Clinical Global Impression-Scale for
Borderline Personality Disorder Patients; CGI-BPD; Pérez 2007) was
used in one trial (Soler 2009), indicating a "moderately to markedly
ill" sample of patients on average.

Another  indicator  of  severity  of  illness  was  the  reported  mean
number  of  fulfilled  BPD  criteria  (five  out  of  nine  are  required  for
a  diagnosis).  These  were  6.8  for  the  samples  of  Koons  2001  and
Nadort 2009, 6.9 for Giesen-Bloo 2006, 7.4 for Van den Bosch 2005
and 7.5 for Gratz 2006.

Davidson  2006  used  the  SFQ  (Social  Functioning  Questionnaire;
Tyrer  2005).  The  score  range  is  0  to  24,  and  a  score  of  10  or
more indicates poor social functioning. The mean SFQ score of the
sample was 14.6, comparable to psychiatric emergencies.

Study

Modifications

Cochrane Database of Systematic Reviews

The  remaining  studies  reported  no  standardised  measures  of
severity.

Interventions

The duration of trial interventions ranged from 1.5 to 36 months.
The mean duration was 10.19 months (SD = 7.02). Seven trials with
interventions of predominantly psychoeducational character had
a  duration  of  less  than  six  months  (Gratz  2006;  Weinberg  2006;
Blum  2008;  Zanarini  2008;  Soler  2009;  Bos  2010;  Morey  2010).  In
addition,  the  inpatient  treatment  in  the  study  of  Steil  2010  was
also  of  less  than  six  months  duration,  that  is,  three  months.  The
studies of Koons 2001; Bellino 2006; Bellino 2007; Carter 2010 lasted
six  months,  those  of  Farrell  2009  and  Bellino  2010  eight  months.
The major part of 10 studies (Linehan 1991; Linehan 1994; Turner
2000; Van den Bosch 2005; Davidson 2006; Linehan 2006; Gregory
2008;  Cottraux  2009;  McMain  2009;  Doering  2010)  were  of  one
year's duration. The three studies of Bateman 1999; Bateman 2009;
Nadort  2009  lasted  18  months,  and  the  trial  of  Giesen-Bloo  2006
was the longest with a duration of 36 months.

In  the  following,  the  interventions  tested  in  the  included  RCTs
will  be  described  briefly.  However,  it  is  not  possible  to  provide  a
comprehensive  account  of  each  psychological  intervention.  Only
very  short  descriptions  will  be  given  and  relevant  references
indicated.

Comprehensive psychotherapies

As depicted above, comprehensive psychotherapies were defined
as  including  individual  psychotherapy  as  substantial  part  of  the
intervention.  Duration  must  have  been  three  months  or  more.
Group therapy may or may not be delivered.

Dialectical behaviour therapy (DBT) and modified DBT-related
treatments (eight studies: Carter 2010; Koons 2001; Linehan 1991;
Linehan 1994; Linehan 2006; McMain 2009; Turner 2000; van den Bosch
2005)

Dialectical  behavioural  therapy  (DBT;  Linehan  1993a;  Linehan
1993b)  is  a  multi-module  psychological  intervention  that  was
developed  using  some  of  the  principles  of  CBT  in  combination
with  mindfulness-based  techniques.  It  aims  to  change  behaviour
by improving skills and the ability to contain difficult feelings, but
also  applies  supportive  elements,  for  example,  in  the  principles
of  validation  of  emotions  and  acceptance.  Problem-oriented
behaviour  "skills"  are  targeted  at  enhanced  stress  tolerance,
interpersonal  situations,  emotion  regulation  and  mindfulness.
DBT  was  originally  designed  as  an  outpatient  treatment.  It
includes weekly individual sessions along with weekly "skills group
training", and telephone access for patients to individual therapists
in times of crisis. Therapists meet in teams for regular supervision
and exchange. Usually DBT is delivered for a period of 12 months.

Dialectical behaviour therapy (DBT) according to Linehan (Linehan
1993a;  Linehan  1993b)  was  used  in  eight  studies  (Linehan  1991;
Linehan  1994;  Turner  2000;  Koons  2001;  Van  den  Bosch  2005;
Linehan  2006;  McMain  2009;  Carter  2010).  A  summary  of  major
modifications and/or adaptations is given in the table below.

Carter 2010

• duration: six months (treatment of 12 months length, but outcome assessment after six)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• telephone  access  was  available  but  not  from  participants'  individual  therapists  but  other  DBT

therapists or the local psychiatric hospital

Koons 2001

• duration: six months
• length of skills training group and therapist consultation meeting shortened to 90 minutes per

week

Linehan 1991

no major modifications

Linehan 1994

no major modifications

Linehan 2006

no major modifications

McMain 2009

Turner 2000

no major modifications

• psychodynamic techniques incorporated to conceptualise patients' behavioural, emotional and

cognitive relationship schemata

• no skills group, skills training provided during individual therapy sessions

Van den Bosch 2005

no major modifications

DBT for Borderline Personality Disorder with Severe Posttraumatic
Stress Disorder after Childhood Sexual Abuse (DBT-PTSD; one study:
Steil 2010)

DBT-PTSD  aims  at  meeting  the  special  demands  of  people  with
both BPD and chronic post-traumatic stress disorder (PTSD) after
sexual abuse in childhood (Steil 2010a). It draws from and employs
principles  and  modules  of  standard  DBT  but  enhances  them  by
PTSD  specific  cognitive  restructuring  and  exposure  techniques.
DBT-PTSD  was  delivered  in  an  inpatient  setting  of  three  months
duration in the study of Steil 2010.

Mentalisation-based treatment (MBT; two studies: Bateman 1999;
Bateman 2009)

Mentalisation-based therapy (MBT; Bateman 2004; Bateman 2006)
is  a  complex  psychoanalytically  and  attachment  theory-based
treatment. It aims to increase the reflective or mentalising capacity
of the participant, helping them to understand and recognise the
feelings  they  evoke  in  others  and  the  feelings  they  experience
themselves  as  a  result  of  others.  Thus,  "mentalising"  means  the
implicit  and  explicit  interpretation  of  the  actions  of  oneself  and
others as meaningful in view of intentional mental states such as
desires, feelings, and needs.

MBT  was  used  in  two  trials,  one  in  a  partial  hospitalised  setting
(MBT-PH;  Bateman  1999)  and  the  other  outpatient  (MBT-OUT;
Bateman 2009).

Cognitive-behavioural approaches (CBT; three studies: Bellino 2007;
Cottraux 2009; Davidson 2006)

Cognitive-behavioural  therapy  (CBT)  as  a  generic  term  refers  to
treatments  that  combine  cognitive  and  behavioural  techniques.
Today,  neither  of  them  is  practiced  without  the  other,  so  the
combined  term  has  prevailed.  Originially,  cognitive  techniques
were  compiled  by  AT  Beck  who  developed  his  approach  initially
for  the  treatment  of  depression  (Beck  1979).  Current  CBT  is
problem-focused,  with  therapeutical  processes  strongly  oriented
towards pre-defined and both patient- and therapist-agreed-upon

treatment  targets.  Overall,  the  major  goal  is  to  help  patients
to  develop  adaptive  (instead  of  maladaptive  and  dysfunctional)
beliefs  about  self  and  others  by  self-directed  learning  processes.
Participants are encouraged to identify their core beliefs, evaluate
and modify their behaviour accordingly and gain new experiences
(Beck  1990;  Beck  1995).  Cognitive-behavioural  approaches  (CBT)
were used in three RCTs.

In  the  trial  of  Bellino  2007,  the  participants  of  which  all  had  an
additional major depressive episode, CBT was delivered according
to the basic works of Beck (Beck 1990; Beck 1995). Cottraux 2009
delivered CBT based on further developments of A T Beck's working
group for the treatment of people with personality disorders (esp.:
Layden  1993;  Young  1994).  Davidson  2006  used  a  CBT  approach
based on AT Beck work that she has specially formulated for the
practical  treatment  of  those  with  Cluster  B  personality  disorders
(Davidson 2000).

Interpersonal Psychotherapy (IPT) and related treatments (IPT-BPD;
three studies: Bellino 2006; Bellino 2007; Bellino 2010)

Interpersonal Psychotherapy (IPT) is a brief and highly structured
manual-based psychotherapy that addresses interpersonal issues.
It was originally developed for the treatment of depression, to the
exclusion of all other foci of clinical attention (Klerman 1984). It acts
on the assumption that interpersonal factors play an important role
in the development and maintenance of psychological problems,
and emphasises interpersonal processes rather than intrapsychic
ones.  Participants  are  encouraged  to  acquire  interpersonal  skills
and thus adapt their behaviour to current roles and situations.

IPT was used in the studies of Bellino 2006 and Bellino 2007. In a
more recent trial (Bellino 2010), a BPD-specific adaptation of IPT,
called IPT-BPD, was used (Markowitz 2005; Markowitz 2006).

Transference-Focused Psychotherapy (TFP; two studies: Doering 2010;
Giesen-Bloo 2006)

Another  popular  psychodynamically-based  approach  is  the  one
of  transference-focused  psychotherapy  (TFP;  Clarkin  1999).  By

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

analysis  of  the  transference  within  the  therapeutic  relationship,
integrated  representations  of  self  and  others,  modification  of
primitive defensive operations and resolution of identity diffusion
are  to  be  achieved.  Primitive  object  relations  (for  example,  split,
polarised into 'good' and 'bad') are to be transformed to advanced
ones (for example, differentiated, integrated).

TFP  was  used  in  two  trials.  Doering  2010  compared  TFP  with  a
control condition, and it served as comparison treatment for SFT in
the study of Giesen-Bloo 2006.

Schema-focused therapy (SFT; two studies: Giesen-Bloo 2006; Nadort
2009)

Schema-focused  therapy  (SFT;  Young  2003)  draws  from  both
behavioural as well as psychoanalytic theories and helps patients
to  identify  their  self-defeating  core  themes  that  evolved  from
unmet  emotional  needs  in  childhood  and  implicate  maladaptive
coping styles in adulthood. The goal of SFT is to aid patients to get
their needs met.

SFT was tested in two trials, those of Giesen-Bloo 2006 and Nadort
2009.  The  first  one  strongly  stuck  to  the  original  SFT  treatment
regimen.  Nadort  2009  investigated  the  effects  of  standard  SFT  in
a regular mental health care setting and SFT plus additional crisis
telephone support by individual therapists outside the office hours
(SFT+).

Client-centered therapy (CCT) and related treatments (two studies:
Cottraux 2009; Turner 2000)

Client-centered  (or  patient-centered)  therapy  (CCT;  Rogers  1951)
is a non-directive approach that aims at encouraging participants
to find their own solutions to their problems. This is achieved by
creating a safe, non-judgmental therapy setting in which therapists
meet  their  clients  with  un-conditional  respect,  demonstrating
warmth,  empathy,  and  genuineness  while  "active  listening".
Participants  are  encouraged  to  explore  their  own  experiences  in-
depth and express their feelings, so they can decide for themselves
in what ways they need to change.

CCT  based  on  C  Rogers'  work  was  one  of  the  conditions  of  the
RCT of Cottraux 2009. Turner 2000 used R Carkhuff's approach, a
further development of Rogers' CCT (Carkhuff 1969; Carkhuff 1976),
emphasising therapeutic core conditions as crucial for the client's
growth and development.

Dynamic deconstructive psychotherapy (DDP; one study: Gregory
2008)

Dynamic deconstructive psychotherapy (DDP) has been developed
to  treat  those  people  with  BPD  having  co-occurring  disorders,
such as substance use disorders or additional personality disorders
(Gregory  2008a;  Gregory  2010).  BPD  is  regarded  a  disorder  of
aberrant  processing  of  emotional  experiences.  Therefore,  DDP
aims  to  enhance  neurocognitive  self-capacities  by  elaborating
affect-laden  interpersonal  experiences  and  integrate  attributions
by  narrative  construction  through  association  techniques.  Thus,
a  differentiated  view  of  self  versus  others  is  to  be  developed,
supported  by  novel  experiences  within  the  patient-therapist
relationship.

DDP was used in a RCT conducted by its developer (Gregory 2008).

Cochrane Database of Systematic Reviews

Non-comprehensive psychotherapeutic interventions

As  depicted  above,  non-comprehensive  psychotherapies  were
defined  as  not  including  individual  psychotherapy  as  substantial
part  of  the  intervention.  They  mainly  focus  on  psychoeducation
as  delivered  in  a  group-therapy  settings,  are  of  limited  duration
(that is, beyond six months) and focus on impartation of knowledge
rather  than  individual  therapy.  These  interventions  may  or  may
not be administered as an adjunctive module to ongoing individual
treatments,  but  individual  psychotherapy  is  not  part  of  these
interventions themselves.

DBT-skills training only (DBT-ST; one study: Soler 2009)

One trial investigated the effects of DBT-skills training only (Soler
2009): three months of standard-DBT based skills training sessions
were delivered to people who did not receive any of the remaining
usual DBT components.

Emotion regulation group training (ERG; one study: Gratz 2006)

ERG is an eclectic treatment approach that draws from Acceptance
and  Commitment  Therapy  (ACT;  Hayes  1999),  DBT  and  includes
aspects  of  emotion-focused  psychotherapy  (Greenberg  2002)  as
well as behavioural therapy. ERG was delivered for a duration of 3.5
months in the trial of Gratz 2006.

Schema-focused therapy-group (SFT-G; one study: Farrell 2009)

Farrell  2009  used  a  shortened  group-only  format  of  SFT  (SFT-
G),  based  on  schema  change  work  according  to  J.  Young  (Young
1994;  Young  2003)  in  combination  with  BPD  psychoeducation,
emotional  awareness  training  and  distress  management  training
(Farrell 1994). This intervention was delivered for eight months.

Manual-assisted cognitive treatment (MACT; two studies: Morey 2010;
Weinberg 2006)

Weinberg  2006  and  Morey  2010  tested  MACT,  a  bibliotherapeutic
approach  for  acutely  self-harming  patients.  The  intervention
comprises six individual sessions that are each structured around
a  chapter  of  a  self-help  book  (Schmidt  2004).  Weinberg  2006
compared MACT with a control group, whereas Morey 2010 tested
the  effects  of  both  standard  MACT  as  well  as  MACT  enhanced  by
a therapeutic assessment (MACT+TA). The therapeutic assessment
comprised  an  individualised  collaborative  assessment  including
development of questions the client would like to be answered by
the test results and development of individualised treatment goals.

Systems training for emotional predictability and problem solving for
borderline personality disorder (STEPPS; two studies: Blum 2008; Bos
2010)

Two studies (Blum 2008; Bos 2010) applied the "Systems training
for  emotional  predictability  and  problem  solving  for  borderline
personality  disorder"  (STEPPS)  training.  STEPPS  is  a  20-week
seminar-like  group  treatment  program.  It  combines  cognitive-
behavioural  elements  and  skills  training  with  a  systematic
approach by involving participants' relatives and other treatment
providers.  Blum  2008  employed  the  generic  STEPPS  training  as
an  add-on  to  any  ongoing  individual  treatments,  whereas  Bos
2010 combined STEPPS with a complementary individual therapy
(STEPPS-IT)  aiming  to  help  consolidate  the  skills  that  had  been
acquired during STEPPS group into the individual lives of patients.
However,  the  authors  explicitly  refer  to  the  individual  sessions
as  "limited  individual  [...]  developed  as  an  adjunct  to  STEPPS
to  help  consolidate  the  newly  acquired  skills  and  to  stimulate

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

their  use"  (Bos  2010,  p.  300).  Thus,  the  STEPPS  group  remains
the  core  element,  and  we  decided  to  classify  STEPPS+IT  as  non-
comprehensive psychotherapeutic intervention.

Psychoeducation only (PE; one study: Zanarini 2008)

Zanarini  2008  used  a  very  generic  form  of  psychoeducation.
People  newly  diagnosed  with  BPD  participated  in  a  single,
half-day  workshop.  Topics  of  the  workshop  curriculum  were
phenomenology, aetiology, treatment and course of BPD.

Comparisons

Comparisons  included  both  active  as  well  as  classic  control
conditions.

Controls

• Treatment  as  usual  (TAU):  TAU  was  the  most  commonly  used
control  condition.  TAU  means  that  participants  are  allowed
to  use  any  kind  of  treatment  they  would  or  would  not  have
used  in  case  they  had  not  been  involved  in  the  actual  trial.
However, TAU conditions differ slightly, especially in the extent
to  which  the  use  of  any  alternative  treatment  was  obligatory
or  not,  the  extent  to  which  alternative  treatments  reflect  the
supposed usual treatment and the extent to which alternative
treatments were homogenous among all participants assigned
to that condition.
◦ obligatory/all control participants in some kind of treatment:
▪ Bateman  1999:  homogeneous;  standard  treatment  in
formal

the  general  psychiatric  services,  excluding 
psychotherapy

▪ Bateman  2009:  homogeneous; 

structured  clinical
management  according  to  best  generic  practice  for
BPD  offered  by  non-specialist  practitioners  within  UK
psychiatric services

▪ Bos 2010: homogeneous; standard treatment for BPD as

offered at the participating sites

▪ Davidson  2006:  homogeneous;  standard  treatment  a
patient  would  have  received  if  the  trial  had  not  been  in
place as offered at the study sites

▪ Farrell  2009:  homogeneous;  participants  had  to  be  in
any  individual  psychotherapy  to  be  eligible  for  study
participation, and they had to continue this treatment for
the duration of the study

Cochrane Database of Systematic Reviews

◦ optional/treatment usage:

▪ Blum  2008:  heterogeneous;  participants  "encouraged  to

continue their usual care" of any kind

▪ Carter  2010:  heterogeneous;  treatment  as  usual  plus

waiting list (six months)

▪ Gregory 2008: heterogeneous; participants (all with either
alcohol abuse or dependence) were referred to an alcohol
rehabilitation  centre  and  given  names  of  psychiatric
clinics  and  therapists  in  the  community  but  were  also
allowed to keep their current psychotherapist, if any
▪ Linehan  1991:  heterogeneous;  participants  were  given

alternative therapy referrals

▪ Linehan  1994:  heterogeneous;  participants  received
alternative  therapy  referrals  and  were  allowed  to
participate  in  any  type  of  treatment  available  in  the
community

▪ Steil 2010: heterogeneous; treatment as usual plus waiting

list (six months)

to 

received 

the  control  condition 

• Community  treatment  by  experts  (CTBE):  all  participants
allocated 
treatment
by  experienced  psychotherapists  in  the  community.  Thus,
treatment  was  obligatory,  and  it  was  standardised  in  that
all  psychotherapists  were  known  experts  through  long-term
experience in that field.
◦ Doering  2010:  treatment  by  community  psychotherapists
who were known as experienced and particularly interested
in people with BPD

◦ Linehan  2006:  community  treatment  by  experts  who  had
been  nominated  by  community  mental  health  leaders;  the
treatment  provided  was  uncontrolled  by  the  study  but
therapists' characteristics (sex, experience, mean number of
clients etc.) were balanced among both groups

• Non-specific  comparison  programmes:  treatments  mainly
designed  to  control  for  attention  biases  or  the  like  by
providing  an  alternative  programme.  Specific  techniques  or
putative efficacious interventions are explicitly avoided. Those
treatments  are  subsumed  in  an  extra  category  since  they  will
usually not be found in usual health care settings.
◦ Soler  2009:  "Standard  group  therapy"  (SGT);  "oriented  to
provide a relational experience allowing people with BPD to
share  their  characteristic  difficulties";  therapists  present  to
conduct group interaction

▪ Gratz 2006: homogeneous; participants had to be in any

• Clinical management (CM):

individual therapy and continue during the study

◦ Bellino  2006:  appointments  with  a  psychiatrist,  fluoxetine

▪ Koons  2001:  homogeneous;  participants  received  60
minutes  of  weekly  individual  therapy  with  a  clinician  of
the  participating  clinics  of  different  orientations  (none
DBT) and were offered attendance of several supportive
and psychoeducational group

▪ Van den Bosch 2005: homogeneous; clinical management
from  the  original  referral  source,  that  is,  addiction
treatment  centres  or  psychiatric  services;  generally  no
more than two sessions per month

▪ Weinberg 2006: heterogeneous; all participants took part

in additional, ongoing treatments

medication (both groups received fluoxetine)

◦ Bellino  2010:  appointments  with  the  local  Service  for
Personality  Disorders,  fluoxetine  medication  (both  groups
received fluoxetine)

• Waiting list without treatment (WL):

◦ Zanarini  2008:  waiting  list,  weekly  screening  appointments
but no psychiatric treatment for the duration of the waiting
period (12 weeks)

Active comparators

The following studies compared two active treatments (description
of interventions see above).

• Bellino 2007: cognitive therapy versus interpersonal therapy
• Cottraux 2009: cognitive therapy versus client-centered therapy

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• Giesen-Bloo 2006: schema-focused therapy versus transference-

Primary outcomes  

focused therapy

• McMain  2009:  dialectical  behaviour  therapy  versus  APA
guidelines-based  treatment  algorithm  (general  psychiatric
the  American  Psychiatric
management  derived 
Association (APA) guideline recommendations; combination of
psychodynamically  informed  therapy  and  symptom-targeted
medication management)

from 

• Morey 2010: manual assisted cognitive therapy versus manual-

assisted cognitive therapy plus therapeutic assessment

• Nadort  2009:  schema-focused  therapy  versus  schema-focused
therapy  plus  therapist  telephone  crisis  support  outside  office
hours

• Turner  2000:  dialectical  behaviour  therapy  versus  client-

centered therapy

Outcomes

In the case of availability of several measures relating to the same
outcome construct (for example, data from several questionnaires
for  the  assessment  of  depression),  the  one  most  often  used
in  the  whole  pool  of  included  studies  was  used  for  effect  size
calculation,  in  order  to  minimise  heterogeneity  of  outcomes  in
form  and  content.  If  a  study  reported  data  of  two  assessment
instruments that were equally frequently used, two review authors
(JS,  BV)  discussed  the  issue  and  chose  the  one  which  was  in  its
content  most  appropriate  for  assessing  BPD-relevant  pathology.
Self-rated  measures  were  preferred.  If  there  was  more  than  one
post-treatment assessment available, we used the one which was
assessed  closest  to  the  end  of  psychotherapeutic  treatment.  For
the  studies  of  Steil  2010  and  Zanarini  2008,  several  assessments
were considered for use as post-treatment data: Steil 2010 reported
data that were assessed immediately at end of the three months
inpatient  treatment  and,  additionally,  data  that  were  assessed
after  a  subsequent  booster  session  six  weeks  after  dismissal.  As
the booster session was a pre-defined part of treatment, we used
the post-booster session data. Zanarini 2008 conducted a singular
psychoeducation workshop and assessed data on a weekly basis
up to week 12. We decided to use the data from week 12 to ensure
observation periods throughout the whole pool of studies were as
homogeneous as possible.

All available outcomes that were included in this review are listed
below as well as specific measures and the respective studies that
used them.

1. BPD severity

a. Borderline  evaluation  of  severity  over  time  (BEST):  Gratz

2006; Blum 2008; Gregory 2008

b. Borderline personality disorder checklist-40 (BDP-40) - total

score: Bos 2010

c. Borderline  personality  disorder  severity  index  (BPDSI-IV)  -
total score: Giesen-Bloo 2006; Nadort 2009; Bellino 2010

d. Borderline symptom list (BSL): Steil 2010
e. Borderline syndrome index (BSI): Farrell 2009
f. Clinical  global  impression  scale  for  borderline  personality

disorder patients (CGI-BPD) - global: Soler 2009

g. Mean  number  of  DSM-IV  diagnostic  criteria  for  BPD:  Koons

2001; Doering 2010

h. Personality assessment inventory - borderline features scale

total (PAI-BOR-total): Morey 2010

i. Zanarini  rating  scale  for  borderline  personality  disorder

(ZAN-BPD) - total score: McMain 2009
2. Affective dysregulative cluster symptoms

a. anger

i. Borderline personality disorder severity index (BPDSI-IV) -

anger: Bellino 2010

ii. Clinical global impression scale for borderline personality

disorder patients (CGI-BPD) - anger: Soler 2009

iii. Spielberger  anger  expression  scale  (STAXI)  -  anger  out:

Koons 2001; McMain 2009

iv. Spielberger  anger  expression  scale  (STAXI)  -  trait  anger:

Linehan 1994

v. Target behaviour rating (TBR) - anger: Turner 2000

b. affective instability

i. Borderline personality disorder severity index (BPDSI-IV) -

affective instability: Bellino 2010

ii. Clinical global impression scale for borderline personality
disorder  patients  (CGI-BPD)  -  affective  instability:  Soler
2009

iii. Diagnostic  Interview  for  BPD-Revised  (DIB-R)  -  affect

subscale: Farrell 2009

iv. Difficulties in emotion regulation scale (DERS) - emotion

dysregulation: Gratz 2006

v. Personality  assessment  inventory  -  affective  instability

(PAI-BOR-A): Morey 2010

vi. Zanarini  rating  scale  for  borderline  personality  disorder

(ZAN-BPD) - affective instability: Blum 2008

c. chronic feelings of emptiness

i. Borderline personality disorder severity index (BPDSI-IV) -

emptiness: Bellino 2010

ii. Clinical global impression scale for borderline personality

disorder patients (CGI-BPD) - emptiness: Soler 2009

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

3. Impulsive cluster symptoms

a. parasuicidality

a.

impulsivity
i. Barrett impulsiveness scale (BIS): Blum 2008
ii. Borderline personality disorder severity index (BPDSI-IV) -

a. Borderline personality disorder severity index (BPDSI-IV) -

parasuicidal behaviour score: Bellino 2010

b. Deliberate  self-harm  inventory  (DSHI)  -  frequency  score:

impulsivity: Van den Bosch 2005; Bellino 2010

Gratz 2006

iii. Clinical global impression scale for borderline personality
disorder patients (CGI-BPD) - impulsivity: Soler 2009
iv. Diagnostic Interview for BPD-Revised (DIB-R) - impulsive

c. LPC-self-mutilative  acts  during  previous  three-month

period: Van den Bosch 2005

d. Mean  number  of  suicidal  and  self-injurious  episodes:

subscale: Farrell 2009

McMain 2009

v. Difficulties  in  emotion  regulation  scale  (DERS)  -  impulse

e. Mean number of self-harming acts during previous three-

dyscontrol: Gratz 2006
impulsivity 

vi. Eysenck 

venturesomeness 

empathy

f. Number  of  patients  scoring  above  BPDSI-IV-parasuicide

month period: Koons 2001

questionnaire (IVE) - impulsivity: Cottraux 2009

cut-off: Bos 2010

vii.Number  of  participants  scoring  above  BPDSI-IV-

g. Number  of  patients  with  parasuicide  during  previous

impulsivity cut-off score: Bos 2010

three-month period: Gregory 2008

viii.Target  behaviour  rating  (TBR)  -  impulsiveness:  Turner

2000

ix. Zanarini  rating  scale  for  borderline  personality  disorder

(ZAN-BPD) - impulsivity: Zanarini 2008

b. suicidality

i. Beck hopelessness scale (BHS): Cottraux 2009
ii. Beck scale for suicidal ideation (BSS): Turner 2000; Koons

2001

iii. Clinical global impression scale for borderline personality

disorder patients (CGI-BPD) - suicidality: Soler 2009

iv. Number  of  participants  with  suicide  attempt  during
previous six-month period: Bateman 1999; Bateman 2009
v. Number of participants with suicidal act during previous

12 months:Davidson 2006; Doering 2010

vi. Personality assessment inventory - suicidal ideation (PAI-

SI): Morey 2010

vii.Suicidal  behaviours  questionnaire  (SBQ):  Linehan  2006;

Weinberg 2006

h. Number  of  patients  with  self-harming  behaviour  during
previous six-month period: Bateman 1999; Bateman 2009;
Carter 2010

i. Number  of  patients  with  self-harming  behaviour  during
previous  12-month  period:  Linehan  1991;  Doering  2010;
Davidson 2006

j. Personality  assessment  inventory  -  borderline  features

scale self-harm (PAI-BOR-S): Morey 2010

k. Parasuicide history interview (PHI) - deliberate self-harm

frequency: Weinberg 2006

l. Self-harming behaviours checklist (SHBCL): Cottraux 2009
m. Target behaviour rating (TBR) - frequency of parasuicide:

Turner 2000

1. Interpersonal cluster symptoms

a.

interpersonal problems general
i. Borderline personality disorder severity index (BPDSI-IV) -

interpersonal relationships: Bellino 2010

ii. Clinical global impression scale for borderline personality
disorder  patients  (CGI-BPD)  -  unstable  relations:  Soler
2009

iii. Diagnostic 

interview 
interpersonal subscale: Farrell 2009

for  BPD-revised 

(DIB-R) 

-

iv. Inventory of interpersonal problems (IIP): Bateman 1999;

Bateman 2009
v.
Inventory of interpersonal problems (IIP-C): McMain 2009
vi. Inventory of interpersonal problems-short form (IIP-SC):

Davidson 2006

vii.Personality  assessment  inventory  -  borderline  features
scale negative relationships (PAI-BOR-N): Morey 2010
viii.World Health organization quality of life assessment-Bref
(WHOQOL-Bref)  -  social  relationships  score:  Bos  2010;
Carter 2010

ix. Zanarini  rating  scale  for  borderline  personality  disorder
(ZAN-BPD)  -  disturbed  relationships  score:  Blum  2008;
Zanarini 2008

b. avoidance of abandonment

i. Borderline personality disorder severity index (BPDSI-IV) -

abandonment: Bellino 2010

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2. Cognitive cluster symptoms
identity disturbance
i. Borderline personality disorder severity index (BPDSI-IV) -

a.

identity disturbance: Bellino 2010

ii. Personality  assessment  inventory  -  borderline  features

scale - identity disturbance: Morey 2010

4. Mental health status/functioning

a. Brief disability questionnaire (BDQ) - days out of role: Carter

2010

b. Clinical  global  impressions  scale  (CGI)  -  severity  of  illness
(CGI-S): Bellino 2006; Bellino 2007; Blum 2008; Cottraux 2009;
Bellino 2010

b. dissociation/stress-related paranoid ideation

c. Clinical  global  impressions  scale  (CGI)  -  improvement,

i. Borderline personality disorder severity index (BPDSI-IV) -

patient-rated (CGI-I-SR): Soler 2009

paranoid ideation: Bellino 2010

d. Global assessment of functioning scale (GAF): Bateman 2009;

ii. Brief  psychiatric  rating  scale  (BPRS):  Turner  2000;  Soler

Farrell 2009; Doering 2010

2009;

iii. Diagnostic  interview  for  BPD-revised  (DIB-R)  -  cognitive

subscale: Farrell 2009

iv. Dissociative experiences scale (DES):Koons 2001; Gregory

2008; Steil 2010

v. Zanarini rating scale for borderline personality disorder -

cognitive subscale: Blum 2008

Secondary outcomes

1. Depression

a. Beck  depression  inventory  (BDI):  Bateman  1999;  Turner
2000; Koons 2001; Blum 2008; Gregory 2008; Bateman 2009;
Cottraux 2009; McMain 2009; Doering 2010

b. Beck  depression  inventory-II  (BDI-II):  Davidson  2006;  Steil

e. Global assessment scale (GAS): Linehan 1994
f. Social functioning questionnaire (SFQ): Davidson 2006

5. Leaving the study early

a. Number  of  participants  lost  after  randomisation  for  any

reason; available or calculable for all primary studies

6. Adverse effects: no data available from any primary study

Excluded studies

The  main  primary  studies  that  readers  might  be  expected  to  be
included  but  in  fact  were  not  are  listed  in  the  Characteristics  of
excluded studies table with individual reasons for exclusion. Please
note  that  only  one  reason  may  be  listed,  though  actually  several
inclusion criteria may not have been met.

2010

Risk of bias in included studies

c. Depression  anxiety  stress  scales  (DASS)  -  depression:  Gratz

2006

d. Hamilton  depression 

inventory  (Ham-D):  Bellino  2006;

Bellino 2007; Bellino 2010

e. Hamilton  depression 

inventory  -  17-item  (Ham-D-17):

Linehan 2006; Soler 2009

2. Anxiety

a. Beck anxiety inventory (BAI):Turner 2000; Cottraux 2009;
b. Depression anxiety stress scales (DASS) - anxiety: Gratz 2006
c. Hamilton  anxiety  rating  scale  (HARS):  Koons  2001;  Bellino

2006; Bellino 2007; Soler 2009; Bellino 2010

d. Spielberger  state-trait  anxiety  inventory  (STAI)  -  state:  Steil

2010

e. Spielberger  state-trait  anxiety 

inventory  (STAI)  -  trait:

Bateman 1999; Davidson 2006; Doering 2010

3. General psychopathology

a. Brief  symptom  inventory  (BSI)  -  global  severity  index  (BSI-

GSI): Davidson 2006; Doering 2010

b. Symptom  checklist-90-revised  -  (SCL-90-R)  -  global  severity
index  (SCL-90-R-GSI):  Bateman  1999;  Blum  2008;  Bateman
2009; Farrell 2009; McMain 2009; Soler 2009; Steil 2010

c. Symptom checklist-90-Dutch version (SCL-90-R-DV): Giesen-

Bloo 2006; Nadort 2009; Bos 2010

Figure 2 and Figure 3 show the review authors' judgements about
each risk of bias item for each single study and across all studies.

Allocation

Sequence generation

All  trials  were  stated  to  be  randomised.  Those  providing  further
information  on  how  the  randomisation  sequence  had  been
achieved,  or  that  a  minimisation  or  matching  method  had  been
used,  were  judged  as  having  'low'  risks  of  bias  (Linehan  1991;
Linehan  1994;  Van  den  Bosch  2005;  Davidson  2006;  Giesen-Bloo
2006; Gratz 2006; Linehan 2006; Bellino 2007; Blum 2008; Gregory
2008;  Bateman  2009;  Cottraux  2009;  Farrell  2009;  McMain  2009;
Soler  2009;  Bellino  2010;  Bos  2010;  Carter  2010;  Steil  2010).  The
remaining trials (Bateman 1999; Turner 2000; Koons 2001; Bellino
2006; Weinberg 2006; Zanarini 2008; Doering 2010; Morey 2010) did
not describe how treatment allocation had exactly been achieved,
and  the  risk  of  bias  was  judged  'unclear'.  However,  there  is
evidence that poor reporting of randomisation increases the odds
of presenting 'significant' outcomes (Chalmers 1983; Schulz 1995).

Allocation concealment

Those  trials  reporting  on  confident,  off-site  randomisation  or
notification  of  assignment  by  research  coordinators  not  involved
in  therapy  delivery  were  rated  as  having  a  'low'  risk  of  bias
(Davidson  2006;  Giesen-Bloo  2006;  Linehan  2006;  Gregory  2008;
Bateman 2009; Cottraux 2009; McMain 2009; Nadort 2009; Bos 2010;
Carter 2010; Doering 2010; Steil 2010). All remaining trials did not
provide further information to judge about adequacy of allocation
concealment,  and  the  risk  of  bias  was  judged  'unclear'  (Linehan
1991; Linehan 1994; Bateman 1999; Turner 2000; Koons 2001;Van
den Bosch 2005; Bellino 2006; Gratz 2006; Weinberg 2006; Bellino
2007;  Blum  2008;  Zanarini  2008;  Farrell  2009;  Nadort  2009;  Soler
2009; Bellino 2010; Morey 2010).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blinding

It  is  almost  impossible  to  keep  psychotherapy  trials  participants
blind  to  treatment  allocation.  Thus,  the  risk  of  bias  due  to
non-blindness  of  participants  is  present  in  psychotherapy  trials
throughout.

One trial report stated clearly that there was no blinding. Since only
self-rated outcomes were used, we judged there was no risk of bias
due  to  lack  of  blinding  (Gratz  2006).  The  majority  of  trials  report
that outcome assessors were intended to be kept blind to treatment
allocation (Linehan 1991; Linehan 1994; Turner 2000; Koons 2001;
Van  den  Bosch  2005;  Bellino  2006;  Davidson  2006;  Giesen-Bloo
2006; Gratz 2006; Linehan 2006; Weinberg 2006; Bellino 2007; Blum
2008;  Gregory  2008;  Bateman  2009;  Cottraux  2009;  McMain  2009;
Soler  2009;  Bellino  2010;  Carter  2010;  Doering  2010;  Morey  2010;
Steil  2010).  Some  of  them  (  Van  den  Bosch  2005;  Giesen-Bloo
2006; Gratz 2006; Blum 2008; Gregory 2008; Cottraux 2009; McMain
2009;  Soler  2009;  Carter  2010)  also  discussed  the  issue  of  partial
non-maintenance  of  blindness  throughout  the  whole  course  of
the study, since patients may have unintendedly indicated which
group  they  were  in,  although  they  had  been  told  not  to  do  so.
These  studies  were,  nevertheless,  rated  as  having  a  'low'  risk  of
bias  due  to  partial  break  of  blindness,  since  we  felt  it  was  not
appropriate  to  downgrade  these  studies  that  discuss  issues  that
may also have concerned those studies that did not discuss them.
Nadort 2009 clearly reported that outcome assessors could not be
kept blind to treatment conditions. However, since most outcomes
were  self-assessed  by  the  trial  participants,  the  risk  of  bias  was
judged 'unclear'.

Two trials did not mention blinding of outcome assessors (Bateman
1999; Zanarini 2008), and the risk of bias was judged 'unclear'. One
trial (Farrell 2009) providing mainly interviewer-assessed outcomes
reported  that  the  interviewers  were  not  blind  to  treatment
allocation, and the risk of bias was judged likely.

Selective reporting

For  seven  studies  (Davidson  2006;  Gregory  2008;  Bateman  2009;
Cottraux  2009;  McMain  2009;  Nadort  2009;  Doering  2010),  study
protocols  were  available  from  trial  registers,  and  there  was  no
indication  of  selective  outcome  reporting.  The  detailed  study
protocol  of  Steil  2010  was  also  available,  and  there  was  also  no
indication of selective reporting. Those eight studies were rated as
having a 'low' risk of bias in this regard.

For the study of Blum 2008, the study protocol was also available
from a study register, but the information provided did not permit
judgement of the presence of selective reporting. For the remaining
studies (Linehan 1991; Linehan 1994; Bateman 1999; Turner 2000;
Koons 2001; Van den Bosch 2005; Bellino 2006; Giesen-Bloo 2006;
Gratz  2006;  Linehan  2006;  Weinberg  2006;  Bellino  2007;  Zanarini
2008; Farrell 2009; Soler 2009; Bellino 2010; Bos 2010; Carter 2010;
Morey  2010),  no  protocols  were  available.  The  risk  of  bias  was
judged 'unclear' for these trails.

Other potential sources of bias

Insufficient treatment adherence

Most  trials  specified  either  routine  supervision  and/or  objective
means  assessment  to  assure  treatment  adherence.  All  trials
reporting any means of treatment adherence assurance were rated
as having a 'low' risk of bias in this regard (Linehan 1991; Linehan

Cochrane Database of Systematic Reviews

1994; Bateman 1999; Koons 2001; Van den Bosch 2005; Davidson
2006;  Giesen-Bloo  2006;  Linehan  2006;  Bellino  2007;  Blum  2008;
Gregory 2008; Bateman 2009; Cottraux 2009; Farrell 2009; McMain
2009; Nadort 2009; Bos 2010; Doering 2010; Morey 2010; Steil 2010).
One study reported that the only therapist was the developer of the
treatment, so adherence to the original treatment regimen should
be assured, and the risk of bias was also rated as 'low' (Gratz 2006).

Carter 2010 reports regular therapist supervision groups, but also
says  that  there  may  have  been  "a  possible  inferiority  of  training
of  DBT  therapists  to  that  of  those  in  other  studies  or  inferior
adherence to the DBT methods despite adequate training." (Carter
2010, p. 170). However, there were no objective means of adherence
assessment, so the risk of bias was judged 'unclear'. Three studies
depicted therapists as experienced, but did not make mention of
any kind of routine supervision or objective adherence assessment.
The  risk  was  judged  'unclear'  for  these  trials  (Bellino  2006;  Soler
2009; Bellino 2010). Zanarini 2008 did neither specify the therapists'
training nor any means of assurance of treatment integrity, so the
risk of bias was also judged 'unclear'.

Weinberg 2006 reports that "this study did not monitor adherence
and competence" (Weinberg 2006, p. 482). The risk of bias was rated
'probable' for this study.

Allegiance bias

The  possibility  of  allegiance  bias  was  judged  possible  for  the
trials  of  Linehan  1991;  Linehan  1994;  Bateman  1999,  Davidson
2006; Gratz 2006; Linehan 2006; Blum 2008; Gregory 2008; Zanarini
2008;  Bateman  2009;  Farrell  2009;  Steil  2010  since  the  treatment
developers were directly involved as main investigators.

Attention bias

Only  10  studies  (Koons  2001;  Giesen-Bloo  2006;  Linehan  2006;
Bellino  2007;  Bateman  2009;  Cottraux  2009;  Nadort  2009;  Soler
2009;  Doering  2010;  Morey  2010)  were  rated  as  providing  similar
amounts  of  attention  as  obligatory  components  of  the  study
protocol to all trial groups.The participants allocated to the control
group of Gregory 2008 did not get an obligatory control treatment,
but  were  referred  to  alternative  treatments  in  the  community
and  had  not  less  but  markedly  more  professional  contact  hours
during  most  of  the  study  period.  The  risk  of  attention  bias  was
therefore also judged low for this trial. All remaining trials provided
more  attention  (that  is,  in  terms  of  frequency  of  appointments,
involvement  in  additional  group  treatments  etc.)  to  one  group,
usually the experimental group (EG).

Effects of interventions

See: Summary of findings 1 Dialectical Behaviour Therapy (DBT)
versus  treatment  as  usual  (TAU)  for  people  with  borderline
personality disorder; Summary of findings 2 Dialectical Behaviour
Therapy  (DBT)  versus  general  management  (GM)  according  to
APA  guidelines  for  people  with  borderline  personality  disorder;
Summary of findings 3 Dialectical Behaviour Therapy (DBT) versus
community treatment by experts (CTBE) for people with borderline
personality disorder; Summary of findings 4 Dialectical Behaviour
Therapy  for  BPD  with  post-traumatic  stress  disorder  (DBT-PTSD)
versus  waiting  list  (WL)  for  people  with  borderline  personality
disorder; Summary of findings 5 Mentalisation-Based Treatment-
partial  hospitalisation  (MBT-PH)  versus  treatment  as  usual  (TAU)
for  people  with  borderline  personality  disorder;  Summary  of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

findings  6  Mentalisation-Based  Treatment-outpatient  (MBT-out)
versus  treatment  as  usual  (TAU)  for  people  with  borderline
personality  disorder;  Summary  of  findings  7  Transference-
Focused  Psychotherapy  (TFP)  versus  community  treatment  by
experts  (CTBE)  for  people  with  borderline  personality  disorder;
Summary  of  findings  8  Cognitive-Behavioural  Therapy  (CBT)
versus treatment as usual (TAU) for borderline personality disorder;
Summary  of  findings  9  Dynamic-Deconstructive  Psychotherapy
(DDP) versus treatment as ususal (TAU) for people with borderline
personality  disorder;  Summary  of  findings  10  Interpersonal
Psychotherapy  (IPT)  versus  clinical  management  (CM)  for  people
with  borderline  personality  disorder;  Summary  of  findings  11
Interpersonal  Psychotherapy  adapted  for  BPD  (IPT-BPD)  versus
clinical  management  (CM)  for  people  with  borderline  personality
disorder; Summary of findings 12 Dialectical Behaviour Therapy-
skills  training  only  (DBT-ST)versus  standard  group  (SG)  for
borderline personality disorder; Summary of findings 13 Emotion
regulation group training (ERG) versus treatment as usual (TAU) for
borderline personality disorder; Summary of findings 14 Schema-
Focused Therapy-Group (SFT-G) versus treatment as usual (TAU) for
borderline personality disorder; Summary of findings 15 Systems
training  for  emotional  predictability  and  problem  solving  for
borderline personality disorder (STEPPS) versus treatment as usual
(TAU) for borderline personality disorder; Summary of findings 16
Systems training for emotional predictability and problem solving
for  borderline  personality  disorder  +  individual  therapy  (STEPPS
+IT)  versus  treatment  as  usual  (TAU)  for  borderline  personality
disorder;  Summary  of  findings  17  Manual-assisted  cognitive
treatment  (MACT)  versus  treatment  as  usual  (TAU)  for  borderline
personality  disorder;  Summary  of  findings  18  Psychoeducation
(PE) versus waiting list (WL) for borderline personality disorder

1.1.3 Impulsive cluster symptoms

BPD-specific impulsivity in general was reported upon by Van den
Bosch 2005. The data indicated a small, non-significant difference
(SMD -0.17; N = 48, one RCT, 95% CI-0.74 to 0.39). One study (Koons
2001)  indicated  a  very  large  significant  effect  in  favour  of  DBT
concerning  the  reduction  of  suicidality  (SMD  -1.26;  N  =  20,  one
RCT,  95%  CI  -2.24  to  -0.29;  Analysis  1.6).  Three  studies  reported
on  parasuicidality  in  terms  of  the  mean  number  of  parasuicidal
acts  (Linehan  1991;  Koons  2001;  Van  den  Bosch  2005).  Their
pooled effect estimates indicated a moderate significant effect of
parasuicidality reduction by DBT (SMD -0.54; N = 110; three RCTs,
95%  CI  -0.92  to  -0.16;  Analysis  1.8).  Carter  2010,  however,  found
no significant difference in the proportion of participants with self-
harm between both groups (risk ratio (RR) 1.11; N = 51, one RCT;
95% CI 0.78 to 1.57; Analysis 1.9).

1.1.4 Interpersonal cluster symptoms

Carter  2010  report  data  indicating  no  statistically  significant
difference  between  treatment  and  control  conditions  regarding
interpersonal  problems,  resulting  in  a  negligible  effect  size  (SMD
-0.04,  N  =  48,  one  RCT,  95%  CI  -0.54  to  0.61;  Analysis  1.10).  No
data  were  available  from  any  relevant  studies  on  avoidance  of
abandonment.

1.1.5 Cognitive cluster symptoms

Koons  2001  report  data  indicating  no  statistically  significant
difference but favouring DBT with regard to dissociative symptoms,
resulting  in  a  large  effect  size  (SMD  -0.90;  N  =  20,  one  RCT,  95%
CI -1.83 to 0.03; Analysis 1.13). No data are available for any other
cognitive cluster symptoms.

No adverse effects data were available for any included study.

1.1.6 Depression

1 Comprehensive psychotherapies versus control

1.1 Dialectical behaviour therapy (DBT) versus treatment as
usual (TAU)

Five studies were included in this comparison: Carter 2010 (female
outpatients;  six  months  treatment;  N  =  73),  Koons  2001  (female
outpatients; six months treatment; N = 28); Linehan 1991 (female
outpatients; 12 months treatment; N = 61); Linehan 1994 (female
outpatients;  12  months  treatment;  N  =  26);  Van  den  Bosch  2005
(female outpatients; high proportion of substance abusers, that is,
53% of those who actually started treatment; 12 months treatment;
N = 64).

1.1.1 BPD total severity

Koons  2001  provided  data  on  BPD  total  severity  indicating  no
significant  difference  but  a  tendency  in  favour  of  DBT  treatment
(standardised mean difference (SMD) -0.29; N = 20, one RCT, 95%
confidence interval (CI) -1.17 to 0.59; Analysis 1.1).

1.1.2 Affective dysregulative cluster symptoms

Anger  symptoms  were  reported  in  two  studies  (Linehan  1994;
Koons  2001).  The  pooled  effect  estimates  indicate  a  large,
significant effect of DBT in terms of anger reduction (SMD -0.83; N
= 46, two RCTs, 95% CI -1.43 to -0.22; Analysis 1.2). No specific data
were available from relevant studies regarding affective instability
or chronic feelings of emptiness.

Koons 2001 report data indicating a large, statistically significant
difference between treatment and control conditions in depression
(SMD -1.12; N = 20, one RCT, 95% CI -2.08 to -0.16; Analysis 1.14).

1.1.7 Anxiety

Koons 2001 report data indicating a large, statistically significant
difference in favour of DBT (SMD -1.22; N = 20, one RCT, 95% CI -2.20
to -0.25; Analysis 1.15).

1.1.8 Mental health status/functioning

Carter 2010 and Linehan 1994 report on the level of functioning. The
pooled effect estimates yield a moderate, significant effect in favour
of DBT (SMD 0.65; N = 74, two RCTs, 95% CI 0.07 to 1.24; Analysis
1.17).

1.1.9 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  1.25;  N  =
252;  five  RCTs;  95%  CI  0.54  to  2.92;  Analysis  1.18).  However,  the
corresponding I2 score of 77% suggests substantial heterogeneity.
A  possible  reason  for  this  may  be  a  higher  likelihood  of  drop-
out  in  rural  areas.  A  post-hoc  sensitivity  analysis  restricting  the
results to non-rural areas, that is, leaving out the results of Carter
2010, resulted in a more homogenous effect (RR 0.80; N = 179; four
RCTs; 95% CI 0.47 to 1.36; I2 = 35%; Analysis 1.19) supporting this
hypothesis.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

the  outcome  of  general
for 
No  data  were  available 
psychopathology.  See  Table  1  for  an  overview  of  primary  effect
outcome effect estimates.

1.2 Dialectical behaviour therapy (DBT) versus general
management (GM) according to APA guidelines

One  study  was  included  in  this  comparison:  McMain  2009
(outpatients, 92% female; 12 months treatment; N = 180).

1.2.1 BPD total severity

McMain 2009 reported data on this outcome indicating a marginal,
non-statistically significant difference (SMD -0.04; N = 180, 95% CI
-0.33 to 0.25; Analysis 1.1).

terms of suicidality (SMD -0.12; N = 89, 95% CI -0.54 to 0.30; Analysis
1.6).

1.3.2 Depression

indicating  a  small  to  moderate,
Linehan  2006  report  data 
statistically  non-significant  difference  between  groups  but
favouring DBT (SMD -0.39; N = 89, 95% CI -0.81 to 0.04; Analysis 1.14).

1.3.4 Leaving the study early

Reported data indicate a statistically significant difference between
treatment  and  control  conditions  for  leaving  the  study  early  if
considering all participants randomised, favouring DBT (RR 0.43; N
= 101; 95% CI 0.28 to 0.67; Analysis 1.18).

1.2.2 Affective dysregulative cluster symptoms

Data on anger symptoms indicated a very small, statistically non-
significant difference between the two treatments (SMD -0.03; N =
180, 95% CI -0.32 to 0.26; Analysis 1.2).

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective  dysregulative, 
interpersonal  and  cognitive
cluster  symptoms;  anxiety,  general  psychopathology,  mental
health status/functioning. See Table 1 for an overview of primary
effect outcome effect estimates.

1.2.3 Impulsive cluster symptoms

The findings indicate no significant difference in terms of the mean
number of suicidal and/or self-injurious episodes, but favour DBT
(SMD  -0.23;  N  =  180,  95%  CI  -0.52  to  0.06;  Analysis  1.8)  with  a
small difference. No data were available for effects on impulsivity
in general.

1.2.4 Interpersonal cluster symptoms

McMain  2009  report  data  indicating  a  marginal,  statistically  non-
significant difference between treatment and control conditions in
this regard (SMD -0.03, N = 180, 95% CI-0.32 to 0.26; Analysis 1.10).

1.2.5 Depression

McMain  2009  report  data  indicating  a  small,  statistically,  non-
significant difference between both groups (SMD -0.17; N = 180, 95%
CI -0.46 to 0.12; Analysis 1.14).

1.2.6 General psychopathology

McMain  2009  report  data  indicating  a  marginal,  non-significant
difference between both groups (SMD -0.01; N = 180, 95% CI -0.30
to 0.28; Analysis 1.16).

1.2.7 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early if considering all participants randomised (RR 1.03; N = 180;
95% CI 0.71 to 1.49; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  cognitive
cluster-related  symptoms,  anxiety  and  mental  health  status/
functioning. See Table 1 for an overview of primary effect outcome
effect estimates.

1.4 DBT adapted for BPD + post-traumatic stress disease (DBT-
PTSD) versus waiting list (WL)

One  trial  was  included  in  this  comparison:  Steil  2010  (inpatients;
100% females with comorbid PTSD from childhood sexual abuse;
three months inpatient treatment plus additional booster session
6 months after discharge; N = 32).

1.4.1 BPD total severity

Steil 2010 report data indicating a moderate to large, statistically
significant difference between experimental and control conditions
in terms of overall BPD severity after treatment,favouring DBT-PTSD
(SMD -0.74; N = 31; 95% CI -1.47 to -0.01; Analysis 1.1).

1.4.2 Cognitive cluster symptoms

Reported  data  indicate  a  small  to  moderate,  statistically  non-
significant difference between experimental and control conditions
in  terms  of  dissociation  (SMD  -0.34;  N  =  30;  95%  CI  -1.06  to  0.38;
Analysis 1.13).

1.4.3 Depression

Steil 2010 provided data indicating a large, statistically significant
difference  between  both  conditions,  with  less  pathology  for  the
DBT-PTSD-treated group (SMD -1.06; N = 30; 95% CI -1.84 to -0.29;
Analysis 1.14).

1.4.4 Anxiety

Data  also  indicate  a  large,  statistically  significant  difference
between experimental and control conditions for the outcome of
anxiety, favouring the experimental intervention (SMD -0.96; N = 30;
95% CI -1.72 to -0.20; Analysis 1.15).

1.4.5 General psychopathology

1.3 Dialectical behaviour therapy (DBT) versus community
treatment by experts (CTBE)

One study was included in this comparison: Linehan 2006 (female
outpatients; 12 months treatment; N = 101).

No  statistically  significant  difference  is  indicated  by  the  reported
data for the outcome of general psychopathology (SMD -0.70; N =
30; 95% CI -1.45 to 0.04; Analysis 1.16). However, the data indicate
a favourable moderate to large effect.

1.3.1 Impulsive cluster symptoms

1.4.6 Leaving the study early

Linehan  2006  report  data  indicating  a  small,  statistically  non-
significant difference between treatment and control conditions in

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

early if considering all participants randomised exclusive of those
that  were  excluded  due  to  meeting  exclusion  criteria,  which
became clear after randomisation but before start of treatment (RR
1.94; N = 32; 95% CI 0.44 to 8.57; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  affective-
dysregulative,  impulsive  and  interpersonal  cluster  symptoms;
mental  health  status/functioning.  See  Table  1  for  an  overview  of
primary effect outcome effect estimates.

1.5 Mentalisation based treatment - partial hospitalisation
(MBT-PH) versus treatment as usual (TAU)

One  study  was  included  in  this  comparison:  Bateman  1999
(partially hospitalised versus outpatient participants, 58% females;
18 months treatment; N = 44).

1.5.1 Impulsive cluster symptoms

No data available on general impulsivity. Bateman 1999 report data
indicating large, significant effects on both less suicidality (RR 0.08;
N = 38, 95% CI 0.01 to 0.58; Analysis 1.7) and parasuicidality (RR 0.44;
N = 38, 95% CI 0.24 to 0.81; Analysis 1.9) favouring the experimental
group.

1.5.2 Interpersonal cluster symptoms

Bateman  1999  report  data  indicating  a  very  large,  significant
effect of less interpersonal pathology in partially-hospitalised MBT
patients (SMD -2.22; N = 38, 95% CI -3.04 to -1.39; Analysis 1.10). No
further data on avoidance of abandonment available.

1.5.3 Depression

Bateman  1999  report  data  indicating  a  very  large,  statistically
significant difference in favour of MBT-PH (SMD -1.98; N = 38, 95%
CI -2.78 to -1.19; Analysis 1.14).

1.5.4 Anxiety

Bateman 1999 report data indicating a moderate, statistically non-
significant difference in terms of anxious pathology (SMD -0.49; N =
38, 95% CI -1.14 to 0.16; Analysis 1.15).

1.5.5 General psychopathology

Bateman  1999  report  data  indicating  a  small  to  moderate,
statistically  non-significant  difference  (SMD  -0.39;  N  =  38,  95%  CI
-1.03 to 0.26; Analysis 1.16).

1.5.6 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  1.00;  N  =  44;
95% CI 0.23 to 4.42; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective-dysregulative  and  cognitive  cluster  symptoms;
mental  health  status/functioning.  SeeTable  2  for  an  overview  of
primary effect outcome effect estimates.

1.6 Mentalisation based treatment - outpatient (MBT-out) versus
treatment as usual (TAU)

One  study  was  included  in  this  comparison:  Bateman  2009
(outpatients, 80% females; 18 months treatment; N = 134).

Cochrane Database of Systematic Reviews

1.6.1 Impulsive cluster symptoms

No  data  available  on  general  impulsivity.  Bateman  2009  report
data indicating large, significant effects of smaller proportions of
participants with both suicidality (RR 0.11; N = 134, 95% CI 0.03 to
0.46; Analysis 1.7) and parasuicidality (RR 0.56; N = 134, 95% CI 0.34
to 0.92; Analysis 1.9) in the experimental group.

1.6.2 Interpersonal cluster symptoms

Bateman 2009 report data indicating a large, statistically significant
difference  in  favour  or  MBT-outpatient  treatment  in  terms  of
interpersonal pathology (SMD -0.95; N = 134, 95% CI -1.30 to -0.59;
Analysis  1.10).  No  further  data  on  avoidance  of  abandonment
available.

1.6.3 Depression

Bateman  2009  report  data  indicating  a  moderate,  statistically
significant difference in favour of MBT-out (SMD -0.45; N = 134, 95%
CI -0.79 to -0.10; Analysis 1.14).

1.6.4 General psychopathology

Bateman  2009  report  data 
indicating  a  moderate  to  large
statistically  significant  difference  between  the  two  treatment
conditions in favour of MBT-outpatient treatment (SMD -0.67, N =
134, 95% CI -1.02 to -0.33; Analysis 1.16).

1.6.5 Mental health status/functioning

Bateman  2009  report  data  indicating  a  statistically  significant
difference between the two treatment conditions in favour of MBT-
outpatient  treatment  (SMD  0.55,  N  =  134,  95%  CI  0.20  to  0.89;
Analysis 1.17).

1.6.6 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early if considering all participants randomised (RR 1.05; N = 134;
95% CI 0.59 to 1.87; Analysis 1.18).

No data were available for the following outcomes: BPD severity;
affective-dysregulative  and  cognitive  cluster  symptoms;  anxiety.
SeeTable  2  for  an  overview  of  primary  effect  outcome  effect
estimates.

1.7 Transference-focused therapy (TFP) versus community
treatment by experts (CTBE)

One study was included in this comparison: Doering 2010 (female
outpatients; 12 months treatment; N = 104).

1.7.1 BPD total severity

Data  reported  by  Doering  2010  indicate  a  moderate,  statistically
significant effect in favour of TFP concerning overall BPD severity
reduction (SMD -0.55; N = 104, 95% CI -0.95 to -0.16; Analysis 1.1).

1.7.2 Impulsive cluster symptoms

Doering  2010  report  data  indicating  no  statistically  significant
difference in the proportion of participants with any suicidal act (RR
0.64; N = 104, 95% CI 0.27 to 1.51; Analysis 1.7) or any self-harming
behaviour (RR 1.09; N = 104, 95% CI 0.84 to 1.40; Analysis 1.9). No
data available on impulsivity in general.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.7.3 Depression

1.8.5 General psychopathology

Doering 2010 report data indicating a very small, statistically non-
significant  difference  between  the  groups  in  terms  of  depression
(SMD 0.12; N = 104, 95% CI -0.26 to 0.51; Analysis 1.14).

General  psychopathological  burden  was  not  found  to  differ
statistically significant between both groups, and was also marginal
in size (SMD -0.03; N = 99, 95% CI -0.43 to 0.36; Analysis 1.16).

1.7.4 Anxiety

1.8.6 Mental health status/functioning

Doering  2010  report  data  indicating  a  marginal,  statistically  non-
significant difference between the groups regarding anxiety (SMD
0.04; N = 104, 95% CI -0.35 to 0.42; Analysis 1.15).

1.7.5 General psychopathology

Doering  2010  report  data  indicating  a  marginal,  statistically  non-
significant  difference  between  the  groups  in  terms  of  general
psychopathology(SMD 0.08; N = 104, 95% CI -0.31 to 0.46; Analysis
1.16).

1.7.6 Mental health status/functioning

Doering  2010  report  data  indicating  a  small,  statistically  non-
significant  difference  between  the  groups  in  terms  of  overall
functioning (SMD 0.34; N = 104, 95% CI -0.05 to 0.73; Analysis 1.17).

1.7.7 Leaving the study early

Reported data indicate a statistically significant difference between
treatment  and  control  conditions  for  leaving  the  study  early  if
considering all participants randomised, favouring TFP (RR 0.57; N
= 104; 95% CI 0.39 to 0.85; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  Affective-
dysregulative, interpersonal and cognitive cluster symptoms. See
Table 3 for an overview of primary effect outcome effect estimates.

1.8 Cognitive-behavioural therapy (CBT) versus TAU

One  study  was  included  in  this  comparison:  Davidson  2006
(outpatients, 84% females; 12 months treatment; N = 106).

1.8.1 Impulsive cluster symptoms

Reported  data  indicate  a  smaller  proportion  of  participants  with
any suicidal act in the CBT group (RR 0.78; N = 101; 95% CI 0.47 to
1.27; Analysis 1.7, but a higher proportion of participants with any
self-mutilation (RR 1.17; N = 99; 95% CI 0.86 to 1.60; Analysis 1.9).
Neither of these effects was statistically significant.

1.8.2 Interpersonal cluster symptoms

Data indicate a small, but statistically non-significant difference in
terms of interpersonal pathology between the two conditions (SMD
0.23; N = 99; 95% CI -0.16 to 0.63; Analysis 1.10).

1.8.3 Depression

We found only a very small, statistically non-significant difference
between both groups in terms of depression (SMD -0.11; N = 99; 95%
CI -0.50 to 0.29; Analysis 1.14).

1.8.4 Anxiety

There  was  no  indication  of  a  statistically  significant  difference
between both conditions in terms of anxious pathology, the effect
size was only marginal in size (SMD -0.03; N = 99; 95% CI -0.42 to
0.37; Analysis 1.15).

Data indicated no statistically significant difference between both
groups in terms of the level of functioning at the end of treatment
(SMD 0.00; N = 99, 95% CI -0.39 to 0.39; Analysis 1.17). The numerical
effect  size  indicated  no  difference  between  the  two  treatment
groups.

1.8.7 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early if considering all participants randomised (RR 0.48; N = 106;
95% CI 0.09 to 2.52; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective-dysregulative  and  cognitive  cluster  symptoms.
See  Table  4  for  an  overview  of  primary  effect  outcome  effect
estimates.

1.9 Deconstructive dynamic psychotherapy (DDP) versus
treatment as usual (TAU)

One  study  was  included  in  this  comparison:  Gregory  2008
(outpatients,  80%  females,  all  with  active  alcohol  abuse  or
dependence; 12 months treatment; N = 30)

1.9.1 BPD total severity

Reported  data  indicate  a  moderate,  statistically  non-significant
difference between both conditions (SMD -0.44; N = 30; 95% CI -1.16
to 0.29; Analysis 1.1).

1.9.2 Affective dysregulative cluster symptoms

No data available.

1.9.3 Impulsive cluster symptoms

Gregory  2008  report  data  that  indicate  no  statistically  significant
difference  between  both  conditions  in  terms  of  proportion  of
participants with self-mutilating behaviour (RR 0.89; N = 30; 95% CI
0.47 to 1.67, Analysis 1.9).

1.9.4 Cognitive cluster symptoms

indicate  no  statistically
As  for  dissociation,  reported  data 
significant difference between the two conditions (SMD 0.25; N = 30;
95% CI -0.47 to 0.97; Analysis 1.13).

1.9.5 Depression

Reported data indicate a moderate but statistically non-significant
difference  between  the  conditions  in  terms  of  depression  (SMD
-0.52; N = 30; 95% CI -1.24 to 0.21; Analysis 1.14).

1.9.6 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.83;  N  =  30;
95% CI 0.32 to 2.15; Analysis 1.18).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

No data were available for the following outcomes: interpersonal
cluster  symptoms;  anxiety,  general  psychopathology,  mental
health status/functioning. See Table 5 for an overview of primary
effect outcome effect estimates.

1.10 Interpersonal psychotherapy (IPT) + fluoxetine versus
clinical management (CM) + fluoxetine

included 

One  trial  was 
in  this  comparison:  Bellino  2006
(outpatients,  all  with  current  major  depressive  episode,
60%  females;  six  months  treatment;  additional  antidepressive
medication  was  given  (fluoxetine  20-40mg/d)  to  participants  of
both conditions; N = 39).

1.10.1 Depression

Reported  data  indicate  a  large,  statistically  significant  difference
between  both  conditions  favouring  combined  treatment  (that  is,
IPT  plus  medication;  SMD  -0.90;  N  =  32;  95%  CI  -1.63  to  -0.16;
Analysis 1.14).

1.10.2 Anxiety

There  is  no  indication  of  a  statistically  significant  difference
between  both  groups  (SMD  0.20;  N  =  32;  95%  CI  -0.49  to  0.90;
Analysis 1.15). Data indicated a small effect.

1.10.3 Mental health status/functioning

Again, there is no indication of a statistically significant difference,
with a very small effect size (SMD 0.12; N = 32; 95% CI -0.57 to 0.81;
Analysis 1.17).

1.10.4 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.79;  N  =  39;
95% CI 0.20 to 3.07; Analysis 1.18).

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective-dysregulative,  impulsive,  interpersonal  and
cognitive cluster symptoms; general psychopathology. See Table 6
for an overview of primary effect outcome effect estimates.

1.11 IPT adapted to BPD (IPT-BPD) + fluoxetine versus clinical
management + fluoxetine

included 

One  trial  was 
in  this  comparison:  Bellino  2010
(outpatients,  67%  females;  eight  months  treatment,  additional
antidepressive  medication  was  given  (fluoxetine  20-40  mg/d)  to
participants of both conditions; N = 55).

1.11.1 BPD total severity

Bellino  2010  report  data  that  indicate  no  clinical  or  statistically
significant difference between both conditions (SMD -0.03; N = 44;
95% CI -0.62 to 0.56; Analysis 1.1).

1.11.2 Affective dysregulative cluster symptoms

Reported  data  indicate  no  clinical  or  statistically  significant
differences  between  both  conditions  in  terms  of  inappropriate
anger  (SMD  0.01;  N  =  44;  95%  CI  -0.58  to  0.60;  Analysis  1.2)  and
chronic feelings of emptiness (SMD 0.09; N = 44; 95% CI -0.50 to 0.68;
Analysis 1.4). A large, statistically significant difference is indicated
for affective instability, favouring IPT-BPD (SMD -0.92; N = 44; 95%
CI -1.54 to -0.30; Analysis 1.3).

Cochrane Database of Systematic Reviews

1.11.3 Impulsive cluster symptoms

Bellino  2010  report  data  indicating  only  a  marginal,  statistically
non-significant  difference  between  both  groups  in  terms  of
parasuicidality (SMD 0.02; N = 44; 95% CI -0.58 to 0.61; Analysis 1.8)
but in terms of general impulsivity, favouring IPT-BPD with a large
effect (SMD -0.91; N = 44; 95% CI-1.53 to -0.28; Analysis 1.5).

1.11.4 Interpersonal cluster symptoms

There is indication for a statistically significant difference between
both groups in terms of interpersonal problems, favouring IPT-BPD
with a large effect (SMD -0.82; N = 44; 95% CI -1.44 to -0.20; Analysis
1.10). However, both groups did not different in terms of avoidance
of abandonment (SMD 0.01; N = 44; 95% CI -0.58 to 0.60; Analysis
1.11).

1.11.5 Cognitive cluster symptoms

Reported data indicate neither a statistically significant difference
between both groups for the outcome of identity disturbance (SMD
-0.03; N = 44; 95% CI -0.62 to 0.56; Analysis 1.12) nor for the outcome
of paranoid ideation (SMD 0.10; N = 44; 95% CI -0.49 to 0.70; Analysis
1.13), with very small effect sizes for both outcomes.

1.11.6 Depression

No  indication  is  given  for  a  statistically  significant  difference
between both conditions in terms of depression (SMD -0.05; N = 44;
95% CI -0.64 to 0.55; Analysis 1.14).

1.11.7 Anxiety

There  is  no  indication  for  a  statistically  significant  difference
between  both  groups  (SMD  -0.52;  N  =  44,  95%  CI  -1.12  to  0.08;
Analysis 1.15). However, data indicate a moderate favourable effect
of IPT-BPD.

1.11.8 Mental health status/functioning

Reported  data  indicate  no  statistically  significant  difference
between both groups with regard to this outcome (SMD -0.04; N =
44; 95% CI -0.63 to 0.55; Analysis 1.17).

1.11.9 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.35;  N  =  55;
95% CI 0.08 to 1.57; Analysis 1.18).

No  data  were  available 
the  outcome  of  general
for 
psychopathologiy burden. See Table 6 for an overview of primary
effect outcome effect estimates.

2 Non-comprehensive psychotherapeutic interventions versus
control

2.1 Dialectical behaviour therapy-skills training only (DBT-ST)
versus standard group (SG)

One  study  was 
(outpatients, 83% females; three months treatment; N = 60).

in  this  comparison:  Soler  2009

included 

2.1.1 BPD total severity

Reported  data  indicate  a  very  large,  statistically  significant
difference at end of treatment between both conditions, favouring
DBT-ST (SMD -1.01; N = 59; 95% CI-1.55 to -0.47; Analysis 2.1).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2.1.2 Affective dysregulative cluster symptoms

2.2.1 BPD total severity

Data indicate large to very large statistically significant differences
in favour of DBT-ST concerning inappropriate anger (SMD-0.84; N =
59; 95% CI -1.37 to -0.30; Analysis 2.2) and affective instability (SMD
-1.07;  N  =  59;  95%  CI  -1.61  to  -0.52;  Analysis  2.3).  No  statistically
significant difference was found for the outcome of chronic feelings
of emptiness, with a moderate effect size (SMD -0.43; N = 59; 95% CI
-0.95 to 0.09; Analysis 2.4).

2.1.3 Impulsive cluster symptoms

Available  data 
indicate  a  moderate,  statistically  significant
difference favouring DBT-ST in terms of impulsivity (SMD -0.61; N =
59; 95% CI -1.14 to -0.09; Analysis 2.5) but not suicidality (SMD -0.10;
N = 59; 95% CI -0.61 to 0.41; Analysis 2.7). For suicidality, the effect
size indicates only a very small to marginal difference.

2.1.4 Interpersonal cluster symptoms

There  was  no  indication  of  a  statistically  significant  difference
concerning interpersonal pathology, with a small effect size (SMD
-0.29; N = 59; 95% CI -0.80 to 0.23; Analysis 2.10).

Reported  data  indicate  a  very  large,  statistically  significant
difference favouring ERG treatment (SMD -1.02; N = 22; 95% CI -1.92
to -0.11; Analysis 2.1).

2.2.2 Affective dysregulative cluster symptoms

Available  data  indicate  a  very  large,  statistically  significant
difference  favouring  ERG  over  TAU  alone  regarding  affective
instability (SMD -1.65; N = 22; 95% CI -2.65 to -0.55; Analysis 2.3).

2.2.3 Impulsive cluster symptoms

indicate  very 

Data 
large,  statistically  significant  differences
between both conditions favouring ERG regarding the outcomes of
impulsivity (SMD -1.30; N = 22; 95% CI -2.24 to -0.36; Analysis 2.5)
and parasuicidality (SMD -0.98; N = 22; 95% CI -1.88 to -0.09; Analysis
2.8).

2.2.4 Depression

Reported data indicate very large, statistically significant difference
(SMD -1.20; N = 22; 95% CI -2.13 to -0.28; Analysis 2.12).

2.1.5 Cognitive cluster symptoms

2.2.5 Anxiety

Data indicate a moderate to large statistically significant difference
favouring DBT-ST in terms of psychotic symptoms (SMD -0.66; N =
59; 95% CI -1.18 to -0.13; Analysis 2.11).

There  was  also  indication  of  a  large,  statistically  significant
difference regarding anxious pathology (SMD -0.89; N = 22; 95% CI
-1.78 to -0.01; Analysis 2.13).

2.1.6 Depression

2.2.6 Leaving the study early

A  large,  statistically  significant  difference  is  indicated  by  the
reported  data  favouring  DBT-ST  with  regard  to  depressive
pathology (SMD -0.97; N = 59; 95% CI -1.51 to -0.43; Analysis 2.12).

2.1.7 Anxiety

There is also an indication of statistically superiority with regard to
anxious pathology with a moderate effect size (SMD -0.67; N = 59;
95% CI -1.20 to -0.15; Analysis 2.13).

2.1.8 General psychopathology

A small to moderate, but statistically non-significant difference was
found for general psychopathology (SMD -0.42; N = 59; 95% CI -0.93
to 0.10; Analysis 2.14).

2.1.9 Mental health status/functioning

Data  indicated  a  small  but  statistically  non-significant  difference
regarding the overall level of functioning (SMD -0.29; N = 59; 95% CI
-0.80 to 0.22; Analysis 2.15).

2.1.10 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.58;  N  =  60;
95% CI 0.34 to 1.00; Analysis 2.16).

No data were available for the following outcomes: interpersonal
and cognitive cluster symptoms; general psychopathology, mental
health status/functioning. See Table 8 for an overview of primary
effect outcome effect estimates.

2.3 Schema-focused therapy - group intervention (SFT-G) versus
treatment as usual (TAU)

One  study  was  included  in  this  comparison:  Farrell  2009  (female
outpatients; 8 months treatment; N = 32).

2.3.1 BPD total severity

Farrell  2009  report  data  indicating  a  very  large,  statistically
significant effect in favour of SFT-G (SMD -1.66; N = 28, 95% CI -2.54
to -0.78; Analysis 2.1).

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.58;  N  =  60;
95% CI 0.34 to 1.00; Analysis 2.16).

2.3.2 Affective dysregulative cluster symptoms

Reported  data  indicate  a  very  large,  statistically  significant
difference with regard to general affective instability (SMD -1.41; N
= 28, 95% CI -2.26 to -0.57; Analysis 2.3).

See  Table  7  for  an  overview  of  primary  effect  outcome  effect
estimates.

2.2 Emotion regulation group (ERG) versus treatment as usual
(TAU)

One  trial  was  included  in  this  comparison:  Gratz  2006  (female
outpatients; 3.5 months treatment; N = 24)

2.3.3 Impulsive cluster symptoms

Farrell  2009  found  a  very  large,  statistically  significant  difference
favouring SFT-G with regard to BPD-specific impulsivity (SMD -1.92;
N = 28, 95% CI -2.85 to -1.00; Analysis 2.5).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2.3.4 Interpersonal cluster symptoms

2.5.1 BPD total severity

There was a very large, statistically significant difference between
both  groups  with  regard  to  interpersonal  pathology  in  favour  of
SFT-G (SMD -1.94, N = 28, 95% CI -2.87 to-1.02; Analysis 2.10).

Reported  data 
indicate  a  small,  statistically  non-significant
difference between the treatment groups (SMD -0.17; N = 124; 95%
CI -0.52 to 0.19; Analysis 2.1).

2.3.5 Cognitive cluster symptoms

2.5.2 Affective dysregulative cluster symptoms

Reported  data  indicate  a  very  large,  statistically  significant
difference  in  favour  of  SFT-G  with  regard  to  cognitive-cluster
symptoms (SMD -1.37, N = 28, 95% CI -2.21 to -0.53; Analysis 2.11).

There was a small, statistically non-significant difference between
conditions in terms of affective instability (SMD -0.32; N = 124; 95%
CI -0.67 to 0.04; Analysis 2.3).

2.3.6 General psychopathology

2.5.3 Impulsive cluster symptoms

Farrell  2009  report  data  indicating  a  very  large,  statistically
significant  difference  between  the  two  conditions  with  better
outcomes for the SFT-G group (SMD -1.06, N = 28, 95% CI -1.87 to
-0.25; Analysis 2.14).

2.3.7 Mental health status/functioning

Again, Farrell 2009 report data indicating a very large, statistically
significant difference in favour of SFT-G (SMD 1.20; N = 28, 95% CI
0.38 to 2.03; Analysis 2.15).

2.3.8 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.11;  N  =  32;
95% CI 0.01 to 1.91; Analysis 2.16).

No  data  were  available  for  the  following  outcomes:  depression,
anxiety.  See  Table  9  for  an  overview  of  primary  effect  outcome
effect estimates.

2.4 Manual-assisted cognitive treatment (MACT) versus
treatment as usual (TAU)

One trial was included in this comparison: Weinberg 2006 (female
outpatients; 1.5 months treatment; N = 30)

Available  data 
indicate  a  small,  statistically  non-significant
difference between both groups for BPD-speciifc impulsivity (SMD
-0.29; N = 124; 95% CI -0.64 to 0.07; Analysis 2.5).

2.5.4 Interpersonal cluster symptoms

We  found  a  small  to  moderate  statistically  significant  difference
favouring  STEPPS  treatment  for  the  outcome  of  interpersonal
pathology (SMD -0.42; N = 124; 95% CI -0.78 to -0.06; Analysis 2.10).

2.5.5 Cognitive cluster symptoms

There  was  also  a  small  to  moderate  statistically  significant
difference with better outcomes of cognitive cluster symptoms in
the STEPPS group (SMD -0.42; N = 124; 95% CI -0.78 to -0.06; Analysis
2.11).

2.5.6 Depression

Data  indicate  a  small,  but  statistically  non-significant  difference
between conditions for the outcome of depression (SMD -0.24; N =
124; 95% CI -0.59 to 0.11; Analysis 2.12).

2.5.7 General psychopathology

There  was  a  small,  statistically  non-significant  difference  for  the
outcome of general psychopathology (SMD -0.29; N = 124; 95% CI
-0.64 to 0.07; Analysis 2.14).

2.4.1 Impulsive cluster symptoms

2.5.8 Mental health status/functioning

Reported data indicate statistically significant differences favouring
MACT for the outcomes of suicidality (SMD -0.86; N = 28; 95% CI -1.64
to -0.07; Analysis 2.7) and parasuicidality (SMD -0.88; N = 28; 95% CI
-1.67 to -0.10; Analysis 2.8) with large effects.

The treatment groups differed statistically significantly at the end
of  treatment  with  a  small  to  moderate  effect  indicating  better
results for STEPPS, that is, better mental health status (SMD 0.38; N
= 124; 95% CI 0.02 to 0.73; Analysis 2.15).

2.4.2 Leaving the study early

2.5.9 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.20;  N  =  30;
95% CI 0.01 to 3.85; Analysis 2.16).

Reported data indicate a statistically significant difference between
both condition in terms of different proportion of those leaving the
study early (RR 2.27; N = 124; 95% CI 1.08 to 4.76; Analysis 2.15), with
a higher drop-out rate for STEPPS.

No  data  were  available  for  the  following  outcomes:  BPD
total severity; affective-dysregulative, interpersonal and cognitive
cluster symptoms; depression, anxiety, general psychopathology,
mental health status/functioning. See Table 10 for an overview of
primary effect outcome effect estimates.

2.5 Systems training for emotional predictability and problem
solving for BPD (STEPPS) versus treatment as usual (TAU)

One trial was included in this comparison: Blum 2008 (outpatients,
83% females; five months treatment; N = 124).

No data were available for the outcome of anxiety. See Table 11 for
an overview of primary effect outcome effect estimates.

2.6 Systems training for emotional predictability and problem
solving for BPD + individual therapy (STEPPS) versus treatment
as usual (TAU)

One study was included in this comparison: Bos 2010 (outpatients,
86% females; 6 months treatment; N = 79)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2.6.1 BPD total severity

Bos  2010  report  data  indicating  a  moderate,  statistically  non-
significant difference between both conditions, but the boundaries
of the 95% CI are very close to significance, favouring STEPPS + IT
(SMD -0.55; N = 52; 95% CI -1.11 to 0.00; Analysis 2.1).

2.6.2 Impulsive cluster symptoms

3 Comprehensive psychotherapies: active versus active
conditions

3.1 Dialectical behaviour therapy (DBT) versus Client-centered
therapy (CCT)

This comparison included one trial: Turner 2000 (outpatients, 79%
females; 12 months therapy; N = 24)

There  are  no  statistically  significant  differences  between  both
conditions in terms of proportion of those participants beyond the
cut-off scores of clinically relevant impulsivity (RR 0.93; N = 58; 95%
CI 0.66 to 1.29; Analysis 2.6) and clinically relevant parasuicidality
(RR 1.32; N = 58; 95% CI 0.78 to 2.22; Analysis 2.9).

3.1.1 Affective dysregulative cluster symptoms

Data  indicate  a  tendency  towards  better  results  of  DBT  with  a
large effect for the outcome of anger, but no statistically significant
difference (SMD -0.79; N = 24; 95% CI -1.62 to 0.05; Analysis 3.2).

2.6.3 Interpersonal cluster symptoms

3.1.2 Impulsive cluster symptoms

Data  indicate  a  small,  statistically  non-significant  difference
between  both  treatment  groups 
interpersonal
pathology (SMD -0.27; N = 53; 95% CI -0.81 to 0.27; Analysis 2.10).

in  terms  of 

2.6.4 General psychopathology

There was a moderate, statistically significant difference between
both conditions in favour of STEPPS + IT (SMD -0.60; N = 51; 95% CI
-1.16 to -0.04; Analysis 2.14).

2.6.5 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  1.47;  N  =  79;
95% CI 0.59 to 3.65; Analysis 2.16).

No  data  were  available  for  the  following  outcomes:  affective-
dysregulative and cognitive cluster symptoms; depression, anxiety,
mental health status/functioning. See Table 11 for an overview of
primary effect outcome effect estimates.

2.7 Psychoeducation (PE) versus waiting list (WL)

The  only  study  included  in  this  comparison  was  Zanarini  2008
(newly-diagnosed female outpatients; three months treatment; N
= 50)

2.7.1 Impulsive cluster symptoms

Data indicate a small to moderate but statistically non-significant
difference between both groups in terms of impulsivity baseline to
endpoint  change  scores  (SMD  -0.47;  N  =  50;  95%  CI  -1.04  to  0.10;
Analysis 2.5).

2.7.2 Interpersonal cluster symptoms

We  found  a  moderate  to  large,  statistically  significant  difference
between both groups in terms of interpersonal pathology baseline
to endpoint change scores (SMD -0.75; N = 50; 95% CI -1.33 to -0.16;
Analysis 2.10).

Reported  data  indicate  large  to  very  large  statistically  significant
differences  between  both  groups  for  impulsive  symptom  cluster
outcomes, all favouring DBT over CCT (impulsivity: SMD -1.05, N =
24, 95% CI -1.92 to -0.19, Analysis 3.3; suicidality: SMD -0.87, N = 24,
95% CI -1.71 to -0.02, Analysis 3.4; parasuicidality: SMD -1.28, N = 24,
95% CI -2.17 to -0.38, Analysis 3.5).

3.1.3 Cognitive cluster symptoms

There  was  also  a  very  large,  statistically  significant  difference  for
the  outcome  of  psychotic  symptoms,  favouring  DBT  over  CCT
treatment (SMD -1.11; N = 24; 95% CI -1.98 to -0.24; Analysis 3.6).

3.1.4 Depression

Available  data  also  indicate  a  very  large,  significant  difference
for the outcome of depression, with lower burden in DBT-treated
participants (SMD -1.26; N = 24; 95% CI -2.15 to -0.37; Analysis 3.7).

3.1.5 Anxiety

Data indicate no significant difference between both conditions for
the  outcome  of  anxiety,  but  a  moderate  to  large  difference  (SMD
-0.70; N = 24; 95% CI -1.53 to 0.13; Analysis 3.8).

3.1.6 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.50;  N  =  24;
95% CI 0.16 to 1.55; Analysis 3.11).

No  data  were  available 
BPD  total  severity; 
psychopathology, mental health status/functioning.

following  outcomes:
interpersonal  cluster  symptoms;  general

the 

for 

3.2 Schema-focused therapy (SFT) versus Transference-focused
therapy (TFP)

One  trial  was  included  in  this  comparison:  Giesen-Bloo  2006
(outpatients, 93% females; 36 months treatment; N = 88).

2.7.3 Leaving the study early

3.2.1 BPD total severity

All  participants  attended  every  visit,  there  were  no  non-
attendances in either group.

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective-dysregulative  and  cognitive  cluster  symptoms;
depression,  anxiety,  general  psychopathology,  mental  health
status/functioning. See Table 12 for an overview of primary effect
outcome effect estimates.

Giesen-Bloo  2006  report  data  indicating  a  moderate,  statistically
significant difference between both treatment groups. SFT-treated
participants showed significantly lower levels of BPD total severity
(SMD -0.45; N = 86; 95% CI -0.88 to -0.02; Analysis 3.1)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

3.2.2 General psychopathology

3.4.3 Anxiety

Data  indicate  no  statistically  significant  difference  between  both
conditions for the outcome of general psychopathology (SMD -0.09;
N = 86; 95% CI -0.52 to 0.33; Analysis 3.9), with a marginal effect size.

3.2.3 Leaving the study early

Reported data indicate a statistically significant difference between
both condition in terms of a different proportion of those leaving
the study early (RR 0.52; N = 88; 95% CI 0.30 to 0.92; Analysis 3.11),
with a smaller drop-out rate for SFT.

No  data  were  available  for  the  following  outcomes:  affective-
dysregulative, 
interpersonal  and  cognitive  cluster
symptoms; depression, anxiety, mental health status/functioning.

impulsive, 

3.3 Schema-focused therapy (SFT) versus Schema-focused
therapy + Therapist Telephone Availability (SFT+TTA)

One  trial  was 
(outpatients, 9´7% females; 18 months treatment; N = 62).

in  this  comparison:  Nadort  2009

included 

3.3.1 BPD total severity

Data  indicate  no  clinically  or  statistically  significant  difference
between  both  conditions  for  the  outcome  of  BPD  total  severity
(SMD -0.03; N = 61; 95% CI -0.53 to 0.47; Analysis 3.1).

3.3.2 General psychopathologiy

Data  indicate  a  very  small,  statistically  non-significant  difference
between  both  conditions 
the  outcome  of  general
for 
psychopathology (SMD 0.14; N = 61; 95% CI -0.37 to 0.64; Analysis
3.9).

3.3.3 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between both conditions in terms of a different proportion of those
leaving the study early (RR 0.91; N = 62; 95% CI 0.35 to 2.41; Analysis
3.11).

No  data  were  available  for  the  following  outcomes:  affective-
dysregulative, 
interpersonal  and  cognitive  cluster
symptoms; depression, anxiety, mental health status/functioning.

impulsive, 

3.4 Cognitive therapy (CT) versus Client-centered therapy (CCT)

One  trial  was 
(outpatients, 77% females; 12 months treatment; N = 65)

in  this  comparison:  Cottraux  2009

included 

3.4.1 Impulsive cluster symptoms

Data  were  available  for  the  outcomes  of  impulsivity,  suicidality
and  parasuicidality.  Neither  indicated  a  statistically  significant
difference between the experimental conditions (impulsivity: SMD
-0.22,  N  =  38,  95%  CI  -0.86  to  0.41,  Analysis  3.3;  suicidality:  SMD
0.13, N = 38, 95% CI -0.51 to 0.77, Analysis 3.4; parasuicidality: SMD
0.59, N = 38, 95% CI -0.06 to 1.24, Analysis 3.5). The data favoured
CT for impulsivity with a small effect, and CCT for the outcomes of
suicidality (very small effect) and parasuicidality (moderate effect).

3.4.2 Depression

Data  indicate  a  very  small,  statistically  non-significant  difference
between the two conditions (SMD 0.10; N = 38; 95% CI -0.54 to 0.73;
Analysis 3.7).

There was also no indication of a statistically significant difference
between the two conditions in terms of anxious pathology, with a
moderate  effect  favouring  CT  (SMD  -0.51;  N  =  38;  95%  CI  -1.16  to
0.13; Analysis 3.8).

3.4.4 Mental health status/functioning

The two treatments did also not differ in a statistically significant
way regarding the outcome of general psychopathological burden,
with a small effect favouring CT (SMD 0.30; N = 38; 95% CI -0.34 to
0.94; Analysis 3.10).

3.4.5 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  0.90;  N  =  65;
95% CI 0.51 to 1.60; Analysis 3.11).

No  data  were  available  for  the  following  outcomes:  BPD
total severity; affective-dysregulative, interpersonal and cognitive
cluster symptoms; general psychopathology.

3.5 Cognitive therapy (CT) versus Interpersonal psychotherapy
(IPT)

One  study  was 
in  this  comparison:  Bellino  2007
(outpatients  with  concurrent  major  depressive  disorder,  79%
females; six months treatment; N = 32).

included 

3.5.1 Depression

Data indicated no statistically significant difference between both
conditions  with  regard  to  the  outcome  of  depression,  with  a
marginal effect size (SMD -0.07; N = 26; 95% CI -0.84 to 0.70; Analysis
3.7).

3.5.2 Anxiety

There was also no indication of a statistically significant difference
between  the  two  conditions  in  terms  of  anxious  pathology  (SMD
-0.53; N = 26; 95% CI -1.32 to 0.26; Analysis 3.8). However, the effect
was moderate in size, favouring CT.

3.5.3 Mental health status/functioning

Data indicated no statistically significant difference between both
conditions with regard to the outcome of the level of functioning,
favouring CT with a small effect (SMD 0.19; N = 26; 95% CI -0.58 to
0.97; Analysis 3.10).

3.5.4 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  leaving  the  study
early  if  considering  all  participants  randomised  (RR  2.00;  N  =  32;
95% CI 0.42 to 9.42; Analysis 3.11).

No  data  were  available  for  the  following  outcomes:  BPD  total
severity;  affective-dysregulative,  impulsive,  interpersonal  and
cognitive cluster symptoms; general psychopathology.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

4. Non-comprehensive psychotherapeutic interventions:
active versus active conditions

4.1 Manual-assisted cognitive therapy (MACT) versus manual-
assisted cognitive therapy plus therapeutic assessment (MACT
+TA)

One  study  was 
(outpatients, 81% females; six weekly sessions; N = 16)

in  this  comparison:  Morey  2010

included 

4.1.1 BPD total severity

Data  indicated  a  small,  statistically  non-significant  difference
between both conditions with regard to the outcome of BPD total
severity (SMD -0.33; N = 16; 95% CI -1.32 to 0.66; Analysis 4.1).

4.1.2 Affective dysregulative cluster symptoms

Available  data  indicated  a  moderate  to  large,  statistically  non-
significant  difference  in  terms  of  affective  instability  scores  after
treatment, favouring MACT (SMD -0.71; N = 16; 95% CI -1.73 to 0.31;
Analysis 4.2).

4.1.3 Impulsive cluster symptoms

Morey 2010 reported both on suicidality as well as parasuicidality.
Both rendered marginal, statistically not different between-group
effects (suicidality: SMD -0.03; N = 16; 95% CI -1.01 to 0.95; Analysis
4.3; parasuicidality: SMD 0.08; N = 16; 95% CI -0.90 to 1.06; Analysis
4.4).

4.1.4 Interpersonal cluster symptoms

Data  indicated  a  marginal,  statistically  non-significant  difference
between  both  conditions  with  regard  to  the  outcome  of
interpersonal  problems  (SMD  -0.04;  N  =  16;  95%  CI  -1.02  to  0.94;
Analysis 4.5).

4.1.5 Cognitive cluster symptoms

There was also no indication of a statistically significant difference
between the two conditions in terms of identity disturbance, with
a small to moderate effect favouring MACT (SMD -0.45; N = 16; 95%
CI -1.44 to 0.55; Analysis 4.6).

4.1.6 Leaving the study early

Reported  data  indicate  no  statistically  significant  difference
between  treatment  and  control  conditions  for  the  risk  of  non-
completing all six therapy sessions (RR 0.80; N = 16; 95% CI 0.33 to
1.92; Analysis 4.7).

No  data  were  available  for  the  following  outcomes:  depression,
anxiety,  general  psychopathology,  mental  health 
status/
functioning.

D I S C U S S I O N

Summary of main results

The following summary is ordered according to the overall number
of  trials  available  for  a  certain  treatment  or  adaptations  of  the
"original"  treatment.  For  a  summary  of  primary  outcome  effect
estimates of controlled comparisons, see Table 1 to Table 12.

Dialectical  Behaviour  Therapy  (DBT)  and  DBT-derived  treatments
have  been  studied  most  intensively  among  the  included  trials.
Findings  from  five  studies  comparing  DBT  to  treatment  as
usual  (TAU)  (Koons  2001;  Linehan  1991;  Linehan  1994;  Van

Cochrane Database of Systematic Reviews

den  Bosch  2005;  Carter  2010)  indicate  statistically  significantly
beneficial  effects  for  the  broadest  range  of  outcomes  relative  to
remaining  treatments.  The  comparison  of  DBT  to  TAU  was  the
only  comparison  that  allowed  for  meta-analytic  pooling  of  effect
estimates  from  several  studies,  but  only  for  the  outcomes  of
anger,  parasuicidality  and  mental  health  status.  Standard  DBT
was  found  to  have  beneficial  effects  in  terms  of  anger  (large
effect),  suicidal  behaviour  (very  large  effect)  and  parasuicidality
(moderate effect), associated psychopathology such as depression
(very large effect) and anxiety (very large effect) and overall mental
health status (moderate to large effect). The remaining statistically
non-significant  findings  were  based  on  single  study  results  each,
yielding  a  large  effect  for  the  outcome  of  dissociation  and  small
effects  for  the  outcomes  of  overall  BPD  severity,  impulsivity  and
interpersonal problems.

However,  if  compared  to  more  rigorous  control  conditions,
that  is,  general  management  according  to  the  APA  guidelines
(McMain 2009) or community treatment by experts (CTBE) (Linehan
2006), there were no statistically significant group differences for
pathology-related outcomes, but DBT was statistically superior to
CTBE  in  terms  of  treatment  retention.  DBT  was  only  marginally
superior  to  APA  guidelines  general  management  (BPD  severity,
anger,  interpersonal  problems,  general  psychopathology),  and
small  differences  were  found  for  the  outcomes  of  parasuicidality
and depression, favouring DBT. Compared with CTBE, there was a
very small effect favouring DBT in terms of suicidality, and a small to
moderate effect in terms of less depression in DBT-treated patients.

DBT-PTSD,  a  modified  DBT  approach  developed  to  meet  the
specific needs of those with comorbid PTSD, was also found to be
effective in the reduction of overall BPD severity, depression and
anxiety  (Steil  2010),  with  moderate  (BPD  severity)  and  very  large
(depression,  anxiety),  statistically  significant  effects.  Statistically
non-significant  effects  were  found  for  the  outcomes  of  general
psychopathology (moderate to large effect) and dissociation (small
effect).

As compared to Client-Centered Therapy CCT (the effects of which
have not been tested against a control condition in BPD treatment
up  to  now,  and  the  efficacy  of  which  thus  is  unclear),  DBT
showed  better  results  in  the  reduction  of  impulsivity,  suicidality,
parasuicidality, dissociative pathology and depression, with large
to  very  large,  statistically  significant  effects  throughout  (Turner
2000).  DBT  had  also  favourable  results  for  the  outcomes  of
anger,  depression  and  anxiety,  with  moderate  to  very  large,  but
statistically non-significant effects.

findings  are  consolidated  by 

These 
trials  of  short-term
interventions  derived  from  or  including  elements  of  DBT.  A
trial  of  DBT  skills  training  only  (DBT-ST)  as  compared  to  a
non-specific  standard  group  (Soler  2009)  resulted  in  statistically
significant  results  favouring  DBT-ST  for  BPD  severity,  anger,
affective  instability,  impulsivity,  dissociation,  depression  and
anxiety  with  moderate  to  very  large  effects.  Small  to  moderate,
statistically non significant effects were found for the outcomes of
chronic feelings of emptiness, suicidality, interpersonal problems,
general  psychopathology  and  overall  mental  health  status,  each
favouring DBT-ST.

Emotion  Regulation  Group  Training  (ERG),  which  was  developed
as  a  short-time,  group-based  approach  and  combines  elements
of  DBT  and  Acceptance  and  Commitment  Therapy  (ACT),  also

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

showed  encouraging,  statistically  significant  results  in  terms  of
amelioration  of  BPD  severity,  affective  instability,  impulsivity,
parasuicidality,  depression  and  anxiety,  with  large  to  very  large
effects (Gratz 2006).

In sum, DBT and related treatments provide the most solid (but not
sufficiently  robust)  evidence  of  efficacy  relative  to  all  treatments
that have been investigated in RCTs so far.

Mentalisation-Based  treatment  (MBT)  is,  second  to  DBT,  the  one
treatment  that  provides  most  robust  evidence  of  its  efficacy.
It  has  been  compared  with  control  groups  in  two  trials,  one
testing  MBT  in  a  partial  hospitalisation  (MBT-PH;  Bateman  1999)
and  one  testing  MBT  in  an  outpatient  setting  (MBT-out;  Bateman
2009).  Both  show  consistently  beneficial  effects  concerning  the
reduction  of  suicidality,  parasuicidality,  interpersonal  problems
and  depression,  with  very  large,  statistically  significant  effects.
In  addition,  data  indicate  beneficial  effects  also  in  terms  of
amelioration of general psychopathology and overall functioning
for  the  outpatient  setting.  Small  to  moderate,  statistically  non-
significant  effects  were  found  for  the  reduction  of  anxiety  and
general psychopathology by MBT-PH.

Transference-Focused  Psychotherapy  (TFP)  was  tested  in  an
outpatient  study  against  an  unspecific  control  therapy  (CTBE;
treatment  period  12  months;  Doering  2010)  and  directly  against
SFT  (treatment  period  three  years;  Giesen-Bloo  2006).  Though
tested  against  a  rigorous  comparison  treatment  (CTBE),  TFP  was
found  to  have  encouraging  effects  for  the  reduction  of  BPD
severity  (statistically  significant,  moderate  effect)  and  treatment
retention.  There  were  small,  unfavourable  but  statistically  non-
significant effects for the outcomes of parasuicidality, depression,
anxiety  and  general  psychopathology,  and  a  small,  statistically
non-significant  effect  in  favour  of  TFP  for  the  outcome  of  overall
functioning.  As  compared  to  Schema-Focused  Therapy  (SFT),
results  indicated  statistical  superiority  of  SFT  over  TFP  in  the
reduction of overall BPD severity (moderate effect) and treatment
retention. As concerns general psychopathology, both treatments
differed only marginally, resulting in a non-significant finding.

SFT  and  derived  treatments  were  subject  to  three  trials:  First,
SFT  was  compared  with  TFP  (Giesen-Bloo  2006),  with  the  above
reported  results  of  SFT  being  more  effective  in  reducing  overall
BPD  severity  and  keeping  patients  in  treatment,  but  not  in
terms  of  reducing  general  psychopathology.  Second,  modified
SFT  in  a  group  only  format  (SFT-G)  was  subject  to  another  trial
(Farrell 2009). The authors report findings resulting in very large,
statistically  significant  effects  for  all  reported  pathology-related
outcomes,  that  is,  BPD  severity,  affective  instability,  impulsivity,
interpersonal problems, dissociative/psychotic symptoms, general
psychopathology,  and  overall  mental  health  status.  Third,  SFT
was  compared  with  a  modified  form  of  SFT  with  additional
therapist telephone availability in times of crisis (SFT+TTA; Nadort
2009).  Both  treatments  did  not  differ  in  a  statistically  significant
way,  with  marginal  effects  in  terms  of  BPD  severity  and  general
psychopathology.

Interpersonal Psychotherapy (IPT) (Bellino 2006) and IPT adapted
for  BPD  (IPT-BPD;  Bellino  2010)  were  supported  by  statistically
significant  findings  of  single  trials  each.  IPT  had  statistically
significant  beneficial  effects  in  terms  of  an  amelioration  of
depression,  with  a  large  effect,  though  effects  on  BPD  core
pathology  were  not  assessed  and  remain  unclear.  IPT-BPD,

Cochrane Database of Systematic Reviews

however,  showed  large,  statistically  significant  effects  in  the
reduction  of  affective  instability  impulsivity  and  interpersonal
problems.  The  remaining  statistically  non-significant  effects
were  marginal  in  size  (anger,  chronic  feelings  of  emptiness,
parasuicidality, avoidance of abandonment, identity disturbance,
dissociative/psychotic  symptoms,  depression  and  mental  health
status). However, there was a moderate, statistically non significant
effect favouring IPT-BPD for the outcome of anxiety.

Cognitive-Behaviour  Therapy  (CBT)  was  compared  with  TAU  in  a
single trial (Davidson 2006). There were no statistically significant
between-group differences at post-treatment for any out outcome.
There  was  a  trend  of  better  results  for  CBT  for  the  outcomes
of  suicidality,  depression,  anxiety,  general  psychopathology  and
mental health status. For two outcomes, the effects were opposite,
favouring  the  control  group  with  very  small  (parasuicidality)  and
small (interpersonal problems), statistically non-significant effects.

Cognitive  Therapy  (CT)  was  compared  with  two  alternate  active
treatments, that is, CCT (Cottraux 2009) and IPT (Bellino 2007). Both
comparisons yielded no statistically significant differences for any
outcome.  As  compared  to  CCT,  results  indicated  a  superiority  of
CT  over  CCT  for  the  outcomes  of  impulsivity,  suicidality,  anxiety
and  mental  health  status  with  very  small  to  moderate  effects,
and  superiority  of  CCT  for  parasuicidality  (moderate  effect)  and
depression  (very  small  effect).  As  compared  to  IPT,  better  results
were found for CT for the outcomes anxiety (moderate effect) and
mental health status (small effect). For the outcome of depression,
the difference was marginal in size.

Dynamic  Deconstructive  Psychotherapy 
(DDP)  was  also
investigated  in  a  single  trial  only  (Gregory  2008).  There  were  no
statistically significant results, but DDP was indicated to be superior
to the control group in terms of BPD severity and parasuicidality
and depression with small to moderate effects.

Systems training for emotional predictability and problem solving
for  borderline  personality  disorder  (STEPPS)  was  subject  to  two
trials. First, STEPPS was compared with TAU (Blum 2008). All results
favoured  STEPPS  with  statistically  significant,  small  to  moderate
effects for interpersonal problems, dissociation and mental health
status,  and  small,  statistically  non-significant  effects  for  the
outcomes of overall BPD severity, affective instability, impulsivity,
depression  and  general  psychopathology.  Notably,  there  was  a
statistically significant higher drop-out rate in the STEPPS group.
Another  trial  compared  STEPPS  plus  limited  individual  therapy
(STEPPS + IT; Bos 2010) to TAU. There was a statistically significant,
moderate effect indicating beneficial effects of STEPPS in terms of
general psychopathology. Statistically non-significant, favourable
effects  were  found  for  the  reduction  of  BPD  severity  (moderate
in  size),  impulsivity  (small  effect),  and  interpersonal  problems
(small  effect).  For  the  outcome  of  parasuicidality,  there  was
statistically non-significant effect indicating more such pathology
in the STEPPS + IT group.

Manual-Assisted Cognitive Treatment (MACT) was also tested in two
trials: First, it was compared with TAU (Weinberg 2006). There were
two  large,  significant  effects  favouring  MACT  over  TAU  in  terms
of  suicidality  and  parasuicidality.  Second,  MACT  was  compared
with  MACT  enhanced  by  pre-treatment  individual  therapeutic
assessment  (Morey  2010).  There  were  no  statistically  significant
differences, with a moderate to large effect for affective instability,
a  moderate  for  identity  disturbance  and  a  small  one  for  BPD

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

severity, all favouring MACT. Differences in terms of suicidality and
parasuicidality were marginal.

At  last,  a  very  generic  psychoeducative  intervention  (PE)  was
compared  with  a  waiting  list  (WL)  control  group  (Zanarini  2008).
There  was  a  nearly  large,  statistically  significant  effect  for  the
reduction  of  interpersonal  problems,  and  an  almost  moderate
but  non-significant  effect  for  the  reduction  of  impulsivity  by  this
intervention.

Overall completeness and applicability of evidence

Participants

Most  trial  participants  were  women.  Overall,  89%  of  included
participants  were  female,  and  there  was  not  a  single  study  with
more men than women, or even balanced proportions. This pattern
may  reflect  reality  in  clinical  settings,  where  about  75%  of  all
BPD  diagnoses  are  given  to  women  (APA  2000).  However,  some
doubt  that  the  'real'  prevalence  of  BPD  is  actually  higher  in
women than men, and there are contradictory findings of balanced
proportions  or  even  higher  prevalence  rates  in  men  (Torgersen
2009).  Men  with  BPD  may  exhibit  another  clinical  picture  than
women, and especially antisocial features may be more prevalent
in men than women with BPD (Skodol 2009). From a clinical point
of  view,  this  may  yield  different  treatment  approaches  or  special
requirements that may not be reflected in the actual findings from
the RCT evidence. In contrast, antisocial features or full antisocial
personality disorder were reasons for exclusion in several trials (see
Types  of  participants).  Thus,  the  applicability  of  findings  of  this
review, and most BPD research findings, to men may be confined.

Objective  measures  of  levels  of  functioning  at  baseline  were  not
available from all studies, and if so, different measures were used,
rendering comparability of single study samples difficult. Overall,
drawing from those studies that reported objective measures such
as  GAF,  GAS,  CGI  or  SFQ,  the  severity  of  illness  ranged  between
major  impairment,  comparable  to  psychiatric  emergencies,  and
mild  illness,  with  the  majority  of  samples  exhibiting  serious  to
moderate  levels  of  illness.  Regarding  comorbidity,  those  with
comorbid  "severe  mental  disorders"  such  as  psychotic  and/or
bipolar  disorders  were  not  eligible  for  study  participation  in
most  trials,  as  were  those  with  mental  impairments,  organic
brain  disorder  and  severe  organic  conditions.  Substance-related
disorders  were  also  common  reasons  for  exclusion  (17  studies;
some  differentiated  between  substance  abuse  and  addiction  or
specific  substances,  some  did  not  (see.  Types  of  participants).
Some studies, however, concentrated on participants with distinct
comorbid  conditions,  such  as  alcohol  abuse  or  dependence
(Gregory 2008), post-traumatic stress disorder (Steil 2010) or major
depressive disorder episodes (Bellino 2006; Bellino 2007).

Notably, acute endangerment of self and/or others was explicitly
specified  a  reason  for  exclusion  only  in  three  trials.  However,
it  seems  not  improbable  that  others  may  also  have  excluded
patients  in  acute  crisis.  However,  anxiety-related  disorders  or
eating disorders were not explicit reasons of exclusion in any study.
There was only one trial that explicitly did not include patients with
concurrent major depressive episode (Soler 2009).

Most  studies  were  conducted  either  in  Western  Europe  (14  trials:
Bateman 1999; Van den Bosch 2005; Bellino 2006; Davidson 2006;
Giesen-Bloo  2006;  Bellino  2007;  Bateman  2009;  Cottraux  2009;
Nadort  2009;  Soler  2009;  Bellino  2010;  Bos  2010;  Doering  2010;

Cochrane Database of Systematic Reviews

Steil 2010) or North America (13 trials: Linehan 1991; Linehan 1994;
Turner 2000; Koons 2001; Gratz 2006; Linehan 2006; Weinberg 2006;
Blum 2008; Gregory 2008; Zanarini 2008; Farrell 2009; McMain 2009;
Morey  2010).  One  study  was  conducted  in  New  Zealand  (Carter
2010).  Thus,  the  applicability  of  findings  to  other  locations  and
ethnicities, that is, as found in South America, Asia, Africa and also
other parts of Europe and Oceania remains unclear.

In  summary,  the  findings  may  be  mostly  applicable  to  a  female,
moderately  to  severely  ill  BPD  patient  without  any  comorbid
severe mental condition such as psychotic disorder or substance-
related  disorder,  mental  retardation  or  severe  organic  condition.
However, we tried to exactly specify and describe all studies with
regard  to  their  crucial  characteristics  (see  Description  of  studies,
Characteristics of included studies) in order to let the reader decide
about  applicability  of  relevant  study  characteristics  to  his  or  her
decisive situation.

Interventions    

All  major  psychotherapeutic  treatments  for  BPD  (DBT,  MBT,  SFT,
TFP) have been tested in RCTs so far, though the number of RCTs
varies with most trials investigating DBT. Treatment periods range
broadly. Even if looking at long-term treatments only (defined here
as  covering  a  period  of  more  than  six  months),  there  is  a  broad
range from six up to 36 months. It may surely depend of the specific
national  mental  health  care  setting  which  treatment  periods  fit
into  the  context  of  current  practice,  that  is,  which  "amounts"  of
psychotherapeutic treatment a patient may be enabled to use.

A  new  trend  of  group-based  short-time  interventions  can  be
observed  in  recent  trials,  with  all  referring  studies  dating  from
2006  or  later.  Those  short-time  interventions  draw  from  already-
established interventions, especially DBT, and combine them with
new  elements  and/or  modify  them  according  to  group  settings.
Thus,  a  certain  eclecticism  can  be  observed,  and  in  some  cases
it  remains  unclear  which  sources  have  been  used.  Short-term
interventions  show  encouraging  results,  however,  the  long-term
stability  of  effects  has  to  be  established.  From  a  clinical  point  of
view, it should also be made clear which "experience of treatment"
a  patient  must  already  have  to  profit  from  those  interventions,
or  if  they  should  only  be  recommended  to  those  patients  who
can  use  them  as  "booster  treatment"  on  basis  of  their  already-
gained treatment experience or as add-on to concurrent individual
psychotherapies only.

Most trials allowed concurrent psychotropic treatments. With the
exception of the trials of Bellino 2006, Bellino 2007 and Bellino 2010,
the  participants  of  which  were  all  given  the  SSRI  antidepressant
fluoxetine, most trialists did not prevent participants from taking
concomitant medication. Some cited the APA guidelines as a rough
orientation  for  medication  regimens  (Giesen-Bloo  2006;  Gregory
2008; Bateman 2009, McMain 2009 for control group patients). Most
DBT trials explicitly encouraged tapering-off of medications as an
explicit treatment goal (Linehan 1991; Linehan 1994; Linehan 2006;
McMain 2009). Thus, the actual use of medications during the study
period differed between DBT and control groups as a consequence
of  the  psychotherapy  treatment  goal  of  tapering-off  medications
("rely  on  skills  over  pills"),  but  the  study  groups  did  not  differ  at
pretreatment. Overall, the wide-spread use of pharmacotherapy in
patients with BPD (Ansell 2007; Hörz 2010) is adequately reflected
by the included primary studies.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

During  the  time-span  that  the  included  trials  cover  (that  is,
publication  years  range  from  1991  to  2011),  the  understanding
of  the  relative  efficacy  of  medications  in  BPD  has  changed.  For
example,  SSRIs  that  were  once  regarded  the  first-line  treatment
for  BPD  (compare  APA  guidelines:  APA  2001;  Rush  2005)  for
the  treatment  of  various  symptom  clusters  lack  corresponding
evidence,  whereas  mood  stabilisers  and  second-generation
antipsychotics are supported by some evidence (Stoffers 2010). It
is therefore possible that  the efficacy of concurrent medications
may have changed throughout  this long time-span and may have
confounded  the  corresponding  findings.  Within  this  review,  this
could possibly concern the comparison of DBT to TAU as this was
the only comparison for which several study findings were pooled,
covering a time-span of publication years 1991 to 2010. However,
in examining more closely the actual concomitant drug treatment
in these studies, it becomes clear that antidepressants were most
frequently used in all studies, rendering them studies comparable
and limiting the risk of any confounding medication effects.

Comparisons

There was a large heterogeneity of control group treatments. Even
"treatment  as  usual",  a  very  common  control  condition,  varied
between  studies.  Some  TAU  participants  were  completely  free  to
use  or  not  to  use  any  kind  of  care  they  would  have  used  if  not
included into the study. Some TAU participants, however, received
some  minimum  standard  of  care,  for  example,  referrals  to  other
providers  (that  participants  could  follow  up  or  not)  or  a  rough,
guideline-oriented  but  non-specific  treatment  regimen.  What  is
more, TAU will certainly vary internationally, the "usual" standards
of  mental  health  care  are  known  to  be  different  depending  on
national health care systems.

There  is  a  clear  trend  towards  new  kinds  of  control  conditions
such as CTBE (Linehan 2006; Doering 2010) or guideline-oriented
treatments (Bateman 2009; McMain 2009). Reasons may be ethical
considerations taking into account that severely ill patient should
not  be  left  untreated  if  established  treatments  such  as  DBT  are
available. In addition, it is interesting for the assessment of a certain
therapy  if  this  therapy  not  only  works  compared  with  TAU  but
also  if  compared  with  experienced  therapists  or  therapists  using
guidelines. However, such comparisons will yield smaller between-
group  effects  if  using  more  rigorous  comparison  conditions,  and
this  should  be  taken  into  account  if  comparing  data  from  such
studies  with  those  studies  that  use  less  rigorous  control  groups.
From a reviewer's point of view, it is sometimes difficult to classify
these newer comparison treatments. One may argue to group them
as controls or as active comparisons, as well. Here, we decided to
classify them as controls, since they do not use specific treatment
manuals but only rough guidelines, so that there could have been
variation in the type of treatment received by participants within
the same control group. .

Another problem is the head-to-head testing of treatments before
investigating the mere effects of the two treatments against control
treatments  (for  example,  CCT,  SFT).  Thus,  it  remains  unclear
what  a  between-group  difference  really  means.  What  is  more,
not  only  controlled  studies  but  also  pilot  studies  are  mostly
missing. This is in some ways astonishing taking into account the
burden conducting a psychotherapy RCT to both investigators and
participants.

Cochrane Database of Systematic Reviews

Outcomes

Starting from the phenomenological diversity of BPD, there is also a
high variety of possible outcomes, and by now there is only a small
consensus  about  really  important  outcomes.  Identifying  theory-
inherent outcomes related to putative mechanisms of change is a
major problem especially in psychotherapy research. The real core
symptoms that people with BPD and caregivers may be interested
in  when  looking  for  a  helpful  treatment  option  are  sometimes
neglected.  Trialists  should  keep  in  mind  that  anyone  concerned
will certainly not be interested in how a change will putatively be
achieved  but  if  a  change  will  be  achieved  at  all,  to  what  extent,
and in terms of which pathology. The development of new outcome
scales  such  as  BPDSI-IV,  CGI-BPD  or  ZAN-BPD  allows  for  distinct
assessment of BPD symptoms. These scales, encouragingly, have
potential to measure outcomes such as change in chronic feelings
of emptiness or in avoidance of abandonment, which are significant
traits in many people with BPD.

Attrition data must be interpreted with caution. There is a high risk
of bias especially in small sample studies with, for example, also
small  numbers  of  therapists.  What  is  more,  there  is  a  substantial
likelihood of attrition rates depending on the kind of control groups
used.  For  example,  waiting  list  participants  seem  to  be  more
prone to leaving the study early than TAU participants. In addition,
geographical conditions and accessibility of study centres can play
an important role (for example, if it is a rural region with high costs
and burden for participants to go study assessments, higher drop-
out  rates  can  be  expected  than  in  urban  settings,  cf.  Blum  2008;
Carter 2010).

None of the studies considered adverse or undesired effects. Some
argue that psychotherapy, constituing a potent intervention, may
both  have  the  potential  to  cure  and  harm.  A  broad  range  of
possible  adverse  outcomes  has  been  discussed  so  far,  including,
e.g., the lack of significant improvement, acceleration of ongoing
deterioration or increase of substance use if a certain intervention
inducing high emotional arousal (Berk 2009).

Quality of the evidence

Overall, a total of 28 studies involving 1804 participants have been
included in this review. Study sample sizes ranged between 16 and
180.  However,  except  for  DBT,  the  review  findings  are  based  on
single  study  effects  only.  There  were  either  single  trials  available
for  a  certain  intervention  (for  example,  CBT,  DDP,  ERG,  MACT),  or
the  intervention  had  actually  been  tested  in  several  trials,  but
in  modified  forms  (for  example,  MBT  and  MBT-PH;  SFT  and  SFT-
G,  STEPPS  and  STEPPS  +  IT),  and/or  it  had  been  compared  with
different conditions (for example, CT, IPT), so the study effects could
not be pooled either. 'Summary of findings' tables (see Summary
of findings 1 to Summary of findings 18) are provided for all active
to  control  group  comparisons,  focusing  on  primary  outcomes.
The  comparison  of  DBT  with  TAU  was  the  only  comparison  that
allowed for pooling of several effect estimates. The overall quality
of  evidence  ranges  between  moderate  and  low,  depending  on
overall  sample  sizes.  According  to  the  GRADE  system,  a  rating  of
'high quality' requires as a rule of thumb large sample sizes of at
least 400 due to statistical precision issues. To date, there are no
such sample sizes available for any psychotherapy.

Key  methodological  limitations  were,  as  usual  in  psychotherapy
research,  the  lack  of  caregiver  and  patient  blinding.  Another

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

limitation was potential bias due to allegiance effects, which were
present in the majority of trials. However, it seems inevitable that
psychotherapists who must undergo a thorough, often time- and
cost-intensive training to be able to deliver a certain psychotherapy
properly, are allied to a certain psychotherapy they have "invested"
in.  On  the  other  hand,  a  certain  allegiance  may  also  motivate
them  to  deliver  the  treatment  as  properly  as  possible.  However,
treatment  developers  who  also  act  as  main  investigators  of  their
treatments  should  be  prevented  from  suspicions  that  positive
results stem from biased study designs or bias study conducting,
so there is an urgent need for independent research endeavours to
undermine available findings.

Another  major  limitation  of  most  studies  was  attention  bias.  In
the  majority  of  trials,  control  group  participants  did  not  receive
comparable  amounts  of  professional  attention  as  obligatory
elements of their treatment regimen. Findings of beneficial effects
by  one  treatment  may  then  primarily  result  from  simply  being
paid attention to or being provided with some kind of intervention
rather than from a specific mechanism of action.

Most  studies  had  comparatively  small  samples  (12  out  of  28
trials  included  39  participants  or  less).  As  a  consequence,  the
experimental  groups  may  seem  to  be  imbalanced  at  baseline,

which  was,  for  example,  the  case  in  the  RCT  of  Gregory  2008.  Dr
Gregory,  the  main  investigator  of  this  trial,  has  raised  concerns
about the appropriateness of using endpoint data alone for effect
size  calculation,  and  referred  to  "substantially  greater  baseline
psychopathology" in the active group, which may have led to an
underestimation  of  positive  treatment  effects  and  a  Type  II  error
(Gregory  2017).  However,  group  allocation  was  randomised  (as
in  any  here-included  study),  so  any  imbalances  at  baseline  are
regarded to be due to chance alone, and the the statistical methods
used in this review allow for such chance differences.

Nevertheless,  we  are  aware  that  the  power  of  studies  including
smaller samples (such as Gregory 2008) may be too small to detect
a real effect as statistically significant if it exists. Therefore, we have
not only reported statistically significance throughout the text but
also referred to their magnitude ("small, moderate, large").

A  funnel  plot  was  drawn  for  all  controlled  comparisons  and  the
outcome of parasuicidality (cf. Figure 4). The funnel plot is rather
symmetric in shape and indicates no selection bias (for example,
publication,  delayed-publication  or  location  bias)  or  spurious
inflation of effects in smaller studies due to poor methodological
quality.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Funnel plot of comparison of all controlled comparisons for the outcome of parasuicidality

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-4

-2

0

2

SMD

4

Subgroups
CBT vs. TAU
DBT vs. TAU
DBT vs. GM
DBT vs. CTBE
DBT-ST vs. SG

DDP vs. TAU
ERG vs. TAU
IPT-BPD+fl vs. CM+fl
MACT vs. TAU
MBT-PH vs. TAU

MBT-out vs. TAU
SFT-G vs. TAU
STEPPS vs. TAU
STEPPS+IT vs. TAU
TFP vs. CTBE

Potential biases in the review process

With  regard  to  our  inclusion  criteria,  we  tried  to  retain  a
homogeneous  pool  of  primary  studies.  However,  there  were
some  inconsistencies  between  studies,  particularly  pertaining
to  psychiatric  comorbidity  of  study  participants.  For  example,
presence of a substance-related disorder was a common exclusion
criterion  (see  Types  of  participants),  whereas  one  study  (Gregory
2008)  required  participants  to  have  such  a  disorder,  and  another
study  included  a  mixed  sample  of  participants  with  and  without
substance abuse problems (Van den Bosch 2005). In addition, the
severity of illness varied between studies, covering a range of severe
to mild.

Many  studies  provide  outcome  measures  that  appear  to  reflect
theory-inherent, putative mechanisms of change than consumer-
relevant data. We tried to deal with this by first defining all patient-
relevant  outcome  variables  that  are  directly  (primary  outcomes)
or  indirectly  (secondary  outcomes)  associated  with  BPD,  that  is,

all outcome variables that a consumer and his or her therapist are
likely  to  be  interested  in,  and  took  BPD  pathology  as  defined  in
the DSM-IV criteria (APA 2000) as a guideline for primary outcomes.
We feel that these are most likely to be shared by the majority of
patients with BPD, and did not regard cost-related issues.

We  decided  to  focus  on  RCTs  only  as  they  provide  the  only  way
to  prevent  systematic  differences  and  confounders.  One  major
concern  against  uncontrolled  trials  of  BPD  treatment  outcome
pertains to the characteristically unstable course of BPD, findings
of amelioration over time and high affective responsiveness, which
render simple pre-post comparisons (within-subject) difficult and
prone to bias. Another practical consideration was the availability
of  reliable  methods  for  identifying  studies  of  another  type.  The
identification of 28 relevant RCTs seems to vindicate this strategy.

A potential bias in the review process may have resulted from the
decision not to include RCTs that do not provide any outcome of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

interest. Thus, the trials of Linehan 1999 and Linehan 2002 that both
concentrate  on  outcome  measures  related  to  substance-related
disorders were excluded. In addition, the lack of usable data led to
exclusion of Clarkin 2007 (see Characteristics of excluded studies).

We strived to identify all relevant published and unpublished RCT
evidence  (see  Search  methods  for  identification  of  studies).  The
search was not restricted to any language. In spite of great efforts
to  minimise  publication  bias,  we  were  able  to  include  only  one
unpublished  study,  the  publication  of  which  is  impending  (Steil
2010).

Agreements and disagreements with other studies or
reviews

This review differs from its preceding version (Binks 2006) insofar
as  more  RCTs  are  available  for  inclusion.  The  previous  version
included seven studies compared to the 28 in the current version.
However,  the  statement  that  "the  studies  are  too  few  and
small  to  inspire  full  confidence  in  their  results"  (Binks  2006)
remains relevant. The variety of available treatments has increased,
whereas  robustness  has  not,  with  the  exception  of  DBT  and
MBT.  On  the  other  hand,  the  earlier  conclusion  that  "some  of
the  problems  frequently  encountered  by  people  with  borderline
personality  disorder  may  be  amenable  to  talking/behavioural
treatments" (Binks 2006) has been strengthened.

Though  this  Cochrane  Collaboration  review  is  not  a  guideline,
to  be  checked  against  guideline
its 
recommendations and the following may be relevant.

findings  are 

likely 

The  current  APA  guidelines  (APA  2001;  Oldham  2005)  are
substantially  outdated,  with  the  most  recent  psychotherapy  RCT
evidence  included  dating  from  2003.  In  their  2005  update,  the
guideline  authors  conclude:  "All  in  all,  the  database  is  growing,
and further evidence is accumulating that BPD is a condition that
can be effectively treated by a combination of psychotherapy and
symptom-targeted  pharmacotherapy."  (Oldham  2005,  p.  4).  We
can  not  draw  any  distinct  conclusions  about  the  combination  of
psychotherapy  and  pharmacotherapy  from  this  review.  However,
there were two RCTs in which all participants were given fluoxetine,
and  a  psychotherapeutic  approach  (Bellino  2006:  IPT;  Bellino
2010:  IPT-BPD)  was  compared  with  CM  in  each  case.  Both  trials
consistently indicate that the group receiving combined treatment
of  psychotherapy  and  pharmacotherapy  had  superior  results  as
compared  to  medication  plus  CM  only.  This  finding  advocates
in  particular  for  the  conclusion  of  the  APA  guidelines  that
"...psychotherapy represents the primary, or core, treatment for this
disorder and that adjunctive, symptom-targeted pharmacotherapy
can be helpful." (Oldham 2005, p. 3).

The  comparison  of  pharmacotherapeutic  and  psychotherapeutic
interventions  was  neither  the  scope  of  this  review  nor  can  it
be  answered  from  the  here-included  evidence.  The  effects  of
pharmacotherapy  of  BPD  is  the  subject  of  two  other  Cochrane
Collaboration  reviews  (Lieb  2010;  Stoffers  2010).  One  may  argue
that  in  the  light  of  comparable  effect  sizes  and  a  by  and  large
comparable  robustness  of  underlying  evidence,  it  is  not  clear
if  either  drug  treatment  or  psychotherapy  should  be  regarded
the  first-line  treatment  and  which  one  the  adjunctive  one.
Again,  this  question  can  neither  be  answered  from  this  review
nor  can  the  results  of  the  two  reviews  be  directly  compared
with  each  other.  However,  some  observations  from  the  two

Cochrane Database of Systematic Reviews

reviews:  the  pharmacotherapy  review  (Stoffers  2010)  included
three trials testing psychotherapy plus drug against psychotherapy
plus  placebo  (Simpson  2004;  Soler  2005;  Linehan  2008).  The
findings  were  not  conclusive  in  terms  of  a  clear  superiority  of
combined  treatments.  In  contrast,  there  were  indeed  favourable
results  for  psychotherapy  plus  placebo  over  psychotherapy  plus
drug,  especially  with  regard  to  self-harming  and  dissociative
behaviour.  As  discussed  previously,  the  two  trials  included  here
testing drug treatment plus psychotherapy against drug treatment
plus  clinical  management  only  (Bellino  2006;  Bellino  2010),
indicated  superior  results  for  those  participants  who  received
additional psychotherapy. As a consequence, drug treatment plus
psychotherapy seems not clearly superior to psychotherapy alone,
whereas psychotherapy plus drug treatment had favourable results
as compared to drug treatment alone. These findings support the
role of psychotherapy as the core treatment, as also suggested by
the APA guidelines (APA 2001; Oldham 2005).

However, the effectiveness of therapies in combination still remains
unclear on basis of this review and the available RCT evidence.

The  UK  National  Institute  for  Health  and  Clinical  Excellence
(NICE)  published  their  guidelines  in  2009  (NICE  2009),  covering
relevant  evidence  available  up  to  April  2008.  This  review  now
includes  21  more  studies.  However,  the  conclusions  that  "There
are  few  studies;  low  numbers  of  patients  and  therefore  low
power; multiple outcomes with few in common between studies;
and  a  heterogeneous  diagnostic  system  which  makes  it  hard
to  target  specific  treatment  on  patients  with  specific  sets  of
symptoms."  (NICE  2009,  p.  204)  remain  relevant.  This  review  is
also in line with NICE concerning the valuation that especially DBT
and  MBT  are  supported  by  the  current  evidence.  However,  TFP
and  SFT  must  be  added  to  the  class  of  treatments  that  showed
beneficial effects in at least one methodologically sound, medium-
size trial. NICE concluded that "very brief interventions (less than 3
months) do not appear to be effective in the treatment of borderline
personality disorder" (NICE 2009, p. 204). From our findings, based
also  on  more  recent  RCTs,  short-time  interventions  of  up  to  six
months duration show at least encouraging results in small studies,
though the necessary contexts that patients can profit from these
interventions remains unclear as previously discussed (see Overall
completeness and applicability of evidence).

A U T H O R S '   C O N C L U S I O N S

Implications for practice

In  sum,  the  up-to-date  available  randomised  controlled  trial
(RCT)  evidence  for  psychotherapeutic  treatments  is  scarce,  and
replicative  studies  would  be  most  desirable  for  each  type  of
treatment. Therefore, conclusions have to be drawn carefully.

Most  "robust"  conclusions  can  be  drawn  from  evidence  of
dialectical behaviour therapy (DBT). It is the only psychotherapy for
which, in comparison with treatment as usual (TAU), data could be
accumulated from several trials. For all remaining comparisons and
psychotherapies, single study effects are available only. Thus, the
evidence is not as robust as would be desirable, but the findings
indicate  the  usefulness  of  both  comprehensive  psychotherapies
and  non-comprehensive  psychotherapeutic  interventions  in  the
treatment  of  both  core  borderline  personality  disorder  (BPD)
pathology and its associated pathology.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comorbid  conditions  have  been  recognised  by  RCT  research,
but  the  evidence  base  for  BPD  treatment  in  the  presence  of
defined  comorbidities  (for  example,  substance-related  disorders,
post-traumatic  stress  disorder  (PTSD),  depressive  episodes)  is
still  small  and  only  single  studies  are  available.  Studies  of
DBT-PTSD  for  patients  with  BPD  with  comorbid  PTSD  and
dynamic  deconstructive  psychotherapy  (DDP)  for  patients  with
concurrent addictive disorders found encouraging effects on core
BPD  pathology  as  well  as  associated  pathology,  indicating  that
psychotherapy may have beneficial effects in severely ill groups of
patients. Interpersonal psychotherapy (IPT) which was developed
for  people  with  depressive  disorders  was  successful  in  reducing
depressive  pathology,  but  the  effects  on  BPD  core  pathology
remain unclear as no such data were assessed.

Trials  of  non-comprehensive  psychotherapeutic  interventions
suggest large effects for several approaches and indicate that these
rather short-term interventions may (at least as add-ons to long-
term treatments) be helpful; further research is required. To date,
it  is  rather  unclear  if  these  interventions  are  equally  effective  in
patients with BPD who have already experienced several individual
therapies as in patients who are "psychotherapy naive".

In  sum,  it  can  be  concluded  that  disorder-specific  treatments
should  be  used.  Although  nonspecific  treatments  were  scarcely
investigated, those that were (cognitive behavioural therapy (CBT),
client-centered therapy (CCT), IPT) showed no encouraging effects
for  the  treatment  of  BPD  core  pathology.  Beneficial  findings
from  group-only  interventions  are  mostly  based  on  studies  of
participants  with  another  ongoing  individual  treatment,  and  it  is
therefore  unclear  which  treatment  exerts  the  major  effect.  The
optimal  length  of  treatment  is  unclear  from  the  up-to-date  RCT
evidence. On the basis of the available findings, a treatment of 12
to 18 months seems to be appropriate.

Implications for research

First, replication studies would be most desirable, especially from
independent researchers not involved in treatment development
and/or delivery. Future studies should focus on male patients with
BPD  who  have  been  neglected  in  BPD  treatment  studies  so  far,
and treatment efficacy in patients with BPD with defined comorbid
conditions  should  be  investigated  in  more  detail.  In  addition,
it  remains  unclear  how  psychotherapy  and  pharmacotherapy
interact. There is some evidence that psychotherapy may enhance
pharmacotherapy  effects  (Lieb  2010;  Stoffers  2010).  There  is  a
need for agreement on a minimum core battery of BPD outcomes.

Cochrane Database of Systematic Reviews

There is currently a huge heterogeneity of outcome variables and
assessment instruments. A consensus on a minimum set of therapy
outcome  variables  that  are  most  likely  to  be  of  interest  for  any
patient with BPD would be desirable. Outcome assessment should
be  more  specific  and  sensitive  to  BPD  pathology.  Assessment
instruments  have  been  developed  lately  to  reflect  BPD  core
pathology  as  described  precisely  by  the  DSM-IV  criteria  (for
example,  the  BPDSI  scale  by  Arntz  2003,  the  CGI-BPD  scale  by
Perez  2007,  or  the  ZAN-BPD  scale  by  Zanarini  2003a).  Further
investigation  of  the  impact  of  different  treatment  settings,  that
is, inpatient, outpatient, and day hospital, during acute and non-
acute  stages  of  the  course  of  illness  would  also  be  helpful.
Some researchers advocate for the development of an integrated
psychotherapy on the basis of effective treatments that combines
methods which work from all therapies (for example, Livesley 2007;
Livesley  2012).  However,  as  discussed  previously,  there  is  still  an
urgent  need  for  additional  evidence  to  answer  the  question  of
which treatments are really effective, and which work for whom.

A C K N O W L E D G E M E N T S

We  are  grateful  to  Jane  Dennis,  Margaret  Anderson,  Laura
MacDonald,  Elaine  McKay,  Chris  Champion  and  Geraldine
MacDonald  from  the  Cochrane  Developmental,  Psychosocial  and
Learning  Problems  Group.  In  particular,  we  thank  Jane  Dennis,
Margaret  Anderson,  Nick  Huband,  Mike  Ferriter,  Nadja  Smajlaigic
and Melanie Powney for their help in identifying relevant studies.
We  would  also  like  to  thank  all  primary  study  authors  who
responded to our requests and provided further information, and
Mr H A Glazener who helped translating a Dutch paper.

We would like to thank the previous authors of this review, Claire
Binks,  Mark  Fenton,  Lucy  McCarthy,  Tracy  Lee,  Clive  Adams  and
Conor Duggan. Additionally, we thank the German Cochrane Centre
for supporting this work. We are grateful to Gerd Antes, director of
the German Cochrane Centre, who made contact with CDPLPG and
helped in gaining grants for financing this work. We are also grateful
to  Martin  Schumacher,  director  of  the  Institute  of  Biostatistics
and Medical Informatics at the University Medical Center Freiburg,
who  gave  support  in  application  submission.  We  are  grateful  to
the  German  Ministry  of  Education  and  Research  (BMBF;  grant
no.  01KG0609),  the  research  committee  of  the  University  Medical
Center Freiburg and the NHS Cochrane Collaboration Programme
Grant Scheme (NIHR), UK for supporting this work. JS would like to
thank the Ministry of Science, Research and Arts of the federal state
of Baden-Württemberg for supporting this work by a stipend.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Bateman 1999 {published data only}

Bateman A, Fonagy P. 8-year follow-up of patients treated for
borderline personality disorder: mentalization-based treatment
versus treatment as usual. American Journal of Psychiatry
2008;165(5):631-8.

*  Bateman A, Fonagy P. Effectiveness of partial hospitalization
in the treatment of borderline personality disorder: a
randomized controlled trial. American Journal of Psychiatry
1999;156(10):1563-9.

Bateman A, Fonagy P. Health care utilization costs for borderline
personality disorder patients treated with psychoanalytically
oriented partial hospitalization versus general psychiatric care.
American Journal of Psychiatry 2003;160:169-71.

Bateman A, Fonagy P. Treatment of borderline personality
disorder with psychoanalytically oriented partial
hospitalization: an 18-month follow-up. American Journal of
Psychiatry 2001;158(1):36-42.

Bateman A, editors(s). Intensive outpatient and partial hospital
care for BPD. Proceedings of the 157th American Psychiatric
Association Annual Meeting; 1-6 May 2004. New York: American
Psychiatric Association, 2004:NO.100B.

Bateman A. Important: Question regarding your BPD trial
for systematic review in Cochrane Collaboration [personal
communication]. Email to: K Lieb, J Stoffers 14 December 2010.

Bateman AW, Fonagy P. Partial hospitalization for borderline
personality disorder: reply. American Journal of Psychiatry
2001;158(11):1932-3.

Evans C. Treatment benefits of psychoanalytically oriented
partial hospitalisation were maintained over 18 months in
borderline personality disorder. Evidence-Based Mental Health
2001;4(3):73.

Fonagy P, Bateman AW. Mentalizing and borderline personality
disorder. Journal of Mental Health 2007;16(1):83-101.

Stern R. Partial hospitalization for borderline personality
disorder. American Journal of Psychiatry 2001;158(11):1932.

Bateman 2009 {published data only}

*  Bateman A, Fonagy P. Randomized controlled trial of
outpatient mentalization-based treatment versus structured
clinical management for borderline personality disorder.
American Journal of Psychiatry 2009;166(12):1355-64.

Bateman A, Fonagy P. Randomized controlled trial
of outpatient mentalization-based treatment versus
structured clinical management for borderline personality
disorder. Online data supplement to article of same
title. http://ajp.psychiatryonline.org/cgi/content/full/
appi.ajp.2009.09040539/DC1 (accessed 20 April 2010).

Bateman AW. Mentalization, borderline personality disorder
and what works for whom? In: 11th International Congress

of the International Society for the Study of Personality
Disorders; 2009 Aug 21-23; New York. Available from
www.borderlinepersonalitydisorder.com/Conferences/ISSPD/
isspd_ 09_ Bateman.pdf. New York: National Education Alliance
for Borderline Personality Disorder, (accessed 21 April 2010).

ISRCTN27660668. Randomised controlled trial of manualised
out-patient individual and group therapy for borderline
personality disorder. http://www.controlled-trials.com/
ISRCTN27660668 (accessed 28 October 2010).

Bellino 2006 {published data only}

Bellino S, Paradiso E, Zizza M, Di Lorenzo R, Bogetto F.
Combined therapy with interpersonal psychotherapy of major
depressed patients with borderline personality disorder:
a comparison with pharmacotherapy. Italian Journal of
Psychopathology 2005;11(1):34-42.

*  Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined treatment
of major depression in patients with borderline personality
disorder: a comparison with pharmacotherapy. Canadian
Journal of Psychiatry (Revue Canadienne de Psychiatrie)
2006;51(7):453-60.

Bellino S. Question regarding your BPD trials [electronic mail on
the internet]. Email to: J Stoffers. 16 December 2010.

Bellino 2007 {published data only}

*  Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined therapy
of major depression with concomitant borderline personality
disorder: comparison of interpersonal and cognitive
psychotherapy. Canadian Journal of Psychiatry - Revue
Canadienne de Psychiatrie 2007;52(11):718-25.

Bellino S. Re: Question regarding your BPD trials [personal
communication]. Email to: J Stoffers. 16 December 2010.

Bellino 2010 {published data only}

Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal
psychotherapy to borderline personality disorder: a comparison
of combined therapy and single pharmacotherapy. Canadian
Journal of Psychiatry 2010;55:74-81.

Zizza M, Fenocchio M, Rinaldi C, Bellino S. Combined treatment
of borderline personality disorder: a trial of modified
interpersonal therapy. World Psychiatry 2009;8(Suppl 1):234.

Blum 2008 {published data only}

Black D W, Blum N, Pfohl B, St John D. The STEPPS group
treatment program for outpatients with borderline
personality disorder. Journal of Contemporary Psychotherapy
2004;34(3):193-210.

Black D. Question regarding your BPD trial [personal
communication]. Email to: J Stoffers. 04 January 2011.

Black DW, Allen J, St John D, Pfohl B, McCormick B, Blum N.
Predictors of response to systems training for emotional
predictability and problem solving (STEPPS) for borderline
personality disorder: an exploratory study. Acta Psychiatrica
Scandinavica 2009;120:53-61.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Black DW, Blum N, Pfohl BM, St John D. Randomised clinical
trial of stepps versus treatment as usual. In: 158th Annual
Meeting of the American Psychiatric Association; 2005 May
21-26; Atlanta, GA. 2005:1B.

Blum N, Allen J, McCormick B, Black DW. Effectiveness of
adjunctive STEPPS group treatment in borderline personality
disorder patients: reply. American Journal of Psychiatry Oct
2008;165(10):1354-5.

Blum N, Franklin J, Hansel R, McCormick B, St John D, et
al. Relationship of age to symptom severity, psychiatric
comorbidity and health care utilization in persons with
borderline personality disorder. Personality and Mental Health
2008;2(1):25-43.

Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et
al. Systems Training for Emotional Predictability and Problem
Solving (STEPPS) for outpatients with borderline personality
disorder: A randomized controlled trial and 1-year follow-up:
correction. American Journal of Psychiatry Jun 2008;165(6):777.

*  Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et
al. Systems training for emotional predictability and problem
solving (STEPPS) for outpatients with borderline personality
disorder: a randomized controlled trial and 1-year follow-up.
American Journal of Psychiatry 2008;165(4):468-78.

Davidson KM. Borderline personality disorder: STEPPS
improves symptoms. Evidence-Based Mental Health
2008;11(4):120.

NCT00055315. Treatment for borderline personality disorder.
http://clinicaltrials.gov/ct2/show/study/NCT00055315
(accessed 09 August 2011).

Bos 2010 {published data only}

*  Bos EH, Van Wel E, Bas AMT, Verbraak MJP. A randomized
controlled trial of a Dutch version of systems training for
emotional predictability and problem solving for borderline
personality disorder. Journal of Nervous and Mental Disease
2010;198(4):299-304.

Van Wel EB, Bos EH, Appelo MT, Berendsen EM, Willgeroth FC,
Verbraak MJPM. The efficacy of the systems training for
emotional predictability and problem solving (stepps) in the
treatment of borderline personality disorder: a randomized
controlled trial [De effectiviteit van de vaardigheidstraining
emotieregulatiestoornis (VERS) in de behandeling van de
borderlinepersoonlijkheidsstoornis: een gerandomiseerd
onderzoek]. Tijdschrift voor Psychiatrie 2009;51:291-301.

Carter 2010 {published data only}

Carter G. Question regarding your BPD trial [personal
communication]. Email to: J Stoffers. 21 December 2010.

*  Carter GL, Willcox CH, Lewin TJ, Conrad AM, Bendit N.
Hunter DBT project: randomized controlled trial of dialectical
behaviour therapy in women with borderline personality
disorder. Australian and New Zealand Journal of Psychiatry
2010;44(2):162-73.

Cochrane Database of Systematic Reviews

Cottraux 2009 {published data only}

*  Cottraux J, Note ID, Boutitie F, Milliery M, Genouihlac V,
Yao SN, et al. Cognitive therapy versus rogerian supportive
therapy in borderline personality disorder. Psychotherapy and
Psychosomatics 2009;78:307-16.

NCT00131781. Cognitive therapy versus supportive therapy in
borderline personality disorder. http://clinicaltrials.gov/ct2/
show/record/NCT00131781 (accessed 09 August 2011).

Davidson 2006 {published data only}

*  Davidson K, Norrie J, Tyrer P, Gumley A, Tata P, Murray H, et al.
The effectiveness of cognitive behavior therapy for borderline
personality disorder: results from the borderline personality
disorder study of cognitive therapy (BOSCOT) trial. Journal of
Personality Disorders 2006 Oct;20(5):450-65.

Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, Palmer S, et al.
A randomized controlled trial of cognitive behavior therapy for
borderline personality disorder: rationale for trial, method, and
description of sample. Journal of Personality Disorders 2006
Oct;20(5):431-49.

Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive
therapy v usual treatment for borderline personality disorder:
prospective 6-year follow-up. British Journal of Psychiatry
2010;197:456-62.

ISRCTN86177428. Borderline personality disorder study of
cognitive therapy trial. http://www.controlled-trials.com/
ISRCTN86177428 (accessed 02 November 2010).

NCT00538135. BOSCOT: A randomised controlled trial of
cognitive behavioural therapy in borderline personality
disorder. http://clinicaltrials.gov/show/NCT00538135 (accessed
09 August 2011).

Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et
al. The cost-effectiveness of cognitive behavior therapy for
borderline personality disorder: results from the BOSCOT trial.
Journal of Personality Disorders 2006;20(5):466-81.

Doering 2010 {published data only}

*  Doering S, Hörz S, Rentrop M, Fischer-Kern M, Schuster P,
Benecke C, et al. Transference-focused psychotherapy v.
treatment by community psychotherapists for borderline
personality disorder: randomised controlled trial. British
Journal of Psychiatry 2010;196(5):389-95.

Doering S. Question regarding your BPD trial for systematic
review in Cochrane Collaboration [personal communication].
Email to: K Lieb, J Stoffers. 10 December 2010.

NCT00714311. Efficacy of transference-focused psychotherapy
for borderline personality disorder. http://clinicaltrials.gov/ct2/
show/record/NCT00714311 (accessed 09 August 2011).

Farrell 2009 {published data only}

*  Farrell JM, Shaw IA, Webber MA. A schema-focused
approach to group psychotherapy for outpatients with
borderline personality disorder: a randomized controlled
trial. Journal of Behavior Therapy and Experimental Psychiatry
2009;40(2):317-28.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Farrell JM. Question regarding your BPD trials [personal
communication]. Email to: K Lieb, J Stoffers. 09 December 2010.

alcohol use disorders. Journal of Nervous and Mental Disease
2010;198(4):292-7.

Giesen-Bloo 2006 {published and unpublished data}

Giesen-Bloo J, Arntz A. Outpatient psychotherapy for borderline
personality disorder: A randomized trial of schema-focused
therapy vs transference-focused psychotherapy: reply. Archives
of General Psychiatry May 2007;64(5):610-1.

Gregory RJ, Remen AL, Soderberg M, Ploutz-Snyder RJP.
A controlled trial of psychodynamic psychotherapy for
co-occurring boderline personality disorder and alcohol
use disorder: six-month outcome. Journal of the American
Psychoanalytic Association 2009;57(1):199-205.

*  Giesen-Bloo J, Van Dyck R, Spinhoven P, Van Tilburg W,
Dirksen C, Van Asselt T, et al. Outpatient psychotherapy for
borderline personality disorder: randomized trial of schema-
focused therapy vs transference-focused psychotherapy.
[erratum appears in Arch Gen Psychiatry. 2006 Sep;63(9):1008].
Archives of General Psychiatry 2006;63(6):649-58.

Giesen-Bloo. Outpatient psychotherapy for borderline
personality disorder: randomized trial of schema-focused
therapy vs transference-focused psychotherapy. Archives of
General Psychiatry 2006;63(9):1008.

Spinhoven P, Giesen-Bloo J, Van Dyck R, Kooiman K, Arntz A.
The therapeutic alliance in schema-focused therapy and
transference-focused psychotherapy for borderline personality
disorder. Journal of Consulting and Clinical Psychology
2007;76(1):104-15.

Van Asselt ADI, Dirksen CD, Arntz A, Giesen-Bloo JH, Van Dyck R,
Spinhoven P, et al. Out-patient psychotherapy for borderline
personality disorder: cost-effectiveness of schema-focused
therapy v. transference-focused psychotherapy. British Journal
of Psychiatry 2008;192:450-7.

Van Asselt ADI, Dirksen CD, Arntz A, Severens JL. Difficulties
in calculating productivity costs: work disability associated
with borderline personality disorder. Value in Health
2008;11(4):637-44.

Gratz 2006 {published data only}

*  Gratz KL, Gunderson JG. Preliminary data on an acceptance-
based emotion regulation group intervention for deliberate
self-harm among women with borderline personality disorder.
Behavior Therapy 2006;37(1):25-35.

Gratz KL. Question regarding your BPD trials [personal
communication]. Email to: J Stoffers. 11 December 2010.

Gregory 2008 {published data only}

Gregory RJ, Chlebowski S, Kang D, Remen A, Soderberg M.
Psychodynamic therapy for borderline personality disorder and
co-occurring alcohol use disorders: a newly designed ongoing
study. Journal of the American Psychoanalytic Association
2006;54(4):1331-4.

*  Gregory RJ, Chlebowski S, Kang D, Remen AL, Soderberg MG,
Stepkovitch J, et al. A controlled trial of psychodynamic
psychotherapy for co-occurring borderline personality disorder
and alcohol use disorder. Psychotherapy 2008;45(1):28-41.

Gregory RJ, DeLucia-Deranja E, Mogle JA. Dynamic
deconstructive psychotherapy versus optimized community
care for borderline personality disorder co-occuring with

NCT00145678. Psychodynamic therapy for co-occurring
borderline personality disorder and alcohol use disorder. http://
clinicaltrials.gov/show/NCT00145678 (accessed 09 August
2011).

Koons 2001 {published data only}

Koons CR, Robins CJ, Tweed JL, Lynch TR, Gonzalez AM,
Morse JQ, et al. Efficacy of dialectical behavior therapy in
women veterans with borderline personality disorder. Behavior
Therapy 2001;32(2):371-90.

Linehan 1991 {published data only}

Lindenboim Noam. To know me is to keep me: self-verification,
validation, and therapy dropout in the treatment of borderline
personality disorder [PhD thesis]. Dissertation Abstracts
International 5831;70(9):2010.

*  Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL.
Cognitive-behavioral treatment of chronically parasuicidal
borderline patients. Archives of General Psychiatry
1991;48(12):1060-4.

Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of
a behavioral treatment for chronically parasuicidal borderline
patients.[Erratum appears in Arch Gen Psychiatry 1994
May;51(5):422]. Archives of General Psychiatry 1993;50(12):971-4.

Linehan MM, Heard HL. Impact of treatment accessibility on
clinical course of parasuicidal patients-reply. Archives of General
Psychiatry 1993;50(2):157-8.

Linehan 1994 {published data only}

Heard HL. Cost-effectiveness of dialectical behavior therapy in
the treatment of borderline personality disorder. Dissertation
Abstracts International: Section B: The Sciences and Engineering
2000;61(6-B):3278.

Lindenboim Noam. To know me Is to keep me: self-verification,
validation, and therapy dropout in the treatment of borderline
personality disorder. Dissertation Abstracts International
5831;70(9):2010.

Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of
a behavioral treatment for chronically parasuicidal borderline
patients.[Erratum appears in Arch Gen Psychiatry 1994
May;51(5):422]. Archives of General Psychiatry 1993;50(12):971-4.

*  Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal
outcome of cognitive behavioral treatment for chronically
suicidal borderline patients. American Journal of Psychiatry
1994;151(12):1771-6.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Linehan 2006 {published data only}

Brown MZ, Linehan MM, Comtois KA, Murray A, Chapman AL.
Shame as a prospective predictor of self-inflicted injury in
borderline personality disorder: a multi-modal analysis.
Behavior Research and Therapy 2009;47:815-22.

Harned MS, Chapman AL, Dexter-Mazza ET, Murray A,
Comtois KA, Linehan MM. Treating co-occurring Axis I disorders
in recurrently suicidal women with borderline personality
disorder: a 2-year randomized trial of dialectical behavior
therapy versus community treatment by experts. Personality
Disorders: Theory, Research, and Treatment Aug 2009;S(1):35-45.

Harned MS, Chapman AL, Dexter-Mazza ET, Murray A,
Comtois KA, Linehan MM. Treating co-ocurring axis I disorders
in recurrently suicidal women with borderline personality
disorder: a 2-year randomized trial of dialectical behavior
therapy versus community treatment by experts. Journal of
Consulting and Clinical Psychology 2008;76(6):1068-75.

Harned MS, Jackson SC, Comtois KA, Linehan MM. Dialectical
behavior therapy as a precursor to PTSD treatment for suicidal
and/or self-injuring women with bordreline personality
disorder. Journal of Traumatic Stress 2010;23(4):421-9.

Lindenboim N, Comtois KA, Linehan MM. Skills practice in
dialectical behavior therapy for suicidal women meeting criteria
for borderline personality disorder. Cognitive and Behavioral
Practice 2007;14(2):147-56.

*  Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ,
Heard HL, et al. Two-year randomized controlled trial and
follow-up of dialectical behavior therapy vs therapy by experts
for suicidal behaviors and borderline personality disorder.
Archives of General Psychiatry 2006;63(7):757-66.

Linehan MM. Erratum: Two-year randomized controlled trial
and follow-up of dialectical behavior therapy vs therapy by
experts for suicidal behaviors and borderline personality
disorder. Archives of General Psychiatry 2007;64(12):1401.

McMain S. Dialectic behaviour therapy reduces suicide attempts
compared with non-behavioural psychotherapy in women with
borderline personality disorder. Evidence-Based Mental Health
2007 Feb;10(1):18.

Neacsiu AD, Rizvi SL, Linehan MM. Dialectical behavior
therapy skills use as a mediator and outcome of treatment
for borderline personality disorder. Behaviour Research and
Therapy Sep 2010;48(9):832-9.

McMain 2009 {published data only}

Case BG. Dialectical behavior therapy versus general
psychiatric management in the treatment of borderline
personality disorder. The American Journal of Psychiatry Apr
2010;167(4):475.

ISRCTN02634417. Evaluating the clinical and health services
impact of dialectical behaviour therapy (DBT) in individuals
with borderline personality disorder: a randomised controlled
trial. www.controlled-trials.com/ISRCTN02634417/02634417
(accessed 02 November 2010).

*  McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ,
Korman L, et al. A randomized trial of dialectical behavior
therapy versus general psychiatric management for borderline
personality disorder. American Journal of Psychiatry
2009;166:1365-74.

McMain Shelley F. Dialectical behavior therapy versus general
psychiatric management in the treatment of borderline
personality disorder: reply. The American Journal of Psychiatry
Apr 2010;167(4):475-6.

NCT00154154. Hope for the chronically suicidal patient.
http://clinicaltrials.gov/ct2/show/NCT00154154?
term=NCT00154154&rank=1 (accessed 09 August 2011).

Morey 2010 {published data only}

Morey LC, Lowmaster SE, Hopwood CJ. A pilot study of manual-
assisted cognitive therapy with a therapeutic assessment
augmentation for borderline personality disorder. Psychiatry
Research 2010;178(3):531-5.

Nadort 2009 {published data only}

NTR1781. Implementation of out-patient schema-focused
therapy for borderline personality disorder in regular mental
healthcare. www.trialregister.nl/trialreg/admin/rctview.asp?
TC=1781 (accessed 09 December 2010).

*  Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom J,
Spinhoven P, et al. Implementation of outpatient schema
therapy for borderline personality disorder with versus
without crisis support by the therapist outside office
hours: a randomized trial. Behaviour Research and Therapy
2009;47(11):961-73.

Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M,
Spinhoven P, et al. Implementation of outpatient schema
therapy for borderline personality disorder: study design. BMC
Psychiatry 2009;9:64.

Soler 2009 {published data only}

*  Soler J, Pascual JC, Tiana T, Cebrià A, Barrachina J,
Campins MJ, et al. Dialectical behaviour therapy skills training
compared to standard group therapy in borderline personality
disorder: a 3-month randomised controlled clinical trial.
Behaviour Research and Therapy 2009;47(5):353-8.

Soler J. Question regarding your BPD trials [personal
communication]. Email to: J Stoffers. 15 December 2010.

Steil 2010 {unpublished data only}

DBT working group at the Central Institute for Mental Health,
Mannheim, Germany. Requested supplementary data (as
supplied 1 October 2010). Data on file.

*  Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M. Dialectical
Behavior Therapy for Posttraumatic Stress Disorder related to
childhood sexual abuse: a pilot study of an intensive treament
program. submitted 2010.

Turner 2000 {published data only}

Turner RM. Naturalistic evaluation of dialectical behavior
therapy-oriented treatment for borderline personality disorder.
Cognitive and Behavioral Practice 2000;7:413-9.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Van den Bosch 2005 {published data only}

Beecham 2006 {published data only}

Van den Bosch LM, Verheul R, Schippers GM, Van den Brink W.
Dialectical Behavior Therapy of borderline patients with and
without substance use problems. Implementation and long-
term effects. Addictive Behaviors 2002;27:911-23.

Beecham J, Sleed M, Knapp M, Chiesa M, Drahorad C. The costs
and effectiveness of two psychosocial treatment programmes
for personality disorder: a controlled study. European Psychiatry
2006;21(2):102-9.

*  Van den Bosch LMC, Koeter MWJ, Stijnen T, Verheul R, Van
den Brink W. Sustained efficacy of dialectical behaviour therapy
for borderline personality disorder. Behaviour Research and
Therapy 2005;43(9):1231-41.

Van den Bosch LMC. Efficacy of dialectical behaviour therapy
in the treatment of female borderline patients with and
without substance abuse problems: results of a Dutch study
[Dialectische gedragstherapie bij nederlandse vrouwen
met een borderline persoonlijkheidsstoornis, met en
zonder verslavingsproblemen]. Tijdschrift voor psychiatrie
2005;47(3):127-37.

Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA,
Stijnen T, Van den Brink W. Dialectical behaviour therapy
for women with borderline personality disorder: 12-month,
randomised clinical trial in The Netherlands. British Journal of
Psychiatry 2003;182:135-40.

Weinberg 2006 {published data only}

Weinberg I, Gunderson JG, Hennen J, Cutter Jr CJ. Manual
assisted cognitive treatment for deliberate self-harm in
borderline personality disorder patients. Journal of Personality
Disorders 2006;20(5):482-92.

Zanarini 2008 {published data only}

Zanarini MC, Frankenburg FR, editors(s). A randomized trial of
psychoeducation for patients with BPD. Proceedings of the 57th
annual meeting of the American Psychiatry Association; 1-6 May
2004. New York: American Psychiatric Association, 2004.

*  Zanarini MC, Frankenburg FR. A preliminary, randomized trial
of psychoeducation for women with borderline personality
disorder. Journal of Personality Disorders 2008;22(3):284-90.

Bellino 2005 {published data only}

Bellino S, Zizza M, Di Lorenzo R, Rinaldi C, Bogetto F. Combined
therapy with interpersonal psychotherapy of major depressed
patients: comparison between patients with borderline
personality disorder and patients with other personality
disorders [La terapie combinata con psicoterapia interpersonale
della depressione maggiore: confronto tra pazienti con disturbo
boderline di personalità e pazienti con altre diagnosi di asse II].
Giornale Italiano di Psicopatologia 2005;11:157-64.

Berget 2008 {published data only}

Berget B, Ekeberg Ø, Braastad BO. Animal-assisted therapy with
farm animals for persons with psychiatric disorders: effects on
self-efficacy, coping ability yand quality of life, a randomized
controlled trial. Clinical Practice and Epidemiology in Mental
Health 2008;4:9.

Blum 2002 {published data only}

Blum N, Pfohl B, St John D, Monahan P, Black D. STEPPS:
a cognitive-behavioral systems-based group treatment for
outpatients with borderline personality disorder - a preliminary
report. Comprehensive Psychiatry 2002;43:301-10.

Bohus 2000 {published data only}

Bohus M, Haaf B, Stiglmayr C, Pohl U, Böhme R, Linehan M.
Evaluation of inpatient dialectical-behavioral therapy for
borderline personality disorder - a prospective study. Behaviour
Research and Therapy 2000;38:875-87.

Bohus 2004 {published data only}

Bohus M, Haaf B, Simms T, Limberger MF, Schmahl C, Unckel C,
et al. Effectiveness of inpatient dialectical behavioral therapy
for borderline personality disorder: a controlled trial. Behaviour
Research and Therapy 2004;42:487-99.

References to studies excluded from this review

Brassington 2006 {published data only}

Abbass 2008 {published data only}

Abbass A, Sheldon A, Gyra J, Kalpin A. Intensive short-term
dynamic psychotherapy for DSM-IV personality disorders - a
randomized controlled trial. The Journal of Nervous and Mental
Disease 2008;196(3):211-6.

Arnevik 2009 {published data only}

Arnevik E, Wilberg T, Urnes Ø, Johansen M, Monsen JT,
Karterud S. Psychotherapy for personality disorders: short-
term day hospital psychotherapy versus outpatient individual
therapy - a randomized controlled study. European Psychiatry
2009;24(2):71-8.

Ball 2007 {published data only}

Ball SA. Comparing individual therapies for personality
disordered opioid dependent patients. Journal of Personality
Disorders 2007;21(3):305-21.

Brassington J, Krawitz R. Australasian dialectical behaviour
therapy pilot outcome study: effectiveness, utility and
feasibility. Australasian Psychiatry 2006;14:313-9.

Brown 2004 {published data only}

Brown GK, Newman CF, Charlesworth SE, Crits-Christoph P,
Beck AT. An open clinical trial of cognitive therapy for
borderline personality disorder. Journal of Personality Disorders
2004;18:257-71.

Carter 2007 {published data only}

Carter GL, Clover K, Whyte IM, Dawson AH, D'Este C. Postcards
from the EDge: 24-month outcomes of a randomised controlled
trial for hospital-treated self-poisoning. British Journal of
Psychiatry 2007;191:548-53.

Chanen 2008 {published data only}

Chanen AM, Jackson HJ, McCutcheon LK, Jovev M, Dudgeon P,
Yuen HP, et al. Early intervention for adolescents with

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

borderline personality disorder using cognitive analytic
therapy: randomised controlled trial. The British Journal of
Psychiatry 2008;193:477-84.

Chiesa 2000 {published data only}

Chiesa M, Fonagy P. Cassel Personality Disorder Study. British
Journal of Psychiatry 2000;176:485-91.

Clarkin 2007 {published data only}

*  Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF.
Evaluating three treatments for borderline personality
disorder: a multiwave study. American Journal of Psychiatry
2007;164:922-8.

Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. The
Personality Disorders Institute/Borderline Personality Disorder
Research Foundation randomized control trial for borderline
personality disorder: rationale, methods, and patient
characteristics. Journal of Personality Disorders 2004;18:52-72.

Colom 2004 {published data only}

Colom F, Vieta E, Sánchez-Moreno J, Martínez-Arán A, Torrent C,
Reinares M, et al. Psychoeducation in bipolar patients with
comorbid personality disorders. Bipolar Disorders 2004;6:294-8.

Dolan 1997 {published data only}

Dolan B, Warren F, Norton K. Change in borderline symptoms
one year after therapeutic community treatment for
severe personality disorder. British Journal of Psychiatry
1997;171:274-9.

Evans 1999a {published data only}

Evans K, Tyrer P, Catalan J, Schmidt U, Davidson K, Dent J,
et al. Manual-assisted cognitive-behaviour therapy (MACT):
a randomized controlled trial of a brief intervention with
bibliotherapy in the treatment of recurrent deliberate self-harm.
Psychological Medicine 1999;29:19-25.

Evans 1999b {published data only}

Evans MO, Morgan HG, Hayward A, Gunnell DJ. Crisis telephone
consultation for deliberate self-harm patients: effects on
repetition. British Journal of Psychiatry 1999;175:23-7.

Gabbard 2000 {published data only}

Gabbard GO, Coyne L, Allen JG, Spohn H, Colson DB, Vary M.
Evaluation of intensive inpatient treatment of patients with
severe personality disorders. Psychiatric Services 2000;51:893-8.

Guthrie 2001 {published data only}

Guthrie E, Kapur N, Mackway-Jones K, Chew-Graham C,
Moorey J, Mendel E, et al. Randomised controlled trial of brief
psychological intervention after deliberate self poisoning. BMJ
2001;323:1-5.

Hagen 2005 {published data only}

Hagen R, Nordahl HM, Kristiansen L, Morken G. A randomized
trial of cognitive group therapy vs. waiting list for patients
with co-morbid psychiatric disorders: effect of cogniitve group
therapy after treatment and six and twelve months follow-up.
Behavioural and Cognitive Psychotherapy 2005;33:33-44.

Cochrane Database of Systematic Reviews

Huband 2007 {published data only}

Huband N, McMurran M, Evans C, Duggan C. Social problem-
solving plus psychoeducation for adults with personality
disorders. British Journal of Psychiatry 2007;190:307-13.

Kool 2003 {published data only}

Kool S, Dekker J, Duijsens IJ, De Jonghe F, Puite B. Changes in
personality pathology after pharmacotherapy and combined
therapy for depressed patients. Journal of Personality Disorders
2003;17:60-72.

Korner 2006 {published data only}

Korner A, Gerull F, Meares R, Stevenson J. Borderline personality
disorder treated with the conversational model: a replication
study. Comprehensive Psychiatry 2006;47:406-11.

Kröger 2006 {published data only}

Kröger C, Schwieger U, Sipos V, Arnold R, Kahl KG, Schunert T, et
al. Effectiveness of dialectical behaviour therapy for borderline
personality disorder in an inpatient setting. Behaviour Research
and Therapy 2006;44:1211-7.

Linehan 1999 {published data only}

Linehan MM, Schmidt H III, Dimeff LA, Craft JC, Kanter J,
Comtois KA. Dialectical behavior therapy for patients with
personality disorder and drug-dependence. The American
Journal on Addictions 1999;8:279-92.

Linehan 2002 {published data only}

Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS,
Heagerty P, et al. Dialectical behavior therapy versus
comprehensive validation therapy plus 12-step for the
treatment of opioid dependent women meeting criteria for
borderline personality disorder. Drug and Alcohol Dependence
2002;67:13-26.

López 2004 {published data only}

López D, Cuevas P, Gómez A, Mendoza J. Transference-focused
psychotherapy in borderline personality disorder [Psicoterapia
focalizada en la transferencia para el trastorno límite de la
personalidad]. Salud Mental 2004;27:44-54.

Lynch 2007 {published data only}

Lynch TR, Cheavens JS, Cukrowicz KC, Thorp SR, Bronner L,
Beyer J. Treatment of older adults with co-morbid personality
disorder and depression: a dialectical behavior therapy
approach. International Journal of Geriatric Psychiatry
2007;22:131-43.

McQuillan 2005 {published data only}

McQuillan A, Nicastro R, Guenot F, Girard M, Lissner C, Ferrero F.
Intensive dialectical behavior therapy for outpatients with
borderline personality disorder who are in crisis. Psychiatric
Services 2005;56:193-7.

Meares 1999 {published data only}

Meares R, Stevenson J, Comerford A. Psychotherapy with
borderline patients: a comparison between treated and
untreated cohorts. Australian and New Zealand Journal of
Psychiatry 1999;33:467-72.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mueser 2004 {published data only}

Stanley 2007 {published data only}

Mueser KT, Clark RE, Haines M, Drake RE, McHugo GJ, Bond GR,
et al. The Hartford Study of supported employment for persons
with severe mental illness. Journal of Consulting and Clinical
Psychology 2004;72:479-90.

Munroe-Blum 1995 {published data only}

Munroe-Blum H, Marziali E. A controlled trial of short-term
group treatment for borderline personality disorder. Journal of
Personality Disorders 1995;9:190-8.

Muran 2009 {published data only}

Muran JC, Safran JD, Gorman BS, Samstag LW, Eubanks-
Carter C, Winston A. The relationship of early alliance
ruptures and their resolution to process and outcome
in three time-limited psychotherapies for personality
disorders. Psychotherapy Theory, Research, Practice, Training
2009;46:233-48.

Petersen 2008 {published data only}

Petersen B, Toft J, Christensen NB, Foldager L, Munk-
Jörgensen P, Lien K, et al. Outcome of a psychotherapeutic
programme for patients with severe personality disorders.
Nordic Journal of Psychiatry 2008;62:450-6.

Ranger 2009 {published data only}

Ranger M, Tyrer P, Miloseska K, Fourie H, Khaleel I, North B, et
al. Cost-effectiveness of nidotherapy for comorbid personality
disorder and severe mental illness: randomized controlled trial.
Epidemiologia e Psichiatria Sociale 2009;18:128-36.

Rathus 2002 {published data only}

Rathus JH, Miller AL. Dialectical behavior therapy adapted for
suicidal adolescents. Suicide and Life-Threatening Behavior
2002;32:146-57.

Stanley B, Brodsky B, Nelson JD, Dulit R. Brief dialectial
behavior therapy (DBT-B) for suicidal behavior and non-suicidal
self injury. Archives of Suicide Research 2007;11:337-41.

Stevenson 1992 {published data only}

Stevenson J, Meares R. An outcome study of psychotehrapy for
patients with borderline personality disorder. American Journal
of Psychiatry 1992;149:358-62.

Stiles 2006 {published data only}

Stiles WB, Barkham M, Twigg E, Mellor-Clark J, Cooper M.
Effectiveness of cognitive-behavioural, person-centered and
psychodynamic therapies as practised in UK National Health
Service settings. Psychological Medicine 2006;36:555-66.

Trupin 2002 {published data only}

Trupin EW, Stewart DG, Beach B, Boesky L. Effectiveness of
a dialectical behaviour therapy program for incarcerated
female juvenile offenders. Child and Adolescent Mental Health
2002;7:121-7.

Tyrer 2003 {published data only}

Tyrer P, Thompson S, Schmidt U, Jones V, Knapp M,
Davidson K, . Randomized controlled trial of brief cognitive
behaviour therapy versus treatment as usual in recurrent
deliberate self-harm: the POPMACT study. Psychological
Medicine 2003;33:969-76.

Tyrer 2009 {published data only}

Tyrer P, Cooper S, Rutter D, Seivewright H, Duggan C, Maden T,
et al. The assessment of dangerous and severe personality
disorder: lessons from a randomised controlled trial linked
to qualitative analysis. The Journal of Forensic Psychiatry &
Psychology 2009;20:132-46.

Sachsse 2006 {published data only}

Vinnars 2009 {published data only}

Sachsse U, Vogel C, Leichsenring F. Results of
psychodynamically oriented trauma-focused inpatient
treatment for women with complex posttraumatic stress
disorder (PTSD) and borderline personality disorder (BPD).
Bulletin of the Menninger Clinic 2006;70:125-44.

Schuppert 2009 {published data only}

Schuppert HM, Giesen-Bloo J, Van Gemert TG, Wiersema HM,
Minderaa RB, Emmelkamp PM, et al. Effectiveness of an
emotion regulation group training for adolescents - a
randomized controlled pilot study. Clinical Psychology &
Psychotherapy 2009;16(6):467-78.

Vinnars B, Thormählen B, Gallop R, Norén K, Barber JP.
Do personality problems improve during psychodynamic
supportive-expressive psychotherapy? Secondary outcome
results from a randomized controlled trial for psychiatric
outpatients with personality disorders. Psychotherapy: Theory,
Research, Practice, Training 2009;46:362-75.

Waltz 2009 {published data only}

Waltz J, Dimeff LA, Koerner K, Linehan MM, Taylor L, Miller C.
Feasibility of using video to teach a dialectical behavior therapy
skill to clients with borderline personality disorder. Cognitive
and Behavioral Practice 2009;16:214-22.

Slee 2008 {published data only}

Weertman 2007 {published data only}

Slee N, Garnefski N, Van der Leeden R, Arensman E,
Spinhoven P. Cognitive-behavioural intervention for self-
harm: randomised controlled trial. British Journal of Psychiatry
2008;192:202-11.

Springer 1996 {published data only}

Springer T, Lohr NE, Buchtel HA, Silk KR. A preliminary report
of short-term cognitive-behavioral group therapy for inpatients
with personality disorders. Journal of Psychotherapy Practice
and Research 1996;5(1):57-71.

Weertman A, Arntz A. Effectiveness of treatment of childhood
memories in cognitive therapy for personality disorders: a
controlled study contrasting methods focusing on the present
and methods focusing on childhood memories. Behaviour
Research and Therapy 2007;45:2133-43.

Wildgoose 2001 {published data only}

Wildgoose A, Clarke S, Waller G. Treating personality
fragmentation and dissociation in borderline personality

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

disorder: a pilot study of the impact of cognitive analytic
therapy. British Journal of Medical Psychology 2001;74:47-55.

Yen 2009 {published data only}

Yen S, Johnson J, Costello E, Simpson EB. A 5-day dialectical
behavior therapy partial hospital program for women with
borderline personality disorder: predictors of outcome from
a 3-month follow-up study. Journal of Psychiatric Practice
2009;15:173-82.

Zorn 2007 {published data only}

Zorn P, Roder V, Müller DR, Tschacher W, Thommen M. Schema
Focussed Emotive Behavioural Therapy (SET): a randomised
controlled trial on patients with cluster B and C personality
disorders [Schemazentrierte emotiv-behaviorale Therapie
(SET): eine randomisierte evaluationsstudie an patienten
mit persönlichkeitsstörungen aus den Clustern B und C].
Verhaltenstherapie 2007;17:233-41.

References to ongoing studies

ACTRN12605000594628 {published data only}

ACTRN12605000594628. A pilot study to evaluate the feasibility,
safety and efficacy of psychotherapeutic intervention for
comorbid BPD and first-episode psychosis. www.anzctr.org.au/
ACTRN12605000594628.aspx (accessed 8 August 2011).

ACTRN12606000206527 {published data only}

ACTRN12606000206527. Process and outcome of acceptance
based outpatient skills training groups for people with four
or more criteria of borderline personality disorder. http://
www.anzctr.org.au/trial_view.aspx?ACTRN=12606000206527
(accessed 8 August 2011).

ACTRN12610000100099 {published data only}

ACTRN12610000100099. A randomised controlled trial
(RCT) of specialised early intervention, with and without
psychotherapy, versus a standard youth mental health
intervention, for youth presenting with first presentation
borderline personality disorder (BPD). www.anzctr.org.au/
ACTRN12610000100099.aspx (accessed 9 August 2011).

DRKS00000068 {published data only}

DRKS00000068. Psychoanalytical interactional
psychotherapy in cluster B personality disorders
[Psychoanalytisch-Interaktionelle Therapie bei
Cluster B-Persönlichkeitsstörungen]. https://drks-
neu.uniklinik-freiburg.de/drks_web/navigate.do?
navigationId=trial.HTML&TRIAL_ID=DRKS00000068 (accessed
08 August 2010).

ISRCTN12440268 {published data only}

ISRCTN12440268. JOSHUA: a pilot randomised controlled trial
of joint crisis plans for people who self harm. www.controlled-
trials.com/ISRCTN12440268/12440268 (accessed 31 July 2011).

Moran P, Borschman R, Flach C, Barrett B, Byford S, Hogg J,
et al. The effectiveness of joint crisis plans for people with
borderline personality disorder: protocol for an exploratory
randomised controlled trial. Trials 2010;11:18.

Cochrane Database of Systematic Reviews

ISRCTN51304415 {published data only}

ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity,
Self-Harm and Eating Disorders: the NOURISHED study. http://
www.controlled-trials.com/ISRCTN51304415 (accessed 08
August 2011).

ISRCTN54233644 {published data only}

ISRCTN54233644. Dialectical behaviour therapy in patients
with borderline personality disorder who self-harm: a
pragmatic exploratory trial. www.controlled-trials.com/
ISRCTN54233644/54233644 (accessed 31 July 2011).

ISRCTN72677277 {published data only}

ISRCTN72677277. Psychological treatments for severe and
complex mental health problems/personality disorder. A phase
II randomised controlled trial (SPeDi). http://www.controlled-
trials.com/ISRCTN72677277 (accessed 08 August 2011).

ISRCTN79187618 {published data only}

ISRCTN79187618. Psychoanalytically oriented brief
group treatment for borderline personality disorder: a
randomised controlled trial. http://www.controlled-trials.com/
ISRCTN79187618 (accessed 08 August 2011).

ISRCTN98982683 {published data only}

ISRCTN98982683. Mentalisation-based treatment for dual
diagnoses. www.controlled-trials.com/ISRCTN98982683
(accessed 02 November 2010).

Jørgensen 2009 {published data only}

Jørgensen CR, Kjølbye M, Freund C, Bøye R, Jordet H,
Andersen D. Level of functioning in patients with borderline
personality disorder. The Risskov-I study. Nordic Psychology
2009;61(1):42-60.

NCT00117741 {published data only}

NCT00117741. Evaluation of DBT compared to drug counseling
for opiate addicts. www.clinicaltrials.gov/ct2/show/
NCT00117741?term=00117741&rank=1 (accessed 9 August
2011).

NCT00183651 {published data only}

NCT00183651. Treatment of suicidal women with borderline
personality disorders. www.clinicaltrials.gov/ct2/show/
NCT00183651?term=00183651&rank=1 (accessed 9 December
2010).

NCT00218595 {published data only}

NCT00218595. DBT compared to I/GDC for the treatment
of opiate addiction in emotionally dysregulated patients.
www.clinicaltrials.gov/show/NCT00218595 (accessed 3 January
2011).

NCT00247234 {published data only}

NCT00247234. Effectiveness of group based schema therapy in
the treatment of personality disorders. www.clinicaltrials.gov/
show/NCT00247234 (accessed 9 August 2011).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00378248 {published data only}

NCT00378248. Ullevål personality project. http://
clinicaltrials.gov/show/NCT00378248 (accessed 09 August
2011).

NCT00533117 {published data only}

NCT00533117. Treating suicidal behavior and self-
mutilation in people with borderline personality
disorder. www.clinicaltrials.gov/ct2/show/NCT00533117?
term=00533117&rank=1 (accessed 3 January 2011).

NCT00603421 {published data only}

NCT00603421. Effectiveness of a 24 hour phone line on
the rate of suicide attempts in borderline patients. http://
clinicaltrials.gov/show/NCT00603421 (accessed 09 August
2011).

Pham-Scottez A. Impact of a 24/24 phone permanency on
suicide attempts of borderline patients. Annales Medico-
Psychologiques 2010;168(2):141-3.

NCT00834834 {published data only}

NCT00834834. Comparing treatments for self-injury and
suicidal behavior in people with borderline personality
disorder. www.clinicaltrials.gov/ct2/show/NCT00834834?
term=00834834&rank=1 (accessed 3 January 2011).

NCT00980824 {published data only}

NCT00980824. ENGAGE - Meeting mental health needs of
complex comorbid patients attending A&E following a suicide
attempt. A pilot study. www.clinicaltrials.gov/ct2/show/
NCT00980824?term=00980824&rank=1 (accessed 8 December
2010).

NCT01033708 {published data only}

NCT01033708. A randomized control trial of narrative exposure
therapy versus treatment as usual in the therapy of borderline
personality disorder (NET). www.clinicaltrials.gov/show/
NCT01033708 (accessed 9 August 2011).

NCT01081314 {published data only}

NCT01081314. Treating PTSD in patients with borderline
personality disorder. www.clinicaltrials.gov/ct2/show/
NCT01081314?term=01081314&rank=1 (accessed 9 December
2010).

NCT01132976 {published data only}

NCT01132976. The personal concerns inventory study (PCI).
http://clinicaltrials.gov/show/NCT01132976 (accessed 9 August
2011).

NCT01193205 {published data only}

NCT01193205. Evaluating the effectiveness of dialectical
behaviour skills training for suicidality in borderline personality
disorder. www.clinicaltrials.gov/ct2/show/NCT01193205?
term=01193205&rank=1 (accessed 9 December 2010).

NTR1186 {published data only}

Bernstein D, Arntz A. Schema focused therapy for forensic
patients with personality disorders: new research findings.
In: New Diagnostic Approaches in psychiatry: Relevance for

Cochrane Database of Systematic Reviews

Research and Practice in Europe. Proceedings of the 17th
European Congress of Psychiatry of the European Psychiatric
Association; January 2009. Lisbon, Portugal: European
Psychiatric Association, 2009:38.

NTR1186. Efficacy of schema-focused therapy versus usual
treatment in forensic patients with personality disorder: a
three-year randomized clinical trial. www.trialregister.nl/
trialreg/admin/rctview.asp?TC=1186 (accessed 3 January 2011).

NTR2175 {published data only}

NTR2175. Mentalisation-based treatment versus care-as-usual
in the treatment of severe borderline personality disorders.
www.trialregister.nl/trialreg/admin/rctview.asp?TC=2175
(accessed 9 December 2010).

NTR2292 {published data only}

NTR2292. Intensive outpatient mentalisation-based treatment
versus day hospital mentalisation-based treatment: a
randomised controlled trial. http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC=2292 (accessed 9 August 2011).

NTR2392 {published data only}

ACTRN1261100015965. Group Schema Therapy for Borderline
Personality Disorder. International multi-site RCT of two
versions of Group Schema Therapy compared to treatment as
usual for Borderline Personality Disorder in reducing symptom
severity and improving quality of life. http://www.anzctr.org.au/
ACTRN12611000158965.aspx (accessed 9 August 2011).

NTR2392. Group schema therapy for borderline personality
disorder. www.trialregister.nl/trialreg/admin/rctview.asp?
TC=2392 (accessed 9 December 2010).

Additional references

Ansell 2007

Ansell EB, Sanislow CA, McGlashan TH, Grilo CM. Psychosocial
impairment and treatment utilization by patients with
borderline personality disorder, other personality disorders,
mood and anxiety disorders, and a healthy comparison group.
Comprehensive Psychiatry 2007;48:329-36.

APA 1980

American Psychiatric Asssociation. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III). 3rd edition. Washington,
DC: American Psychiatric Association, 1980.

APA 1987

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III-R). 3rd edition.
Washington, DC: American Psychiatric Association, 1987.

APA 2000

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR). 4th edition.
Washington, DC: American Psychiatric Association, 2000.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

APA 2001

Carkhuff 1969

American Psychiatric Association. Practice guideline for the
treatment of patients with borderline personality disorder.
American Journal of Psychiatry 2001;158(suppl. 2-2):1-52.

Arntz 2003

Arntz A, Van den Hoorn M, Cornelis J, Verheul R, Van den
Bosch W, De Bie AJHT. Reliability and validity of the Borderline
Personality Disorder Severity Index. Journal of Personality
Disorders 2003;17(1):45-59.

Bateman 2004

Bateman A, Fonagy P. Psychotherapy for Borderline Personality
Disorder: Mentalisation Based Treatment. Oxford, UK: Oxford
University Press, 2004.

Bateman 2006

Bateman A, Fonagy P. Mentalization Based Treatment: a
Practical Guide. Oxford, UK: Oxford University Press, 2006.

Bateman 2010

Bateman A. Important: Question regarding your BPD trial
for systematic review in Cochrane Collaboration [personal
communication]. Email to: K Lieb, J Stoffers 14 December 2010.

Beck 1979

Beck AT, Rush AJ, Schaw BF, Emery G. Cognitive Therapy of
Depression. New York: The Guilford Press, 1979.

Beck 1990

Beck AT, Freeman A. Cognitive Therapy of Personality Disorders.
New York: Guilford Press, 1990.

Beck 1995

Carkhuff RR. Helping and Human Relations. New York: Holt,
Rinehart & Winston, 1969.

Carkhuff 1976

Carkhuff RR, Pierce R, Cannon J. The Art of Helping. Amherst,
MA: Human Resources Press, 1976.

Carter 2010a [pers comm]

Carter G. Question regarding your BPD trial [personal
communication]. Email to: J Stoffers. 21 December 2010.

Chalmers 1983

Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment
assignment in controlled clinical trials. New England Journal of
Medicine 1983;309:1358-61.

Chinn 2000

Chinn S. A simple method for converting an odds ratio to
effect size for use in meta-analysis. Statistics in Medicine
2000;19:3127-31.

Clarkin 1999

Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for
Borderline Personality. New York (NY): J. Wiley & Sons, 1999.

Cohen 1988

Cohen J. Statistical Power Analysis in the Behavioural Sciences.
2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988.

Conte 1980

Conte HR, Plutchik R, Karasu TB, Jerrett I. A self-report
borderline scale. Discriminative validity and preliminary norms.
Journal of Nervous and Mental Disease 1980;100:428-35.

Beck JS. Cognitive Therapy: Basics and Beyond. New York: The
Guilford Press, 1995.

Davidson 2000

Bellino 2010a [pers comm]

Bellino S. Question regarding your BPD trials [personal
communication]. Email to: J Stoffers. 16 December 2010.

Berk 2009

Berk M, Parker G. The elefant on the couch: side-effects
of psychotherapy. Australian and New Zealand Journal of
Psychiatry 2009;43:787-94.

Bohus 2004

Bohus M, Haaf B, Simms T, Limberger MF, Schmal C, Unckel C,
et al. Effectiveness of inpatient dialectical behavioral therapy
for borderline personality disorder: a controlled trial. Behaviour
Research and Therapy 2004;42(5):487-99. [DOI: 10.1016/
S0005-7967(03)00174-8] [PMID: 15033496]

Boutron 2008

Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, the
CONSORT group. Extending the CONSORT Statement to
randomised trials of nonpharmacologic treatment: explanation
and elaboration. Annals of Internal Medicine 2008;148:295-309.

Davidson KM. Cognitive Therapy for Personality Disorders: a
Guide for Clinicans. Oxford: Butterworth Heinemann Press,
2000.

Davidson 2006a

Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, Palmer S, et al.
A randomized controlled trial of cognitive behavior therapy
for borderline personality disorder: rationale for trial, method,
and description of sample. Journal of Personality Disorders
2006;20(5):431-49.

DBT working group at CIMH

DBT working group at the Central Institute for Mental Health,
Mannheim, Germany. Requested supplementary data (as
supplied 1 October 2010). Data on file.

De Groot 2008

De Groot ER, Verheul R, Trijsburg RW. An integrative perspective
on psychotherapeutic treatments for borderline personality
disorders. Journal of Personality Disorders 2008;22(4):332-52.

Distel 2011

Distel MA, Carlier A, Middeldorp CM, Derom CA, Lubke GH,
Boomsma DI. Borderline personality traits and adult attention-
deficit hyperactivity disorder symptoms: a genetic analysis

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

of comorbidity. American Journal of Medical Genetics Part B
2011;156:817-25.

Donner 1980

Donner A, Koval JJ. The estimation of intraclass correlation in
the analysis of family data. Biometrics 1980;36(1):19-25.

Elbourne 2002

Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV,
Vaillancourt JM. Meta-analyses involving cross-over trials:
methodological issues. International Journal of Epidemiology
2002;31:140-9.

Endicott 1976

Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global
Assessment Scale: A procedure for measuring overall severity
of psychiatric disturbance. Archives of General Psychiatry
1976;33:766-71.

ESSPD 2010

ESSPD 2010. In: Proceedings of the 1st International Congress
on Borderline Personality Disorder; 1-3 July 2010, Berlin,
Germany. European Society for the Study of Personality
Disorders, 2011.

Farrell 1994

Farrell JM, Shaw IA. Emotional awareness training: a
prerequisite to effective cognitive-behavioral treatment of
borderline personality disorder. Cognitive and Behavioral
Practice 1994;1:71-91.

Ferrer 2010

Ferrer M, Andión Ó, Matalí J, Valero S, Navarro JA, Ramos-
Quiroga JA, et al. Comorbid attention-deficit/hyperactivity
disorder in borderline patients defines an impulsive subtype of
borderline personality disorder. Journal of Personality Disorders
2010;24(6):812-22.

First 1997

First MB, Spitzer RL, Gibbon M, Williams JB, Benjamin LS.
Structured Clinical Interview for DSM-IV Axis II Personality
Disorders (SCID-II). Washington (DC): American Psychiatric
Press, 1997.

Cochrane Database of Systematic Reviews

Gregory 2017

Gregory RJ. Comment to 'Psychological therapies for people
with borderline personality disorder'. Received via the Cochrane
Feedback mechanism 14 February 2017.

Gunderson 1981

Gunderson JG, Kolb JE, Austin V. The diagnositc interview for
borderlines. American Journal of Psychiatry 1981;138:896-903.

Guy 1976

Guy W. Assessment manual for psychopharmacology-revised.
In: DHEW Publ No ADM 76-338. Rockville, MD: Department
of Health, Education, and Welfare, Public Health Service,
Alcohol, Drug Abuse, and Mental Health Administration, NIMH
Psychopharmacology Research Branch, Division of Extramural
Research Programs, 1976:218-222.

Hayes 1999

Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment
Therapy: an Experiential Approach to Behavior Change. New
York: Guilford Press, 1999.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Green S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011). The
Cochrane Collaboration, 2011. Available from www.cochrane-
handbook.org.

Higgins 2011a

Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special
topics in statistics. In: Higgins JPT, Green S (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.

Higgins 2011b

Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies
and collecting data. In: Higgins JPT, Green S (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.

Greenberg 2002

Higgins 2011c

Greenberg LS. Emotion-focused Therapy: Coaching Clients
to Work Through Their Feelings. Washington, DC: American
Psychiatric Press, 2002.

Gregory 2008a

Gregory RJ, Remen AL. A manual-based psychodynamic
therapy for treatment-resistant borderline personality
disorder. Psychotherapy: theory, research, practice, training
2008;45:15-27.

Gregory 2010

Gregory RJ. Remediation for treatment-resistant borderline
personality disorder: manual of dynamic deconstructive
psychotherapy (c). http://www.upstate.edu/psych/education/
psychotherapy/pdf/ddp_ manual.pdf (accessed 19 February
2010).

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing
data and undertaking meta-analysis. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011). The
Cochrane Collaboration, 2011. Available from www.cochrane-
handbook.org.

Higgins 2017 [pers comm]

Higgins JPT. Seeking advice on comments rec'd through
Feedback system [personal communication]. Email to: J Dennis
27 February 2017.

Hörz 2010

Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G.
Ten-year use of mental health services by patients with

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

borderline personality disorder and with other axis II disorders.
Psychiatric Services 2010;61:612-6.

disorder: a double-blind, placebo-controlled pilot study.
Journal of Clinical Psychiatry 2008;69(9):999-1005.

ISSPD 2007

Livesley 2007

Proceedings of the Xth International Congress of the
International Society for the Study of Personality Disorders
(ISSPD); 22-29 Sept 2007; The Hague, The Netherlands.
International Society for the Study of Personality Disorders.

ISSPD 2009

Proceedings of the XIth International Congress of the
International Society for the Study of Personality Disorders
(ISSPD); Aug 21-23 2009; New York, NY. International Society for
the Study of Personality Disorders.

ISSPD 2011

Proceedings of the XIIth International Congress of the
International Society for the Study of Personality Disorders
(ISSPD); 1-4 Mar 2011; Melbourne, Australia. International
Society for the Study of Personality Disorders.

Livesley WJ. An integrated approach to the treatment
of personality disorder. Journal of Mental Health
2007;16(1):131-48.

Livesley 2012

Livesley WJ. Integrated treatment: a conceptual framework for
an evidence-based approach to the treatment of personality
disorder. Journal of Personality Disorder 2012;26(1):17-42.

Loranger 1988

Loranger A. Personality Disorder Examination Manual. Yonkers,
NY: D. V. Communications, 1988.

Loranger 1995

Loranger AW. International Personality Disorder Examination
(IPDE) manual. White Plains (NY): Cornell Medical Center, 1995.

Jakobsen 2014

Luborsky 1975

Jakobsen JC, Gluud C, Kongerslev M, Larsen KA, Sørensen P,
Winkel P, et al. Third-wave cognitive therapy versus
mentalisation-based treatment for major depressive disorder:
a randomised clinical trial. BMJ Open 2014;4(8):e004903. [DOI:
10.1136/bmjopen-2014-004903]

Klerman 1984

Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES.
Interpersonal Psychotherapy of Depression. New York (NY):
Basic Books, 1984.

Layden 1993

Layden MA, Newman CF, Freeman A, Morse SB. Cognitive
Therapy of Borderline Personality Disorder. Boston: Allyn &
Bacon, 1993.

Luborsky L, Singer B, Luborsky L. Comparative studies of
psychotherapies. Is it true that "everyone has won and all must
have prizes"? Archives of General Psychiatry 1975;32:995-1008.

Markowitz 2005

Markowitz JC. Interpersonal therapy of personality disorders.
In: Oldham JM, Skodol AE, Bender BS, editors(s). Textbook of
Personality Disorders. Washington (DC): American Psychiatric
Press, 2005:321-34.

Markowitz 2006

Markowitz JC, Skodol AE, Bleiberg K. Intersonal psychotherapy
for borderline personality disorder: possible mechanisms of
change. Journal of Clinical Psychology 2006;62(4):431-44.

Nadort 2009b

Leykin 2009

Leykin Y, DeRubeis RJ. Allegiance in psychotherapy outcome
research: separating association from bias. Clinical Psychology
in Science and Practice 2009;16:54-65.

Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M,
Spinhoven P, et al. Implementation of outpatient schema
therapy for borderline personality disorder: study design. BMC
Psychiatry 2009;9:64.

Lieb 2010

NICE 2009

Lieb K, Völlm BA, Rücker G, Timmer A, Stoffers JM. Cochrane
systematic review of randomised trials. British Journal of
Psychiatry 2010;196:4-12.

Linehan 1993a

Linehan MM. Cognitive Behavioral Treatment of Borderline
Personality Disorder. New York: Guilford, 1993.

Linehan 1993b

Linehan MM. The Skills Training Manual for Treating Borderline
Personality Disorder. New York: Guilford, 1993.

Linehan 2008

National Collaborating Centre for Mental Health commissioned
by theNational Institute for Health& Clinical Excellence.
Borderline personality disorder. The NICE guideline on
treatment and management. London, UK: The British
Psychological Society and The Royal College of Psychiatrists,
2009.

NLM 2009

United States National Library of Medicine (NLM) [Medical
Subject Headings (MeSH Browser)]. www.nlm.nih.gov/
mesh/2009/mesh_browser/MBrowser.html (accessed 31 March
2009).

Linehan MM, McDavid JD, Brown MZ, Syrs JHR, Gallop RJ.
Olanzapine plus dialectical behavior therapy for women with
high irritability who meet criteria for borderline personality

Oldham 2005

Oldham JM. Guideline watch: practice guideline for the
treatment of patients with borderline personality disorder.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

American Psychiatric Association. Available at: www.psych.org
2005.

Perez 2007

Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ,
Puigdemont D, et al. The clinical global impression scale for
borderline personality disorder patients (CGI-BPD): a scale
sensible to detect changes [Impresión clinica global para
pacientes con trastorno límite de la personalidad (ICG-TLP):
una escala sensible al cambio]. Actas Espanolas de Psiquiatria
2007;35(4):229-35.

Simpson 2004

Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J.
Combined dialectical behavior therapy and fluoxetine in the
treatment of borderline personality disorder. Journal of Clinical
Psychiatry 2004;65(3):379-85.

Skodol 2009

Skodol AE. Manifestations, clinical diagnosis, and comorbidity.
In: 1, editors(s). Essentials of Personality Disorders. 37-61
edition. American Psychiatric Publishing: Oldham JM, Skodol
AE, Bender DS, 2009.

Pfohl 1997

Soler 2005

Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-
IV Personality (SIPD-IV). Washington (DC): American Psychiatric
Publishing, 1997.

Philipsen 2008

Philipsen A, Limberger MF, Lieb K, Feige B, Kleindienst M,
Ebner-Primer U, et al. Attention-deficit hyperactivity disorder
as a potentially aggravating factor in borderline personality
disorder. British Journal of Psychiatry 2008;192:118-23.

Pérez 2007

Pérez V, Barrachina J, Soler J, Pascual JC, Campins MJ,
Puigdemont D, et al. The clinical global impression scale for
borderline personality disorder patients (CGI-BPD): a scale
sensible to detect changes. Actas Espanolas de Psiquiatria
2007;35:229-35.

Reiss 2014

Reiss N, Lieb K, Arntz A, Shaw IA, Farrell J. Responding to the
treatment challenge of patients with severe BPD: results of
three pilot studies of inpatient schema therapy. Behavioural
and Cognitive Psychotherapy 2014;42(3):355-67. [DOI: 10.1017/
S1352465813000027]

RevMan 2011 [Computer program]

The Cochrane Collaboration Review Manager (RevMan)
Version 5.1. Copenhagen: The Nordic Cochrane Centre. The
Cochrane Collaboration, 2011.

Rogers 1951

Rogers C. Client-centered Therapy. Boston (MA): Houghton
Miflin, 1951.

Rush 2005

Rush JA. Handbook of Psychiatric Measures. Washington (DC):
American Psychiatric Association, 2005.

Schmidt 2004

Schmidt U, Davidson K. Life After Self-harm: A Guide to the
Future. Hove, East Essex: Brunner-Routledge, 2004.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence
of bias: dimensions of methodological quality associated with
estimates of treatment effects in controlled trials. Journal of the
American Medical Association 1995;273:408-12.

Soler J Pascual JC, Campins J, Barrachina J, Puigdemont D,
Alvarez E, et al. Double-blind, placebo-controlled study of
dialectical behavior therapy plus olanzapine for borderline
personality disorder. American Journal of Psychiatry
2005;162:1221-4.

Spitzer 1985

Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-
III-R Personality Disorders (SCID-II). New York (NY): New York
State Psychiatric Institute, Biometrics Research, 1985.

Steil 2010a

Steil R, Krüger A, Dyer A, Priebe K, Feldmann Jr RE, Bohus M.
Dialectical behaviour therapy for posttraumatic stress disorder
and pervasisve emotional dysregulation in survivors of
childhood sexual abuse [Dialektisch Behaviorale Therapie zur
Behandlung der Posttraumatischen Belastungsstörung mit
schwerer Störung der Emotionsregulation nach sexualisierter
Gewalt in der Kindheit und Jugend]. Trauma & Gewalt:
Forschung und Praxisfelder 2010;4(2):106-17.

Stoffers 2010

Stoffers J, Völlm BA, Rücker G, Timmer A, Lieb K.
Pharmacological interventions for borderline personality
disorder. Cochrane Database of Systematic Reviews 2010, Issue
6. Art. No: CD005653. [DOI: 10.1002/14651858.CD005653.pub2]

Storebø 2020

Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT,
Mattivi JT, Jørgensen MS, et al. Psychological therapies for
people with borderline personality disorder. Cochrane Database
of Systematic Reviews 2020, Issue 5. Art. No: CD012955. [DOI:
10.1002/14651858.CD012955.pub2] [PMID: 32368793]

Torgersen 2009

Torgersen S. Prevalence, sociodemographics, and functional
impairment. In: Oldham JM, Skodol AE, Bender DS, editors(s).
Essentials of Personality Disorders. 1 edition. Arlington, VA:
American Psychiatric Publishing, 2009:83-101.

Tyrer 2005

Tyrer P, Nur U, Crawford M, Karlsen S, McLean C, Rao B, et
al. The social functioning questionnaire: a rapid and robust
measure of perceived functioning. International Journal of
Social Psychiatry 2005;51(3):265-75.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ukoumunne 1999

Zanarini 1996

Zanarini MC, Frankenburg FR, Sickel AE & Young L. Diagnostic
interview for DSM-IV personality disorders, Unpublished
measure. Boston, McLean Hospital 1996.

Zanarini 2003

Zanarini MC. Zanarini Rating Scale for Borderline Personality
Disorder (Zan-BPD): a continuous measure of DSM-IV
borderline psychopathology. Journal of Personality Disorders
2003;17(3):233-42.

Zanarini 2004

Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health
service utilization by borderline personality disorder patients
and axis II comparison subjects followed prospectively for six
years. Journal of Clinical Psychiatry 2004;65:28-36.

Zanarini 2007

Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI,
McSweeney LB. The subsyndromal phenomenology of
borderline personality disorder: a 10-year follow-up study.
American Journal of Psychiatry 2007;164:929-35.

References to other published versions of this review

Binks 2006

Binks C, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C.
Psychological therapies for people with borderline personality
disorder. Cochrane Database of Systematic Reviews 2006, Issue
1. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652]

* Indicates the major publication for the study

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG.
Methods for evaluating area-wide and organisation based
interventions in health and health care: a systematic review.
Health Technology Assessment 1999;3(5):iii-92.

Verheul 2003

Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA,
Stijnen T, Van den Brink W. Dialectical behaviour therapy
for women with borderline personality disorder: 12-month,
randomised clinical trial in The Netherlands. British Journal of
Psychiatry 2003;182(0007-1250 (Print)):135-40.

Young 1994

Young J. Cognitive Therapy for Personality Disorders: A Shama-
focused Approach. Sarasota (FL): Professional Resource
Exchange, 1994.

Young 2003

Young JE, Klosko JS, Weishaar ME. Schema therapy: a
practicioner's guide.. New York (NY): Guilford, 2003.

Zanarini 1987

Zanarini MC, Frankenburg FR, Chauncey DL, Gunderson JG. The
Diagnostic Interview for Personality Disorders: interrater and
test-retest reliability. Comprehensive Psychiatry 1987;28:467-80.

Zanarini 1989

Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. The
Revised Diagnostic Interview for Borderlines: discriminating
BPD from other Axis II disorders. Journal of Personality Disorders
1989;3:10-8.

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Bateman 1999 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 22/38 females (57.9%)

age: eligible: 31.8 years on average

location: UK

setting: partially hospitalised/outpatient

exclusions: schizophrenia, bipolar disorder, substance misuse, mental impairment, evidence of organ-
ic brain disorder

level of functioning/severity of illness: "individuals with severe borderline personality disorder who
frequently harmed themselves and attempted suicide, while exhibiting severe levels of depression, suf-
fering from high levels of symptomatic distress, and demonstrating comorbidity for affective disorder-
s" (Bateman 1999, p. 1568)

DIB scores at baseline: group 1 mean score = 7.9, SD = 0.4; group 2 mean score = 7.6, SD = 0.5

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 1999  (Continued)

Cochrane Database of Systematic Reviews

BPD diagnosis according to: DSM-III-R (both sets of criteria of SCID and DIB had to be met)

means of assessment: both SCID and DIB-R

Interventions

group 1 (EG): mentalisation-based treatment (MBT) oriented partially hospitalisation 5 days a week:
once-weekly individual psychotherapy, thrice-weekly group analytic psychotherapy, once-weekly
expressive therapy (psychodrama techniques oriented), once-weekly community meeting; monthly
meeting with case administrator and medication review by resident psychiatrist

group 2 (CG): standard treatment in the general psychiatric services: regular psychiatric review with
psychiatrist when necessary (twice-monthly on average); inpatient admission as appropriate (90%, av-
erage stay 11.6 days) with discharge to non-psychoanalytic partial hospitalisation focusing on problem
solving (72%, average stay 6 months) and standard aftercare (100%, outpatient and community fol-
low-up by every-2-week visits by a community psychiatric nurse); no formal psychotherapy

duration: up to 18 months (average length of stay in EG: 17.4 months

concomitant psychotherapy: none

concomitant pharmacotherapy: antidepressant and antipsychotic drugs prescribed as appropriate,
polypharmacy was discouraged

Outcomes

outcomes considered in this review

self-rated: interpersonal problems (IIP), depression (BDI), anxiety (STAI), general psychopathology
(SCL-90-R-GSI)

observer-rated: number of patients with self-harming behaviour during last 6-month period, number
of patients with suicide attempt during last 6-month period (both assessed via the Suicide and Self-
Harm Inventory, a semi-structured interview)

time-points used here: 18 months (post-treatment)

analyses: per protocol (22 randomised to each group, only 19 per group analysed since treated per
protocol)

Authors' judgement

Support for judgement

Low risk

Use of a minimisation method (Bateman 2010).

Low risk

Central allocation at the university (Bateman 2010).

Low risk

Outcome assessors were blind (Bateman 2010).

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

Adherence to therapy was monitored through supervision, verbatim session
reports, and completion of a monitoring form about activities and interven-
tions of therapists.

Allegiance effect improba-
ble?

High risk

There is no indication given for an allegiance effect. However, as both au-
thors are the founders of MBT, the treatment actually used in the experimental
group, an allegiance effect seems not improbable.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

High risk

More attention paid to EG participants.

Bateman 1999  (Continued)

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Bateman 2009 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 107/134 females (79.9%)

age: eligible: 18-65 years of age; mean age of participants allocated to outpatient mentalisation-based
treatment (MBT-OP): 31.3 years, SD 7.6; mean age of participants allocated to structured clinical man-
agement (SCM): 30.9 years, SD 7.9

location: UK

setting: outpatient

exclusions: psychotic disorder, bipolar I disorder, opiate dependence requiring specialist treatment,
mental impairment, evidence of organic brain disorder, being in long-term psychotherapeutic treat-
ment

level of functioning/severity of illness: only subjects with "suicide attempt or episode of life-threat-
ening self-harm within last 6 months" were eligible (Bateman 2009, p. 1356).

mean GAF score at baseline: 41.0, i.e. participants had "serious symptoms OR any serious impairment
in social, occupational, or school functioning"

BPD diagnosis according to: DSM-IV

means of assessment: SCID-II

Interventions

group 1 (EG): MBT-OP; weekly individual and group psychotherapy

group 2 (CG): SCM according to generic practice for borderline personality disorder offered by non-
specialist practitioners within U.K. psychiatric services; regular individual and group sessions with ap-
pointments every 3 months for psychiatric review

duration: 18 months

concomitant psychotherapy: patients already being in long-term psychotherapeutic treatment were
not eligible

concomitant pharmacotherapy: patients were prescribed medication according to the APA guide-
lines; all patients were offered medication reviews every 3 months

Outcomes

outcomes considered in this review

self-rated: interpersonal problems (IIP), depression (BDI), general psychopathology (SCL-90-R-GSI)

observer-rated: suicidal ideation (number of patients with suicide attempt during previous 6-month
period), self-harming behaviour (number of patients with self-harming behaviour during previous 6-
month period), mental health status (GAF)

time-points used here: 18 months (post-treatment)

Notes

analyses: intention-to-treat analysis based on treatment assignment

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bateman 2009  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"randomization using a stochastic minimization program (MINIM) balancing
for age (blocked as 18-25, 26-30, >30 years), gender, and presence of antisocial
personality disorder." (Bateman 2009, p. 1357)

Allocation concealment
(selection bias)

Low risk

"Treatment allocation was made offsite [...] A study psychiatrist informed pa-
tients of their assignment." (Bateman 2009, p. 1357)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Assessors were blind to treatment group." (Bateman 2009, p. 1358)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (ISRCTN27660668). No indication for selective report-
ing.

Treatment adherence?

Low risk

"All sessions were audiotaped. Adherence to the MBT-OP and SCM-OP manuals
was determined by randomly selected audiotapes of individual and group ses-
sions drawn from two distinct 6-months periods of each case using a modified
version of the recommended adherence rating scale." (Bateman 2009, online
data supplement, p. 1)

Allegiance effect improba-
ble?

High risk

There is no indication given for an allegiance effect. However, as both au-
thors are the founders of MBT, the treatment actually used in the experimental
group, an allegiance effect seems not improbable.

Low risk

Equal amounts of attention paid to both groups.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Bellino 2006 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 60% females ("The ratio of men to women was 3 to 5."; Bellino 2006, p. 455

age: 26.4 years on average, SD = 3.7

location: Italy

setting: outpatient

exclusions: lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizo-
phrenia or other psychotic disorders, patients whose major depressive episode was an expression of
bipolar disorder; current diagnosis of substance abuse disorder, treatment with psychotropic drugs or
psychotherapy during the 2 months prior to the study, female patients not using an adequate method
of birth control

level of functioning/severity of illness: mean baseline CGI-S = 4.35, i.e. "moderately ill".

BPD diagnosis according to: DSM-IV-TR, comorbid diagnosis of mild to moderate major depressive
episode required for inclusion

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2006  (Continued)

means of assessment: SCID

Cochrane Database of Systematic Reviews

Interventions

group 1 (EG): Fluoxetine + interpersonal therapy (IPT; 1 weekly session)

group 2 (CG): Fluoxetine + clinical management (CM; 6 appointments, first two fortnightly, monthly af-
terwards)

duration: 24 weeks

concomitant psychotherapy: patients having received psychotherapy during the 2 months prior to
the study were not eligible

concomitant pharmacotherapy: all study participants received 20 to 40 mg fluoxetine daily; patients
with psychotropic treatment during the 2 months prior to the study were not eligible for inclusion

Outcomes

outcomes considered in this review

self-rated: anxiety (HARS)

observer-rated: depression (Ham-D), mental health status (CGI-S)

time-points used here: week 24 (post-treatment)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

analyses: per protocol (39 randomised, only 32 analysed since treated per protocol, N = 16 per group)

Authors' judgement

Support for judgement

Low risk

Use of a computer random number generator (Bellino 2010a [pers comm]).

Low risk

Central allocation (Bellino 2010a [pers comm]).

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"assessments were performed by an investigator who was blind to the treat-
ment methods" (Bellino 2006, p. 455);

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

High risk

"psychotherapist [...] had 5 years of experience practising IPT" (Bellino 2006, p.
455)

no specific measures to monitor treatment adherence (Bellino 2010a [pers
comm])

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Low risk

The authors seem not to be associated with IPT.

High risk

More attention paid to EG participants.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2007 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

design: randomised controlled trial

Participants

sex: 63.2% females ("The ratio of men to women was 7 to 19"; Bellino 2007, p. 720)

age: 30.55 years on average, SD = 5.75

location: Italy

setting: outpatient

exclusions: lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizo-
phrenia, other psychotic disorders, patients whose major depressive episode was an expression of
bipolar disorder; current diagnosis of substance abuse disorder; treatment with psychotropic drugs or
psychotherapy during 2 months prior to study, female patients of child-bearing age not using adequate
method of birth control

level of functioning/severity of illness: Mean baseline CGI-S = 3.4, i.e. "mildly ill".

BPD diagnosis according to: DSM-IV-TR, comorbid diagnosis of mild to moderate major depressive
episode required for inclusion

means of assessment: SCID

Interventions

group 1 (EG1): Fluoxetine + interpersonal therapy (IPT; 1 weekly session)

group 2 (EG2): Fluoxetine + cognitive therapy of therapy according of depression according to Beck
(CT; 1 weekly session)

duration: 24 weeks

concomitant psychotherapy: patients having received psychotherapy during the 2 months prior to
the study were not eligible

concomitant pharmacotherapy: all study participants received 20 to 40 mg fluoxetine daily, with
7 appointments, the first 2 fortnightly and the last 5 monthly; patients with additional current psy-
chotropic treatment were not eligible for inclusion

Outcomes

outcomes considered in this review

self-rated: anxiety (HARS)

observer-rated: depression (Ham-D), mental health status (CGI-S)

time-points used here: week 24 (post-treatment)

Notes

Risk of bias

Bias

analyses: per protocol (32 randomised, only 26 analysed since treated per protocol, N = 14 in the IPT
and N = 12 in the CT group)

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Patients [...] were randomized using the web program Research Randomiz-
er v3.0 (Urbaniak & Plous, Social Psychology Network, 2007)" (Bellino 2007, p.
720)

Allocation concealment
(selection bias)

Low risk

Central allocation (Bellino 2010a [pers comm]).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2007  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

"A psychiatrist provided pharmacotherapy. He was blind to which type of psy-
chotherapy the patients were receiving [...] The assessments were performed
by an investigator who was blind to the treatment methods." (Bellino 2007, p.
720)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Both psychotherapists received supervision during the treatment to assess
their adherence to the psychotherapy manuals." (Bellino 2007, p. 720)

Low risk

The authors seem neither to be associated with neither IPT nor CT.

Low risk

Equal amounts of attention paid to both groups.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Bellino 2010 

Study characteristics

Methods

design: parallel-arm, randomised controlled trial

Participants

sex: 37/55 females (67.3%)

age: combined treatment group: mean age 26.23 years, SD 6.4; pharmacotherapy group: mean age
25.86 years, SD 7.2

location: Italy

setting: outpatient

exclusions: concomitant diagnoses of Axis I or Axis II disorders; esp. schizophrenia or other psychotic
disorders, bipolar disorder; lifetime diagnosis of delirium, dementia, amnestic disorder, other cognitive
disorders, not using adequate methods of birth control if in childbearing age, receiving psychotropic
drugs during last 2 months, psychotherapy in last 6 months

level of functioning/severity of illness: mean CGI-S at baseline: 5.45, i.e. participants were "markedly
ill"; participants had no comorbid axis-I or II comorbidities

BPD diagnosis according to: DSM-IV-TR

means of assessment: SCID-II

Interventions

group 1 (EG): combined therapy of fluoxetine (20 to 40 mg/d) plus weekly individual sessions of IPT
adapted to BPD (IPT-BPD)

group 2 (CG): single pharmacotherapy treatment with fluoxetine (20 to 40 mg/d), clinical management
(medical appointments lasting 15 to 20 minutes every 2 weeks, dealing with clinical issues)

duration: 32 weeks

concomitant psychotherapy: eligible patients were not in psychotherapeutic treatment during the
last 6 months prior to study entry

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2010  (Continued)

Cochrane Database of Systematic Reviews

concomitant pharmacotherapy: eligible patients were not receiving psychotropic drugs during the
last two months prior to study entry

Outcomes

outcomes considered in this review

self-rated: anxiety (HARS)

observer-rated: BPD severity (BPDSI-IV-total), anger (BPDSI-IV-anger), affective instability (BPDSI-
IV-affective instability), chronic feelings of emptiness (BPDSI-IV-emptiness), impulsivity (BPDSI-IV-im-
pulsivity), self-harming behaviour (BPDSI-iV-parasuicidal behaviour score), interpersonal problems
(BPDSI-IV-interpersonal relationships), avoidance of abandonment (BPDSI-IV-abandonment), identity
disturbance (BPDSI-IV-identity disturbance), dissociation/stress-related paranoid ideation (BPDSI-IV-
paranoid ideation), depression (Ham-D), mental health status (CGI-S)

time-points used here: week 32 (post-treatment)

analyses: per protocol (27 randomised to fluoxetine + IPT-BPD, 28 to fluoxetine + CM; only data of the
22 completers in each group were analysed)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"Randomization was performed using the web program Research Randomizer
version 3.0 (Urbaniak and Plous, [...])." (Bellino 2010, p. 75)

Allocation concealment
(selection bias)

Unclear risk

No further details.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Assessments were performed by an investigator who was blind to the treat-
ment methods." (Bellino 2010, p. 76)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

High risk

"Patients in the IPT-BPD group were treated by a psychotherapist [...] who had
at least 5 years of experience practising IPT" (Bellino 2010, p. 76). No further in-
formation, adherence seems not to have been monitored.

Allegiance effect improba-
ble?

Low risk

The working group seems to be experienced in but not to be associated with
IPT (cf. Bellino 2006; Bellino 2007).

High risk

More attention paid to EG participants.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Blum 2008 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 103/124 females, i.e. 83.1%

age: 31.5 years on average, SD = 9.5

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blum 2008  (Continued)

location: USA

setting: outpatient

Cochrane Database of Systematic Reviews

exclusions: not speaking English, psychotic or primary neurological disorder, cognitively impaired pa-
tients, current substance abuse or dependence, participated in STEPPS treatment previously

level of functioning/severity of illness: baseline CGI-S = 5.1 (SD = 0.8) in EG, baseline CGI-S = 4.9 (SD =
0.9) in CG; i.e. patients were "markedly ill"

BPD diagnosis according to: DSM-IV

means of assessment: SIDP-IV

Interventions

group 1 (EG): STEPPS: 20 2-hour weekly group therapy sessions + homework assignments + 1 session
for family members or significant others; no individual therapy

group 2 (CG): Treatment as usual (TAU): subjects were encouraged to continue their usual care, includ-
ing individual psychotherapy, medication, and case management

duration: 20 weeks

concomitant psychotherapy: participants were encouraged to continue with ongoing concomitant
treatments. 59% of all participants had an additional individual therapy (EG: 63%, CG: 54%; difference
not significant)

concomitant pharmacotherapy: 90% of subjects reported at least one psychotropic medication at
baseline; on average, participants received 2.9 psychotropic medications, SD = 2.3 (EG: 3.0, SD = 2.5;
CG: 2.7, SD = 2.1; difference not significant)

Outcomes

outcomes considered in this review

self-rated: BPD total severity (BEST), Barratt Impulsiveness Scale (BIS), depression (BDI), general psy-
chopathology (SCL-90-R-GSI)

observer-rated: affective instability (ZAN-BPD-affective subscale), interpersonal problems (ZAN-BPD-
disturbed relationships subscale), cognitive disturbance (ZAN-BPD-cognitive subscale), mental health
status (CGI-S)

time-points used here: week 20 (post treatment)

analysis: ITT of those actually having received allocated intervention, regardless of completion or non-
completion. However, 40 participants that had been randomly allocated did not receive the allocated
intervention and were not included in analyses. "Subjects with at least one postbaseline assessment
were included in the analyses." (Blum 2008, p. 470).

Authors' judgement

Support for judgement

Low risk

"Subjects were assigned by coin toss" (Blum 2008, p. 469)

Low risk

No indication of bias.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

"While we intended to conduct blind assessments, we found it nearly impos-
sible to maintain blindness. The convergence of both rater- and patient-ad-
ministered scales suggests that this may not have been an important deficien-
cy." (Blum 2008, p. 477).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blum 2008  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Treatment adherence?

Low risk

Cochrane Database of Systematic Reviews

Study protocol is available, but there is no information about primary or sec-
ondary outcomes. The authors report a broad range of outcomes, so there is
no indication for selective reporting given. However, there is insufficient infor-
mation to permit judgment of 'Yes' or 'No'.

"Adherence to the manual was rated on a 5-point scale [...] A score of 4 (good)
or higher was considered acceptable. Two Ph.D.-level psychologists who were
not involved with the randomized controlled trial but familiar with STEPPS rat-
ed 43 randomly selected video-taped session. The mean adherence score was
4.4 (SD = 0.8)."

Allegiance effect improba-
ble?

High risk

There is no indication given for an allegiance effect. However, as some au-
thors are founders of STEPPS, the treatment actually used in the experimental
group, an allegiance effect seems not improbable.

High risk

More attention paid to EG participants.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Bos 2010 

Study characteristics

Methods

design: multi-centre, parallel-arm, randomised controlled trial

Participants

sex: 86.1% female

age: mean age 32.4 years (EG: 32.9, SD = 5.6; CG: 31.8, SD = 9.2)

location: The Netherlands

setting: outpatient

Interventions

exclusions: insufficient commend of Dutch language, intellectual disability, in coercive treatment,
acute endangering self or others

level of functioning/severity of illness: years of illness history 13.3 years (group 1) and 11.8 years
(group 2). No further details.

BPD diagnosis according to: DSM-IV

means of assessment: SCID-II, PDQ-4+

group 1 (EG): STEPPS-group program plus limited individual therapy (STEPPS + LIT; STEPPS: 18 week-
ly sessions and a single follow-up session 4 to 6 months after conclusion of the program, main topics:
psychoeducation about BPD, emotion management skills, behaviour management skills; inclusion of
near relatives and friends as "support group"; LIT: one session every other week, developed as adjunct
to STEPPS group to help consolidate newly acquired skills in each patient's everyday life)

group 2 (CG): treatment as usual (TAU, i.e. standard treatment for BPD offered at the participating
sites, consisting of individual therapy from a psychotherapist, psychologist, or psychiatric nurse, of-
fered every 1 to 4 weeks)

duration: 4.5 months

concomitant psychotherapy: STEPPS-related treatments like DBT or family groups for family mem-
bers of the patients were not allowed; all participants were allowed to have contacts with social worker
or another health care professional

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bos 2010  (Continued)

Cochrane Database of Systematic Reviews

concomitant pharmacotherapy: all participants were allowed to have (medication) contacts with a
psychiatrist

Outcomes

outcomes considered in this review

self-rated: BPD total severity (BPD-40), interpersonal problems (WHOQOL-BREF-social relationships),
general psychopathology (SCL-90-R-dutch version)

observer-rated: impulsivity (number of patients scoring above BPDSI-IV cut-off score), self-harming
behaviour (number of patients scoring above BPDSI-IV parasuicide cut-off score)

time-points used here: post-treatment, i.e. after the final of 18 weekly sessions

Notes

Risk of bias

Bias

analyses: per protocol

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation was determined by drawing of lots (equal numbers for both groups
at each study site) some weeks before start of the STEPPS group after inclu-
sion of all participants. (see van Wel 2009, p. 292)

Allocation concealment
(selection bias)

Low risk

Randomisation was carried out by a research assistant. (see van Wel 2009, p.
292)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

"Interviews were conducted by research assistants who were not blind to
treatment group assignment." (Bos 2010, p. 300)"

Non-blindness of interviewers may have affected interviewer-assessed out-
comes, i.e. BPDSI-IV impulsivity and parasuicide scores. All other outcomes
were self-rated by participants.

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"STEPPS therapists met twice a year under the supervision of expert trainers
to evaluate the procedure and to preserve uniformity. Individual therapists in
the STEPPS condition received a 1-day training and monthly phone supervi-
sion. After each session, individual therapists in both conditions completed a
self-report questionnaire by which the content and frequency of the therapy
contacts could be checked." (Bos 2010, p. 300)

Allegiance effect improba-
ble?

Low risk

"[...] this RCT on STEPPS is the first done by others than its developers." (Bos
2010, p. 303)

High risk

More attention paid to EG.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Carter 2010 

Study characteristics

Methods

design: parallel-arm, randomised controlled trial

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carter 2010  (Continued)

Participants

sex: 73/73 females (100%)

Cochrane Database of Systematic Reviews

age: mean age 42.5 years, SD = 6.1; eligible: 18-65 years of age

location: Australia

setting: outpatient

exclusions: schizophrenia, bipolar affective disorder, psychotic depression, florid antisocial behaviour,
developmental disability, disabling organic condition; "The psychiatrist assessor had the option of de-
termining if any potential subjects were unsuitable for inclusion in therapy or unmotivated to partici-
pate, although there were no specific criteria for this exclusion." (Carter 2010, p. 164)

level of functioning/severity of illness: all participants had a history of at least three self-reported
self-harm episodes in the preceding 12 months

BPD diagnosis according to: DSM-IV

means of assessment: clinical interview, IPDE-Q

group 1 (EG): DBT (weekly individual therapy, weekly group-based skills training, telephone access to
an individual therapist, therapist supervision) modified insofar that telephone access was delivered us-
ing a group roster of DBT individual therapists in the daytime, but not contact with each participants's
individual therapist, and the local psychiatric hospital at night; skills training groups dealt with all usu-
al modules except of mindfulness

group 2 (CG): TAU + Waiting List: participants were offered DBT treatment after a 6 month waiting peri-
od

duration: 6 months (all participants were offered 12 months of DBT treatment, but the comparison be-
tween groups was restricted to the first 6 months of DBT vs. TAU+WL)

concomitant psychotherapy: participants were asked to discontinue psychological therapy of any
sort for at least the 12 month duration of DBT

Interventions

concomitant pharmacotherapy: not specified;

Outcomes

outcomes considered in this review

self-rated: interpersonal problems (WHOQOL-BREF-social relationships), mental health status (Brief
Disability Questionnaire - days out of role)

observer-rated: number of patients with self-harming behaviour

time-points used here: 6 months

analyses: per protocol (DBT group: 20 completers of treatment and self-reports out of 38 allocated to
this group; TAU group: 31 completers of waitlist and self-reports out of 35 allocated)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

We used a computerised random number generator to generate allocations
- placed into sealed opaque envelopes (in blocks of 8). Envelope drawn after
baseline assessments complete. (Carter 2010a [pers comm])

Allocation concealment
(selection bias)

Low risk

"Randomization was carried out by the research staff. [...] participants were al-
located by selecton of sealed opaque envelopes." (Carter 2010, p. 164)

Blinding of outcome as-
sessment (detection bias)

Low risk

"Outcomes were determined [...] by assessors blinded to allocation. [...] All
reasonable attempts were made to maintain blindness to allocation status for

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carter 2010  (Continued)

All outcomes

Cochrane Database of Systematic Reviews

these raters, but this could not achieve perfect blindness." (Carter 2010, pp.
164 et seq.)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Unclear risk

"The intervention condition was based on the comprehensive DBT model, a
team-based approach including [...] therapist supervision groups." (Carter
2010, p. 163 et seq.)

"[...] possible inferiority of training of DBT therapists to that of those in oth-
er studies or inferior adherence to the DBT methods despite adequate train-
ing" (Carter 2010, p. 170)

No mention of any objective means of assessment.

Low risk

No indication of an allegiance effect.

High risk

More attention paid to EG participants.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Cottraux 2009 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 50/65 females, i.e. 76.9%

age: cognitive therapy (CT) group: mean age 34.3 years, SD 10.2; Rogerian supportive therapy (RST)
group: mean age 32.6 years, SD 8.3

location: France

setting: outpatient

exclusions: age under 18 or over 60 years, psychotic disorders with current delusions, significant drug
or alcohol addiction, antisocial behaviours, living too far from the study centres

level of functioning/severity of illness: mean CGI-S at baseline: 5.21, i.e. "markedly ill"

BPD diagnosis according to: DSM-IV

means of assessment: structured interview screening form, DIB-R

Interventions

group 1 (EG): cognitive therapy: individual 1-hour sessions, weekly for 6 months (24 sessions), every
fortnight for another 6 months (12 sessions)

group 2 (CG): Rogerian supportive therapy: individual 1-hour sessions, weekly for 6 months (24 ses-
sions), every fortnight for another 6 months (12 sessions)

duration:1 year

concomitant psychotherapy: eligible patients were not to be following psychotherapy at the time of
the study

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cottraux 2009  (Continued)

Cochrane Database of Systematic Reviews

concomitant pharmacotherapy: participants could keep their medication as long as they accepted to
have it monitored by the principal investigator

Outcomes

outcomes considered in this review

self-rated: impulsivity (Eysenck Impulsivity Venturesomeness Empathy Questionnaire IVE - impulsivi-
ty), suicidality (Beck Hopelessness Scale BHS), depression (BDI), anxiety (BAI)

observer-rated: self-harming behaviour (SHBCL), mental health status (CGI-S)

time-points used here: week 52 (post-treatment)

analyses: per protocol, i.e. treatment completers (of 33 people randomised to CT and 32 to RST, 20 and
18 completed, resp.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"The randomisation process used blocks of 4 patients for each centre, and was
organised by the Lyon University Hospital's Biostatistics Department." (Cot-
traux 2009, p. 309)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

"The allocation was confidential and delivered via phone call [of the Biostas-
tics Department] to the secretary of each centre." (Cottraux 2009, p. 309)

"Psychologists who had not taken part in the treatments performed the asess-
ment. They had no information on either the randomisation or the treatment
and did not attend the team meetings about the patients." (Cottraux 2009, p.
310)

"[...] evaluators may have received inadvertent or indirect information from
the patients about the treatment underway. The evaluators' blindness was not
tested." (Cottraux 2009, p. 313)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (NCT00131781). No indication for selective reporting.

Treatment adherence?

Low risk

"At the end of each session, the therapists were to complete a checklist of the
techniques they used, which was revised and discussed with the prinicipal in-
vestigator [...] weekly supervision session." (Cottraux 2009, p. 309).

Allegiance effect improba-
ble?

Low risk

There is no indication given for an allegiance effect. None of the authors was,
to our knowledge, among the developers of any of the treatments under inves-
tigation.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Davidson 2006 

Study characteristics

Methods

Low risk

Equal amounts of attention paid to both groups.

design: multi-centre, parallel-arm RCT (randomisation stratified by study centre and by pre-defined
high or low episodes of self-harm; randomised permuted blocks of size 4)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2006  (Continued)

Participants

sex: 89/106 females (84.0%)

age: 31.9 years on average, SD = 9.1

location: UK

setting: outpatient

Cochrane Database of Systematic Reviews

exclusions: patients currently receiving in-patient treatment for a mental state disorder, currently re-
ceiving a systematic psychological therapy of specialist service, insufficient knowledge of English; evi-
dence of organic illness, mental impairment, alcohol or drug dependence, schizophrenia or bipolar af-
fective disorder; drug or alcohol abusing patients were eligible for inclusion

level of functioning/severity of illness: mean social functioning (SFQ) score at baseline 14.6 (SD =
3.9),

BPD diagnosis according to: DSM-IV; patients had to have received either in-patient psychiatric ser-
vices or an assessment at accident and emergency services or an episode of deliberate self-harm (ei-
ther suicidal act or self-mutilation) in the previous 12 months

means of assessment: SCID

Interventions

group 1 (EG): Cognitive Behaviour Therapy + treatment as usual (CBT + TAU), up to 30 sessions, 27 ses-
sions (SD = 13) on average

group 2 (CG): treatment as usual (TAU; inpatient and outpatient hospital services, A&E services, com-
munity based services, primary and community care services such as general practitioner, practice of
Community Psychiatric Nurse)

duration: one year

concomitant psychotherapy: patients currently receiving in-patient treatment for a mental state dis-
order or a systematic psychological therapy or specialist service were excluded. All other kinds of treat-
ments a patient would have received if the trial had not been in place (e.g., general practitioner care,
contact with community mental health teams) were allowed. 90% of participants were in contact with
mental health services.

concomitant pharmacotherapy: may have been comprised in TAU. There are no details how many of
the study participants actually received psychotropic medical treatment.

Outcomes

outcomes considered in this review

self-rated: interpersonal problems (IIP-SC), depression (BDI-II), anxiety (STAI-trait), general psy-
chopathology (BSI-GSI)

observer-rated: suicidality (mean number of patients with suicidal act during previous 12 months),
parasuicidality (number of patients with self-harming behaviour during previous 12-month period)

Notes

Risk of bias

Bias

time-points used here: 12 months (post-treatment)

analyses: ITT

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"The randomization schedules were generated by the study center at [...] Glas-
gow University, and kept securely and confidentially by the trial coordinator at
the Study Coordinating Centre." (Davidson 2006a, p. 437)

Allocation concealment
(selection bias)

Low risk

"The randomization schedules were [...] kept securely and confidentially by
the trial coordinator [...] The trial coordinator informed the referring agent of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2006  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

the result of randomization immediately and in writing, and then contacted
the CBT therapist/s in each area with the patients details so that CBT therapy
could be initiated." (Davidson 2006a, p. 437).

106 patients enrolled and randomised

"The research assistants on each site carry out all assessments and are blind
to treatment group allocation. In addition, research assistants request that
patients do not mention any details of any psychological treatment they may
be receiving. [...] The research assistants responsible for the recording of
outcomes were unaware of the treatment allocated or received." (Davidson
2006a, p. 439).

Selective reporting (re-
porting bias)

Low risk

Study protocol available (ISRCTN86177428). No indication for selective report-
ing.

Treatment adherence?

Low risk

"All therapists received training in the protocol at the beginning of the trial and
regular meetings of all therapists were held to ensure consistency of approach
across the sites. In addition, all therapists received weekly supervision from
CBT experts at each site." (Davidson 2006, p. 452)

Allegiance effect improba-
ble?

High risk

There is no indication given for an allegiance effect. However, as one of the au-
thors is the founder of the two EG treatment, an allegiance effect seems not
improbable.

High risk

More attention paid to EG participants.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Doering 2010 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 104/104 females (100%)

age: 27.3 years on average

location: Germany, Austria

setting: outpatient

exclusions: schizophrenia, bipolar I and Ii disorder with a major depressive, manic, or hypomanic
episode during the previous six months, substance dependency (including alcohol) during the previous
six months, subjects meeting three or more DSM-IV criteria for antisocial personality disorder, organic
pathology, mental retardation, insufficient command of the German language

level of functioning/severity of illness: mean GAF score at baseline was 52.3, i.e. patients had moder-
ate symptoms OR any moderate difficulty in social, occupational, or school functioning.

BPD diagnosis according to: DSM-IV

means of assessment: SCID

Interventions

group 1 (EG): Transference-Focused Psychotherapy (TFP; i.e. twice weekly individual psychotherapy
sessions)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Doering 2010  (Continued)

Cochrane Database of Systematic Reviews

group 2 (CG): Treatment by Experienced Community Psychotherapist (TBE; i.e. treatment was deliv-
ered by therapists known as experienced and particularly interested in BPD patients by the local ad-
ministrators; therapists were free to choose the frequency of sessions according to their method; ther-
apists' main orientations were: psychoanalytic (19), behavioral (17), client-centered (4), systematic (4),
Gestalt (1), dynamic group (1), psychodynamic (1); psychotherapies continued if deemed necessary by
the therapist and the patient and if paid by the insurance company

duration: 12 months

concomitant psychotherapy: psychotherapy other than the study treatment was not allowed in the
EG

concomitant pharmacotherapy: medication was not restricted but registered continuously

Outcomes

outcomes considered in this review

self-rated: depression (BDI), anxiety (STAI-trait), general psychopathology (BSI-GSI)

observer-rated: BPD severity (mean number of DSM-IV diagnostic criteria for BPD), suicidality (mean
number of patients with suicidal act during previous 12 months), self-harming behaviour (number of
patients with self-harming behaviour during previous 12-month period)

Notes

Risk of bias

Bias

time-points used here: 12 months (post treatment)

analyses: ITT, LOCF

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Use of random numbers, matching after inclusion of 35th patient according to
severity of self-harming behaviour during the last year and personality organi-
sation (Doering 2010, personal communication.

Allocation concealment
(selection bias)

Low risk

"The results of the first assessments [screening for inclusion criteria] were sent
to a researcher outside the two study centers who performed the randomiza-
tion." (Doering 2010, p. 5) . "After randomization patients were referred to a
therapist." (Doering 2010, p. 6)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Research assistants who conducted assessments before randomization and
after one year of treatment were blinded for the therapy delivered." (Doering
2010, p. 7)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (NCT00714311). No indications for selective report-
ing.

Treatment adherence?

Low risk

"Video recordings of all [EG] sessions were performed and used in the group
supervision. [...] Every case was supervised at least every four to six weeks.
[...] Experienced community psychotherapists [i.e., CG therapists] attended
supervisions according to their usual routine." (Doering 2010, p. 10f.) "For
the assessment of adherence and competence of the transference-focused
psychotherapists a German translation of a specific Rating of Adherence and
Competence [...] was used. [...] The rating was performed by the supervisor af-
ter every video-guided supervision of a therapy session." (Doering 2010, p. 11)

Allegiance effect improba-
ble?

Unclear risk

Some of the study authors are experienced TFP therapists, but none was per-
sonally involved in treatment development.

Attention bias: equal
amounts of attention to all

Low risk

Less attention may have been paid to CG patients depending on the CTBE ther-
apist's main orientation; however, every participant was provided the specifi-
cally full amount of necessary attention.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Doering 2010  (Continued)

groups (obligatory treat-
ment components)?

Farrell 2009 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 32/32 females (100%)

age: 35.6 years on average

location: USA

setting: outpatient

exclusions: axis I diagnosis of a psychotic disorder confirmed by an open clinical interview, below av-
erage IQ

level of functioning/severity of illness: mean baseline GAF score was 49.0, i.e. patients had "serious
symptoms OR any serious impairment in social, occupational, or school functioning"

BPD diagnosis according to: diagnostic criteria unclear

means of assessment: Diagnostic Interview for Personality Disorders Revised, Borderline Syndrome
Index

Interventions

group 1 (EG): Group Schema Focused Therapy + individual psychotherapy treatment as usual (GSFT +
PTAU); thirty sessions of schema therapy group program in addition to weekly individual psychothera-
py in the community (i.e. eclectic in orientation, primarily supportive)

group 2 (CG): individual psychotherapy treatment as usual (PTAU), eclectic in orientation and primarily
supportive; GSFT to be received after 14-month waiting period

duration: eight months

concomitant psychotherapy: all participants were in individual psychotherapy (eclectic, mainly sup-
portive) throughout the study

concomitant pharmacotherapy: psychopharmacological treatment was not controlled for; all partici-
pants were stable on at least one psychotropic medication at the start of the study, mostly low doses of
antipsychotics and/or SSRI

Outcomes

outcomes considered in this review

self-rated: BPD severity (BSI), general psychopathology (SCL-90-R-GSI)

observer-rated: affective instability (DIB-R-affect subscale), impulsivity (DIB-R-impulsive subscale), in-
terpersonal problems (DIB-R-interpersonal subscale), dissociation/stress-related paranoia (DIB-R-cog-
nitive subscale), mental health status (GAF)

Notes

Risk of bias

Bias

time-points used here: eight months (post-treatment)

analyses: per protocol (EG: N = 16, CG: N = 12)

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Farrell 2009  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

"Patients were randomly assigned using a random number table" (Farrell
2009, p. 319)

Allocation concealment
(selection bias)

Unclear risk

No further details.

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

After screening for eligibility of 40 patients, N = 8 were excluded. Reasons for
exclusion are only given for 3 of them (1 declined participation, 2 did not meet
inclusion criteria).Thus, N = 16 were allocated to EG, N = 16 to CG.

"The DIB-R structured interviews were conducted by two Ph.D. Clinical Psy-
chologists not involved in treatment delivery. Efforts were made to keep them
blind to treatment group membership, but for 10% of the subjects the blind
was broken due to patient report." (Farrell 2009, p. 319) "Therapists were given
a GAFS [Global Assessment of Function Scale] checklist to use so that the an-
chors for assigning scores were in front of them when they recorded their rat-
ings. They were chosen as raters since they were removed from the hypothe-
ses of the study, although not blind to their patients's group membership and
no inter-rater reliability was possible." (Farrell 2009, p. 319) Overall, observ-
er-rated outcomes were not assessed by blind raters.

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Two of the three groups had the two program developers as therapists and
the third had one developer and one clinical psychologist [...] Weekly super-
vision meetings took place during the course of the study and random video-
tapes of sessions were reviewed for fidelity by the program developers. The
manual developed for the study acted as an additional fidelity check. (Farrell
2009, p. 322)

Allegiance effect improba-
ble?

High risk

"Two of the three groups had the two program developers as therapists and
the third had one developer and one clinical psychologist" (Farrell 2009, p.
322)

High risk

More attention paid to EG participants.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Giesen-Bloo 2006 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 80/86 females (93.0%)

age: 30.6 years on average

location: The Netherlands

setting: outpatient

exclusions: BPD not main diagnosis, psychotic disorders (except short, reactive psychotic episodes),
bipolar disorder, dissociative identity disorder, antisocial personality disorder, attention-deficit/hyper-
activity disorder, addiction of such severity that clinical detoxification was indicated (after which en-
tering treatment was possible), psychiatric disorders secondary to medical conditions, mental retarda-
tion, no Dutch literacy

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Giesen-Bloo 2006  (Continued)

Cochrane Database of Systematic Reviews

level of functioning/severity of illness: mean number of SCID II BPD criteria met at baseline: group 1:
6.70, SD = 0.16; group 2: 7.12, SD = 0.19

BPD diagnosis according to: DSM-IV

means of assessment: SCID, BPDSI-IV

Interventions

group 1 (EG): Schema-Focused Therapy (SFT), 50-minute sessions twice a week

group 2 (CG): Transference-Focused Psychotherapy (TFP), 50-minute sessions twice a week

duration: up to three years, depending on treatment success

concomitant psychotherapy: no additional psychotherapeutic treatment allowed

concomitant pharmacotherapy: Prescribing according to good clinical practice, similar to American
Psychiatric Association guidelines, by psychiatrists from different orientations (2 SFT therapists, 3 TFP
therapists). At baseline, 74.0% of patients used psychotropic medication

Outcomes

outcomes considered in this review

self-rated: none

observer-rated: Borderline severity (BPDSI-IV-total), general psychopathology (SCL-90-R-dutch ver-
sion)

Notes

Risk of bias

Bias

time-points used here: 36 months (post-treatment)

analyses: ITT, LOCF

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Randomization to SFT or TFP was stratified across 4 community mental
health centers and was performed [...] after the adaptive biased urn proce-
dure" (Giesen-Bloo 2006, p. 650)

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Randomization to SFT or TFP [...] was performed by a study independent
person [...] We used this procedure (1) to keep allocation at each site un-
predictable until the last patient to avoid unintentionally affecting ongoing
screening procedures [...]." (Giesen-Bloo 2006, p. 650)

173 patients were screened for eligibility. 85 of them were excluded, reasons
are given (40 declined participation, 24 did not meet inclusion criteria, 19 met
exclusion criteria, 2 had insufficient availability).

88 randomised, of 45 allocated to SFT, 44 were included in analyses (1 patient
excluded owing to unreliable assessments due to increased patient blindness),
of 43 allocated to TFP, 42 were included in analyses (1 patient excluded be-
cause untraceable after randomisation; never met or spoke to therapist)

"assessments were made [...] by independent research assistants [...] Study re-
searchers, screeners, research assistant, and SFT/TFP therapists were masked
to treatment allocation during the screening procedure and the first assess-
ment" (Giesen-Bloo 2006, p. 650) "most research assistants learned their pa-
tients' treatment allocation as the study progressed, as patients talked about
their treatment and therapists. However, the results of secondary comput-
er-assessed self-report measures [...] concurred with the observer-rated (inter-
view) findings, making it unlikely that results can be contributed to knowledge
of treatment allocation." (Giesen-Bloo 2006, p. 657)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Giesen-Bloo 2006  (Continued)

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Weekly local supervision [...], a 1-day central supervision every 4 months, and
a 2-day central supervision every 9 months. [...] Treatment integrity was mon-
itored by means of supervision. All the raters were independent of the study
and masked to treatment outcome. One psychologist, masked to allocation,
listened to 1 randomly selected tape of each patient, then stated the treat-
ment administered [...] Other trained therapists for each orientation assessed
the TFP Rating of Adherence and Competence Scale or the SFT Therapy Adher-
ence and Competence Scale for BPD." (Giesen-Bloo 2006, p. 650-651)

Low risk

Experts from both therapies supervised therapists.

Low risk

Equal amounts of attention spent to both groups.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Gratz 2006 

Study characteristics

Methods

design: parallel-arm randomised controlled trial

Participants

sex: 25/25 females (100%)

age: 33.3 years on average (SD = 9.98)

location: USA

setting: outpatient

Interventions

exclusions: diagnosis of a psychotic disorder, bipolar I disorder, substance dependence, reporting one
or more suicide attempts rated as having a "high" risk of death or greater within the past 6 months, re-
porting greater than "some chance" of attempting suicide within the next year, participation in a DBT
skills group within the past 6 months; for inclusion, a history of repeated deliberate self-harm, with at
least one episode in the past 6 months was required

level of functioning/severity of illness: 7.50 BPD criteria were met on average

BPD diagnosis according to: DSM-IV

means of assessment: Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV, Zanarini 1996)

group 1 (EG): Emotion regulation group intervention + treatment as usual, treatment by individual
therapist required (ERG+TAU; 14 weekly 1.5 hour sessions; acceptance-based, behavioural group, com-
bining elements of Acceptance and Commitment Therapy (ACT) and Dialectical Behaviour Therapy
(DBT) as well as aspects of emotion-focused psychotherapy and traditional behaviour therapy)

group 2 (CG): Treatment as usual + Waiting List (TAU+WL; treatment by individual therapist required)

duration: 14 weeks

concomitant psychotherapy: Participants were required to have an individual therapist; average
number of individual therapy per week was 1.38 hours. 41% of therapists were clinical psychologists,
27% were psychiatrists, 32% were licensed clinical social workers

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gratz 2006  (Continued)

Cochrane Database of Systematic Reviews

concomitant pharmacotherapy: Participants received 3.64 psychiatric medications on average

Outcomes

outcomes considered in this review

self-rated: BPD severity (BEST), affective instability (DERS-emotion dysregulation), impulsivity (DERS-
impulse control), self-harming behaviour (DSHI-frequency score), depression (DASS-depression), anxi-
ety (DASS-anxiety)

observer-rated: none

time-points used here: 14 weeks (post-treatment)

analyses: per protocol (EG: N = 16, CG: N = 12)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"Participants [...] were matched on level of emotion dysregulation and number
of lifetime incidents of self-harm and randomly assigned to either the group
treatment plus TAU condition or the TAU waitlist condition." (Gratz 2006, p. 27)

Allocation concealment
(selection bias)

Unclear risk

24 were included and randomised. 2 drop-outs, one from each condition, no
reasons given.

Finally, analyses refer to N = 22 patients, N = 12 in EG, N = 10 in TAU condition.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Research team members were not blind to condition; however, all outcome
measures were self-report, and there was limited interaction between partici-
pants and assessors." (Gratz 2006, p. 30)

Outcomes are not likely to be influenced by lack of blinding.

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Unclear risk

Treatment approach was developed by the first author who also was the ther-
apist; no further information.

High risk

First author developed the treatment approach investigated here.

High risk

More attention paid to EG participants.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Gregory 2008 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 24/30 females (80%)

age: 28.7 years on average (SD = 7.7)

location: USA

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gregory 2008  (Continued)

setting: outpatient

Cochrane Database of Systematic Reviews

Interventions

exclusions: schizophrenia, schizoaffective disorder, mental retardation, neurological condition
that may produce secondary psychiatric symptoms (e.g., stroke, multiple sclerosis, partial complex
seizures, or traumatic brain injury)

level of functioning/severity of illness: "Only 10 participants (33%) were engaged in part-time or full-
time employment (Hollingshead categories 1-7)" (Gregory 2008, p. 30)

BPD diagnosis according to: DSM-IV; in addition, a comorbid diagnosis of active alcohol abuse or de-
pendence (not in full sustained remission) was required for inclusion

means of assessment: SCID

group 1 (EG): Dynamic deconstructive psychotherapy (DDP; weekly individual sessions over 12 to 18
months; DDP participants were also encouraged to participate in some form of group therapy, usually
with interpersonal focus or 12-step; about one quarter did attend a professionally led group therapy for
the first 6 months but none by 12 months)

group 2 (CG):Treatment as usual (TAU; if not already in treatment, participants were referred to an al-
cohol rehabilitation centre and were also given names of psychiatric clinics and therapists in the com-
munity; they were also allowed to keep their current psychotherapist, if any)

duration: post assessments were done after 12 months; DDP treatment could continue up to 18
months, however

concomitant psychotherapy: If not already in treatment, CG patients were referred to an alcohol reha-
bilitation centre and given names of clinics an therapists in the community. If they had one, TAU partic-
ipants were allowed to keep their current psychotherapist. EG participants were required to end treat-
ment with their present psychotherapist, unless that person served primarily as a case manager or sub-
stance use counsellor; 70.0% of participants received individual psychotherapy or alcohol counselling;
30.0% received an additional professional group therapy, 36.7% participated in self-help groups

concomitant pharmacotherapy: 63.3% of all participants received separate medication manage-
ment, the mean number of psychotropic medications was 2.9; medication management was provid-
ed by the DDP therapist for the EG group patients according to the American Psychiatric Association
guidelines for BPD, medications specifically targeting substance use disorders were not prescribed

Outcomes

outcomes considered in this review

self-rated: BPD severity (BEST), dissociation/stress-related paranoia (DES), depression (DASS-depres-
sion), anxiety (DASS-anxiety)

observer-rated: self-harming behaviour (number of patients with parasuicide during previous 3-
month period)

time-points used here: 12 months (post-treatment)

analyses: per protocol (EG: 10/15 allocated; CG: 9/15 allocated)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"A minimization method was employed for group assignment [...] ensuring
comparability of the two groups on key variables or factors [...] The specific
factors that we adjusted for included: age, gender, alcohol abuse versus de-
pendence, current alcohol use, antisocial personality disorder, inpatient uti-
lization, and number of parasuicides." (Gregory 2008, p. 31-32)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gregory 2008  (Continued)

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

"participants were assigned by the research coordinator to either the investi-
gation treatment or to treatment as usual (TAU) in the community" (Gregory
2008, p. 31)

"An independent, trained research assistant administered the primary and
secondary outcome measures [...] blind to treatment group at the time of in-
terviews, but blindedness was only partial, as she was able to correctly guess
group assignment 67% of the time (50% correct guesses were expected by
chance alone)." (Gregory 2008, p. 35)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (NCT00145678). No indications for selective report-
ing.

Treatment adherence?

Low risk

"Six therapists provided DDP, including the principal investigator [who is one
of the two developers of DDP] (PI; N = 6 study participants) and five psychia-
try residents (N = 9 participants) who were in their third year of residency train-
ing [...] After achieving competency, adherence to technique and treatment in-
tegrity for resident therapists was assured through weekly group supervision
[...] and individual supervision of videotaped sessions with the PI [principal in-
vestigator, developer of DDP] every other week throughout treatment." (Gre-
gory 2008, p. 34)

High risk

Both developers of the experimental treatment are among study authors.

Low risk

Though participants of the control group did not receive an alternate, obliga-
tory control treatment, but were free to join alternative treatments, they did
not receive less professional attention. Indeed, "[...] DDP participants received
fewer overall treatment contact hours than did participants receiving commu-
nity care." (Gregory 2008, p. 39). Also cf. Gregory 2008, Tab. 2, p. 33

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Koons 2001 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 28/28 females (100%)

age: 35.0 years on average

location: USA

setting: outpatient

exclusions: schizophrenia, bipolar disorder, substance dependence, antisocial personality disorder

level of functioning/severity of illness: At baseline, study participants met 6.8 out of 8 DSM-III-R BPD
criteria on average

BPD diagnosis according to: DSM-III-R

means of assessment: SCID

Interventions

group 1 (EG): Dialectical Behavior Therapy (DBT; weekly individual therapy, weekly group skills train-
ing)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Koons 2001  (Continued)

Cochrane Database of Systematic Reviews

group 2 (CG): treatment as usual (TAU; weekly individual therapy with a clinician, possibility of attend-
ing one or more supportive and psychoeducational groups, 4 participants did)

duration: 6 months

concomitant psychotherapy: all participants received individual psychotherapy (TAU: 4 of the thera-
pists described themselves as cognitive-behavioural in primary orientation, 2 as psychodynamic, and
2 as eclectic). Group psychotherapy was part of DBT treatment while TAU patients were offered several
group therapies at the hospital (4 out of 10 actually attended group therapy).

concomitant pharmacotherapy: all participants, except one in the DBT condition, received pharma-
cotherapy(including SSRIs in each case and/or an additional mood stabiliser or low-dose neuroleptic
in "some" cases; Koons 2001, p. 376) pharmacotherapy and psychotherapy were provided by separate
clinicians in all but one TAU case

Outcomes

outcomes considered in this review

self-rated: anger (STAXI-anger-out), suicidality (BSS), dissociation (DES), depression (BDI)

observer-rated: BPD severity (mean number of DSM-IV diagnostic criteria for BPD), self-harming be-
haviour (mean number of parasuicides during 3 months period), anxiety (HARS)

Notes

Risk of bias

Bias

time-points used here: 6 months (i.e. post-treatment)

analyses: per protocol (EG: N = 10; CG: N = 10)

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

"28 women were randomized to treatment." (Koons 2001, p. 374). No further
information given.

Allocation concealment
(selection bias)

Unclear risk

No further details.

28 participants were randomised. 8 were not included in analyses due to not
completing treatment (reasons: 2 did not attend the first appointment, 2 in
TAU and 3 in DBT dropped out after more than one appointment in the first
half of treatment citing distance from the medical centre as reason)

Analyses refer to N = 10 patients in the DBT and N = 10 patients in the TAU
group.

"Assesment interviews were conducted by two psychology interns who [...]
were unaware of subjects' treatment condition." (Koons 2001, p. 376)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

EG therapists: "All [DBT therapists] attended the weekly consultation group,
and several received additional individual supervision from each other. Two
clinicians received supervision briefly from a senior trainer from Linehan's
group. [...] All individual and group sessions were videotaped for later coding
for adherence using the DBT Expert Rating Scale [...] At the end of treatment, a
sample of eight tapes from each therapist-patient dyad, including the first ses-
sion and seven others selected randomly, was coded for adherence." (Koons
2001, p. 377) CG therapists: "Five [out of eight TAU] clinicians [...] received
weekly supervision on their cases from attending psychiatrists or staff psychol-
ogists." (Koons 2001, p. 378)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

No indication given.

Low risk

Equal amounts of attention paid to both groups.

Koons 2001  (Continued)

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Linehan 1991 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 61/61 females (100%)

age: women between 18 and 45 years were eligible, no further details

location: USA

setting: outpatient

exclusions: schizophrenia, bipolar disorder, substance dependence, mental retardation

level of functioning/severity of illness:

BPD diagnosis according to: DSM-III

means of assessment: DIB

Interventions

group 1 (EG): Dialectical Behavior Therapy (DBT; weekly individual therapy, weekly group therapy,
telephone contact with the individual therapist between sessions)

group 2 (CG): Treatment as usual in the community (TAU; all subjects were given alternative therapy
referrals, usually by the original referral source; 9 had stable individual therapy for the year

duration: 12 months

concomitant psychotherapy: 13 out of 22 TAU participants were in ongoing individual psychotherapy
at pretreatment, 9 out of 22 TAU participants had stable individual therapy for the year.

concomitant pharmacotherapy: "Subjects had to consent to taper off psychotropic medications be-
fore entering the study. However, once in the study, failure to terminate or resuming use of medication
was not cause for removal from the study." (Linehan 1991, p. 1061)

Outcomes

outcomes considered in this review

self-rated:

observer-rated: Number of patients with self-harming behaviour during previous 12-month period,

Notes

Risk of bias

Bias

time-points used here: 12 months (post-treatment)

analyses: per protocol (EG: N = 22; CG: N = 22)

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1991  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Cochrane Database of Systematic Reviews

"Subjects were matched on the number of lifetime parasuicides and psychi-
atric hospitalization, age, and good vs poor clinical prognosis (with a sub-
threshold diagnosis on schizophrenia or substance dependence constituting
poor prognosis) and randomly assigned to a treatment condition." (Linehan
1991, p. 1061)

Allocation concealment
(selection bias)

Unclear risk

No further details.

10 dropped out during pretreatment assessment (EG: N = 5, CG: N = 5)

7 were dropped following pretreatment assessment for refusal or inability to
meet study conditions (EG: N = 3, CG: N = 4)

2 EG participants quit the study with four or fewer DBT sessions and were
dropped from all analyses other than treatment maintenance analyses

Major analyses were conducted for 44 participants, N = 22 in EG and N = 22 in
CG treatment

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Screening and assessment interviews were administered by a team of 13 re-
search assessors. Every effort was made to keep the assessors blind about
treatment condition." (Linehan 1991, p. 1061)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Dialectical behavior therapy was supervised by the senior author (M.M.L.)
who trained all therapists, listened to audiotapes at regular intervals, and con-
ducted weekly individual and group supervision." (Linehan 1991, p. 1061)

Allegiance effect improba-
ble?

High risk

The senior author (M.M.L.) is the founder of DBT. However, there are no indica-
tions for a systematic bias given.

High risk

More attention spent to EG.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Linehan 1994 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 26/26 (100%)

age: 26.7 years on average (SD=7.8)

location: USA

setting: outpatient

exclusions: subjects currently meeting criteria for schizophrenia, bipolar disorder, primary substance
dependence, mental retardation

level of functioning/severity of illness: mean pretreatmen GAS scores: DBT 37.73 (SD=7.53), TAU
33.77 (SD=9.50), i.e. "some impairment in reality testing or communication OR major impairment in
several areas, such as work or school, family relations, judgment, thinking or mood"

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1994  (Continued)

BPD diagnosis according to: DSM-III-R

means of assessment: SCID, DIB-R

Cochrane Database of Systematic Reviews

Interventions

group 1 (EG): Dialectical Behavior Therapy (DBT; weekly individual behavioural psychotherapy, weekly
psychoeducational skills training groups)

group 2 (CG): Treatment as usual (TAU; subjects received alternative therapy referrals and were al-
lowed to participate any type of treatment available in the community)

duration: 12 months

concomitant psychotherapy: patients assigned to DBT treatment had to terminate other professional
mental health care

concomitant pharmacotherapy: No between-group differences in number of subjects using psy-
chotropic medications at pretreatment (use of: antidepressants, anticonvulsants, lithium, anxiolytics).
DBT participants should taper off psychotropic medications as one goal of therapy, and eight out of 13
discontinued medication before start of treatment.

The remaining five DBT subjects reported using a mean of 1.80 medications (sedatives, antidepres-
sants, anxiolytics, lithium) over the treatment year, while nine out of 13 TAU subjects reported using a
mean of 3.89 different medications (antidepressants, anxiolytics, neuroleptics, sedatives, anticonvul-
sants).

Outcomes

outcomes considered in this review

self-rated: anger (STAXI-trait)

observer-rated: mental health status (GAS)

time-points used here: 12 months (post treatment)

analyses: per protocol (EG: N=13; CG: N=13)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"assignment of subjects to treatment conditions [...] described in detail in the
original outcome study [i.e., Linehan 1991]" (Linehan 1994, p. 1772): "Subjects
were matched on the number of lifetime parasuicides and psychiatric hospi-
talization, age, and good vs poor clinical prognosis (with a subthreshold diag-
nosis on schizophrenia or substance dependence constituting poor prognosis)
and randomly assigned to a treatment condition." (Linehan 1991, p. 1061) No
further details.

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

No further details.

26 women were included, data set for 26 subjects (DBT: N = 13, TAU: N = 13)
provided

Low risk

"Interviews blind to treatment conditions" (Linehan 1994, p. 1772)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

No details provided if supervision and/or adherence ratings had been con-
ducted. However, the same study design was used as for Linehan 1991 ("two
cohorts", cf. Linehan 1994, p. 1772), where regular supervision was explicitely

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1994  (Continued)

Cochrane Database of Systematic Reviews

Allegiance effect improba-
ble?

High risk

"The study was conducted at the institution where the treatment was devel-
oped." (Linehan 1994, p. 1775)

defined (cf. Characteristics of included studies, Risk of bias table for Linehan
1991).

High risk

More attention spent to EG.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Linehan 2006 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 101/101 females (100%)

age: 29.3 years on average, SD = 7.5

location: USA

setting: outpatient

exclusions: lifetime diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, psychotic
disorder not otherwise specified, mental retardation; seizure disorder requiring medication, mandate
to treatment, need for primary treatment for another debilitating condition

level of functioning/severity of illness:

BPD diagnosis according to: DSM-IV

means of assessment: SCID, IPDE

Interventions

group 1 (EG): Dialectical Behavior Therapy (DBT, i.e. weekly individual psychotherapy, group skills
training, telephone consultation)

group 2 (CG): non-behavioural Community Treatment by Experts (CTBE; eligible therapists were nomi-
nated by community mental health leaders as experts in treating difficult clients; therapists were asked
to provide the same type and dose of therapy that they believed was most suited to the patient, with a
minimum of 1 scheduled individual session per week; the therapists described themselves as "eclectic
but nonbehavioral" or "mostly psychodynamic", cognitive behaviour therapists were not eligible; ther-
apists were free to attend a clinical supervision group at the Seattle Psychoanalytic Society and Insti-
tute)

duration: 12 months

concomitant psychotherapy: no information given regarding further concomitant psychotherapy

concomitant pharmacotherapy: There were no differences in types or amounts of psychotropic med-
ication use at pretreatment, and the use of psychotropic medications decreases significantly more in
the EG than the CG. No further details.

Outcomes

outcomes considered in this review

self-rated: suicidality (SBQ)

observer-rated: depression (Ham-D-17)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Linehan 2006  (Continued)

Notes

Risk of bias

Bias

time-points used here: 12 months, i.e. post-treatment

analyses: ITT (except of training and pilot cases)

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

"Using a computerized adaptive minimization randomization procedure, eli-
gible subjects were matched to treatment condition on 5 primary prognostic
variables: (1 and 2) the number of lifetime suicide attempts or nonsuicidal self-
injuries combined and psychiatric hospitalizations; (3) a history of only suicide
attempts, only nonsuicidal self-injury, or both; (4) age; and (5) a negative prog-
nostic indicator of a Beck Depression Inventory score higher than 30 or a Glob-
al Assessment of Functioning score lower than 45 for a comorbid condition [...]
Based on 0.8 power to detect significant differences between conditions (P
= .05, 1-sided), this procedure was used to randomize 101 subjects to DBT (n =
52) or to CTBE (n = 49)." (Linehan 2006, p. 758)

"The randomization program assigned clients to DBT and CTBE therapists,
matching on sex, doctoral vs master's training, and years of clinical experi-
ence. Results indicated that therapists' sex and training did not differ in the 2
conditions. The CTBE therapists, however, had more clinical experience, which
was expected because they were selected for their expertise." (Linehan 2006,
p. 760)

"The participant coordinator, who was not blinded to treatment condition, ex-
ecuted the randomization program" (Linehan 2006, p. 758) Improbable that
computerised assignment could be foreseen and thus bias be introduced.

101 participants were randomised, and N = 60 allocated to the EG and N = 51
to the CG arms. 8 DBT "training cases" and 2 CBT "pilot cases" were excluded
from analyses, but the remaining N = 52 EG and 49 CG subjects were analysed
regardless of discontinuation or getting lost to follow-up.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Assessments were conducted by blinded independent clinical asses-
sors" (Linehan 2006, p. 758)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Psychotherapists recommended by colleagues as potentially good DBT ther-
apists were recruited for the study; 8 had no previous DBT exposure and 8
had experience that ranged from workshop attendance to applied practice.
[...] Training consisted of a 45-hour DBT seminar followed by supervised prac-
tice. [...] Individual therapists were hired once 6 of 8 consecutive training case
sessions were rated as adherent to DBT. During the study, adherence was as-
sessed by coding a random selection of sessions on the DBT Global Rating
Scale [...] which codes DBT adherence." (Linehan 2006, p. 759)

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

High risk

The primary author (M.L.L.) is developer of DBT.

Low risk

Equal amounts of attention spent to both groups.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McMain 2009 

Study characteristics

Methods

design: parallel-arm randomised controlled trial

Participants

sex: 165/190 female (86.8%)

age: mean 30.4 years, SD = 9.9

location: Canada

setting: outpatient

Interventions

exclusions: psychotic disorder, bipolar I disorder, delirium, dementia, mental retardation, diagnosis
of substance dependence in preceding 30 days, having a medical condition that precluded psychiatric
medications, living outside a 40-mile radius of Toronto, serious medical condition likely to require hos-
pitalisation within the next year, having plans to leave the province

level of functioning/severity of illness: mean GAF score at baseline: 52.4 (SD = 9.7), i.e. participants
had moderate symptoms OR any moderate difficulty in social, occupational, or school functioning.

All participants had two episodes of suicidal or non-suicidal self-injurious behaviour in the past 5 years,
at least one of which was in the 3 months preceding enrolment

BPD diagnosis according to: DSM-IV

means of assessment: IPDE

group 1 (EG): DBT (individual sessions 1 hour weekly, skills group 2 hours weekly, phone coaching 2
hours weekly, consultation team for therapists 2 hours weekly), focus on self-harm and suicidal behav-
iour; bias toward managing crises on an outpatient basis, phone coaching to assist; patients encour-
aged to rely on skills over pills where appropriate, tapering from medications was a treatment goal

group 2 (CG): general psychiatric management according to APA guideline recommendations (individ-
ual sessions 1 hour weekly, including management based on structured drug algorithm, therapist su-
pervision meeting 90 minutes weekly), focus expanded from self-harm and suicidal behaviour; hospi-
talisation if indicated; patients encouraged to use medications concurrently according to medication
algorithms relating to either mood lability or impulsive-aggressiveness

duration: 12 months

concomitant psychotherapy: non-study treatments such as individual, group, case management, day
treatment or inpatient were recorded but participants were not prevented from using

concomitant pharmacotherapy: no restrictions on ancillary pharmacotherapy

Outcomes

outcomes considered in this review

self-rated: anger (STAXI-anger out), interpersonal problems (IIP-C), depression (BDI), general psy-
chopathology (SCL-90-R-GSI)

observer-rated: BPD severity (ZAN-BPD-total), parasuicidality (mean number of suicidal and self-inju-
rious episodes),

Notes

Risk of bias

Bias

time-points used here: 12 months (i.e. post-treatment)

analyses: ITT, LOCF

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMain 2009  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Cochrane Database of Systematic Reviews

"eligible participants were randomly assigned to treatment arms using a pre-
generated block randomization scheme developed and held by the statisti-
cian." (McMain 2009, p. 1366)

Allocation concealment
(selection bias)

Low risk

"[...] statistician, who prepared 45 sealed envelopes, each containing the
group allocations in random order for four participants." (McMain 2009, p.
1366)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"[...] assessors who were well trained on study instruments and blind to treat-
ment assignment. [...] Assessors were polled after the treatment phase to as-
certain whether they could correctly guess participants' treatment assign-
ment; they did not know treatment assignment for 86% of the cases, suggest-
ing that blinding was largely maintained." (McMain 2009, p. 1366)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (NCT00154154). No indication for selective reporting.

Treatment adherence?

Low risk

"Modality-specific adherence scales were used to evaluate treatment fidelity
[...]" (McMain 2009, pp. 1368, 1370)

Allegiance effect improba-
ble?

Unclear risk

The principal investigator (SMM) is affiliated to DBT and head of a DBT clinic.
However, there is no decided indication of an allegiance effect.

High risk

More attention spent to EG.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Morey 2010 

Study characteristics

Methods

design: parallel-arm, randomised controlled trial

Participants

sex: 13/16 females (81.3%)

age: mean age 31.1 years

location: USA

setting: outpatient

exclusions: active psychosis, history of schizophrenia, substance intoxication or withdrawal

level of functioning/severity of illness: no further information

BPD diagnosis according to: DSM-IV

means of assessment: DIPD-IV, PAI-BOR

Interventions

group 1: MACT (6 weekly sessions centred on chapters of a patient workbook)

group 2: MACT+TA (6 weekly sessions centred on chapters of a patient workbook; initial session also in-
cluded an individualised collaborative assessment with development of questions the client would like
to "ask the test data" about themselves and the articulation of specific, individualised treatment goals;
during second session, therapist and client discussed assessment results and motivational feedback
was given; apart from these augmentations of the first two sessions, identical treatment as other group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morey 2010  (Continued)

duration: 1,5 months

Cochrane Database of Systematic Reviews

concomitant psychotherapy: no other psychosocial interventions allowed

concomitant pharmacotherapy: psychotropic medication allowed 56% were taking at baseline

Outcomes

outcomes considered in this review

self-rated:

observer-rated: BPD severity (PAI-BOR-total), affective instability (PAI-BOR-A), suicidality (PAI-BOR-SI),
parasuicidality (PAI-BOR-S), interpersonal problems (PAI-BOR-N), identity disturbance (PAI-BOR-I)

time-points used here: 1,5 months (i.e. post-treatment)

analyses: ITT (completers case analysis also available but not used here)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Unclear

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Unclear

Unclear risk

"[...] assessments [...] were conducted by an independent evaluator" (Morey
2010, p. 533)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Consenting clients in both conditions were assigned to a project therapist,
who worked under the supervision of the primary investigator." (Morey 2010,
p. 532)

Low risk

No indication given.

Low risk

Beyond TA (which was the point of question of the trial), both groups received
comparable amounts of attention.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Nadort 2009 

Study characteristics

Methods

design: parallel-arm, randomised controlled trial

Participants

sex: 60/62 females (96.8%)

age: mean age 32.0 years

location: The Netherlands

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nadort 2009  (Continued)

setting: outpatient

Cochrane Database of Systematic Reviews

exclusions: BPD not main diagnosis, psychotic disorders (except short, reactive psychotic episodes),
bipolar disorder, dissociative identity disorder, antisocial personality disorder, attention-deficit/hyper-
activity disorder, addiction of such severity that clinical detoxification was indicated (after which en-
tering treatment was possible), psychiatric disorders secondary to medical conditions, mental retarda-
tion, no Dutch literacy

level of functioning/severity of illness: mean number of SCID-II BPD criteria met at baseline: 6.8

BPD diagnosis according to: DSM-IV

means of assessment: SCID-II BPD section, BPDSI-IV score >20

Interventions

group 1: SFT; 45 minute individual sessions twice a week for 12 months, one weekly session in the sec-
ond year; no extra crisis support outside office hours

group 2: Schema-focused therapy plus therapist telephone availability outside office hours in case of
crisis (SFT+TTA); 45 minute individual sessions twice a week for 12 months, one weekly session in the
second year; no extra crisis support outside office hours

duration: 18 months (i.e. final evaluation after 18 months post randomisation; mean number of thera-
py sessions: SFT N = 67, SD = 30.85, range 1-130; SFT+TTA: N = 71, SD 34.57, range 2-142

concomitant psychotherapy: no information

concomitant pharmacotherapy: medication use allowed, 58% of patients used psychotropic medica-
tion at baseline

Outcomes

outcomes considered in this review

self-rated: -

observer-rated: Borderline severity (BPDSI-IV-total), general psychopathology (SCL-90-R-dutch ver-
sion)

Notes

Risk of bias

Bias

time-points used here: 18 months

analyses: ITT

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information.

Allocation concealment
(selection bias)

Low risk

"we used a stratified randomization procedure. The stratification procedure
was performed by a study-independent person and concealed for participat-
ing therapists, patients and researchers." (Nadort 2009, p. 962)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

"Study researchers, screeners, research assistants and therapists were masked
to treatment allocation during the screening period and the first assessmen-
t." (Nadort 2009, p. 963)

"A limitation of the present study is that the assessments will be performed
by research assistants who cannot remain blinded to the treatment condi-
tion of the included patients, as is always the case in trials studying the effects
of psychotherapy. Nor are the patients blind to treatment condition. In this
study, however, added to the main interview-based outcome measures, self-
report questionnaires will be administered, that will not be influenced by the
research assistants. (Nadort 2009b)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nadort 2009  (Continued)

Selective reporting (re-
porting bias)

Low risk

Study protocol available (Nadort 2009b), no indication for selective reporting.

Treatment adherence?

Unclear risk

"Treatment adherence was monitored by means of supervision. [...] All the
raters were independent of the study and masked to treatment condition and
outcome. The raters were psychologists trained in ST. We used the ST Thera-
py Adherence and Competence Scale for BPD (Young, Arntz, & Giesen-Bloo,
2006)." (Nadort 2009, p. 965)

Low risk

Both interventions are SFT based.

Low risk

Beyond TTA (which was the point of question of the trial), both groups re-
ceived comparable amounts of attention.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Soler 2009 

Study characteristics

Methods

design: parallel-arm, randomised controlled trial

Participants

sex: 48/59 females (81.3%)

age: mean age 29.2 years

location: Spain

setting: outpatient

exclusions: schizophrenia, drug-induced psychosis, organic brain syndrome, alcohol or other psy-
choactive substance dependence, bipolar disorder, mental retardation, major depressive episode in
course, CGI-S score ≤ 4 (i.e. not at all, borderline, or mildly ill)

level of functioning/severity of illness: mean CGI-BPD (global) scores of both groups: group 1: 4.71;
range 4-7; group 2: 4.9, range 4-7; i.e. mean severity was moderately to markedly ill

BPD diagnosis according to: DSM-IV

means of assessment: SCID-II, DIB-R

Interventions

group 1 (EG): DBT skills training (DBT-ST), including DBT original skills for interpersonal effectiveness,
emotional regulation, mindfulness and distress tolerance; 13 psychotherapy sessions of 120 min each,
conducted by 2 therapists (a male and a female) for each group, in groups of 9-11 participants.

group 2 (CG): Standard Group Therapy (SGT); therapeutic techniques: interpretation, highlighting, ex-
ploration, clarification, confrontation; therapists targeted specially nihilistic or destructive interac-
tions, characteristic BPD interactions and those that could interfere with group functioning; 13 psy-
chotherapy sessions of 120 min each, conducted by 2 therapists (a male and a female) for each group,
in groups of 9-11 participants.

duration: 3 months (i.e. 13 weekly sessions in each condition)

concomitant psychotherapy: participants did not receive any other individual or group psychothera-
py

concomitant pharmacotherapy: pharmacological therapy was continued if initiated prior to inclu-
sion, but type and doses could not be modified during the study period

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Soler 2009  (Continued)

Outcomes

outcomes considered in this review

self-rated: mental health status (CGI-I-self rating)

observer-rated: BPD severity (CBI-BPD-global), anger (CBI-BPD-anger), affective instability (CGI-BPD-
affective instability), chronic feelings of emptiness ((CGI-BPD-emptiness), impulsivity (CGI-BPD-impul-
sivity), suicidality (CGI-BPD-suicidality), interpersonal problems (CGI-BPD-unstable relations), disso-
ciative/psychotic pathology (BPRS), depression (Ham-D-17), anxiety (HARS), general psychopathology
(SCL-90-R-GSI)

Notes

Risk of bias

Bias

time-points used here: 3 months, i.e. post-treatment

analyses: ITT

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Blocks of four generated using the SPSS software program served for the ran-
domisation to DBT-ST or SGT." (Soler 2009, p. 354)

Allocation concealment
(selection bias)

Unclear risk

No further details.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Comprehensible flow diagram of patient progress through phases of study
provided.

"... participants were evaluated every two weeks by experienced psychiatrists.
Subjects were instructed not to disclose any information about the group (top-
ics, group members or therapists) to maintain blind conditions." (Soler 2009,
p. 354)

"Assessment and drug control were carried out by two psychiatrists who were
masked to the experimental conditions." (Soler 2009, p. 355)

"We are unable to affirm that all participants refrained from disclosing infor-
mation about the therapy or the therapists with the psychiatric raters during
assessment visits. [...] Indeed, the observer-rater scales obtained during the in-
terview visits and the results from self-reported measures filled in by patients
during the study showed a good concordance. " (Soler 2009, p.357)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Unclear risk

"DBT-ST intervention was led by two cognitive behavioural psychothera-
pists with prior experience in BPD group therapy (Soler et al., 2001, 2005) and
trained in DBT in courses organised by the 'Behavioural Technology Transfer
Group'." (Soler 2009, p. 355).

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Low risk

No indications for allegiance effect given.

Low risk

Equal amounts of attention spent to both groups.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Steil 2010 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

design: randomised controlled trial

Originally, female participants with a diagnosis of PTSD and at least 4 criteria of DSM-IV-BPD were eligi-
ble. We refer to the subsample data of those participants fulfilling 5 or more criteria.

Participants

sex: 31/31 females (100%)

age: mean age 32.9 years; range 19-52 years

location: Germany

setting: inpatient

Interventions

exclusions: lifetime diagnosis of schizophrenic disorder, severe other mental disorder requiring imme-
diate treatment in a different setting (e.g., eating disorder or acute delirium after withdrawal), suicide
attempt with clear suicidal intention during last 4 months, severe self-injuring behaviour during last 4
months

level of functioning/severity of illness: mean number of BPD criteria 5.85

all participants suffered from concurrent PTSD according to DSM-IV after childhood sexual abuse

BPD diagnosis according to: DSM-IV

means of assessment: IPDE

group 1 (EG): DBT for patients with PTSD after childhood sexual abuse (DBT-PTSD); including: modi-
fied DBT skills training group (1 session of 90 minutes duration per week, modules: mindfulness, inter-
personal skills, emotion regulation, stress tolerance; but less attention on interpersonal and detention
skills as in standard DBT skills group); individual cognitive trauma therapy, exposure and discrimina-
tion training (2 sessions of 45 minutes duration per week); psychoeducation group concerning PTSD
aetiology and treatment; additional group training in mindfulness- and acceptance-based techniques
(three sessions of 20 minutes duration per week); participation in music, arts and exercise therapy

DBT skills training (DBT-ST), including DBT original skills for interpersonal effectiveness, emotional reg-
ulation, mindfulness and distress tolerance; 13 psychotherapy sessions of 120 min each, conducted by
2 therapists (a male and a female) for each group, in groups of 9-11 participants.

group 2 (CG): waiting list (WL): continuation of already ongoing treatments for 6 months, inpatient
DBT-PTSD treatment afterwards; points of measurement: baseline, 3 months, 4.5 months and 6 months
after study inclusion

duration: 3 months of inpatient treatment (i.e. 13 weekly sessions in each condition) + one booster
session 6 weeks after dismissal

concomitant psychotherapy: participants of the experimental group did not receive any other indi-
vidual or group psychotherapy, participants of the waiting list condition continued their usual treat-
ments if any

concomitant pharmacotherapy: depressive episodes were treated with SSRI antidepressive agents
(100-150 mg/d of sertraline, e.g.); difficulties of sleeping were treated with sleep-inducing antidepres-
sants (50-100mg/d of trimipramine, e.g.); no benzodiazepines, no neuroleptics

Outcomes

outcomes considered in this review

self-rated: BPD severity (BSL), dissociation (DES), depression (BDI-II), anxiety (STAI-state), general psy-
chopathology (SCL-90-R-GSI

observer-rated: -

time-points used here: 4.5 months, i.e. post residential treatment and one 6-week follow-up session

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Steil 2010  (Continued)

Notes

Risk of bias

Bias

analyses: ITT

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"randomisation was carried out using the procedure proposed by Efron" (Steil
2010).

Allocation concealment
(selection bias)

Low risk

"Care was taken that the randomization was concealed to both the patient
and to all persons involved in the study until the written informed consent has
been given by the patient." (Steil 2010).

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"Interviewers were blinded. [...] the diagnostician who was assessing the pa-
tient at follow-up was masked to the assignment." (Steil 2010).

Selective reporting (re-
porting bias)

Low risk

Study protocol available (DBT working group at CIMH), no indication for selec-
tive reporting.

Treatment adherence?

Low risk

Therapists were supervised weekly by the treatment developer.

High risk

First author developed the treatment approach investigated here.

High risk

More attention paid to EG.

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Turner 2000 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 19/24 females (79.2%)

age: 22 years on average

location: USA

setting: outpatient

exclusions: schizophrenia, schizoaffective disorder, bipolar disorder, organic mental disorders, mental
retardation

level of functioning/severity of illness:

BPD diagnosis according to: DSM-III-R

means of assessment: DIB, PDE

Interventions

group 1 (EG1): Dialectical Behavior Therapy-oriented treatment (i.e. individual DBT-oriented psy-
chotherapy plus six group sessions with focus on significant persons in patients' natural environments;
DBT modifications were the following: First: psychodynamic techniques were incorporated to concep-
tualise patients' behavioural, emotional, and cognitive relationship schema; second, there was no DBT
skills group, but skills were provided during individual therapy)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Turner 2000  (Continued)

Cochrane Database of Systematic Reviews

group 2 (EG2): Client-centered Therapy (CCT; i.e. two weekly individual sessions when possible; six
group sessions with focus on significant persons in patients' natural environments (same as EG pa-
tients received)

duration: 12 months

concomitant psychotherapy: no details

concomitant pharmacotherapy: pharmacotherapy was not included in the study treatment regimens;
at baseline, 19 patients were out of 24 reported taking prescribed psychotropic medications

Outcomes

outcomes considered in this review

self-rated: anger (TBR-anger), impulsivity (TBR-impulsiveness), suicidal ideation (BSS), parasuicidality
(TBR-frequency of parasuicide), depression (BDI), anxiety (BAI)

observer-rated: dissociative/psychotic symptoms (BPRS)

time-points used here: 12 months, i.e. post-treatment

analyses: ITT

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

"Following the initial assessments, patients were randomly assigned to either
DBT or CCT. " (Turner 2000, p. 415) No further details.

Allocation concealment
(selection bias)

Unclear risk

"Next, patients were sequentially assigned to a mental health clinician." (Turn-
er 2000, p.415).

No further details.

24 participants were randomly assigned to either DBT (N = 12) or CCT (N = 12).
In spite of drop-outs from treatment (DBT: N = 4, CCT: N = 6), assessments were
available for all 24 participants at all times of assessment

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"The outcome evaluation consisted of independent assessor ratings and pa-
tient self-report. The independent assessor was unaware of the patients' treat-
ment condition but was aware of the purpose of the study." (Turner 2000, p.
415)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"The investigator and the senior clinic therapist monitored adherence to the
treatment protocols. Both supervisors met with the therapists weekly in two
separate group supervision meetings. Therapists presented audiotapes of
their previous sessions with patients during supervision." (Turner 2000, p. 415)

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Low risk

No indications for allegiance effect given.

High risk

More attention paid to EG2 (CCT) participants.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Van den Bosch 2005 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 64/64 females (100%)

age: 34.9 years on average, SD = 7.7

location: The Netherlands

setting: outpatient

exclusions: bipolar disorder, (chronic) psychotic disorder, severe cognitive impairments, insufficient
command of the Dutch language

level of functioning/severity of illness: mean number of BPD criteria: 7.3 (SD = 1.3); participants were
also required to have co-morbid substance abuse problems

BPD diagnosis according to: DSM-IV

means of assessment: SCID-II, Personality Diagnostic Questionnaire for DSM-IV (positive endorsement
of BPD criteria was required on both instruments)

Interventions

group 1 (EG): Dialectical Behavior Therapy (DBT; i.e. weekly individual cognitive-behavioural psy-
chotherapy sessions, weekly skills-training groups, phone crisis consultation as needed)

group 2 (CG): Treatment as usual (TAU; i.e. clinical management from the original referral source; two
thirds: psychiatric services, one third addiction treatment centres; TAU patients attended generally no
more than two sessions per month with a psychologist, a psychiatrist or a social worker)

duration: 12 months

concomitant psychotherapy:

concomitant pharmacotherapy: About 75% of participants reported the use of medication from one
or more of the following categories during the study: benzodiazepines, selective serotonin reuptake
inhibitors, tricyclic antidepressants, mood stabilisers and neuroleptics. No significant differences be-
tween the two groups with regard to medication use.

Outcomes

outcomes considered in this review

self-rated: -

observer-rated: impulsivity (BPDSI-IV-impulsivity), parasuicidal behaviour (LPC-self-mutilative acts
during previous 3-month period),

time-points used here: week 52 (i.e. post-treatment)

analyses: per protocol (data based on the number of subjects with valid data at a given measurement
time)

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"...patients were randomly assigned to treatment conditions. A minimisation
method was used to ensure comparability of the two treatment conditions
on age, alcohol problems, drug problems and social problems (as measured
by the European version of the Addiction Severity Index [...]" (Verheul 2003, p.
135)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Van den Bosch 2005  (Continued)

Allocation concealment
(selection bias)

Unclear risk

No further details.

Of 64 eligible patients, N = 31 were assigned to EG and N = 33 to CG.

"Two patients assigned to the treatment-as-usual condition were dropped
from the intention-to-treat analyses because they did not accept the randomi-
sation outcome and therefore refused to cooperate further with the study
protocol, and four patients assigned to dialectical behaviour therapy were
dropped because they refused to start treatment." (Verheul 2003, p. 136)

Thus, analyses refer to N = 27 EG and N = 31 CG subjects that actually started
treatment as allocated to.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

"although the research assessors were not informed about the treatment con-
dition of their interviewees, it is unlikely that they remained 'masked' through-
out the project. Patients might have given them this information, or it could
easily have been derived from some of the interviews." (Verheul 2003, p. 139)

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Low risk

"Training, regular monitoring (using videotapes) and weekly individual and
group supervision were performed by the second author (L.M.C.B.), who re-
ceived intensive training from Professor Linehan in Seattle and is a member of
the international dialectical behaviour therapy training group." (Verheul 2003,
p. 136)

"The median adherence score on a 5-point Likert scale was 3.8 (range 2.5–4.5),
indicating ‘almost good DBT’ in terms of conformity to the treatment manu-
al." (Van den Bosch 2005, p. 1233)

Allegiance effect improba-
ble?

Unclear risk

"[...] second author (L.M.C.B.), who received intensive treatment from Profes-
sor Linehan in Seattle and is a member of the international dialectical behav-
iour therapy training group. (Verheul 2003, p. 136)

High risk

More attention spent to EG participants.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

Weinberg 2006 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 30/30 females (100%)

age: 28.2 years on average

location: USA

setting: outpatient

exclusions: comorbid psychotic disorders, bipolar I disorder, substance dependence, elevated suicide
risk

level of functioning/severity of illness: baseline frequency of self-harming behaviour: group 1: 9.33,
SD = 14.78; group 2: 8.20, SD = 10.46

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Weinberg 2006  (Continued)

BPD diagnosis according to: DSM-IV

means of assessment: SCID, DIB-R (both sets of criteria had to be met for inclusion)

Interventions

group 1 (EG): Manual-assisted cognitive treatment (MACT; i.e. adjunctive intervention to ongoing treat-
ments of the participants; six session therapy incorporating elements of DBT, cognitive behavioural
treatment, and bibliotherapy)

group 2 (CG): Treatment as usual (TAU); all subjects took part in additional treatments not further
specified

duration: 6 weekly sessions

concomitant psychotherapy: both EG and CG participants received treatment as usual; all partici-
pants took part in additional treatments not further specified

concomitant pharmacotherapy: both EG and CG participants received treatment as usual; no further
details on amounts or types of medications used

Outcomes

outcomes considered in this review

self-rated: -

observer-rated: suicidality (SBQ), parasuicidality (Parasuicide History Interview (PHI) - deliberate self-
harm frequency),

time-points used here: 2 months (i.e. post-treatment)

analyses: ITT

Authors' judgement

Support for judgement

Unclear risk

"randomly assigned" (Weinberg 2006, p. 485) No further details.

Unclear risk

No further details.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

After screening of 60 referrals by phone, 37 were invited for further assess-
ments. Reasons for exclusion of N = 7 are given. N = 30 were included in the fi-
nal sample. N = 15 were assigned to the EG and N = 15 to the CG.

"The baseline assessment and administration of the MACT [i.e. the treatment
under test] were performed by the primary investigator." (Weinberg 2006,
p.486) "Interviewers were randomly assigned for following assessments. The
interviewers were blind to baseline ratings and to participants' group alloca-
tion" (Weinberg 2006, p. 487)

Selective reporting (re-
porting bias)

Low risk

No indications for selective reporting.

Treatment adherence?

High risk

"This study did not monitor adherence and competence." (Weinberg 2006, p.
489)

Allegiance effect improba-
ble?

Attention bias: equal
amounts of attention to all

Low risk

No indication for allegiance effect.

High risk

More attention spent to EG participants.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Weinberg 2006  (Continued)
groups (obligatory treat-
ment components)?

Zanarini 2008 

Study characteristics

Methods

design: randomised controlled trial

Participants

sex: 50/50 females (100%)

age: 19.3 years on average (SD = 1.4)

location: USA

setting: outpatient

exclusions: current of lifetime schizophrenia, schizoaffective disorder, bipolar I disorder; current sub-
stance dependence (except for nicotine dependence); any type of current psychiatric treatment

level of functioning/severity of illness: mean GAF score at baseline: 53.3, SD = 1.9; i.e. "moderate
symptoms (e.g., flat affect and circumstantial speech, occasional panic attacks) OR moderate difficulty
in social, occupational, or school functioning (e.g., few friends, conflicts with peers or co-workers)."

mean Sheehan Disability Scale-social impairment score about 4.8; mean vocational impairment sub-
scale score was about 4.3. Scores of 5 or higher are regarded elevated and found to be associated with
an increased risk of mental disorder and significant functional impairment (Rush 2005).

BPD diagnosis according to: DSM-IV; all participants were newly diagnosed with BPD

means of assessment: DIB-R, DIPD-IV (both sets of criteria had to be met for inclusion)

Interventions

group 1 (EG): Psychoeducation workshop (PEW; i.e. latest information on BPD aetiology, phenomenol-
ogy, co-occurring disorders, treatment options, longitudinal course; the workshop took place within a
week of diagnostic disclosure)

group 2 (CG): Waiting List (WL; i.e. subjects were to attend the PEW at the end of the 12-week study)

duration: 12 weeks

concomitant psychotherapy: subjects that were in any type of current psychiatric treatment were not
eligible for study participation

concomitant pharmacotherapy: subjects that were in any type of current psychiatric treatment were
not eligible for study participation

Outcomes

outcomes considered in this review

self-rated: -

observer-rated: Zanarini rating scale for borderline personality disorder (ZAN-BPD) - impulsivity, Za-
narini rating scale for borderline personality disorder (ZAN-BPD) - disturbed relationships score

time-points used here: week 12 (i.e. post-treatment)

analyses: intention-to-treat analysis based on treatment assignment

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zanarini 2008  (Continued)

Random sequence genera-
tion (selection bias)

Unclear risk

Cochrane Database of Systematic Reviews

"Using a 3:2 ratio, subjects were either randomized to a workshop that took
place within a week of diagnostic disclosure or a waitlist." (Zanarini 2008, p.
286). No further details.

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

No further details.

"Fifty subjects were found to meet study criteria for BPD and five who were in-
terviewed did not. These 50 subjects were either randomized to immediate (N
= 30) or delayed (N = 20) psychoeducation." (Zanarini 2008, p. 286) No informa-
tion given about drop-outs during the study course.

Unclear risk

No information given if assessors were blind to treatment allocation.

Selective reporting (re-
porting bias)

Unclear risk

No indication for selective reporting, but Insufficient information to permit
judgement of 'Yes' or 'No'.

Treatment adherence?

Unclear risk

No information.

Allegiance effect improba-
ble?

High risk

"This workshop was led jointly by two research assistants, who used a 63-slide
PowerPoint presentation designed specifically for this study."(Zanarini 2008, p.
285f.) The intervention seems to have been developed by the study authors for
purpose of this study.

Attention bias: equal
amounts of attention to all
groups (obligatory treat-
ment components)?

High risk

More attention spent to EG participants.

APA: American Psychiatric Association
BDI: Beck depression inventory
CBT: cognitive behavioural therapy
CCT: client-centered therapy
CT: cognitive therapy
CTBE: community treatment by experts
DBT: dialectical behaviour therapy
BPD: borderline personality disorder
GAF: Global Assessment of Functioning Scale
GSFT: group schema-focused Therapy
HARS: Hamilton anxiety rating scale
IIP: inventory of interpersonal problems
IPDE: International Personality Disorder ExaminationITT: intention-to-treat
LOCF: last observation carried forward
MACT: manual-assisted cognitive treatment
MBT: mentalisation-based treatment
MBT_OP: outpatient mentalisation-based treatment
PTAU: psychotherapy treatment as usual
PTSD: post-traumatic stress disorder
SD: standard deviation
SFT: schema-focused therapy
SSRIs: selective serotonin reuptake inhibitors
STEPPS: systems training for emotional predictability and problem solving for borderline personality disorder
TAU: treatment as usual
TFP: transference-focused psychotherapy
TTA: therapist telephone availability
WL: waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Characteristics of excluded studies [ordered by study ID]

Study

Abbass 2008

Arnevik 2009

Ball 2007

Reason for exclusion

Participants: less than 70% of participants had a diagnosis of BPD.

Participants: less than 70% of participants had a diagnosis of BPD.

Participants: less than 70% of participants had a diagnosis of BPD.

Beecham 2006

Allocation: not randomised.

Bellino 2005

Berget 2008

Blum 2002

Bohus 2000

Bohus 2004

Allocation: not randomised.

Participants: less than 70% of participants had a diagnosis of BPD.

Allocation: not randomised.

Allocation: not randomised.

Allocation: not randomised.

Brassington 2006

Allocation: not randomised.

Brown 2004

Carter 2007

Allocation: not randomised.

Participants: presence of BPD diagnosis not assessed.

Chanen 2008

Participants: adolescents aged 15 to 18 years.

Chiesa 2000

Clarkin 2007

Colom 2004

Dolan 1997

Evans 1999a

Evans 1999b

Allocation: not randomised.

Outcomes: unable to use data.

Participants: less than 70% of participants had a diagnosis of BPD.

Allocation: not randomised.

Participants: ratio of participants with BPD unclear.

Participants: ratio of participants with BPD unclear.

Gabbard 2000

Allocation: not randomised.

Guthrie 2001

Hagen 2005

Participants: ratio of participants with BPD unclear.

Participants: less than 70% of participants had a diagnosis of BPD.

Huband 2007

Participants: less than 70% of participants had a diagnosis of BPD.

Kool 2003

Korner 2006

Kröger 2006

Participants: less than 70% of participants had a diagnosis of BPD.

Allocation: not randomised.

Allocation: not randomised.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Linehan 1999

Outcomes: no pathology related outcomes of interest.

Linehan 2002

Outcomes: no pathology related outcomes of interest.

Lynch 2007

López 2004

Participants: less than 70% of participants had a diagnosis of BPD.

Allocation: not randomised.

McQuillan 2005

Allocation: not randomised.

Meares 1999

Mueser 2004

Allocation: not randomised.

Participants: less than 70% of participants had a diagnosis of BPD.

Munroe-Blum 1995

Outcomes: no usable data.

Muran 2009

Participants: mixed sample of cluster C PDs.

Petersen 2008

Allocation: not randomised.

Ranger 2009

Participants: mixed sample of patients with severe mental illness, less than 70% of participants had
a diagnosis of BPD.

Rathus 2002

Participants: adolescents.

Sachsse 2006

Allocation: not randomised.

Schuppert 2009

Participants: adolescents 14-19 years, mean age 16.14 years (SD = 1.23).

Slee 2008

Participants: unclear how many participants had a diagnosis of BPD, presence of personality disor-
ders was not assessed.

Springer 1996

Outcomes: no usable data for the BPD subsample available.

Stanley 2007

Allocation: not randomised.

Stevenson 1992

Allociation: not randomised.

Stiles 2006

Trupin 2002

Tyrer 2003

Tyrer 2009

Allocation: not randomised.

Allocation: not randomised.

Participants: less than 70% of participants had a diagnosis of BPD.

Participants: unclear how many of participants actually had a diagnosis of BPD.

Vinnars 2009

Participants: mixed sample of PDs, ratio of participants with BPD unclear.

Waltz 2009

Outcomes: no outcomes of interest for inclusion in this review.

Weertman 2007

Participants: people with BPD were not included.

Wildgoose 2001

Allocation: not randomised.

Yen 2009

Allocation: not randomised.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Zorn 2007

Reason for exclusion

Participants: less than 70% of participants had a diagnosis of BPD.

BPD: borderline personality disorder
PD: personality disorder
SD: standard deviation

Characteristics of ongoing studies [ordered by study ID]

ACTRN12605000594628 

Study name

Methods

Participants

A pilot study to evaluate the feasibility, safety and efficacy of psychotherapeutic intervention for
comorbid BPD and first-episode psychosis

RCT

Males and females aged 15 to 24 years with co-occurring first episode psychosis and full or sub-
threshold BPD

Interventions

1. 16 sessions of Cognitive Analytic Therapy (CAT)

2. TAU

Outcomes

Psychopathology, psychosocial functioning, and quality of life

Starting date

26 August 2005

Contact information

Prof. John Gleeson, Orygen Youth Health, Locked Bag 10, Parkville VIC 3052, Australia; jgleeson@u-
nimelb.edu.au

Dr. Andrew Chanen, Orygen Youth Health, Locked Bag 10, Parkville VIC 3052, Australia; achanen@u-
nimelb.edu.au

Notes

ACTRN12606000206527 

Study name

Process and outcome of acceptance-based outpatient skills training groups for people with four or
more criteria of borderline personality disorder

Methods

RCT

Participants

Males and females with four or more criteria of BPD

Interventions

Phase 1 is a 12 week two hours per week acceptance-based crisis skills training group. Clients
have the option of continuing to Phase 2 which consists of an additional 30 weeks of skills training
groups covering interpersonal skills, emotion regulation skills and mindfulness skills. The groups
are a combination of Acceptance and Commitment Therapy and Dialectical Behaviour Therapy in-
terventions in the context of Acceptance and Commitment Therapy principles of treatment.

Random allocation to immediate start of treatment of 3 months delay

Outcomes

Utilisation of crisis emergency and inpatient services

Starting date

16 March 2006

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12606000206527  (Continued)

Cochrane Database of Systematic Reviews

Contact information

Elise Guymer, Spectrum PO Box 135 Ringwood East VIC 3135, Australia; eliseguymer@netscape.net

Notes

ACTRN12610000100099 

Study name

Monitoring Outcomes of Borderline personality disorder in Youth (MOBY): A randomised controlled
trial (RCT) of specialised early intervention, with and without psychotherapy, versus a standard
youth mental health intervention, for youth presenting with first presentation borderline personal-
ity disorder

Methods

RCT

Participants

Males and females aged 15 to 25 years with a diagnosis of DSM-IV BPD

Interventions

1. HYPE: specialised early intervention service for BPD

2. YMH: Youth mental health care

3. BEF: Befriending

Outcomes

Primary: Interpersonal problems measured by the Inventory of Interpersonal Problems Circumplex
Version (IIP-C); Social Adjustment measured by the Social Adjustment Scale Self Report (SAS-SR) 

Secondary: Client satisfaction measured by the Client Satisfaction Questionnaire (CSQ-8); Suicidal
Ideation as measured by the self-report Beck Suicidal Ideation Scale (BSS) and Mobiletype, a mo-
bile phone program that asks open and closed questions about affect, suicidal ideation and para-
suicidal behaviour; Parasuicidal Acts as measured by the Suicide Attempt and Self-Injury Interview
(SASII) and Mobiletype, a mobile phone program that asks open and closed questions about affect,
suicide ideation and parasuicidal behaviour; Affective Instability as measured by the 10-item self-
report Short PANAS (Positive and Negative Affect Schedule), administered with Mobiletype; Border-
line Personality Disorder Symptoms as measured by the Borderline Personality Disorder Severity
Index (BPDSI-IV); Depression as measured by the self-report Center for Epidemiologic Studies De-
pression Scale - Revised (CESD-R) and the semi-structured interview and rating scale of the Mont-
gomery-Asberg Depression Rating Scale (SIGMA); Substance Use as measured by the self-report Al-
cohol Use Disorders Identification Test (AUDIT) and the interview measure, the Opiate Treatment
Index (OTI - Section II); Therapeutic Alliance as measured by the Working Alliance Inventory (WAI);
Quality of Life as measured by the Assessment of Quality of Life (AQoL-8D); Social and Occupation-
al Functioning as measured by the Social and Occupational Assessment of Functioning Scale (SO-
FAS); Emotion Regulation as measured by the Difficulties in Emotion Regulation Scale (DERS).   

Starting date

10 March 2011

Contact information

Dr Andrew Chanen, Locked Bag 10, Parkville VIC 3052, Australia; achanen@unimelb.edu.au

Notes

DRKS00000068 

Study name

Psychoanalytical interactional psychotherapy in cluster B personality disorders

Methods

RCT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DRKS00000068  (Continued)

Participants

Emotionally unstable personality disorder (ICD 10: F60.31), histrionic personality disorder (ICD 10:
F60.4), dissocial personality disorder (ICD 10: 60.2), other specific personality disorders (ICD 10:
F60.8)

Interventions

Inpatient

1. Psychoanalytic-interactional psychotherapy

2. Psychodynamic therapy as usual

Outcomes

Borderline Personality Inventory (BPI), SCL-90-R, BAI, BDI, IIP

Starting date

01 October 2008

Contact information

Prof Dr Falk Leichsenring, Falk.Leichsenring@psycho.med.uni-giessen.de

Notes

ISRCTN12440268 

Study name

Methods

Participants

JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm

RCT

1. Service users (both males and females) aged 18 years or older 2. Current contact with a local
Community Mental Health Team (CMHT) (will include assessment and brief treatment, continuing
care, home treatment and out-patient clinics attached to these teams) 3. A primary clinical diagno-
sis of emotionally unstable personality disorder (International Statistical Classification of Diseases
and Related Health Problems, 10th Revision [ICD-10] code F60.3) 4. An episode of self-harm in the
previous year

Interventions

6 months of

1. joint crisis plan

2. TAU

Outcomes

Primary: Self-harm history, assessed by a questionnaire at baseline and 6 months (trial end).

Secondary: 1. Client's experience of the treatment that he or she received at a particular service,
assessed by the Treatment Experience Scale assessed at baseline and 6 months 2. Service Engage-
ment Scale at baseline, 6 months (trial end) and trial drop-out 3. The Work and Social Adjustment
Scale (WSAS) at baseline and 6 months (trial end) 4. Euroqol EQ-5D at baseline and 6 months (tri-
al end) 5. Client Satisfaction Questionnaire at baseline and 6 months (trial end) 6. Working Alliance
Inventory - short version (WAI-S) (client version) at baseline and 6 months (trial end). This is a mea-
sure of how well a client and a clinician work together. 7. WAI-S (staff version) at baseline, 6 months
(trial end) and trial drop-out 8. Adult Service Use Schedule (ADSUS) to assess which services clients
have accessed in the preceding 6 months, for health economics purposes, carried out at baseline
and 6 months (trial end) 9. Alcohol Use Disorders Identification Test (AUDIT) at baseline 10. Hospi-
tal Anxiety and Depression scale (HADS) at baseline

Starting date

01 October 2009

Contact information

Dr Paul Moran, Sir David Goldberg Building, Institute of Psychiatry, De Crespigny Park, London SE5
8AF, UK, paul.moran@iop.kcl.ac.uk

Notes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN51304415 

Study name

Methods

Participants

Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: The NOURISHED
Study

A randomised controlled trial of mentalisation based therapy against specialist supportive clinical
management in patients with both eating disorders and symptoms of borderline personality disor-
der

RCT

1. Aged over 18 years, either sex
2. Eating disorder diagnosis
3. Borderline personality disorder (BPD) symptoms. The criteria for "BPD symptoms" are that the
patient fulfils both behavioural criteria of the Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition (DSM-IV), namely:
3.1. Impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sexual be-
haviour, substance abuse, reckless driving, binge eating)
3.2. Recurrent suicidal behaviour, or self-mutilating behaviour
4. Able and willing to provide written informed consent

Interventions

One year of

1. MCT (outpatient)

2. specialist supportive clinical management

Outcomes

Primary: Eating disorder symptoms

Secondary: 1. Borderline Personality Disorder symptoms will be measured 6-monthly using the to-
tal score of the ZAN-BPD (Time points 0, 6, 12, 18 months); 2. The economic evaluation will exam-
ine the costs-effectiveness of Mentalization Based Therapy and Specialist Supportive Clinical Man-
agement including an analysis of incremental cost per QALY; 3. Participant rated general psychi-
atric symptoms of Borderline Personality Disorder will be measured 6-monthly using the DASS-21
(Time points 0, 6, 12, 18 months); 4. Possible mediators of change in Borderline Personality Disor-
der symptoms include reflective function and object relations, measured by the Reflective Func-
tion Questionnaire, The Reading the Mind in the Eyes test and the Object Relations Inventory and
personality factors (e.g. resilience, dysregulation, restriction) thought to be important in Eating
Disorders (Time points 0, 6, 12, 18 months)

Starting date

01 April 2011

Contact information

Dr Paul Robinson, Research Department, St. Ann's Hospital, London; drpaulrobinson@gmail.com

Notes

ISRCTN54233644 

Study name

Methods

Participants

Dialectical behaviour therapy in patients with borderline personality disorder who self-harm: a
pragmatic exploratory trial

DIALECT

RCT

1. Frequent self-harm (more than 5 days with self-harm over 12 months)
2. Aged 16 years and older, either sex

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ISRCTN54233644  (Continued)

3. Sufficient command of English
4. At least one personality disorder

Exclusion: learning disabilities

Cochrane Database of Systematic Reviews

Interventions

DBT and care co-ordination versus waiting list control group with standard NHS care, over 12
months. DBT consists of 3 hours of therapy a week: this comprises 1 hour of individual therapy and
2 hours of group skills classes.

Outcomes

Days with self-harm during the 12 month period.

1. Pre-post changes in self-harming during the 12 month period
2. Number of accident and emergency (A&E) attendances during the 12 month period
3. Inpatient admissions during the 12 month period
4. Use of other services in primary and secondary care during the 12 month period
5. Service costs during the 12 month period
6. Use of medication during the 12 month period
7. Pre-post changes in self-rated and observer-rated symptom level and quality of life at the end of
the 12 month period
8. Quality of the therapeutic relationship at the end of the 12 month period
9. Treatment satisfaction at the end of the 12 month period

Starting date

01 February 2008

Contact information

Prof S Priebe, Unit for Community and Social Psychiatry, Newham Centre for Mental Health, Plais-
tow, London s.priebe@qmul.ac.uk

Notes

ISRCTN72677277 

Study name

Methods

Participants

Psychological treatments for severe and complex mental health problems/personality disorder. A
phase II randomised controlled trial

RCT

Adult out-patients (18-65) of community mental health teams (CMHTs); Minimum one year history
of severe, complex mental health problems, diagnosis of at least one Cluster B personality disorder

Interventions

1. CMHT management alone

2. CMHT management plus cognitively-based psychotherapy

Outcomes

Starting date

01 May 2005

Contact information

Prof G Parry, University of Sheffield, G.D.Parry@sheffield.ac.uk

Notes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN79187618 

Study name

Methods

Participants

Psychoanalytically oriented brief group treatment for borderline personality disorder: A ran-
domised controlled trial

RCT

Clinical diagnosis of Borderline Personality Disorder meeting DSM-IV criteria and clinical judgment
of capacity of psychological mindedness.

Interventions

1. Psychoanalytic brief group treatment, 20 weeks

2. Waiting list

Outcomes

Self harm, suicidal ideation, reduction in symptoms, functioning, cost implications

Starting date

09 January 2006

Contact information

Dr Ravi Lingam, Regional Department of Psychotherapy, Newcastle upon Tyne, Ravi.Lingam@n-
mht.nhs.uk

Notes

ISRCTN98982683 

Study name

Methods

Participants

MBTDD: Mentalisation-Based Treatment for Dual Diagnoses - a randomised controlled trial

RCT

Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for bor-
derline personality disorder, meet DSM-IV criteria for opiate dependence (present or in remission),
ongoing pharmacological treatment with buprenorphine or methadone for at least 3 months, aged
18 to 65 years, either sex

Interventions

18 months of

1. MBT + medication assisted treatment (MAT)

2. MAT alone

Outcomes

Primary: BPDSI-IV

Secondary: 1. Timeline Follow Back and specimens of urine for use of opiates, alcohol and other
drugs, 2. Beck's Suicidal Intent Scale (SIS), 3. Deliberate Self-Harm Inventory (DSHI-9), 4. Global
Assessment of Functioning (GAF), 5. Symptom Check List 90 (SCL-90), 6. Inventory of Interperson-
al Problems (IIP), short version, 7. Social Adjustment Scale - Self Report (SAS-SR), 8. Retention in
treatment, 9. Reflective Functioning Interview (for mediator analysis)
Long-term follow up from register data: 10. Health economy (health care utilisation and work/in-
come), 11. Criminality, 12. Survival

Starting date

01 April 2009

Contact information

Dr. Björn Philips, Stockholm County Council, Center for Dependency Disorders, Stockhol, Sweden;
bjorn.philips@ki.se

Notes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jørgensen 2009 

Study name

Risskov-I study

Methods

RCT

Cochrane Database of Systematic Reviews

Participants

Males and females with diagnosis of BPD according to SCID-II

Interventions

2 years of

1. combined MBT (outpatient; weekly individual psychotherapy, weekly group psychotherapy,
group-based psychoeducation once a month, medical treatment acc. to APA guidelines)

2. supportive psychotherapy (outpatient; two hours of supportive group therapy every two weeks,
group-based psychoeducation once a month, medical treatment acc. to APA guidelines)

Outcomes

SCL-90-R, BDI-II, STAI, BAI, SAS-SR, GAF, suicide attempts and self-destructive behaviour (SUSS),
NEO-PI-R, DSQ-40

Starting date

No information

Contact information

Prof Carsten René Jørgensen PhD, Department of Psychology, University of Aarhus; carsten@p-
sy.au.dk

Notes

NCT00117741 

Study name

Methods

Participants

Evaluation of DBT compared to drug counselling for opiate addicts

RCT

Fulfil SCID-I criteria for opiate dependence, meet IPDE and SCID criteria for BPD (DSM-IV), over 18
years old

Interventions

1. DBT

2. Individual and group drug counselling

Outcomes

Primary: urinalysis (drug screening)

Secondary: suicidal behaviour, depression, anxiety, Axis I diagnostic remission

Starting date

June 2004

Contact information

Marsha Linehan PhD, University of Washington

Notes

NCT00183651 

Study name

Treatment of suicidal women with borderline personality disorder

Methods

RCT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT00183651  (Continued)

Participants

Females with diagnosis of BPD, at least one suicide attempt in the year prior to the study entry and
at least one intentional self-injury within the 8 weeks prior to study entry, aged 18 to 60 years

Interventions

1. Standard DBT

2. Individual DBT without DBT group sessions

3. Group skills DBT without DBT individual sessions

Outcomes

Primary: suicidal thoughts or attempts

Secondary: coping skills

Starting date

April 2004

Contact information

Marsha M Linehan PhD, University of Washington

Notes

NCT00218595 

Study name

Methods

Participants

DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Pa-
tients.

RCT

Meet SCID-I criteria for opiate dependence, meet IPDE and SCID criteria for BPD (DSM-IV), over 18
years old

Interventions

1. DBT + opiate replacement medication

2. Individual and group drug counselling + opiate replacement medication

Outcomes

1. Drug use: The primary outcome measure here is proportions of urinalysis (UA) coded positive for

opiates;

2. Suicidal behaviours: The primary outcome measure here is number of suicides + suicide attempts.
The domain of suicidal behaviours also includes (a) the number, medical risk, risk/rescue score
and suicide intent of all parasuicide, (b) the number of suicide threats and suicide crises, and (c)
the level of suicidal ideation and suicide intent;

3. Therapy-interfering behaviours: The primary outcome measure here is maintenance in therapy;
4. Quality of life interfering behaviours: The primary outcome measure here is combined number of

days on a psychiatric inpatient unit + days in jail (THI, SHI);

5. Behavioral skills: The primary outcome measure here is the DBT Skills scale score from the Revised

Ways of Coping Checklist (RWCCL);

6. Risky sexual behaviour: the primary outcome measure here is the number of risky sexual behav-

iours in the time period [Casual Partners questionnaire revised [CPQ-R] and diary card].

Starting date

August 2004

Contact information

M Zachary Rosenthal PhD, Duke University Medical Center; National Institute on Drug Abuse (NIDA)

Notes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT00247234 

Study name

Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders

Methods

RCT

Participants

BPD or avoidant personality disorder

Interventions

1. Schema therapy

2. Standard psychiatric outpatient care

Outcomes

Primary: Self-report measures of quality of life, depression, anxiety, suicidal ideation interpersonal
function

Secondary: Number of diagnostic criteria (reSCID), Drop-out rate,Social adjustment

Use of psychotropic medication

Starting date

September 2004

Contact information

Gunilla K Fosse, gunilla.fosse@ntnu.no

Notes

NCT00378248 

Study name

Methods

Participants

Interventions

Ullevål personality project

RCT

Patients with personality disorders admitted to Department for personality psychiatry, Psychiatric
division, Ullevål University Hospital

1. 18 weeks day hospital treatment followed by long-term outpatient combined group- and individ-
ual psychotherapy

2. Outpatient individual psychotherapy

Outcomes

Primary: psychosocial functioning, symptom distress, self-esteem, interpersonal problems, self-de-
structive behaviour, personality pathology, quality of life, health care utilisation

Secondary: affect consciousness, reflective functioning

Starting date

May 2004

Contact information

Theresa Wilberg MD PhD, Ullevål University Hospital Oslo, Norway

Notes

NCT00533117 

Study name

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

Methods

RCT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT00533117  (Continued)

Participants

Meet criteria for DSM-IV diagnosis of borderline personality disorder, History of at least one suicide
attempt or self-mutilation episode 12 months prior to study entry, continued urges to self-mutilate
or attempt suicide

Interventions

12 months of

1. DBT + fluoxetine

2. DBT + placebo

3. Supportive psychotherapy + fluoxetine

4. Supportive psychotherapy + placebo

Outcomes

Suicidal ideation, suicide attempts, self-mutilation

Starting date

March 2001

Contact information

Barbara Stanley PhD, bhs2@columbia.edu

Notes

NCT00603421 

Study name

Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients

Methods

RCT

Participants

Borderline patients (male or female) aged 18 to 40 years

Interventions

One year of

1. TAU + access to a 24 hour crisis phone line

2. TAU

Outcomes

Primary: rate of suicide attempts

Secondary: rate of self-injurious behaviours

Starting date

February 2009

Contact information

Alexandra Pham-Scottez, a.pham@ch-sainte-anne.fr; Daniel Guelfi, jd.guelfi@ch-sainte-anne.fr;
Hôpital St. Anne, Paris, France

Notes

NCT00834834 

Study name

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality
Disorder

Methods

RCT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT00834834  (Continued)

Participants

Meet DSM-IV criteria for borderline personality disorder (BPD) - attempted suicide in the past 2
months - at least one additional suicide attempt, suicide-related behaviour, or self-injury episode
in the past year - current suicidal ideation - Able to be managed as an outpatient

Interventions

6 months of

1. SSRI antidepressive medication (fluoxetine or citalopram) + clinical management

2. DBT

Outcomes

Suicidal and self-injurious behaviour

Starting date

March 2009

Contact information

Barbara H Stanley PhD, New York State Psychiatric Institute, bhs2@columbia.edu

Notes

NCT00980824 

Study name

ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a
Suicide Attempt. A Pilot Study.

Methods

RCT

Participants

Patients with a recent episode of suicide, personality disorder and drug or alcohol abuse

Interventions

1. Six sessions of ENGAGE CBT (based on manualised-cognitive therapy, MACT)

2. TAU

Outcomes

Starting date

November 2009

Contact information

Notes

NCT01033708 

Study name

Methods

Participants

Interventions

NET: A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the
Therapy of Borderline Personality Disorder

RCT

DSM-IV -TR Diagnosis axis II: borderline personality disorder; axis I: posttraumatic stress disorder -
stable medication - age 18-45 years, gender female

1. Narrative exposure therapy (NET), trauma-focused treatment for survivors of prolonged and re-
peated exposure to traumatic stress and childhood adversity

2. TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01033708  (Continued)

Outcomes

Primary: Clinician-Administered PTSD Scale (CAPS)

Secondary: Borderline symptom checklist 23 (BSL)

Starting date

October 2009

Contact information

A. Pabst, Zentrum Integrative Psychiatrie, Kiel, Germany; a.pabst@zip-kiel.de

Notes

NCT01081314 

Study name

Treating PTSD in Patients With Borderline Personality Disorder

Methods

RCT

Participants

Females aged 18 to 60 years with BPD and post-traumatic stress disorder

Interventions

1. Standard DBT + PTSD protocol (modified version of prolonged exposure therapy for PTSD)

2. Standard DBT

Outcomes

Primary: PTSD Symptom Scale - Interview, Suicide Attempt Self-Injury Interview

Secondary: Dissociative Experiences Scale, Hamilton Rating Scale for Depression, Suicidal Behav-
iors Questionnaire, Treatment History Interview

Starting date

August 2009

Contact information

Melanie S Harned PhD; University of Washington, USA; mharned@u.washington.edu

Notes

NCT01132976 

Study name

Methods

Participants

The personal concerns inventory study (PCI). The Addition of a Goal-based Motivational Interview
to Standardised Treatment as Usual to Reduce Dropouts From a Service for Patients With Personal-
ity Disorder: A Feasibility Study

RCT

Referred to the Nottinghamshire Personality Disorder and Development Network, aged 18 or older,
male or female

Interventions

1. TAU + goal-based motivational interview

2. TAU

Outcomes

Primary: recruitment (indicating feasibility), acceptability to patients, acceptability of staff

Secondary: Treatment engagement (TER), Client Service Receipt Inventory, treatment attendance

Starting date

December 2009

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01132976  (Continued)

Contact information

Notes

NCT01193205 

Study name

Methods

Participants

Lucy E Hedges, lucy.hedges@nottshc.nhs.uk, Mary McMurran, Mary.McMurran@nottingham.ac.uk;
Nottinghamshire Personality Disorder & Development Network, Nottingham, UK

20 weeks DBT group skills training study

RCT

DSM-IV BPD, 18-60 years of age, two suicidal or non-suicidal self-injurious behaviours in the past
five years with one occurring the past ten weeks prior to study entry

Interventions

1. DBT skills training group

2. Wait list

Outcomes

Primary: deliberate self-harm (DSHI)

Secondary: emergency and psychiatric hospitalizations (THI-2), impulsive behaviour (BIS-11),
anger expressions (STAXI), severity of BPD symptoms (BEST), overall psychopathology (SCL-90-R)

Starting date

July 2010

Contact information

Shelley McMain PhD, Centre for Addiction and Mental Health, Toronto/Canada; shelley_mc-
main@camh.net

Notes

NTR1186 

Study name

Efficacy of Schema-Focused Therapy versus Usual Treatment in Forensic Patients with Personality
Disorders: A Three-Year Randomized Clinical Trial.

Methods

RCT

Participants

Forensic patients with Antisocial, Borderline, Narcissistic, or Paranoid Personality Disorder

Interventions

Forensic setting, three years of

1. individual SFT

2. individual TAU

Outcomes

Primary: severity of personality disorder symptoms, risk of recidivism and violence secondary:
therapy process variables (e.g., therapeutic engagement, quality of the therapeutic alliance), and
changes in the psychological processes (i.e. Early Maladaptive Schemas, Schema Modes) that are
hypothesized to mediate changes in personality disorders in the Schema Focused Therapy model.

Starting date

01 October 2007

Contact information

Prof David Bernstein, University of Maastricht, Departement of Clinical Psychological Science, P.O.
Box 616, 6200 M, Maastricht, NL; D.Bernstein@dmkep.unimaas.nl

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NTR1186  (Continued)

Notes

NTR2175 

Study name

Methods

Participants

Mentalisation-Based Treatment versus care-as-usual in the treatment of severe borderline person-
ality disorders

RCT

A severe BPD on the basis of standardised criteria for borderline personality disorder and assessed
with the Dutch version of the Structured Clinical Interview for DSM-III-R (SCID-II) (13), and the Bor-
derline Personality Disorder Severity Index (BPDSI) (14). Patients must meet the criteria for border-
line personality disorder as determined with the SCID-II and have a total score on the BPDSI of at
least 24, indicating a severe BPD. Patients with co-morbid personality disorders will not be exclud-
ed.

Interventions

36 months of

1. MBT

2. TAU

Outcomes

Primary: frequency and severity of manifestations of BPD as measured with the BPDSI

Secondary: 1. Number of suicide acts; 2. Self-mutilation; 3. Depression; 4. Subjective experiences of
symptoms; 5. Social and interpersonal functioning; 6. Personality functioning; 7. Quality of life; 8.
Treatment adherence

Starting date

01 March 2010

Contact information

Prof Dr J Dekker, Viersprong Institute for Studies on Personality Disorders (BISPD), Department of
Rehabilitation Medicine, VUmc PO Box 7057, 1007 MB, Amsterdam, NL; j.dekker@vumc.nl

Notes

NTR2292 

Study name

Methods

Participants

Interventions

Intensive Outpatient Mentalisation-Based Treatment versus Day Hospital Mentalisation-Based
Treatment: A randomised controlled trial.

RCT

1. Referral to the MBT-program as implemented by De Viersprong, i.e. 18-month psychotherapy
designed specifically for treatment refractory patients with complex personality disorders, often
complicated by multi-morbidity, who have typically had a history of unsuccessful treatments;
2. At least one PD as diagnosed according to DSM-IV criteria.

1. MBT-program consists of a maximum of 18 months MBT and continued by a maximum of 18
months of maintenance mentalising (group) therapy.
2. MBT-DH: The day hospital program includes daily group psychotherapy, weekly individual psy-
chotherapy, individual crisis planning from a mentalising perspective, art therapy twice a week,
mentalising cognitive therapy and writing therapy.
3. MBT-IOP: The outpatient MBT program consists of group psychotherapy twice a week, weekly in-
dividual psychotherapy, and individual crisis planning from a mentalising perspective.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NTR2292  (Continued)

Outcomes

Primary: 1. Frequency and severity of manifestations of (borderline) personality disorder (SCID-II,
PAI-BOR); 2. Number of suicide acts (SSHI); 3. Number of self-mutilation acts (SSHI); 4. Subjective
experience of symptoms (BSI); 5. Quality of life (EQ-5D); 6. Care consumption (TiC-P)secondary: 1.
Axis I diagnosis (SCID-I); 2. Depression (BDI); 3. Interpersonal functioning (IIP); 4. Personality func-
tioning (DAPP-SF); 5. Mentalisation (ECR, RFQ); 6. Treatment adherence

Starting date

08 February 2010

Contact information

PhD Helene Adrea, Viersprong Institute for Studies on Personality Disorders (VISPD), The Nether-
lands

Notes

NTR2392 

Study name

Methods

Participants

Group Schema Therapy for Borderline Personality Disorder

RCT

Age 18-65 year; primary DSM-IV diagnosis of BPD (assessed with the SCID-II interview); BPD severity
above 20 on the BPDSI interview

Interventions

1. 118 group Schema Therapy sessions over 2 years with max. 17 individual sessions.

2. 64 group Schema Therapy over 2 years with max. 61 individual sessions

3. TAU - the standard treatment given for that patient at the treatment centre.

Outcomes

Primary: Borderline Personality Disorder Severity Index, mean score

Secondary: BPD-checklist, BSI, GAF, Work; Social Adjustment Scale, Social Occupational Function-
ing Assessment Scale, Social Adjustment Scale-Self Report; WHOQOL, EuroQol, Happiness Rating;
Schema questionnaire, Schema Mode Inventory, Group Climate Questionnaire (GCQ-S).

Starting date

01 February 2010

Contact information

Prof. Arnoud Arntz, University Maastricht (UM), DMKEP, P.O. Box 616, 6200 MD Maastricht, NL;
Arnoud.Arntz@MP.Unimaas.nl

Notes

CAT: cognitive analytic therapy
CTBE: Community treatment by experts
DBT: dialectical behaviour therapy
BPD: borderline personality disorder
MAT: medication assisted treatment
PD: personality disorder
PTSD: post-traumatic stress disorder
RCT: randomised controlled trial
TAU: treatment as usual

D A T A   A N D   A N A L Y S E S

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 1.   Comprehensive psychotherapies: active vs. control conditions

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 BPD total severity

1.1.1 DBT vs. TAU

1.1.2 DBT vs. general man-
agement

1.1.3 DBT-PTSD vs. WL

1.1.4 TFP vs. CTBE

1.1.5 DDP vs. TAU

1.1.6 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.2 Inappropriate anger

1.2.1 DBT vs. TAU

1.2.2 DBT vs. general man-
agement

1.2.3 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.3 Affective instability

1.3.1 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.4 chronic feelings of
emptiness

1.4.1 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.5 Impulsivity

1.5.1 DBT vs. TAU

1.5.2 IPT-BPD+fluoxetine
vs. CM+fluoxetine

6

1

1

1

1

1

1

4

2

1

1

1

1

1

1

2

1

1

20

180

31

104

30

44

46

180

44

44

44

48

44

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-1.17, 0.59]

Std. Mean Difference (IV, Random,
95% CI)

-0.04 [-0.33, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

-0.74 [-1.47, -0.01]

Std. Mean Difference (IV, Random,
95% CI)

-0.55 [-0.95, -0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.44 [-1.16, 0.29]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.62, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.83 [-1.43, -0.22]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.32, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

0.01 [-0.58, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.92 [-1.54, -0.30]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.50, 0.68]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.74, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

-0.91 [-1.53, -0.28]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.6 Suicidality

1.6.1 DBT vs. TAU

1.6.2 DBT vs. CTBE

1.7 Suicidality

1.7.1 MBT-PH vs. TAU

1.7.2 MBT-outpatient vs.
TAU

1.7.3 TFP vs. CTBE

1.7.4 CBT vs. TAU

1.8 Parasuicidality

1.8.1 DBT vs. TAU

1.8.2 DBT vs. general man-
agement

1.8.3 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.9 Parasuicidality

1.9.1 DBT vs. TAU

1.9.2 MBT-PH vs. TAU

1.9.3 MBT-outpatient vs.
TAU

1.9.4 TFP vs. CTBE

1.9.5 CBT vs. TAU

1.9.6 DDP vs. TAU

1.10 Interpersonal prob-
lems

1.10.1 DBT vs. TAU

1.10.2 DBT vs. general
management

2

1

1

4

1

1

1

1

5

3

1

1

6

1

1

1

1

1

1

6

1

1

20

89

38

134

104

101

110

180

44

51

38

134

104

99

30

48

180

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.26 [-2.24, -0.29]

Std. Mean Difference (IV, Random,
95% CI)

-0.12 [-0.54, 0.30]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.08 [0.01, 0.58]

Risk Ratio (M-H, Random, 95% CI)

0.11 [0.03, 0.46]

Risk Ratio (M-H, Random, 95% CI)

0.64 [0.27, 1.51]

Risk Ratio (M-H, Random, 95% CI)

0.78 [0.47, 1.27]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.54 [-0.92, -0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.23 [-0.52, 0.06]

Std. Mean Difference (IV, Random,
95% CI)

0.02 [-0.58, 0.61]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.11 [0.78, 1.57]

Risk Ratio (M-H, Random, 95% CI)

0.44 [0.24, 0.81]

Risk Ratio (M-H, Random, 95% CI)

0.56 [0.34, 0.92]

Risk Ratio (M-H, Random, 95% CI)

1.09 [0.84, 1.40]

Risk Ratio (M-H, Random, 95% CI)

1.17 [0.86, 1.60]

Risk Ratio (M-H, Random, 95% CI)

0.89 [0.47, 1.67]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.54, 0.61]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.32, 0.26]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.10.3 MBT-PH vs. TAU

1.10.4 MBT-outpatient vs.
TAU

1.10.5 CBT vs. TAU

1.10.6 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.11 Avoidance of aban-
donment

1.11.1 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.12 Identity disturbance

1.12.1 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.13 Dissociation/psy-
choticism

1.13.1 DBT vs. TAU

1.13.2 DBT-PTSD vs. WL

1.13.3 DDP vs. TAU

1.13.4 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1

1

1

1

1

1

1

1

4

1

1

1

1

1.14 Depression

11

1.14.1 DBT vs. TAU

1.14.2 DBT vs. general
management

1.14.3 DBT vs. CTBE

1.14.4 DBT-PTSD vs. WL

1

1

1

1

38

134

99

44

44

44

20

30

30

44

20

180

89

30

Std. Mean Difference (IV, Random,
95% CI)

-2.22 [-3.04, -1.39]

Std. Mean Difference (IV, Random,
95% CI)

-0.95 [-1.30, -0.59]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.16, 0.63]

Std. Mean Difference (IV, Random,
95% CI)

-0.82 [-1.44, -0.20]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.01 [-0.58, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.62, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.90 [-1.83, 0.03]

Std. Mean Difference (IV, Random,
95% CI)

-0.34 [-1.06, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

0.25 [-0.47, 0.97]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.49, 0.70]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.12 [-2.08, -0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.46, 0.12]

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.81, 0.04]

Std. Mean Difference (IV, Random,
95% CI)

-1.06 [-1.84, -0.29]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.14.5 MBT-PH vs. TAU

1.14.6 MBT-outpatient vs.
TAU

1.14.7 TFP vs. CTBE

1.14.8 CBT vs. TAU

1.14.9 DDP vs. TAU

1.14.10 IPT vs. CM

1.14.11 IPT-BPD+fluoxe-
tine vs. CM+fluoxetine

1.15 Anxiety

1.15.1 DBT vs. TAU

1.15.2 DBT-PTSD vs. WL

1.15.3 MBT-PH vs. TAU

1.15.4 TFP vs. CTBE

1.15.5 CBT vs. TAU

1.15.6 IPT vs. CM

1.15.7 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1.16 General psy-
chopathology

1.16.1 DBT vs. general
management

1.16.2 DBT-PTSD vs. WL

1

1

1

1

1

1

1

7

1

1

1

1

1

1

1

6

1

1

38

134

104

99

30

32

44

20

30

38

104

99

32

44

180

30

Std. Mean Difference (IV, Random,
95% CI)

-1.98 [-2.78, -1.19]

Std. Mean Difference (IV, Random,
95% CI)

-0.45 [-0.79, -0.10]

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.26, 0.51]

Std. Mean Difference (IV, Random,
95% CI)

-0.11 [-0.50, 0.29]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.24, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

-0.90 [-1.63, -0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.05 [-0.64, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.22 [-2.20, -0.25]

Std. Mean Difference (IV, Random,
95% CI)

-0.96 [-1.72, -0.20]

Std. Mean Difference (IV, Random,
95% CI)

-0.49 [-1.14, 0.16]

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.35, 0.42]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.42, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.20 [-0.49, 0.90]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.12, 0.08]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.30, 0.28]

Std. Mean Difference (IV, Random,
95% CI)

-0.70 [-1.45, 0.04]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.16.3 MBT-PH vs. TAU

1.16.4 MBT-outpatient vs.
TAU

1.16.5 TFP vs. CTBE

1.16.6 CBT vs. TAU

1.17 Mental health sta-
tus/functioning

1.17.1 DBT vs. TAU

1.17.2 MBT-outpatient vs.
TAU

1.17.3 TFP vs. CTBE

1.17.4 CBT vs. TAU

1.17.5 IPT vs. CM

1.17.6 IPT-BPD+fluoxetine
vs. CM+fluoxetine

1

1

1

1

7

2

1

1

1

1

1

1.18 Leaving the study ear-
ly

15

1.18.1 DBT vs. TAU

1.18.2 DBT vs. general
management

1.18.3 DBT vs. CTBE

1.18.4 DBT-PTSD vs. WL

1.18.5 MBT-PH vs. TAU

1.18.6 MBT-out vs. TAU

1.18.7 TFP vs. CTBE

1.18.8 CBT vs. TAU

1.18.9 DDP vs. TAU

5

1

1

1

1

1

1

1

1

38

134

104

99

74

134

104

99

32

44

252

180

101

32

44

134

104

106

30

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-1.03, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

-0.67 [-1.02, -0.33]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.31, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.43, 0.36]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.65 [0.07, 1.24]

Std. Mean Difference (IV, Random,
95% CI)

0.55 [0.20, 0.89]

Std. Mean Difference (IV, Random,
95% CI)

0.34 [-0.05, 0.73]

Std. Mean Difference (IV, Random,
95% CI)

0.00 [-0.39, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.57, 0.81]

Std. Mean Difference (IV, Random,
95% CI)

-0.04 [-0.63, 0.55]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.25 [0.54, 2.92]

Risk Ratio (M-H, Random, 95% CI)

1.03 [0.71, 1.49]

Risk Ratio (M-H, Random, 95% CI)

0.43 [0.28, 0.67]

Risk Ratio (M-H, Random, 95% CI)

1.94 [0.44, 8.57]

Risk Ratio (M-H, Random, 95% CI)

1.00 [0.23, 4.42]

Risk Ratio (M-H, Random, 95% CI)

1.05 [0.59, 1.87]

Risk Ratio (M-H, Random, 95% CI)

0.57 [0.39, 0.85]

Risk Ratio (M-H, Random, 95% CI)

0.48 [0.09, 2.52]

Risk Ratio (M-H, Random, 95% CI)

0.83 [0.32, 2.15]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.18.10 IPT vs. CM

1.18.11 IPT-BPD+fluoxe-
tine vs. CM+fluoxetine

1.19 Leaving the study
early: sensitivity analysis
(non-rural areas only)

1.19.1 DBT vs. TAU

1.19.2 DBT vs. TAU: non-
rural areas only

1

1

5

5

4

39

55

252

179

Risk Ratio (M-H, Random, 95% CI)

0.79 [0.20, 3.07]

Risk Ratio (M-H, Random, 95% CI)

0.35 [0.08, 1.57]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.25 [0.54, 2.92]

Risk Ratio (M-H, Random, 95% CI)

0.80 [0.47, 1.36]

Analysis 1.1.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 1: BPD total severity

Study or subgroup

active

control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.1.1 DBT vs. TAU

Koons 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

1.1.2 DBT vs. general management

McMain 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.26(P=0.8)

1.1.3 DBT-PTSD vs. WL

Steil 2010

Subtotal ***

10

10

90

90

17

17

3.6 (1.6)

7.9 (6.1)

1.7 (0.7)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.98(P=0.05)

1.1.4 TFP vs. CTBE

Doering 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.77(P=0.01)

1.1.5 DDP vs. TAU

Gregory 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

4.8 (1.5)

33.6 (12.4)

52

52

15

15

4.2 (2.3)

8.2 (5.8)

2.3 (0.9)

5.6 (1.5)

38.4 (8.6)

10

10

90

90

14

14

52

52

15

15

100%

100%

-0.29[-1.17,0.59]

-0.29[-1.17,0.59]

100%

100%

-0.04[-0.33,0.25]

-0.04[-0.33,0.25]

100%

100%

-0.74[-1.47,-0.01]

-0.74[-1.47,-0.01]

100%

100%

-0.55[-0.95,-0.16]

-0.55[-0.95,-0.16]

100%

100%

-0.44[-1.16,0.29]

-0.44[-1.16,0.29]

Favours experimental

-1

-0.5

0

0.5

1

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

active

control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.1.6 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

33.3 (6)

22

22

33.5 (6)

Heterogeneity: Not applicable

Test for overall effect: Z=0.1(P=0.92)

100%

100%

-0.03[-0.62,0.56]

-0.03[-0.62,0.56]

Favours experimental

-1

-0.5

0

0.5

1

Favours control

Analysis 1.2.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 2: Inappropriate anger

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.2.1 DBT vs. TAU

Koons 2001

Linehan 1994

Subtotal ***

14.5 (3.9)

32.2 (7.2)

10

13

23

Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%

Test for overall effect: Z=2.66(P=0.01)

1.2.2 DBT vs. general management

McMain 2009

Subtotal ***

15.8 (5.2)

90

90

Heterogeneity: Not applicable

Test for overall effect: Z=0.19(P=0.85)

1.2.3 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

5.3 (0.7)

22

22

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.05(P=0.96)

17.9 (6.1)

40.1 (8.4)

16 (5.1)

5.3 (0.7)

10

13

23

90

90

22

22

45.26%

54.74%

100%

-0.64[-1.54,0.27]

-0.98[-1.81,-0.16]

-0.83[-1.43,-0.22]

100%

100%

-0.03[-0.32,0.26]

-0.03[-0.32,0.26]

100%

100%

0.01[-0.58,0.6]

0.01[-0.58,0.6]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.3.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 3: Affective instability

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.3.1 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

5.6 (1.2)

22

22

6.6 (1)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

100%

100%

-0.92[-1.54,-0.3]

-0.92[-1.54,-0.3]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: Comprehensive psychotherapies: active
vs. control conditions, Outcome 4: chronic feelings of emptiness

Study or subgroup

active

control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.4.1 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

7.2 (0.4)

22

22

7.1 (0.4)

Heterogeneity: Not applicable

Test for overall effect: Z=0.31(P=0.76)

100%

100%

0.09[-0.5,0.68]

0.09[-0.5,0.68]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.5.   Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 5: Impulsivity

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.5.1 DBT vs. TAU

Van den Bosch 2005

Subtotal ***

0.9 (0.7)

23

23

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.6(P=0.55)

1.5.2 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

5.2 (1.1)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=2.85(P=0)

1.1 (0.8)

6.3 (1.1)

25

25

22

22

100%

100%

-0.17[-0.74,0.39]

-0.17[-0.74,0.39]

100%

100%

-0.91[-1.53,-0.28]

-0.91[-1.53,-0.28]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.6.   Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 6: Suicidality

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.6.1 DBT vs. TAU

Koons 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.53(P=0.01)

1.6.2 DBT vs. CTBE

Linehan 2006

Subtotal ***

26.2 (8)

29.8 (24.5)

10

10

50

50

41.5 (14.3)

32.8 (26.3)

10

10

39

39

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.55(P=0.58)

100%

100%

-1.26[-2.24,-0.29]

-1.26[-2.24,-0.29]

100%

100%

-0.12[-0.54,0.3]

-0.12[-0.54,0.3]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 7: Suicidality

Study or subgroup

1.7.1 MBT-PH vs. TAU

Bateman 1999

Subtotal (95% CI)

Total events: 1 (Active), 12 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.51(P=0.01)

1.7.2 MBT-outpatient vs. TAU

Bateman 2009

Subtotal (95% CI)

Total events: 2 (Active), 16 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.01(P=0)

1.7.3 TFP vs. CTBE

Doering 2010

Subtotal (95% CI)

Total events: 7 (Active), 11 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.02(P=0.31)

1.7.4 CBT vs. TAU

Davidson 2006

Subtotal (95% CI)

Active

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/19

19

2/71

71

7/52

52

12/19

19

16/63

63

11/52

52

100%

100%

0.08[0.01,0.58]

0.08[0.01,0.58]

100%

100%

0.11[0.03,0.46]

0.11[0.03,0.46]

100%

100%

0.64[0.27,1.51]

0.64[0.27,1.51]

18/53

53

21/48

48

100%

100%

0.78[0.47,1.27]

0.78[0.47,1.27]

Total events: 18 (Active), 21 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.01(P=0.31)

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 1.8.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 8: Parasuicidality

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.8.1 DBT vs. TAU

Koons 2001

Linehan 1991

Van den Bosch 2005

Subtotal ***

0.4 (1.3)

6.8 (12.4)

3.3 (13.2)

10

22

22

54

Heterogeneity: Tau2=0; Chi2=0.38, df=2(P=0.83); I2=0%

Test for overall effect: Z=2.76(P=0.01)

1.8.2 DBT vs. general management

McMain 2009

Subtotal ***

4.3 (9.3)

90

90

Heterogeneity: Not applicable

Test for overall effect: Z=1.54(P=0.12)

1 (2.2)

33.5 (70)

41.6 (78.8)

12.9 (51.5)

10

22

24

56

90

90

18.66%

40.2%

41.13%

100%

-0.32[-1.2,0.57]

-0.52[-1.12,0.08]

-0.65[-1.25,-0.06]

-0.54[-0.92,-0.16]

100%

100%

-0.23[-0.52,0.06]

-0.23[-0.52,0.06]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

Favours experimental

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.8.3 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

2 (1.9)

22

22

2 (1.9)

Heterogeneity: Not applicable

Test for overall effect: Z=0.05(P=0.96)

100%

100%

0.02[-0.58,0.61]

0.02[-0.58,0.61]

Favours experimental

-4

-2

0

2

4

Favours control

Study or subgroup

1.9.1 DBT vs. TAU

Carter 2010

Subtotal (95% CI)

Total events: 15 (Active), 21 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.57(P=0.57)

1.9.2 MBT-PH vs. TAU

Bateman 1999

Subtotal (95% CI)

Total events: 7 (Active), 16 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.61(P=0.01)

1.9.3 MBT-outpatient vs. TAU

Bateman 2009

Subtotal (95% CI)

Total events: 17 (Active), 27 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.27(P=0.02)

1.9.4 TFP vs. CTBE

Doering 2010

Subtotal (95% CI)

Total events: 38 (Active), 35 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

1.9.5 CBT vs. TAU

Davidson 2006

Subtotal (95% CI)

Total events: 35 (Active), 27 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1(P=0.32)

1.9.6 DDP vs. TAU

Gregory 2008

Analysis 1.9.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 9: Parasuicidality

Active

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

15/20

20

21/31

31

100%

100%

1.11[0.78,1.57]

1.11[0.78,1.57]

7/19

19

16/19

19

100%

100%

0.44[0.24,0.81]

0.44[0.24,0.81]

17/71

71

27/63

63

100%

100%

0.56[0.34,0.92]

0.56[0.34,0.92]

38/52

52

35/52

52

100%

100%

1.09[0.84,1.4]

1.09[0.84,1.4]

35/52

52

27/47

47

100%

100%

1.17[0.86,1.6]

1.17[0.86,1.6]

8/15

9/15

100%

0.89[0.47,1.67]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

15

15

100%

0.89[0.47,1.67]

Total events: 8 (Active), 9 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.37(P=0.71)

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 1.10.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 10: Interpersonal problems

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.10.1 DBT vs. TAU

Carter 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.13(P=0.9)

1.10.2 DBT vs. general management

McMain 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.19(P=0.85)

1.10.3 MBT-PH vs. TAU

Bateman 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=5.26(P<0.0001)

1.10.4 MBT-outpatient vs. TAU

Bateman 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=5.18(P<0.0001)

1.10.5 CBT vs. TAU

Davidson 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.15(P=0.25)

20

20

90

90

19

19

71

71

52

52

-48.7 (19.4)

100.2 (50.6)

1.9 (0.4)

1.3 (0.1)

60.4 (23.9)

1.10.6 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

5.8 (1.4)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=2.61(P=0.01)

-49.7 (30.2)

101.6 (45.2)

2.6 (0.3)

1.7 (0.6)

55 (22.3)

7 (1.3)

28

28

90

90

19

19

63

63

47

47

22

22

100%

100%

0.04[-0.54,0.61]

0.04[-0.54,0.61]

100%

100%

-0.03[-0.32,0.26]

-0.03[-0.32,0.26]

100%

100%

-2.22[-3.04,-1.39]

-2.22[-3.04,-1.39]

100%

100%

-0.95[-1.3,-0.59]

-0.95[-1.3,-0.59]

100%

100%

0.23[-0.16,0.63]

0.23[-0.16,0.63]

100%

100%

-0.82[-1.44,-0.2]

-0.82[-1.44,-0.2]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.11.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 11: Avoidance of abandonment

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.11.1 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

6.1 (1.6)

22

22

6.1 (1.5)

Heterogeneity: Not applicable

Test for overall effect: Z=0.02(P=0.98)

100%

100%

0.01[-0.58,0.6]

0.01[-0.58,0.6]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.12.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 12: Identity disturbance

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.12.1 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

22

22

2.5 (0.9)

22

22

2.5 (0.9)

Heterogeneity: Not applicable

Test for overall effect: Z=0.11(P=0.91)

100%

100%

-0.03[-0.62,0.56]

-0.03[-0.62,0.56]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.13.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 13: Dissociation/psychoticism

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.13.1 DBT vs. TAU

Koons 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.9(P=0.06)

1.13.2 DBT-PTSD vs. WL

Steil 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.92(P=0.36)

1.13.3 DDP vs. TAU

Gregory 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.68(P=0.5)

10

10

16

16

15

15

1.13.4 IPT-BPD+fluoxetine vs. CM+fluoxetine

13.2 (12)

24 (15)

27.7 (21.4)

30.6 (23.3)

30.1 (20)

22.3 (20.6)

10

10

14

14

15

15

100%

100%

-0.9[-1.83,0.03]

-0.9[-1.83,0.03]

100%

100%

-0.34[-1.06,0.38]

-0.34[-1.06,0.38]

100%

100%

0.25[-0.47,0.97]

0.25[-0.47,0.97]

Bellino 2010

22

4.3 (2.1)

22

4.1 (2.2)

100%

0.1[-0.49,0.7]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

Active

Mean(SD)

N

22

N

22

Cochrane Database of Systematic Reviews

Control

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.1[-0.49,0.7]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.14.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 14: Depression

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.14.1 DBT vs. TAU

Koons 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.29(P=0.02)

1.14.2 DBT vs. general management

McMain 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

1.14.3 DBT vs. CTBE

Linehan 2006

Subtotal ***

13.4 (7.5)

22.2 (16.1)

14 (7.3)

10

10

90

90

50

50

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.79(P=0.07)

1.14.4 DBT-PTSD vs. WL

Steil 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.68(P=0.01)

1.14.5 MBT-PH vs. TAU

Bateman 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=4.91(P<0.0001)

1.14.6 MBT-outpatient vs. TAU

Bateman 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.54(P=0.01)

1.14.7 TFP vs. CTBE

Doering 2010

Subtotal ***

17

17

19

19

71

71

52

52

29.1 (10.6)

20.6 (7)

14.8 (8.6)

21.7 (13.3)

29.3 (17.7)

24.8 (14.8)

17 (8.2)

41.6 (12.3)

35.2 (7.4)

18.7 (8.8)

20 (13.2)

10

10

90

90

39

39

13

13

19

19

63

63

52

52

100%

100%

-1.12[-2.08,-0.16]

-1.12[-2.08,-0.16]

100%

100%

-0.17[-0.46,0.12]

-0.17[-0.46,0.12]

100%

100%

-0.39[-0.81,0.04]

-0.39[-0.81,0.04]

100%

100%

-1.06[-1.84,-0.29]

-1.06[-1.84,-0.29]

100%

100%

-1.98[-2.78,-1.19]

-1.98[-2.78,-1.19]

100%

100%

-0.45[-0.79,-0.1]

-0.45[-0.79,-0.1]

100%

100%

0.12[-0.26,0.51]

0.12[-0.26,0.51]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.63(P=0.53)

1.14.8 CBT vs. TAU

Davidson 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.53(P=0.59)

1.14.9 DDP vs. TAU

Gregory 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.39(P=0.17)

1.14.10 IPT vs. CM

Bellino 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

52

52

15

15

16

16

29.6 (14.8)

21 (11.4)

9.1 (3)

1.14.11 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

10.8 (1.5)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=0.15(P=0.88)

31.3 (16.6)

25.9 (6.4)

12 (3.3)

10.8 (1.5)

47

47

15

15

16

16

22

22

100%

100%

-0.11[-0.5,0.29]

-0.11[-0.5,0.29]

100%

100%

-0.52[-1.24,0.21]

-0.52[-1.24,0.21]

100%

100%

-0.9[-1.63,-0.16]

-0.9[-1.63,-0.16]

100%

100%

-0.05[-0.64,0.55]

-0.05[-0.64,0.55]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.15.   Comparison 1: Comprehensive psychotherapies: active vs. control conditions, Outcome 15: Anxiety

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.15.1 DBT vs. TAU

Koons 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

1.15.2 DBT-PTSD vs. WL

Steil 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

1.15.3 MBT-PH vs. TAU

Bateman 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.49(P=0.14)

10

10

16

16

19

19

19.1 (7.5)

53.4 (15.2)

56.8 (9.1)

32.2 (12.4)

66.1 (9.7)

61 (7.6)

10

10

14

14

19

19

100%

100%

-1.22[-2.2,-0.25]

-1.22[-2.2,-0.25]

100%

100%

-0.96[-1.72,-0.2]

-0.96[-1.72,-0.2]

100%

100%

-0.49[-1.14,0.16]

-0.49[-1.14,0.16]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.15.4 TFP vs. CTBE

Doering 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

1.15.5 CBT vs. TAU

Davidson 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.14(P=0.89)

1.15.6 IPT vs. CM

Bellino 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.58(P=0.56)

52

52

52

52

16

16

55.9 (11.4)

59.7 (10.3)

11 (4.4)

1.15.7 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

9 (1.7)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=1.69(P=0.09)

55.5 (12.9)

60 (11.2)

10.2 (3.1)

9.8 (1.3)

52

52

47

47

16

16

22

22

100%

100%

0.04[-0.35,0.42]

0.04[-0.35,0.42]

100%

100%

-0.03[-0.42,0.37]

-0.03[-0.42,0.37]

100%

100%

0.2[-0.49,0.9]

0.2[-0.49,0.9]

100%

100%

-0.52[-1.12,0.08]

-0.52[-1.12,0.08]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.16.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 16: General psychopathology

Study or subgroup

DBT

TAU

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.16.1 DBT vs. general management

McMain 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.08(P=0.94)

1.16.2 DBT-PTSD vs. WL

Steil 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.85(P=0.06)

1.16.3 MBT-PH vs. TAU

Bateman 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

90

90

17

17

19

19

1.4 (0.9)

1.3 (0.6)

2.1 (0.8)

90

90

13

13

19

19

1.4 (0.8)

1.9 (0.9)

2.4 (0.7)

100%

100%

-0.01[-0.3,0.28]

-0.01[-0.3,0.28]

100%

100%

-0.7[-1.45,0.04]

-0.7[-1.45,0.04]

100%

100%

-0.39[-1.03,0.26]

-0.39[-1.03,0.26]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

DBT

TAU

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.16.4 MBT-outpatient vs. TAU

Bateman 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.79(P=0)

1.16.5 TFP vs. CTBE

Doering 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

1.16.6 CBT vs. TAU

Davidson 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.16(P=0.87)

71

71

52

52

52

52

1.1 (0.6)

1.3 (0.8)

2 (0.9)

63

63

52

52

47

47

1.6 (0.7)

1.3 (0.8)

2 (0.9)

100%

100%

-0.67[-1.02,-0.33]

-0.67[-1.02,-0.33]

100%

100%

0.08[-0.31,0.46]

0.08[-0.31,0.46]

100%

100%

-0.03[-0.43,0.36]

-0.03[-0.43,0.36]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 1.17.   Comparison 1: Comprehensive psychotherapies: active
vs. control conditions, Outcome 17: Mental health status/functioning

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.17.1 DBT vs. TAU

Carter 2010

Linehan 1994

Subtotal ***

-8.1 (11.5)

51.4 (9.7)

20

13

33

Heterogeneity: Tau2=0.06; Chi2=1.43, df=1(P=0.23); I2=30.2%

Test for overall effect: Z=2.18(P=0.03)

1.17.2 MBT-outpatient vs. TAU

Bateman 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.1(P=0)

1.17.3 TFP vs. CTBE

Doering 2010

Subtotal ***

60.9 (15.8)

58.6 (8)

71

71

52

52

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.72(P=0.09)

1.17.4 CBT vs. TAU

Davidson 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-13.1 (4.4)

52

52

-13.1 (11.6)

40.4 (10.8)

53.2 (11.7)

56.1 (6.9)

-13.1 (4.6)

28

13

41

63

63

52

52

47

47

61.88%

38.12%

100%

0.42[-0.16,1]

1.04[0.21,1.86]

0.65[0.07,1.24]

100%

100%

0.55[0.2,0.89]

0.55[0.2,0.89]

100%

100%

0.34[-0.05,0.73]

0.34[-0.05,0.73]

100%

100%

0[-0.39,0.39]

0[-0.39,0.39]

Favours control

-4

-2

0

2

4

Favours experimental

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.17.5 IPT vs. CM

Bellino 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

-2.9 (0.9)

16

16

1.17.6 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal ***

-4.4 (0.5)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=0.13(P=0.89)

-3 (0.7)

-4.3 (0.5)

16

16

22

22

100%

100%

0.12[-0.57,0.81]

0.12[-0.57,0.81]

100%

100%

-0.04[-0.63,0.55]

-0.04[-0.63,0.55]

Favours control

-4

-2

0

2

4

Favours experimental

Analysis 1.18.   Comparison 1: Comprehensive psychotherapies:
active vs. control conditions, Outcome 18: Leaving the study early

Study or subgroup

Experimental

1.18.1 DBT vs. TAU

Carter 2010

Koons 2001

Linehan 1991

Linehan 1994

Van den Bosch 2005

Subtotal (95% CI)

n/N

18/38

3/13

10/30

3/13

14/31

125

Total events: 48 (Experimental), 45 (Control)

Heterogeneity: Tau2=0.64; Chi2=17.36, df=4(P=0); I2=76.96%

Test for overall effect: Z=0.52(P=0.6)

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

4/35

5/15

9/31

1/13

26/33

127

20.9%

18.09%

23.69%

10.25%

27.07%

100%

4.14[1.55,11.06]

0.69[0.2,2.35]

1.15[0.54,2.42]

3[0.36,25.21]

0.57[0.37,0.88]

1.25[0.54,2.92]

1.18.2 DBT vs. general management

McMain 2009

Subtotal (95% CI)

Total events: 35 (Experimental), 34 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.15(P=0.88)

1.18.3 DBT vs. CTBE

Linehan 2006

Subtotal (95% CI)

Total events: 16 (Experimental), 35 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.71(P=0)

1.18.4 DBT-PTSD vs. WL

Steil 2010

Subtotal (95% CI)

Total events: 5 (Experimental), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.88(P=0.38)

35/90

90

34/90

90

100%

100%

1.03[0.71,1.49]

1.03[0.71,1.49]

16/52

52

35/49

49

100%

100%

0.43[0.28,0.67]

0.43[0.28,0.67]

5/18

18

2/14

14

100%

100%

1.94[0.44,8.57]

1.94[0.44,8.57]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Experimental

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.18.5 MBT-PH vs. TAU

Bateman 1999

Subtotal (95% CI)

Total events: 3 (Experimental), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.18.6 MBT-out vs. TAU

Bateman 2009

Subtotal (95% CI)

Total events: 19 (Experimental), 16 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

1.18.7 TFP vs. CTBE

Doering 2010

Subtotal (95% CI)

Total events: 20 (Experimental), 35 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.79(P=0.01)

1.18.8 CBT vs. TAU

Davidson 2006

Subtotal (95% CI)

Total events: 2 (Experimental), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.87(P=0.39)

1.18.9 DDP vs. TAU

Gregory 2008

Subtotal (95% CI)

Total events: 5 (Experimental), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.38(P=0.71)

1.18.10 IPT vs. CM

Bellino 2006

Subtotal (95% CI)

Total events: 3 (Experimental), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

1.18.11 IPT-BPD+fluoxetine vs. CM+fluoxetine

Bellino 2010

Subtotal (95% CI)

Total events: 2 (Experimental), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.38(P=0.17)

3/22

22

3/22

22

100%

100%

1[0.23,4.42]

1[0.23,4.42]

19/71

71

16/63

63

100%

100%

1.05[0.59,1.87]

1.05[0.59,1.87]

20/52

52

35/52

52

100%

100%

0.57[0.39,0.85]

0.57[0.39,0.85]

2/54

54

5/15

15

3/19

19

2/27

27

4/52

52

6/15

15

4/20

20

6/28

28

100%

100%

0.48[0.09,2.52]

0.48[0.09,2.52]

100%

100%

0.83[0.32,2.15]

0.83[0.32,2.15]

100%

100%

0.79[0.2,3.07]

0.79[0.2,3.07]

100%

100%

0.35[0.08,1.57]

0.35[0.08,1.57]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19.   Comparison 1: Comprehensive psychotherapies: active vs. control
conditions, Outcome 19: Leaving the study early: sensitivity analysis (non-rural areas only)

Study or subgroup

Experimental

1.19.1 DBT vs. TAU

Van den Bosch 2005

Koons 2001

Linehan 1991

Linehan 1994

Carter 2010

Subtotal (95% CI)

n/N

14/31

3/13

10/30

3/13

18/38

125

Total events: 48 (Experimental), 45 (Control)

Heterogeneity: Tau2=0.64; Chi2=17.36, df=4(P=0); I2=76.96%

Test for overall effect: Z=0.52(P=0.6)

1.19.2 DBT vs. TAU: non-rural areas only

Van den Bosch 2005

Koons 2001

Linehan 1991

Linehan 1994

Subtotal (95% CI)

14/31

3/13

10/30

3/13

87

Total events: 30 (Experimental), 41 (Control)

Heterogeneity: Tau2=0.1; Chi2=4.58, df=3(P=0.21); I2=34.51%

Test for overall effect: Z=0.83(P=0.41)

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

26/33

5/15

9/31

1/13

4/35

127

26/33

5/15

9/31

1/13

92

27.07%

18.09%

23.69%

10.25%

20.9%

100%

49.4%

15.02%

29.82%

5.76%

100%

0.57[0.37,0.88]

0.69[0.2,2.35]

1.15[0.54,2.42]

3[0.36,25.21]

4.14[1.55,11.06]

1.25[0.54,2.92]

0.57[0.37,0.88]

0.69[0.2,2.35]

1.15[0.54,2.42]

3[0.36,25.21]

0.8[0.47,1.36]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Comparison 2.   Non-comprehensive psychotherapeutic interventions: active vs. control conditions

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 BPD total severity

2.1.1 DBT-ST vs. standard
group

2.1.2 ERG vs. TAU

2.1.3 SFT-G vs. TAU

2.1.4 STEPPS vs. TAU

2.1.5 STEPPS+IT vs. TAU

2.2 Inappropriate anger

5

1

1

1

1

1

1

59

22

28

124

52

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-1.01 [-1.55, -0.47]

Std. Mean Difference (IV, Random, 95%
CI)

-1.02 [-1.92, -0.11]

Std. Mean Difference (IV, Random, 95%
CI)

-1.66 [-2.54, -0.78]

Std. Mean Difference (IV, Random, 95%
CI)

-0.17 [-0.52, 0.19]

Std. Mean Difference (IV, Random, 95%
CI)

-0.55 [-1.11, 0.00]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.2.1 DBT-ST vs. standard
group

2.3 Affective instability

2.3.1 DBT-ST vs. standard
group

2.3.2 ERG vs. TAU

2.3.3 SFT-G vs. TAU

2.3.4 STEPPS vs. TAU

2.4 Chronic feelings of
emptiness

2.4.1 DBT-ST vs. standard
group

2.5 Impulsivity

2.5.1 DBT-ST vs. standard
group

2.5.2 ERG vs. TAU

2.5.3 SFT-G vs. TAU

2.5.4 STEPPS vs. TAU

2.5.5 PE vs. WL

2.6 Impulsivity

2.6.1 STEPPS+IT vs. TAU

2.7 Suicidality

2.7.1 DBT-ST vs. standard
group

2.7.2 MACT vs. TAU

1

4

1

1

1

1

1

1

5

1

1

1

1

1

1

1

2

1

1

59

59

22

28

124

59

59

22

28

124

50

58

59

28

Std. Mean Difference (IV, Random, 95%
CI)

-0.84 [-1.37, -0.30]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-1.07 [-1.61, -0.52]

Std. Mean Difference (IV, Random, 95%
CI)

-1.65 [-2.65, -0.65]

Std. Mean Difference (IV, Random, 95%
CI)

-1.41 [-2.26, -0.57]

Std. Mean Difference (IV, Random, 95%
CI)

-0.32 [-0.67, 0.04]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.43 [-0.95, 0.09]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.61 [-1.14, -0.09]

Std. Mean Difference (IV, Random, 95%
CI)

-1.30 [-2.24, -0.36]

Std. Mean Difference (IV, Random, 95%
CI)

-1.92 [-2.85, -1.00]

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.64, 0.07]

Std. Mean Difference (IV, Random, 95%
CI)

-0.47 [-1.04, 0.10]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.93 [0.66, 1.29]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.10 [-0.61, 0.41]

Std. Mean Difference (IV, Random, 95%
CI)

-0.86 [-1.64, -0.07]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.8 Parasuicidality

2.8.1 ERG vs. TAU

2.8.2 MACT vs. TAU

2.9 Parasuicidality

2.9.1 STEPPS+IT vs. TAU

2.10 Interpersonal prob-
lems

2.10.1 DBT-ST vs. stan-
dard group

2.10.2 SFT-G vs. TAU

2.10.3 STEPPS vs. TAU

2.10.4 STEPPS+IT vs. TAU

2.10.5 PE vs. WL

2.11 Dissociation/psy-
choticism

2.11.1 DBT-ST vs. stan-
dard group

2.11.2 SFT-G vs. TAU

2.11.3 STEPPS vs. TAU

2.12 Depression

2.12.1 DBT-ST vs. stan-
dard group

2.12.2 ERG vs. TAU

2.12.3 STEPPS vs. TAU

2

1

1

1

1

5

1

1

1

1

1

3

1

1

1

3

1

1

1

22

28

58

59

28

124

53

50

59

28

124

59

22

124

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.98 [-1.88, -0.09]

Std. Mean Difference (IV, Random, 95%
CI)

-0.88 [-1.67, -0.10]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.32 [0.78, 2.22]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.80, 0.23]

Std. Mean Difference (IV, Random, 95%
CI)

-1.94 [-2.87, -1.02]

Std. Mean Difference (IV, Random, 95%
CI)

-0.42 [-0.78, -0.06]

Std. Mean Difference (IV, Random, 95%
CI)

-0.27 [-0.81, 0.27]

Std. Mean Difference (IV, Random, 95%
CI)

-0.75 [-1.33, -0.16]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.66 [-1.18, -0.13]

Std. Mean Difference (IV, Random, 95%
CI)

-1.37 [-2.21, -0.53]

Std. Mean Difference (IV, Random, 95%
CI)

-0.42 [-0.78, -0.06]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.97 [-1.51, -0.43]

Std. Mean Difference (IV, Random, 95%
CI)

-1.20 [-2.13, -0.28]

Std. Mean Difference (IV, Random, 95%
CI)

-0.24 [-0.59, 0.11]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.13 Anxiety

2.13.1 DBT-ST vs. stan-
dard group

2.13.2 ERG vs. TAU

2.14 General psy-
chopathology

2.14.1 DBT-ST vs. stan-
dard group

2.14.2 SFT-G vs. TAU

2.14.3 STEPPS vs. TAU

2.14.4 STEPPS+IT vs. TAU

2.15 Mental health sta-
tus/functioning

2.15.1 DBT-ST vs. stan-
dard group

2.15.2 SFT-G vs. TAU

2.15.3 STEPPS vs. TAU

2.16 Leaving the study
early

2.16.1 DBT-ST vs. stan-
dard group

2.16.2 ERG vs. TAU

2.16.3 SFT-G vs. TAU

2.16.4 MACT vs. TAU

2.16.5 STEPPS vs. TAU

2.16.6 STEPPS+IT vs. TAU

2.16.7 PE vs. WL

2

1

1

4

1

1

1

1

3

1

1

1

7

1

1

1

1

1

1

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.67 [-1.20, -0.15]

Std. Mean Difference (IV, Random, 95%
CI)

-0.89 [-1.78, -0.01]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.42 [-0.93, 0.10]

Std. Mean Difference (IV, Random, 95%
CI)

-1.06 [-1.87, -0.25]

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.64, 0.07]

Std. Mean Difference (IV, Random, 95%
CI)

-0.60 [-1.16, -0.04]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [-0.22, 0.80]

Std. Mean Difference (IV, Random, 95%
CI)

1.20 [0.38, 2.03]

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [0.02, 0.73]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.58 [0.34, 1.00]

Risk Ratio (M-H, Random, 95% CI)

0.85 [0.06, 12.01]

Risk Ratio (M-H, Random, 95% CI)

0.11 [0.01, 1.91]

Risk Ratio (M-H, Random, 95% CI)

0.20 [0.01, 3.85]

Risk Ratio (M-H, Random, 95% CI)

2.27 [1.08, 4.76]

Risk Ratio (M-H, Random, 95% CI)

1.47 [0.59, 3.65]

Risk Ratio (M-H, Random, 95% CI)

Not estimable

59

22

59

28

124

51

59

28

124

60

24

32

30

124

79

50

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.1.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 1: BPD total severity

Study or subgroup

active

control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.1.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.64(P=0)

2.1.2 ERG vs. TAU

Gratz 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.21(P=0.03)

2.1.3 SFT-G vs. TAU

Farrell 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.68(P=0)

2.1.4 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.92(P=0.36)

2.1.5 STEPPS+IT vs. TAU

Bos 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.95(P=0.05)

29

29

12

12

16

16

65

65

26

26

3.5 (1.2)

25.8 (5.7)

18.8 (9.5)

31.8 (13.7)

79.7 (25.8)

4.4 (0.5)

34.7 (10.8)

32.8 (5.9)

34.1 (13.8)

95.1 (29.1)

30

30

10

10

12

12

59

59

26

26

100%

100%

-1.01[-1.55,-0.47]

-1.01[-1.55,-0.47]

100%

100%

-1.02[-1.92,-0.11]

-1.02[-1.92,-0.11]

100%

100%

-1.66[-2.54,-0.78]

-1.66[-2.54,-0.78]

100%

100%

-0.17[-0.52,0.19]

-0.17[-0.52,0.19]

100%

100%

-0.55[-1.11,0]

-0.55[-1.11,0]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.2.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 2: Inappropriate anger

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.2.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

29

29

3.1 (1)

30

30

3.9 (0.8)

Heterogeneity: Not applicable

Test for overall effect: Z=3.08(P=0)

100%

100%

-0.84[-1.37,-0.3]

-0.84[-1.37,-0.3]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.3.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 3: Affective instability

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.81(P=0)

2.3.2 ERG vs. TAU

Gratz 2006

Subtotal ***

3.6 (1.2)

79.8 (24)

29

29

12

12

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=3.24(P=0)

2.3.3 SFT-G vs. TAU

Farrell 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.27(P=0)

2.3.4 STEPPS vs. TAU

Blum 2008

Subtotal ***

5.9 (3.4)

3.9 (3.2)

16

16

65

65

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.74(P=0.08)

4.7 (0.7)

115.8 (16.7)

9.8 (1.1)

4.9 (3.1)

30

30

10

10

12

12

59

59

100%

100%

-1.07[-1.61,-0.52]

-1.07[-1.61,-0.52]

100%

100%

-1.65[-2.65,-0.65]

-1.65[-2.65,-0.65]

100%

100%

-1.41[-2.26,-0.57]

-1.41[-2.26,-0.57]

100%

100%

-0.32[-0.67,0.04]

-0.32[-0.67,0.04]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.4.   Comparison 2: Non-comprehensive psychotherapeutic interventions:
active vs. control conditions, Outcome 4: Chronic feelings of emptiness

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.4.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

29

29

4.3 (1.6)

30

30

5 (1.5)

Heterogeneity: Not applicable

Test for overall effect: Z=1.63(P=0.1)

100%

100%

-0.43[-0.95,0.09]

-0.43[-0.95,0.09]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.5.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 5: Impulsivity

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.5.1 DBT-ST vs. standard group

Soler 2009

29

3.6 (1)

30

4.1 (0.6)

100%

-0.61[-1.14,-0.09]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Active

Mean(SD)

N

29

N

30

Control

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.61[-1.14,-0.09]

Study or subgroup

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.3(P=0.02)

2.5.2 ERG vs. TAU

Gratz 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.71(P=0.01)

2.5.3 SFT-G vs. TAU

Farrell 2009

Subtotal ***

10.9 (3.9)

1.6 (1.4)

12

12

16

16

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=4.07(P<0.0001)

2.5.4 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.59(P=0.11)

2.5.5 PE vs. WL

Zanarini 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.6(P=0.11)

72.7 (14.5)

-0.4 (0.9)

65

65

30

30

17.1 (5.3)

5.6 (2.7)

76.8 (13.8)

0.1 (1.1)

10

10

12

12

59

59

20

20

100%

100%

-1.3[-2.24,-0.36]

-1.3[-2.24,-0.36]

100%

100%

-1.92[-2.85,-1]

-1.92[-2.85,-1]

100%

100%

-0.29[-0.64,0.07]

-0.29[-0.64,0.07]

100%

100%

-0.47[-1.04,0.1]

-0.47[-1.04,0.1]

Favours experimental

-4

-2

0

2

4

Favours control

Study or subgroup

2.6.1 STEPPS+IT vs. TAU

Bos 2010

Subtotal (95% CI)

Analysis 2.6.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 6: Impulsivity

Active

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

19/28

28

22/30

30

100%

100%

0.93[0.66,1.29]

0.93[0.66,1.29]

Total events: 19 (Active), 22 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.46(P=0.65)

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.7.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 7: Suicidality

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.7.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

2.7.2 MACT vs. TAU

Weinberg 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.15(P=0.03)

2.4 (1.2)

27.5 (16.9)

29

29

15

15

2.6 (0.9)

42.7 (17.7)

30

30

13

13

100%

100%

-0.1[-0.61,0.41]

-0.1[-0.61,0.41]

100%

100%

-0.86[-1.64,-0.07]

-0.86[-1.64,-0.07]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.8.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 8: Parasuicidality

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.8.1 ERG vs. TAU

Gratz 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.15(P=0.03)

2.8.2 MACT vs. TAU

Weinberg 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.21(P=0.03)

12

12

15

15

2.1 (0.9)

0.6 (0.9)

10

10

13

13

4.5 (3.4)

3.6 (4.8)

100%

100%

-0.98[-1.88,-0.09]

-0.98[-1.88,-0.09]

100%

100%

-0.88[-1.67,-0.1]

-0.88[-1.67,-0.1]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.9.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 9: Parasuicidality

Study or subgroup

2.9.1 STEPPS+IT vs. TAU

Bos 2010

Subtotal (95% CI)

Total events: 16 (Active), 13 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.04(P=0.3)

Active

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16/28

28

13/30

30

100%

100%

1.32[0.78,2.22]

1.32[0.78,2.22]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.10.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 10: Interpersonal problems

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.10.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

2.10.2 SFT-G vs. TAU

Farrell 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=4.1(P<0.0001)

2.10.3 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

2.10.4 STEPPS+IT vs. TAU

Bos 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.99(P=0.32)

2.10.5 PE vs. WL

Zanarini 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.5(P=0.01)

29

29

16

16

65

65

27

27

30

30

4.2 (0.8)

4.9 (4)

2.2 (2.4)

-13 (3.5)

-0.9 (0.9)

30

30

12

12

59

59

26

26

20

20

4.4 (0.7)

12 (2.8)

3.2 (2.3)

-12 (3.7)

-0 (1.4)

100%

100%

-0.29[-0.8,0.23]

-0.29[-0.8,0.23]

100%

100%

-1.94[-2.87,-1.02]

-1.94[-2.87,-1.02]

100%

100%

-0.42[-0.78,-0.06]

-0.42[-0.78,-0.06]

100%

100%

-0.27[-0.81,0.27]

-0.27[-0.81,0.27]

100%

100%

-0.75[-1.33,-0.16]

-0.75[-1.33,-0.16]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.11.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 11: Dissociation/psychoticism

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.11.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

2.11.2 SFT-G vs. TAU

Farrell 2009

Subtotal ***

Heterogeneity: Not applicable

29

29

16

16

8.7 (5.1)

1.7 (2)

11.9 (4.4)

4.3 (1.5)

30

30

12

12

100%

100%

-0.66[-1.18,-0.13]

-0.66[-1.18,-0.13]

100%

100%

-1.37[-2.21,-0.53]

-1.37[-2.21,-0.53]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=3.19(P=0)

2.11.3 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

65

65

2 (2.4)

59

59

3 (2.3)

100%

100%

-0.42[-0.78,-0.06]

-0.42[-0.78,-0.06]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.12.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 12: Depression

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.12.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.51(P=0)

2.12.2 ERG vs. TAU

Gratz 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.54(P=0.01)

2.12.3 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.18)

29

29

12

12

65

65

11.1 (4)

9 (6.5)

22 (16.1)

16 (5.8)

23.2 (15.3)

25.8 (15.4)

30

30

10

10

59

59

100%

100%

-0.97[-1.51,-0.43]

-0.97[-1.51,-0.43]

100%

100%

-1.2[-2.13,-0.28]

-1.2[-2.13,-0.28]

100%

100%

-0.24[-0.59,0.11]

-0.24[-0.59,0.11]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.13.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 13: Anxiety

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.13.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

13 (5.5)

29

29

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2.5(P=0.01)

2.13.2 ERG vs. TAU

Gratz 2006

Subtotal ***

6.3 (6.5)

12

12

16.6 (5)

14 (10)

30

30

10

10

100%

100%

-0.67[-1.2,-0.15]

-0.67[-1.2,-0.15]

100%

100%

-0.89[-1.78,-0.01]

-0.89[-1.78,-0.01]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.97(P=0.05)

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 2.14.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 14: General psychopathology

Study or subgroup

Active

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.14.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.59(P=0.11)

2.14.2 SFT-G vs. TAU

Farrell 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.58(P=0.01)

2.14.3 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.6(P=0.11)

2.14.4 STEPPS+IT vs. TAU

Bos 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.1(P=0.04)

29

29

16

16

65

65

25

25

2.1 (1.1)

1.3 (0.6)

12.5 (8.1)

205.8 (60.6)

2.5 (0.9)

2 (0.8)

14.9 (8.5)

248.5 (77.8)

30

30

12

12

59

59

26

26

100%

100%

-0.42[-0.93,0.1]

-0.42[-0.93,0.1]

100%

100%

-1.06[-1.87,-0.25]

-1.06[-1.87,-0.25]

100%

100%

-0.29[-0.64,0.07]

-0.29[-0.64,0.07]

100%

100%

-0.6[-1.16,-0.04]

-0.6[-1.16,-0.04]

Favours active

-4

-2

0

2

4

Favours control

Analysis 2.15.   Comparison 2: Non-comprehensive psychotherapeutic interventions:
active vs. control conditions, Outcome 15: Mental health status/functioning

Study or subgroup

Experimental

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.15.1 DBT-ST vs. standard group

Soler 2009

Subtotal ***

-3.3 (0.9)

29

29

30

30

-3.6 (1.1)

100%

100%

0.29[-0.22,0.8]

0.29[-0.22,0.8]

Heterogeneity: Not applicable

Test for overall effect: Z=1.1(P=0.27)

2.15.2 SFT-G vs. TAU

Farrell 2009

16

60.5 (10.2)

12

50.1 (5.1)

100%

1.2[0.38,2.03]

Favours control

-4

-2

0

2

4

Favours experimental

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Experimental

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.87(P=0)

2.15.3 STEPPS vs. TAU

Blum 2008

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.08(P=0.04)

Mean(SD)

N

16

N

12

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

1.2[0.38,2.03]

-4.4 (0.8)

65

65

59

59

-4.7 (0.8)

100%

100%

0.38[0.02,0.73]

0.38[0.02,0.73]

Favours control

-4

-2

0

2

4

Favours experimental

Analysis 2.16.   Comparison 2: Non-comprehensive psychotherapeutic
interventions: active vs. control conditions, Outcome 16: Leaving the study early

Study or subgroup

Experimental

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2.16.1 DBT-ST vs. standard group

Soler 2009

Subtotal (95% CI)

Total events: 11 (Experimental), 19 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.97(P=0.05)

2.16.2 ERG vs. TAU

Gratz 2006

Subtotal (95% CI)

Total events: 1 (Experimental), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.12(P=0.9)

2.16.3 SFT-G vs. TAU

Farrell 2009

Subtotal (95% CI)

Total events: 0 (Experimental), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

2.16.4 MACT vs. TAU

Weinberg 2006

Subtotal (95% CI)

Total events: 0 (Experimental), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.07(P=0.29)

2.16.5 STEPPS vs. TAU

Blum 2008

Subtotal (95% CI)

Total events: 20 (Experimental), 8 (Control)

Heterogeneity: Not applicable

11/30

30

19/30

30

100%

100%

0.58[0.34,1]

0.58[0.34,1]

1/13

13

0/16

16

0/15

15

20/65

65

1/11

11

4/16

16

2/15

15

8/59

59

100%

100%

0.85[0.06,12.01]

0.85[0.06,12.01]

100%

100%

0.11[0.01,1.91]

0.11[0.01,1.91]

100%

100%

0.2[0.01,3.85]

0.2[0.01,3.85]

100%

100%

2.27[1.08,4.76]

2.27[1.08,4.76]

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Experimental

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=2.17(P=0.03)

2.16.6 STEPPS+IT vs. TAU

Bos 2010

Subtotal (95% CI)

Total events: 10 (Experimental), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.83(P=0.41)

2.16.7 PE vs. WL

Zanarini 2008

Subtotal (95% CI)

Total events: 0 (Experimental), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

10/42

42

0/30

30

6/37

37

0/20

20

100%

100%

1.47[0.59,3.65]

1.47[0.59,3.65]

Not estimable

Not estimable

Favours experimental

0.1

0.2

0.5

1

2

5

10

Favours control

Comparison 3.   Comprehensive psychotherapies: active vs. active conditions

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.1 BPD total severity

3.1.1 SFT vs. TFP

3.1.2 SFT vs. SFT+TTA

3.2 Inappropriate
anger

3.2.1 DBT vs. CCT

3.3 Impulsivity

3.3.1 DBT vs. CCT

3.3.2 CT vs. CCT

3.4 Suicidality

3.4.1 DBT vs. CCT

3.4.2 CT vs. CCT

3.5 Parasuicidality

3.5.1 DBT vs. CCT

3.5.2 CT vs. CCT

3.6 Psychoticism

2

1

1

1

1

2

1

1

2

1

1

2

1

1

1

86

61

24

24

38

24

38

24

38

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.45 [-0.88, -0.02]

Std. Mean Difference (IV, Random, 95% CI)

-0.03 [-0.53, 0.47]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.79 [-1.62, 0.05]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-1.05 [-1.92, -0.19]

Std. Mean Difference (IV, Random, 95% CI)

-0.22 [-0.86, 0.41]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.87 [-1.71, -0.02]

Std. Mean Difference (IV, Random, 95% CI)

0.13 [-0.51, 0.77]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-1.28 [-2.17, -0.38]

Std. Mean Difference (IV, Random, 95% CI)

0.59 [-0.06, 1.24]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or sub-
group title

3.6.1 DBT vs. CCT

3.7 Depression

3.7.1 DBT vs. CCT

3.7.2 CT vs. CCT

3.7.3 CBT vs. IPT

3.8 Anxiety

3.8.1 DBT vs. CCT

3.8.2 CT vs. CCT

3.8.3 CBT vs. IPT

3.9 General psy-
chopathology

3.9.1 SFT vs. TFP

3.9.2 SFT vs. SFT+TTA

3.10 Mental health sta-
tus/functioning

3.10.1 CBT vs. CCT

3.10.2 CT vs. IPT

3.11 Leaving the study
early

3.11.1 DBT vs. CCT

3.11.2 SFT vs. TFP

3.11.3 SFT vs. SFT+TTA

3.11.4 CT vs. CCT

3.11.5 CBT vs. IPT

No. of studies

No. of partici-
pants

Statistical method

Effect size

1

3

1

1

1

3

1

1

1

2

1

1

2

1

1

5

1

1

1

1

1

24

24

38

26

24

38

26

86

61

38

26

24

88

62

65

32

Std. Mean Difference (IV, Random, 95% CI)

-1.11 [-1.98, -0.24]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-1.26 [-2.15, -0.37]

Std. Mean Difference (IV, Random, 95% CI)

0.10 [-0.54, 0.73]

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.84, 0.70]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.70 [-1.53, 0.13]

Std. Mean Difference (IV, Random, 95% CI)

-0.51 [-1.16, 0.13]

Std. Mean Difference (IV, Random, 95% CI)

-0.53 [-1.32, 0.26]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.09 [-0.52, 0.33]

Std. Mean Difference (IV, Random, 95% CI)

0.14 [-0.37, 0.64]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.30 [-0.34, 0.94]

Std. Mean Difference (IV, Random, 95% CI)

0.19 [-0.58, 0.97]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.50 [0.16, 1.55]

Risk Ratio (M-H, Random, 95% CI)

0.52 [0.30, 0.92]

Risk Ratio (M-H, Random, 95% CI)

0.91 [0.35, 2.41]

Risk Ratio (M-H, Random, 95% CI)

0.90 [0.51, 1.60]

Risk Ratio (M-H, Random, 95% CI)

2.00 [0.42, 9.42]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.1.   Comparison 3: Comprehensive psychotherapies:
active vs. active conditions, Outcome 1: BPD total severity

Study or subgroup

treatment 1

treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.1.1 SFT vs. TFP

Giesen-Bloo 2006

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.04(P=0.04)

3.1.2 SFT vs. SFT+TTA

Nadort 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.11(P=0.91)

17.8 (11.3)

16.8 (9.9)

44

44

30

30

22.7 (10.6)

17.1 (10.9)

42

42

31

31

100%

100%

-0.45[-0.88,-0.02]

-0.45[-0.88,-0.02]

100%

100%

-0.03[-0.53,0.47]

-0.03[-0.53,0.47]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 3.2.   Comparison 3: Comprehensive psychotherapies:
active vs. active conditions, Outcome 2: Inappropriate anger

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.2.1 DBT vs. CCT

Turner 2000

Subtotal ***

12

12

4.7 (1.3)

12

12

5.7 (1.2)

100%

100%

-0.79[-1.62,0.05]

-0.79[-1.62,0.05]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.84(P=0.07)

Favours treatment 1

-4

-2

0

2

4

Favours tretment 2

Analysis 3.3.   Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 3: Impulsivity

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.3.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.39(P=0.02)

3.3.2 CT vs. CCT

Cottraux 2009

Subtotal ***

12

12

20

20

4.6 (1.6)

7.6 (3.8)

12

12

18

18

6.1 (1.1)

8.6 (5)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.69(P=0.49)

100%

100%

-1.05[-1.92,-0.19]

-1.05[-1.92,-0.19]

100%

100%

-0.22[-0.86,0.41]

-0.22[-0.86,0.41]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.4.   Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 4: Suicidality

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.4.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

3.4.2 CT vs. CCT

Cottraux 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

12

12

20

20

3.8 (8)

7.3 (5.4)

11.6 (9.2)

6.6 (5)

12

12

18

18

100%

100%

-0.87[-1.71,-0.02]

-0.87[-1.71,-0.02]

100%

100%

0.13[-0.51,0.77]

0.13[-0.51,0.77]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 3.5.   Comparison 3: Comprehensive psychotherapies:
active vs. active conditions, Outcome 5: Parasuicidality

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.8(P=0.01)

3.5.2 CT vs. CCT

Cottraux 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.77(P=0.08)

12

12

20

20

1.5 (2)

1.8 (1.4)

12

12

18

18

4.3 (2.2)

1.1 (1.1)

100%

100%

-1.28[-2.17,-0.38]

-1.28[-2.17,-0.38]

100%

100%

0.59[-0.06,1.24]

0.59[-0.06,1.24]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 3.6.   Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 6: Psychoticism

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.6.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.49(P=0.01)

18.2 (7.9)

12

12

25.3 (3.9)

12

12

100%

100%

-1.11[-1.98,-0.24]

-1.11[-1.98,-0.24]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.7.   Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 7: Depression

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.7.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.77(P=0.01)

3.7.2 CT vs. CCT

Cottraux 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.3(P=0.77)

3.7.3 CBT vs. IPT

Bellino 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

12

12

20

20

12

12

14.9 (8.3)

13.6 (11.3)

13.7 (5.7)

24.1 (5.6)

12.6 (9.6)

14.1 (5.5)

12

12

18

18

14

14

100%

100%

-1.26[-2.15,-0.37]

-1.26[-2.15,-0.37]

100%

100%

0.1[-0.54,0.73]

0.1[-0.54,0.73]

100%

100%

-0.07[-0.84,0.7]

-0.07[-0.84,0.7]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 3.8.   Comparison 3: Comprehensive psychotherapies: active vs. active conditions, Outcome 8: Anxiety

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.8.1 DBT vs. CCT

Turner 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.65(P=0.1)

3.8.2 CT vs. CCT

Cottraux 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.55(P=0.12)

3.8.3 CBT vs. IPT

Bellino 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.32(P=0.19)

12

12

20

20

12

12

10.2 (6.5)

12.5 (7.8)

12.5 (1.1)

14.8 (6.3)

18.4 (14.3)

13.7 (2.8)

12

12

18

18

14

14

100%

100%

-0.7[-1.53,0.13]

-0.7[-1.53,0.13]

100%

100%

-0.51[-1.16,0.13]

-0.51[-1.16,0.13]

100%

100%

-0.53[-1.32,0.26]

-0.53[-1.32,0.26]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.9.   Comparison 3: Comprehensive psychotherapies:
active vs. active conditions, Outcome 9: General psychopathology

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.9.1 SFT vs. TFP

Giesen-Bloo 2006

Subtotal ***

193.4 (79.4)

44

44

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.44(P=0.66)

3.9.2 SFT vs. SFT+TTA

Nadort 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.53(P=0.6)

214.9 (75.1)

30

30

200.6 (69.7)

207.6 (12.3)

42

42

31

31

100%

100%

-0.09[-0.52,0.33]

-0.09[-0.52,0.33]

100%

100%

0.14[-0.37,0.64]

0.14[-0.37,0.64]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 3.10.   Comparison 3: Comprehensive psychotherapies: active
vs. active conditions, Outcome 10: Mental health status/functioning

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.10.1 CBT vs. CCT

Cottraux 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.93(P=0.35)

3.10.2 CT vs. IPT

Bellino 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.49(P=0.62)

-3.3 (1.4)

-1.7 (1.1)

20

20

12

12

18

18

14

14

-3.8 (1.4)

-1.9 (0.9)

100%

100%

0.3[-0.34,0.94]

0.3[-0.34,0.94]

100%

100%

0.19[-0.58,0.97]

0.19[-0.58,0.97]

Favours treatment 2

-4

-2

0

2

4

Favours treatment 1

Analysis 3.11.   Comparison 3: Comprehensive psychotherapies:
active vs. active conditions, Outcome 11: Leaving the study early

Study or subgroup

Treatment 1

Treatment 2

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

3.11.1 DBT vs. CCT

Turner 2000

Subtotal (95% CI)

Total events: 3 (Treatment 1), 6 (Treatment 2)

Heterogeneity: Not applicable

Test for overall effect: Z=1.2(P=0.23)

3.11.2 SFT vs. TFP

3/12

12

6/12

12

100%

100%

0.5[0.16,1.55]

0.5[0.16,1.55]

Favours treatment 1

0.1

0.2

0.5

1

2

5

10

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment 1

Treatment 2

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Giesen-Bloo 2006

Subtotal (95% CI)

12/45

45

22/43

43

100%

100%

0.52[0.3,0.92]

0.52[0.3,0.92]

Total events: 12 (Treatment 1), 22 (Treatment 2)

Heterogeneity: Not applicable

Test for overall effect: Z=2.26(P=0.02)

3.11.3 SFT vs. SFT+TTA

Nadort 2009

Subtotal (95% CI)

Total events: 6 (Treatment 1), 7 (Treatment 2)

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

3.11.4 CT vs. CCT

Cottraux 2009

Subtotal (95% CI)

6/30

30

7/32

32

100%

100%

0.91[0.35,2.41]

0.91[0.35,2.41]

13/33

33

14/32

32

100%

100%

0.9[0.51,1.6]

0.9[0.51,1.6]

Total events: 13 (Treatment 1), 14 (Treatment 2)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.36(P=0.72)

3.11.5 CBT vs. IPT

Bellino 2007

Subtotal (95% CI)

Total events: 4 (Treatment 1), 2 (Treatment 2)

Heterogeneity: Not applicable

Test for overall effect: Z=0.88(P=0.38)

4/16

16

2/16

16

100%

100%

2[0.42,9.42]

2[0.42,9.42]

Favours treatment 1

0.1

0.2

0.5

1

2

5

10

Favours treatment 2

Comparison 4.   Non-comprehensive psychotherapeutic interventions: active vs. active conditions

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 BPD total severity

4.1.1 MACT vs. MACT+TA

4.2 Affective instability

4.2.1 MACT vs. MACT+TA

4.3 Suicidality

4.3.1 MACT vs. MACT+TA

1

1

1

1

1

1

16

16

16

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.33 [-1.32, 0.66]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.71 [-1.73, 0.31]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.03 [-1.01, 0.95]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.4 Parasuicidality

4.4.1 MACT vs. MACT+TA

4.5 Interpersonal prob-
lems

4.5.1 MACT vs. MACT+TA

4.6 Identity disturbance

4.6.1 MACT vs. MACT+TA

4.7 Leaving the study ear-
ly

4.7.1 MACT vs. MACT+TA

1

1

1

1

1

1

1

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.08 [-0.90, 1.06]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.04 [-1.02, 0.94]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.45 [-1.44, 0.55]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.80 [0.33, 1.92]

16

16

16

16

Analysis 4.1.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 1: BPD total severity

Study or subgroup

treatment 1

treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.1.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

8

8

79 (9)

82.8 (12.1)

8

8

100%

100%

-0.33[-1.32,0.66]

-0.33[-1.32,0.66]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 4.2.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 2: Affective instability

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.2.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.36(P=0.17)

74.6 (5.7)

8

8

79.9 (8.1)

8

8

100%

100%

-0.71[-1.73,0.31]

-0.71[-1.73,0.31]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.3.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 3: Suicidality

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.3.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.07(P=0.95)

80.3 (15.8)

8

8

80.9 (18.9)

8

8

100%

100%

-0.03[-1.01,0.95]

-0.03[-1.01,0.95]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 4.4.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 4: Parasuicidality

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.4.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.16(P=0.87)

73.4 (22.4)

8

8

71.6 (19.2)

8

8

100%

100%

0.08[-0.9,1.06]

0.08[-0.9,1.06]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 4.5.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 5: Interpersonal problems

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.5.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.93)

73.9 (12.1)

8

8

8

8

74.4 (9.7)

100%

100%

-0.04[-1.02,0.94]

-0.04[-1.02,0.94]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Analysis 4.6.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 6: Identity disturbance

Study or subgroup

Treatment 1

Treatment 2

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.6.1 MACT vs. MACT+TA

Morey 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.88(P=0.38)

73.3 (6)

8

8

78.1 (13.3)

8

8

100%

100%

-0.45[-1.44,0.55]

-0.45[-1.44,0.55]

Favours treatment 1

-4

-2

0

2

4

Favours treatment 2

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.7.   Comparison 4: Non-comprehensive psychotherapeutic
interventions: active vs. active conditions, Outcome 7: Leaving the study early

Study or subgroup

Treatment 1

Treatment 2

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

4.7.1 MACT vs. MACT+TA

Morey 2010

Subtotal (95% CI)

Total events: 4 (Treatment 1), 5 (Treatment 2)

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

Comparison 5.   Funnel plot

4/8

8

5/8

8

100%

100%

0.8[0.33,1.92]

0.8[0.33,1.92]

Favours treatment 1

0.1

0.2

0.5

1

2

5

10

Favours treatment 2

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.1 Parasuicidality

18

Std. Mean Difference (IV, Fixed, 95% CI)

-0.24 [-0.36, -0.12]

5.1.1 CBT vs. TAU

5.1.2 DBT vs. TAU

5.1.3 DBT vs. GM

5.1.4 DBT vs. CTBE

5.1.5 DBT-ST vs. SG

5.1.6 DDP vs. TAU

5.1.7 ERG vs. TAU

5.1.8 IPT-BPD+fl vs. CM
+fl

5.1.9 MACT vs. TAU

5.1.10 MBT-PH vs. TAU

5.1.11 MBT-out vs. TAU

5.1.12 SFT-G vs. TAU

5.1.13 STEPPS vs. TAU

5.1.14 STEPPS+IT vs.
TAU

5.1.15 TFP vs. CTBE

1

4

1

1

1

1

1

1

1

1

1

1

1

1

1

Std. Mean Difference (IV, Fixed, 95% CI)

0.10 [-0.29, 0.49]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.35 [-0.69, -0.01]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.23 [-0.52, 0.06]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.12 [-0.54, 0.30]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.10 [-0.61, 0.41]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.08 [-1.15, 0.98]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.98 [-1.87, -0.09]

Std. Mean Difference (IV, Fixed, 95% CI)

0.02 [-0.58, 0.62]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.88 [-1.66, -0.10]

Std. Mean Difference (IV, Fixed, 95% CI)

-1.22 [-2.07, -0.37]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.48 [-0.89, -0.07]

Std. Mean Difference (IV, Fixed, 95% CI)

-1.92 [-2.84, -1.00]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.29 [-0.64, 0.06]

Std. Mean Difference (IV, Fixed, 95% CI)

0.31 [-0.27, 0.88]

Std. Mean Difference (IV, Fixed, 95% CI)

0.15 [-0.31, 0.62]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.2 By sample size -
parasuicidality

5.2.1 0-20

5.2.2 21-50

5.2.3 51-100

5.2.4 101-

18

2

7

6

3

Std. Mean Difference (IV, Fixed, 95% CI)

-0.24 [-0.36, -0.12]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.16 [-0.84, 0.53]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.71 [-0.98, -0.44]

Std. Mean Difference (IV, Fixed, 95% CI)

0.06 [-0.13, 0.26]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.31 [-0.50, -0.11]

Analysis 5.1.   Comparison 5: Funnel plot, Outcome 1: Parasuicidality

Study or subgroup

5.1.1 CBT vs. TAU

Davidson 2006

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

5.1.2 DBT vs. TAU

Carter 2010

Koons 2001

Linehan 1991

Van den Bosch 2005

Subtotal (95% CI)

Experi-
mental

N

Control

N

Std. Mean
Difference

(SE)

52

47

0.1 (0.199)

20

10

22

22

31

10

22

24

0.2 (0.355)

-0.3 (0.452)

-0.5 (0.306)

-0.6 (0.334)

Heterogeneity: Tau2=0; Chi2=3.49, df=3(P=0.32); I2=14.09%

Test for overall effect: Z=2(P=0.05)

Std. Mean Difference

Weight

Std. Mean Difference

IV, Fixed, 95% CI

IV, Fixed, 95% CI

9.79%

9.79%

0.1[-0.29,0.49]

0.1[-0.29,0.49]

3.08%

1.9%

4.14%

3.47%

0.2[-0.5,0.89]

-0.32[-1.2,0.56]

-0.52[-1.12,0.08]

-0.65[-1.31,0.01]

12.59%

-0.35[-0.69,-0.01]

5.1.3 DBT vs. GM

McMain 2009

Subtotal (95% CI)

90

90

-0.2 (0.148)

17.69%

17.69%

-0.23[-0.52,0.06]

-0.23[-0.52,0.06]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.55(P=0.12)

5.1.4 DBT vs. CTBE

Linehan 2006

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=0.56(P=0.58)

5.1.5 DBT-ST vs. SG

Soler 2009

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=0.38(P=0.7)

50

39

-0.1 (0.214)

8.44%

8.44%

-0.12[-0.54,0.3]

-0.12[-0.54,0.3]

29

30

-0.1 (0.26)

5.72%

5.72%

-0.1[-0.61,0.41]

-0.1[-0.61,0.41]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

5.1.6 DDP vs. TAU

Gregory 2008

Subtotal (95% CI)

Experi-
mental

N

Control

N

Std. Mean
Difference

(SE)

10

9

-0.1 (0.545)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.16(P=0.88)

Cochrane Database of Systematic Reviews

Std. Mean Difference

Weight

Std. Mean Difference

IV, Fixed, 95% CI

IV, Fixed, 95% CI

1.31%

1.31%

-0.08[-1.15,0.98]

-0.08[-1.15,0.98]

5.1.7 ERG vs. TAU

Gratz 2006

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=2.15(P=0.03)

5.1.8 IPT-BPD+fl vs. CM+fl

Bellino 2010

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=0.07(P=0.95)

5.1.9 MACT vs. TAU

Weinberg 2006

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=2.2(P=0.03)

5.1.10 MBT-PH vs. TAU

Bateman 1999

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=2.81(P=0.01)

5.1.11 MBT-out vs. TAU

Bateman 2009

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=2.3(P=0.02)

5.1.12 SFT-G vs. TAU

Farrell 2009

Subtotal (95% CI)

12

10

-1 (0.457)

1.86%

1.86%

-0.98[-1.87,-0.09]

-0.98[-1.87,-0.09]

22

22

0 (0.304)

4.2%

4.2%

0.02[-0.58,0.62]

0.02[-0.58,0.62]

15

13

-0.9 (0.401)

2.42%

2.42%

-0.88[-1.66,-0.1]

-0.88[-1.66,-0.1]

19

19

-1.2 (0.435)

2.05%

2.05%

-1.22[-2.07,-0.37]

-1.22[-2.07,-0.37]

71

63

-0.5 (0.208)

8.97%

8.97%

-0.48[-0.89,-0.07]

-0.48[-0.89,-0.07]

16

12

-1.9 (0.472)

1.74%

1.74%

-1.92[-2.84,-1]

-1.92[-2.84,-1]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=4.07(P<0.0001)

5.1.13 STEPPS vs. TAU

Blum 2008

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=1.6(P=0.11)

5.1.14 STEPPS+IT vs. TAU

Bos 2010

Subtotal (95% CI)

65

59

-0.3 (0.181)

11.82%

11.82%

-0.29[-0.64,0.06]

-0.29[-0.64,0.06]

28

30

0.3 (0.293)

4.53%

4.53%

0.31[-0.27,0.88]

0.31[-0.27,0.88]

Favours experimental

-4

-2

0

2

4

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Experi-
mental

N

Control

N

Std. Mean
Difference

(SE)

Std. Mean Difference

Weight

Std. Mean Difference

IV, Fixed, 95% CI

IV, Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.05(P=0.29)

5.1.15 TFP vs. CTBE

Doering 2010

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

52

52

0.2 (0.237)

6.89%

6.89%

0.15[-0.31,0.62]

0.15[-0.31,0.62]

Total (95% CI)

Heterogeneity: Tau2=0; Chi2=38.78, df=17(P=0); I2=56.16%

Test for overall effect: Z=3.88(P=0)

Test for subgroup differences: Chi2=35.29, df=1 (P=0), I2=60.33%

100%

-0.24[-0.36,-0.12]

Favours experimental

-4

-2

0

2

4

Favours control

Analysis 5.2.   Comparison 5: Funnel plot, Outcome 2: By sample size - parasuicidality

Experi-
mental

N

Control

N

Std. Mean
Difference

(SE)

Std. Mean Difference

Weight

Std. Mean Difference

IV, Fixed, 95% CI

IV, Fixed, 95% CI

Study or subgroup

5.2.1 0-20

Gregory 2008

Koons 2001

Subtotal (95% CI)

10

10

9

10

0.1 (0.545)

-0.3 (0.452)

Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%

Test for overall effect: Z=0.45(P=0.66)

5.2.2 21-50

Bateman 1999

Bellino 2010

Farrell 2009

Gratz 2006

Linehan 1991

Van den Bosch 2005

Weinberg 2006

Subtotal (95% CI)

19

22

16

12

22

22

15

Heterogeneity: Tau2=0; Chi2=14.68, df=6(P=0.02); I2=59.13%

Test for overall effect: Z=5.08(P<0.0001)

5.2.3 51-100

Bos 2010

Carter 2010

Davidson 2006

Doering 2010

Linehan 2006

Soler 2009

Subtotal (95% CI)

28

20

52

52

50

29

Heterogeneity: Tau2=0; Chi2=2.13, df=5(P=0.83); I2=0%

Test for overall effect: Z=0.63(P=0.53)

19

22

12

10

22

24

13

30

31

47

52

39

30

-1.2 (0.435)

0 (0.304)

-1.9 (0.472)

-1 (0.457)

-0.5 (0.306)

-0.6 (0.334)

-0.9 (0.401)

0.3 (0.293)

0.2 (0.355)

0.1 (0.199)

0.2 (0.237)

-0.1 (0.214)

-0.1 (0.26)

1.31%

1.9%

3.21%

0.09[-0.98,1.15]

-0.32[-1.2,0.56]

-0.16[-0.84,0.53]

2.05%

4.2%

1.74%

1.86%

4.14%

3.47%

2.42%

-1.22[-2.07,-0.37]

0.02[-0.58,0.62]

-1.92[-2.84,-1]

-0.98[-1.87,-0.09]

-0.52[-1.12,0.08]

-0.65[-1.31,0.01]

-0.88[-1.66,-0.1]

19.88%

-0.71[-0.98,-0.44]

4.53%

3.08%

9.79%

6.89%

8.44%

5.72%

0.31[-0.27,0.88]

0.2[-0.5,0.89]

0.1[-0.29,0.49]

0.15[-0.31,0.62]

-0.12[-0.54,0.3]

-0.1[-0.61,0.41]

38.44%

0.06[-0.13,0.26]

Favours experimental

-2

-1

0

1

2

Favours control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Experi-
mental

N

Control

N

Std. Mean
Difference

(SE)

Std. Mean Difference

Weight

Std. Mean Difference

IV, Fixed, 95% CI

IV, Fixed, 95% CI

Study or subgroup

5.2.4 101-

Bateman 2009

Blum 2008

McMain 2009

Subtotal (95% CI)

71

65

90

63

59

90

-0.5 (0.208)

-0.3 (0.181)

-0.2 (0.148)

Heterogeneity: Tau2=0; Chi2=0.96, df=2(P=0.62); I2=0%

Test for overall effect: Z=3.05(P=0)

Total (95% CI)

Heterogeneity: Tau2=0; Chi2=39.06, df=17(P=0); I2=56.47%

Test for overall effect: Z=3.85(P=0)

Test for subgroup differences: Chi2=20.96, df=1 (P=0), I2=85.68%

8.97%

11.82%

17.69%

38.48%

-0.48[-0.89,-0.07]

-0.29[-0.64,0.06]

-0.23[-0.52,0.06]

-0.31[-0.5,-0.11]

100%

-0.24[-0.36,-0.12]

Favours experimental

-2

-1

0

1

2

Favours control

A D D I T I O N A L   T A B L E S

Table 1.   Spreadsheet of primary outcome effect estimates: Dialectical behaviour therapy (DBT) versus control
groups (comprehensive therapies only) 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

BPD total severity

DBT1 vs. TAU2

DBT vs. GM3

DBT-PTSD4 vs. WL2

Inappropriate anger

DBT vs. TAU

DBT vs. GM

Affective instability

-6

Chronic feelings of emptiness

-

Impulsivity

DBT vs. TAU

Suicidality

1

1

1

2

1

1

20

180

31

46

180

SMD

SMD

SMD

SMD

SMD

-0.29 [-1.17, 0.59]

-0.04 [-0.33, 0.25]

-0.74 [-1.47, -0.01]

-0.83 [-1.43, -0.22]

-0.03 [-0.32, 0.26]

48

SMD

-0.17 [-0.74, 0.39]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   Spreadsheet of primary outcome effect estimates: Dialectical behaviour therapy (DBT) versus control
groups (comprehensive therapies only)  (Continued)

DBT vs. TAU

DBT vs. CTBE7

Parasuicidality

DBT vs. TAU

DBT vs. TAU

DBT vs. GM

Interpersonal problems

DBT vs. TAU

DBT vs. GM

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

DBT vs. TAU

DBT-PTSD vs. WL

1

1

3

1

1

1

1

1

1

20

89

110

51

180

48

180

20

30

SMD

SMD

SMD

RR

SMD

SMD

SMD

-1.26 [-2.24, -0.29]

-0.12 [-0.54, 0.30]

-0.54 [-0.92, -0.16]

1.11 [0.78, 1.57]

-0.23 [-0.52, 0.06]

0.04 [-0.54, 0.61]

-0.03 [-0.32, 0.26]

SMD

SMD

-0.90 [-1.83, 0.03]

-0.34 [-1.06, 0.38]

1Dialectical Behaviour Therapy
2treatment as usual
3general management
4Dialectical Behaviour Therapy for BPD with post-traumatic stress disorder

5waiting list
6No data available for this outcome
7community treatment by experts

Table 2.   Spreadsheet of primary outcome effect estimates: Mentalisation-based treatment (MBT) versus control
groups 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

BPD total severity

-1

Inappropriate anger

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Spreadsheet of primary outcome effect estimates: Mentalisation-based treatment (MBT) versus control
groups  (Continued)

-

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

-

Suicidality

MBT-PH2 vs. TAU

MBT-out3 vs. TAU

Parasuicidality

MBT-PH vs. TAU

MBT-out vs. TAU

Interpersonal problems

MBT-PH vs. TAU

MBT-out vs. TAU

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1

1

1

1

1

1

38

134

38

134

38

134

RR

RR

RR

RR

SMD

SMD

0.08 [0.01, 0.58]

0.11 [0.03, 0.46]

0.44 [0.24 to 0.81]

0.56 [0.34 to 0.92]

-2.22 [-3.04, -1.39]

-0.95 [-1.30, -0.59]

1No data available for this outcome.

2Mentalisation-based Treatment, partial hospitalisation
3TAU: treatment as usual
4Mentalisation-based Treatment, outpatient

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Spreadsheet of primary outcome effect estimates: Transference-focused psychotherapy (TFP) versus
control groups 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Esti-
mate/95% CI

1

104

SMD

-0.55 [-0.95, -0.16]

1

1

104

104

RR

RR

0.64 [0.27, 1.51]

1.09 [0.84, 1.40]

BPD total severity

TFP1 vs. CTBE2

Inappropriate anger

-3

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

-

Suicidality

TFP vs. CTBE

Parasuicidality

TFP vs. CTBE

Interpersonal problems

-

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1Transference-Focused Psychotherapy
2community treatment by experts
3 No data available for this outcome.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 4.   Spreadsheet of primary outcome effect estimates: Cognitive behavioural therapy (CBT) versus control
groups 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Esti-
mate/95% CI

BPD total severity

-1

Inappropriate anger

-

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

-

Suicidality

CBT2 vs. TAU3

Parasuicidality

CBT vs. TAU

Interpersonal problems

CBT vs. TAU

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1

1

1

101

99

99

RR

RR

0.78 [0.47, 1.27

1.17 [0.87, 1.60]

SMD

0.23 [-0.16, 0.63]

1No data available for this outcome.2Cognitive Behavioural Therapy
3treatment as usual

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 5.   Spreadsheet of primary outcome effect estimates: Dynamic Deconstructive psychotherapy (DDP) versus
control groups 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Esti-
mate/95% CI

1

30

SMD

-0.44 [-1.16, 0.29]

1

30

RR

0.89 [0.47, 1.67]

BPD total severity

DDP1 vs. TAU2

Inappropriate anger

-3

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

-

Suicidality

-

Parasuicidality

DDP vs. TAU

Interpersonal problems

-

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

DDP vs. TAU

1

30

SMD

0.25 [-0.47, 0.97]

1Dynamic Deconstructive Psychotherapy
2treatment as usual
3No data available for this outcome.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 6.   Spreadsheet of primary outcome effect estimates: interpersonal therapy (IPT) versus. control groups 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

BPD total severity

IPT-BPD1 vs. CM2

Inappropriate anger

IPT-BPD vs. CM

Affective instability

IPT-BPD vs. CM

Chronic feelings of emptiness

IPT-BPD vs. CM

Impulsivity

IPT-BPD vs. CM

Suicidality

-3

Parasuicidality

IPT-BPD vs. CM

Interpersonal problems

IPT-BPD vs. CM

Avoidance of abandonment

IPT-BPD vs. CM

Identity disturbance

IPT-BPD vs. CM

Dissociation/psychoticism

IPT-BPD vs. CM

1

1

1

1

1

1

1

1

1

1

44

44

44

44

44

44

44

44

44

44

SMD

-0.03 [-0.62, 0.56]

SMD

0.01 [-0.58, 0.60]

SMD

-0.92 [-1.54, -0.30]

SMD

0.09 [-0.50, 0.68]

SMD

-0.91 [-1.53, -0.28]

SMD

0.02 [-0.58, 0.61]

SMD

-0.82 [-1.44, -0.20]

SMD

0.01 [-0.58, 0.60]

SMD

-0.03 [-0.62, 0.56]

SMD

0.10 [-0.49, 0.70]

There are no data available for any primary outcome for the comparison of IPT + fluoxetine to CM + fluoxetine.
Both groups of the IPT-BPD vs. CM comparison received additional fluoxetine medication.
1Interpersonal Psychotherapy adapted for BPD
2Clinical management
3No data available for this outcome

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 7.   Spreadsheet of primary outcome effect estimates: Dialectical behaviour therapy skills training(DBT-ST)
versus control 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

BPD total severity

DBT-ST1 vs. SG2

Inappropriate anger

DBT-ST vs. SG

Affective instability

DBT-ST vs. SG

Chronic feelings of emptiness

DBT-ST vs. SG

Impulsivity

DBT-ST vs. SG

Suicidality

DBT-ST vs. SG

Parasuicidality

-3

Interpersonal problems

DBT-ST vs. SG

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

DBT-ST vs. SG

1

1

1

1

1

1

1

1

1Dialectical Behaviour Therapy-skills training
2standard group
3No data available.

59

59

59

59

59

59

SMD

-1.01 [-1.56, -0.47]

SMD

-0.84 [-1.37, -0.30]

SMD

-1.07 [-1.61, -0.52]

SMD

-0.43 [-0.95, 0.09]

SMD

-0.61 [-1.14, -0.09]

SMD

-0.10 [-0.61, 0.41]

59

SMD

-0.29 [-0.80, 0.23]

59

SMD

-0.66 [-1.18, -0.13]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 8.   Spreadsheet of primary outcome effect estimates: Emotion regulation group therapy (ERG) versus control
condition 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95%
CI

1

1

1

1

22

SMD

-1.02 [-1.92, -0.11]

22

SMD

-1.65 [-1.61, -0.52]

22

SMD

-1.30 [-2.24, -0.36]

22

SMD

-0.98 [-1.88, -0.09]

BPD total severity

ERG1 vs. TAU2

Inappropriate anger

-3

Affective instability

ERG vs. TAU

Chronic feelings of emptiness

-

Impulsivity

ERG vs. TAU

Suicidality

Parasuicidality

ERG vs. TAU

Interpersonal problems

-

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1Emotion Regulation Group Training
2treatment as usual
3No data available.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 9.   Spreadsheet of primary outcome effect estimates: Schema-focused group therapy (SFT-G) versus control
condition 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

BPD total severity

SFT-G1 vs. TAU2

Inappropriate anger

-3

Affective instability

SFT-G vs. TAU

Chronic feelings of emptiness

Impulsivity

SFT-G vs. TAU

Suicidality

Parasuicidality

Interpersonal problems

SFT-G vs. TAU

Avoidance of abandonment

Identity disturbance

Dissociation/psychoticism

SFT-G vs. TAU

1Schema-Focused Therapy-group treatment
2treatment as usual
3No data available.

1

1

1

1

1

28

SMD

-1.66 [-2.54, -0.78]

28

SMD

-1.41 [-2.26, -0.57]

28

SMD

-1.92 [-2.85, -1.00]

28

SMD

-1.94 [-2.87, -1.02]

28

SMD

-1.37 [-2.21, -0.53]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 10.   Spreadsheet of primary outcome effect estimates: manual-assisted cognitive treatment (MACT) versus
controls 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Esti-
mate/95% CI

BPD total severity

-1

Inappropriate anger

-

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

-

Suicidality

MACT2 vs. TAU3

Parasuicidality

MACT vs. TAU

Interpersonal problems

-

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1No data available
2Manual-assisted Cognitive Treatment
3treatment as usual

1

1

28

28

SMD

-0.86 [-1.64, -0.07]

SMD

-0.88 [-1.67, -0.10]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 11.   Spreadsheet of primary outcome effect estimates: systems training for emotional predictability and
problem solving for borderline personality disorder (STEPPS) versus controls 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Estimate/95% CI

124

52

SMD

SMD

-0.17 [-0.52, 0.19]

-0.55 [-1.11, 0.00]

124

SMD

-0.32 [-0.67, 0.04]

124

58

58

124

53

SMD

RR

-0.29 [-0.64, 0.07]

0.93 [0.66, 1.29]

RR

1.32 [0.78, 2.22]

SMD

SMD

-0.42 [-0.78, -0.06]

-0.27 [-0.81, 0.27]

1

1

1

1

1

1

1

1

BPD total severity

STEPPS1 vs. TAU2

STEPPS+IT3 vs. TAU

Inappropriate anger

-4

Affective instability

STEPPS vs. TAU

Chronic feelings of emptiness

-

Impulsivity

STEPPS vs. TAU

STEPPS+IT vs. TAU

Suicidality

-

Parasuicidality

STEPPS+IT vs. TAU

Interpersonal problems

STEPPS vs. TAU

STEPPS+IT vs. TAU

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

STEPPS vs. TAU

1 

124 

SMD 

-0.42 [-0.78, -0.06] 

1Systems Training for Emotional Predictability and Problem Solving for borderline personality disorder

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2Systems Training for Emotional Predictability and Problem Solving for borderline personality disorder plus individual therapy
3treatment as usual

Table 12.   Spreadsheet of primary outcome effect estimates: Psychoeducation (PE) versus control 

Outcome/Subgroup

Studies

Participants

Statistical
Method

Effect Esti-
mate/95% CI

BPD total severity

-1

Inappropriate anger

-

Affective instability

-

Chronic feelings of emptiness

-

Impulsivity

PE2 vs. WL3

Suicidality

-

Parasuicidality

-

Interpersonal problems

PE vs. WL

Avoidance of abandonment

-

Identity disturbance

-

Dissociation/psychoticism

-

1No data available.

2psychoeducation
3waiting list

1

1

50

SMD

-0.47 [-1.04, 0.10]

50

SMD

-0.75 [-1.33, -0.16]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A P P E N D I C E S

Appendix 1. Search strategies

Cochrane Central Register of Controlled Trials (CENTRAL)

#1 MeSH descriptor Personality Disorders explode all trees
#2 (moral near/2 insanity)
#3 (DSM and (axis and II))
#4 (ICD and (F60 or F61 or F62))
#5 ((Odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) near/5 cluster*)
#6 ("Cluster A" or "Cluster B" or "Cluster C")
#7 ((aggressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) near/5 personalit*)
#8 anankastic* or asocial* or avoidant*or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or
obsessiv* or paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*
#9 personalit* near/5 disorder*
#10 character disorder*
#11 anal* next (personalit* or character* or retentiv*)
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11

MEDLINE

1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomi#ed.ab.
4 placebo.ab.
5 drug therapy.fs.
6 randomly.ab.
7 trial.ab.
8 groups.ab.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 exp animals/ not humans.sh.
11 exp Personality Disorders/
12 (moral adj2 insanity).tw.
13 (DSM and (axis and II)).tw.
14 (ICD and (F60 or F61 or F62)).tw.
15 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.
16 ("Cluster A" or "Cluster B" or "Cluster C").tw.
17 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.
18 (personalit$ adj5 disorder$).tw.
19 character disorder$.tw.
20 (anal$ adj (personalit$ or character$ or retentiv$)).tw.
21 9 not 10
22 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or
narciss$ or obsessiv$ or paranoi$ or psychopath or psychopaths or psychopathic or sadist$ or schizoid$ or schizotyp$ or
sociopath$).tw.
23 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 22
24 21 and 23

EMBASE

1 (moral adj2 insanity).tw.
2 (DSM and (axis and II)).tw.
3 (ICD and (F60 or F61 or F62)).tw.
4 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.
5 ("Cluster A" or "Cluster B" or "Cluster C").tw.
6 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.
7 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or
narciss$ or obsessiv$ or paranoi$ or psychopath$ or sadist$ or schizoid$ or schizotyp$ or sociopath$).tw.
8 (personalit$ adj5 disorder$).tw.
9 character disorder$.tw.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

10 (anal$ adj (personalit$ or character$ or retentiv$)).tw.
11 exp personality disorder/
12 or/1-11
13 random$.tw.
14 factorial$.tw.
15 crossover$.tw.
16 cross over$.tw.
17 cross-over$.tw.
18 placebo$.tw. (1
19 (doubl$ adj blind$).tw.
20 (singl$ adj blind$).tw.
21 assign$.tw.
22 allocat$.tw.
23 volunteer$.tw.
24 Crossover Procedure/
25 double-blind procedure.tw.
26 Randomized Controlled Trial/
27 Single Blind Procedure/
28 or/13-27
29 12 and 28

ASSIA

((DE=("personality disorders" or "antisocial personality disorder" or "avoidant personality disorders" or "borderline
personality disorder" or "dependent personality" or "depressive personality disorders" or "gender identity disorder" or
"histrionic personality disorder" or "identity crisis" or "kleptomania" or "multi impulsive personality disorder" or
"multiple personality disorder" or "narcissistic personality disorder" or "passive aggressive personality disorder" or
"sadistic personality disorder" or "schizotypal personality disorders" or "selfdefeating personality disorder")) or((moral
within 2 insanity) or(DSM and (axis and II)) or(icd and (F60 or F61 or F62)) or((odd* or eccentric* or dramatic* or
emotional* or anxious* or fearful*) within 5 cluster*) or("Cluster A" or "Cluster B" or "Cluster C") or((aggressiv* or
anxious* or borderline* or dependent* or emotional* or passiv* or unstable) within 5 personalit*) or(anankastic* or
asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or obsessiv* or
paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*) or(personalit* within 5 disorder*) or(character
disorder*) or(anal* within 1 (personalit* or character* or retentiv*)))) and((DE=("randomized controlled trials" or "clinical
randomized controlled trials" or "cluster randomized controlled trials" or "double blind randomized controlled trials" or
"randomized consent design" or "single blind randomized controlled trials" or "urn randomization" or "random testing"
or "randomization" or "unequal randomization")) or(TI=randomi* or AB=randomi*) or((TI=(single or double) near
blind*)or (AB=(single or double) near blind*)))
BIOSIS

# 15 #14 AND #12
# 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or obsessiv*
or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or sociopath*)
# 12 #11 OR #10
# 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)
# 10 TS=(random* or crossover )
# 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))
# 8 TS=("Cluster B" or "Cluster C")
# 7 TS=("character disorder*")
# 6 TS=(personalit* SAME disorder*)
# 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))
# 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)
# 3 TS=(ICD AND (F60 or F61 or F62))
# 2 TS=(DSM SAME (axis SAME II))
# 1 TS=(moral SAME insanity)

CINAHL

S30 S13 and S29
S29 S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or
S24 or S25 or S26 or S27 or S28

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

S28 allocat* random*
S27 (MH "Quantitative Studies")
S26 (MH "Placebos")
S25 placebo*
S24 random* allocat*
S23 (MH "Random Assignment")
S22 (Randomi?ed control* trial*)
S21 (singl* mask* )
S20 (doubl* mask* )
S19 (tripl* mask* )
S18 (trebl* mask* )
S17 (trebl* blind* )
S16 (tripl* blind* )
S15 (doubl* blind* )
S14 (singl* blind* )
S13 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12
S12 (anal* N1 personalit* or anal* N1 character* or anal N1 retentiv*) and
(S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11)
S11 anal* N1 personalit* or anal* N1 character* or anal N1 retentiv*
S10 character N1 disorder*
S9 personalit* N5 disorder*
S8 anankastic* or asocial* or avoidant* or antisocial* or anti-social* or
compulsiv* or dissocial* or histrionic* or narciss* or obsessiv* or
paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or
sociopath*
S7 aggressiv* N5 personalit* or anxious* N5 personalit* or borderline* N5
personalit* or dependent* N5 personalit* or emotional* N5 personalit* or
passiv* N5 personalit* or unstable N5 personalit*
S6 ("Cluster A" or "Cluster B" or "Cluster C")
S5 odd* N5 cluster* or eccentric* N5 cluster* or dramatic* N5 cluster* or
emotional* N5 cluster* or anxious* N5 cluster* or fearful* N5 cluster*
S4 (ICD and (F60 or F61 or F62))
S3 (DSM and (axis and II))
S2 moral N2 insanity
S1 (MH "Personality Disorders+")

Dissertation Abstracts

Searched using the Proquest keyword " personality disorders"

ICTRP

condition = borderline personality disorder AND recruitment status = all

metaRegister of Controlled Trials

Searched using the search strings:
antisocial personality
borderline personality
compulsive personality
dependent personality
histrionic personality
hysteria
paranoid personality
passive-aggressive personality
schizoid personality
schizotypal personality
personality disorder

National Criminal Justice Reference Service Abstracts (NCJRS)

Searched using the search strings:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

random* AND compulsive personality
random* AND antisocial personality
random* AND borderline personality
random* AND dependent personality
random* AND histrionic personality
random* AND hysteria
random* AND paranoid personality
random* AND passive aggressive personality
random AND schizoid personality
random* AND schizotypal personality
random* AND personality disorder*

PsycINFO

1 (moral adj2 insanity).tw.
2 (DSM and (axis and II)).tw.
3 (ICD and (F60 or F61 or F62)).tw.
4 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.
5 ("Cluster A" or "Cluster B" or "Cluster C").tw.
6 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.
7 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or
narciss$ or obsessiv$ or paranoi$ or psychopath$ or sadist$ or schizoid$ or schizotyp$ or sociopath$).tw.
8 (personalit$ adj5 disorder$).tw.
9 character disorder$.tw.
10 (anal$ adj (personalit$ or character$ or retentiv$)).tw.
11 exp personality disorders/
12 or/1-11
13 randomi$.tw.
14 singl$.tw.
15 doubl$.tw.
16 trebl$.tw.
17 tripl$.tw.
18 blind$.tw.
19 mask$.tw.
20 (or/14-17) adj3 (or/18-19)
21 clin$.tw.
22 trial$.tw.
23 (clin$ adj3 trial$).tw.
24 placebo$.tw.
25 exp PLACEBO/
26 crossover.tw.
27 exp Treatment Effectiveness Evaluation/
28 exp Mental Health Program Evaluation/
29 random$.tw.
30 assign$.tw.
31 allocate$.tw. (
32 (random$ adj3 (assign$ or allocate$)).tw.
33 32 or 28 or 27 or 26 or 25 or 24 or 23 or 20 or 13
34 12 and 33

Science Citation Index

# 15 #14 AND #12
# 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or
narciss* or obsessiv* or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or
sociopath*)
# 12 #11 OR #10
# 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)
# 10 TS=(random* or crossover )
# 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))
# 8 TS=("Cluster B" or "Cluster C")

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

# 7 TS=("character disorder*")
# 6 TS=(personalit* SAME disorder*)
# 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))
# 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)
# 3 TS=(ICD AND (F60 or F61 or F62))
# 2 TS=(DSM SAME (axis SAME II))
# 1 TS=(moral SAME insanity)

Social Science Citation Index

# 15 #14 AND #12
# 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or
narciss* or obsessiv* or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or
sociopath*)
# 12 #11 OR #10
# 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)
# 10 TS=(random* or crossover )
# 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))
# 8 TS=("Cluster B" or "Cluster C")
# 7 TS=("character disorder*")
# 6 TS=(personalit* SAME disorder*)
# 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))
# 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)
# 3 TS=(ICD AND (F60 or F61 or F62))
# 2 TS=(DSM SAME (axis SAME II))
# 1 TS=(moral SAME insanity)

Sociological Abstracts (CSA)
((DE="personality disorders") or(moral within 2 insanity) or(DSM and (axis and II)) or(icd and (F60 or F61 or F62)) or((odd*
or eccentric* or dramatic* or emotional* or anxious* or fearful*) within 5 cluster*) or("Cluster A" or "Cluster B" or "Cluster
C") or((aggressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) within 5 personalit*)
or(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss*
or obsessiv* or paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*) or(personalit* within 5
disorder*) or(character disorder*) or(anal* within 1 (personalit* or character* or retentiv*))) and((TI=randomi* or
DE=(randomi?ed controlled trial*) or AB=randomi*) or(TI=(double* blind*) or AB=(double* blind*) or DE=(double blind
studies)) or(single near blind*))
ZETOC (Conference search)
23 conference: hysteria trial*
22 conference: histrionic personality trial*
21 conference: dependent personality trial*
20 conference: borderline personality trial*
19 conference: antisocial personality trial*
18 conference: compulsive personality trial*
17 conference: compulsive personality random*
16 conference: schizotypal trial*
15 conference: schizotypal random*
14 conference: schizoid trial*
13 conference: schizoid random*
12 conference: passive aggressive trial*
11 conference: passive aggressive random*
10 conference: personality disorder* trial*
9 conference: paranoid personality trial*
8 conference: paranoid personality random*
7 conference: paranoid personality
6 conference: hysteria random*
5 conference: histrionic personality random*
4 conference: dependent personality random*
3 conference: borderline personality random*
2 conference: antisocial personality random*
1 conference: personality disorder* random*

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Appendix 2. Trial register searches

Cochrane Database of Systematic Reviews

We searched the WHO International Clinical Trails Registry Platform on 9 August 2011 (http://apps.who.int/trialsearch/), a meta-register
that includes the following trial registration databases:

• Australian New Zealand Clinical Trials Registry, last data file imported on 9 August 2011
• ClinicalTrials.gov, last data file imported on 9 August 2011
• ISRCTN, last data file imported on 9 August 2011
• Brazilian Clinical Trials Registry (ReBec), last data file imported on 26 July 2011
• Chinese Clinical Trial Registry, last data file imported on 26 July 2011
• Clinical Trials Registry - India, last data file imported on 26 July 2011
• Clinical Research Information Service - Republic of Korea, last data file imported on 26 July 2011
• Cuban Public Registry of Clinical Trials, last data file imported on 26 July 2011
• German Clinical Trials Register, last data file imported on 26 July 2011
• Iranian Registry of Clinical Trials, last data file imported on 2 August 2011
• Japan Primary Registries Network, last data file imported on 26 July 2011
• Pan African Clinical Trial Registry, last data file imported on 26 July 2011
• Sri Lanka Clinical Trials Registry, last data file imported on 26 July 2011
• The Netherlands National Trial Register, last data file imported on 26 July 2011

The following phrase was searched:

condition = borderline personality disorder AND recruitment status = all

Appendix 3. Additional methods for future updates

Issue

Method

Unit of analysis issues/cross-
over trials

Data from randomised cross-over studies up to the point of first cross-over were eligible for inclu-
sion. We excluded data from subsequent phases. Due to the characteristically unstable course of
BPD, it did not seem appropriate to us that participants served as their own controls (within-sub-
ject comparisons). However, we would have used first phase data up to the point of first cross-over
for those studies and applied the inverse variance methods as recommended by Elbourne 2002.

Search methods for identifica-
tion of studies

Contact psychotherapeutic associations directly in order to identify any published and upcoming
research.

F E E D B A C K

Comments on the Gregory et al 2008 study, February 2017

Summary

On 14 February 2017, Dr Robert Gregory submitted the following comments, having identified himself as an author of an included
study within the present review.

I have a number of concerns regarding the 2012 review of “Psychological Therapies for People with Borderline Personality Disorder”, specifically
in regards to your review of Dynamic Deconstructive Psychotherapy (DDP). I realize that several years have passed since the Cochrane review.
However, since the time of its publication, both clinical and academic colleagues have repeatedly brought the review to my attention, citing
it as evidence that DDP is ineffective. So I felt I needed to respond.

I have a great respect for Cochrane reviews and the time and effort needed by the Cochrane authors to make a fair and accurate assessment.
And in such a large review (over 200 pages), it is possible for oversights to occur. Nevertheless, since busy clinicians are making decisions that
affect vulnerable patients based on the review, it’s important to get it right. I have listed my concerns below:

1. My largest concern is how the data from my 2008 study were analyzed and reported. The 2008 study by Gregory and colleagues was a
small randomized controlled trial (n = 30) comparing DDP to TAU for participants suffering from co-occurring borderline personality disorder
(BPD) and alcohol dependence. In their Discussion section, Summary of Main Results, the authors conclude that “There were no statistically

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

significant  results,  but  DDP  was  indicated  to  be  superior  to  the  control  group  in  terms  of  BPD  severity  and  parasuicidality,  with  small  to
moderate effects” (p 74). The authors draw the same conclusion on pages 2 and 31.

This would be a reasonable conclusion based on the Cochrane authors’ method of analysis, which calculated standardized mean differences
“on the basis of post-treatment results” (p 15). The difficulty of that method of analysis for the 2008 study was that there were substantial
differences in baseline scores between the two groups, which were not accounted for in the analysis. Participants assigned to DDP through
randomization had substantially greater baseline psychopathology than control participants (see Gregory 2008 , Table 4, p 37). In fact, on
the continuous outcome variables, participants receiving DDP had baseline scores averaging more than half a standard deviation higher
than the control group! By not taking into account baseline differences in either the analysis, summary of results, or discussion, the Cochrane
authors markedly understate positive treatment effects and leave clinicians with the wrong impression that DDP was shown to be an ineffective
treatment in this RCT, a potential Type II error.

2. There was also a simple error in the same section of the report summarizing results in the wrong direction. The Cochrane authors state: “For
depression, a non-statistically significant effect favouring the control group was found” (p 74). This conclusion contradicts the authors’ own
analysis of treatment effects for depression as outlined on p 164 and p 184 of the report, and is clearly a misstatement and an honest mistake
in a very lengthy report. Nevertheless, it’s important to get it corrected.

3. The Cochrane authors mention concern regarding attentional bias in the 2008 RCT (see p 14, p 26, and p 120). A strength of the RCT ( Gregory
2008 ) is that the control participants were assigned to the best alternative treatment available in the community. In regards to total treatment
contact hours, there were no statistically significant differences between the groups; three of the time points indicated contact hours favoring
the control group (3, 6, and 12 months) and one time point (9 months) favored the DDP group (see Table 2, p 33).

Admittedly, I am focusing on concerns and am omitting all the aspects that the authors did extremely well in this complex and large review. For
that I am very appreciative. Nevertheless, Cochrane has an enormous responsibility given its well-deserved reputation among clinicians for
accurate and unbiased reporting of treatment reviews. The patient population with BPD is high risk, with substantial morbidity and mortality.
Clinicians need to get the most accurate information possible and I hope you will consider amending your report to take these concerns into
account.

Sincerely,

Robert J. Gregory, MD

Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your comment?:
I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment.
_____________________________________________________________________________________________________________________

Reply

On 20 February the Feedback Editor of the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG) sent
the above comments to Professor Julian Higgins, Statistical Editor of the CDPLPG, for advice / comment, which was duly supplied
on 27 February. This was then circulated to other members of CDPLPG's editorial team, approved and sent on to the author team.

On 27 March 2017, Dr Jutta Stoffers-Winterling submitted the following comments on behalf of the author team as a whole:

First,  we  would  like  to  thank  Dr  Gregory  for  his  most  respectful  and  appreciative  feedback.  We  understand  his  concerns,  and  take  them
seriously.

Though an update of this review is currently being finalised by our working group, we would like to address Dr Gregory’s comments and
concerns. In the following, we will try to reply to each of the points raised by Dr Gregory.

Ad 1: We agree that obviously greater pathology scores were observed in the experimental group (DDP) at baseline for most measures (cf.
Gregory 2008 , Table 4, p 37). We have sought statistical advice and were reassured that this is a situation that often occurs in samples of
smaller size. However, as this is a randomised trial (using a minimization procedure), the trialists have gone to some lengths to try and ensure
balance. That means, if baseline imbalance occurs, it is due to chance. The statistical methods used in our review to compare the groups allow
for such chance differences, and we were advised not to change them ( Higgins 2017 [pers comm]).

We understand your concerns regarding the possibility of Type II errors, and have, therefore, inserted the following amendment (see 'Discussion
> Quality of the evidence'):

"Most studies had comparatively small samples (12 out of 28 trials included 39 participants or less). As a consequence, the experimental
groups  may  seem  to  be  imbalanced  at  baseline,  which  was,  for  example,  the  case  in  the  RCT  of  Gregory  2008.  Dr  Gregory,  the  main
investigator of this trial, has raised concerns about the appropriateness of using endpoint data alone for effect size calculation, and referred
to "substantially greater baseline psychopathology" in the active group, which may have led to an underestimation of positive treatment
effects and a Type II error (Gregory 2017). However, group allocation was randomised (as in any here-included study), so any imbalances

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

at baseline are regarded to be due to chance alone, and the the statistical methods used in this review allow for such chance differences."
See Quality of the evidence.

Nevertheless, we are aware that the power of studies that include smaller samples (such as Gregory 2008 ) may be too small to detect a
real effect as statistically significant if it exists. Therefore, we have not only reported statistical significance throughout the text but also
referred to their magnitude ("small, moderate, large").

Ad 2: We apologise for this mistake! Actually, this finding was reported correctly elsewhere in the text but erroneously in the 'Discussion >
Summary of main results' section. We have corrected this, so that it now reads:

“Dynamic  Deconstructive  Psychotherapy  (DDP)  was  also  investigated  in  a  single  trial  only  (Gregory  2008).  There  were  no  statistically
significant results, but DDP was indicated to be superior to the control group in terms of BPD severity, parasuicidality and depression with
small to moderate effects.” See Summary of main results.

Ad 3: Thank you for bringing this to our attention. We agree that there is actually a low risk of bias due to a higher amount of attention spent
to the participants of the treatment of investigation (DDP).

We have now changed the judgement of attention bias from 'high risk' to 'low risk'. The 'Risk of bias' table now reads:

Low risk

Though participants of the control group did not receive an alternate, obligatory control treat-
ment, but were free to join alternative treatments, they did not receive less professional attention.
Indeed, "[...] DDP participants received fewer overall treatment contact hours than did participants
receiving community care." (Gregory 2008, p 39). Also, cf. Gregory 2008, Table 2, p 33.

Figures 2 (“Risk of bias graph”) and 3 (“Risk of bias summary) were updated accordingly.

We also changed the text in the 'Results > Risk of Bias in included studies > Other potential sources of bias > Attention bias' section:

"Only  10  studies  (Koons  2001;  Giesen-Bloo  2006;  Linehan  2006;  Bellino  2007;  Bateman  2009;  Cottraux  2009;  Nadort  2009;  Soler  2009;
Doering 2010; Morey 2010) were rated as providing similar amounts of attention as obligatory components of the study protocol to all
trial groups. The participants allocated to the control group of Gregory 2008 did not get an obligatory control treatment, but were referred
to alternative treatments in the community and had not less but markedly more professional contact hours during most of the study
period. The risk of attention bias was therefore also judged low for this trial. All remaining trials provided more attention (that is, in terms
of frequency of appointments, involvement in additional group treatments etc.) to one group, usually the experimental group (EG)." See
Other potential sources of bias.

We hope we have addressed your concerns adequately. An update of this review is currently under way, and publication is intended for the
end of this year/early 2018. Of course, any changes incorporated now will also be included in the updated version.

We are aware that without the most valuable, time-consuming and hard work of the primary study authors, no meta-analysis or systematic
review would exist. What is more, the study sample in Dr Gregory’s study included persons with BPD plus substance-related disorder (alcohol
abuse or dependence), who are usually considered as most difficult to treat (or to be kept in treatment at all), and we can understand how
much work and effort this study must have meant.

Sincerely,

Jutta Stoffers-Winterling, University Medical Center, Mainz, Germany

Contributors

Robert J Gregory, MD, SUNY Upstate Medical University, New York, USA
Email address: gregoryr@upstate.edu

Jutta Stoffers-Winterling, University Medical Center, Mainz, Germany
Email address: jutta.winterling@gmail.com

(on behalf of the review author team — Jutta Stoffers-Winterling, Birgit A Völlm, Gerta Rücker, Antje Timmer, Nick Huband, Klaus Lieb)

From the editorial board of the CDPLPG:

Professor Julian Higgins, University of Bristol, UK (Statistical Editor, CDPLPG)
Email address: julian.higgins@bristol.ac.uk

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jane Dennis, PhD, University of Bristol, UK (Feedback Editor, CDPLPG)
Email address: jane.dennis@bristol.ac.uk

Professor Geraldine Macdonald, Coordinating Editor, University of Bristol, UK (Coordinating Editor, CDPLPG)
Email address: geraldine.macdonald@bristol.ac.uk

Joanne Wilson, PhD, Managing Editor, Queens University Belfast, UK (Managing Editor, CDPLPG)
Email address: CDPLPG@qub.ac.uk

W H A T ' S   N E W

Date

Event

Description

4 September 2020

Review declared as stable

4 September 2020

Amended

H I S T O R Y

Review first published: Issue 1, 2006

This review is no longer being updated. It was super-
seded by a new review (with the same title) in the
CDSR in 2020, see: www.cochranelibrary.com/cd-
sr/doi/10.1002/14651858.CD012955.pub2/full. See also Pub-
lished notes.

Abstract, Plain language summary and Notes amended to ex-
plain that this review was superseded by a review published in
the Cochrane Database of Systematic Reviews (CDSR) in 2020.

Date

Event

Description

14 March 2017

Feedback has been incorporated

31 January 2013

Amended

1 November 2012

Amended

6 June 2012

New citation required and conclusions
have changed

Feedback by Dr Gregory (via Cochrane Feedback mechanism,
supplied to CDPLPG by Wiley 14 February 2017) incorporated.
Changes included:
- correction of wording within Summary of main results;
- new paragraph inserted within Quality of the evidence;
- 'Risk of bias' rating changed for Gregory 2008 ('Risk of Bias ta-
ble > Attention bias'); and
- wording changed accordingly in Other potential sources of bias.

Conclusions of review unchanged.

Correction of data extraction error in relation to Davidson 2006
(analyses 1.7.4 and 1.9.5). Conclusions unchanged.

Minor edit in the description of the exclusion criteria in two stud-
ies.

Change in conclusions
New authorship
Accumulation of changes: change in methods section; rewriting
of background section; changing of conclusions due to new iden-
tified evidence

10 October 2010

New search has been performed

New search

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

C O N T R I B U T I O N S   O F   A U T H O R S

Cochrane Database of Systematic Reviews

Jutta Stoffers: wrote final report, selected studies, obtained papers, extracted data, appraised quality of trials, entered data.
Birgit Völlm: helped write final report, selected studies, obtained papers, extracted data, appraised quality of trials, entered data.
Gerta Rücker: helped write final report, gave statistical support and helped extract data.
Antje Timmer: helped design review, corrected final report.
Nick Huband: helped write final report, selected studies
Klaus Lieb: sought funds, wrote to authors of papers for additional information, revised final report.

D E C L A R A T I O N S   O F   I N T E R E S T

Jutta M Stoffers is a board-certified psychologist (cognitive behaviour therapy), who has worked on a Dialectical Behaviour Therapy (DBT)
ward, and attended courses on DBT and Schema-focused therapy (SFT).
Birgit A Völlm — none known.
Gerta Rücker — none known.
Antje Timmer — none known.
Nick Huband was employed as a Clinical Research Fellow with the Institute of Mental Health, Nottingham and Nottinghamshire Healthcare
NHS Trust during the production of this review.
Klaus Lieb is an Editor with Cochrane Developmental, Psychosocial and Learning Problems. He is a board-certified cognitive behaviour
therapist with a special interest in schema therapy. KL has been involved in trials investigating inpatient DBT (Bohus 2004) and inpatient
schema-focused therapy (Reiss 2014).

S O U R C E S   O F   S U P P O R T

Internal sources

• Research Committee of the University Hospital Freiburg, Germany, Germany
• Nottinghamshire Healthcare NHS Trust, UK

External sources

• German Federal Ministry of Education and Research, grant no. 01KG0609, Germany
• NHS Cochrane Collaboration Programme Grant Scheme (NIHR), UK
• Ministry of Science, Research and Arts, federal state of Baden-Württemberg, Germany

Stipend to JS

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

The outcomes are different from the previous version of this review and we have used the new Cochrane Collaboration tool to update the
risk of bias assessment of the studies. We changed the planned sensitivity analyses.

N O T E S

This is an update of a published review (Binks 2006), but it is no longer being updated because it was superseded by a new review in 2020
(Storebø 2020).

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Behavior Therapy;  Borderline Personality Disorder  [psychology]  [*therapy];  Psychoanalysis;  Psychotherapy  [*methods]; 
Psychotherapy, Group;  Randomized Controlled Trials as Topic

MeSH check words

Humans

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200
